[
    "The sample is a phase 1 clinical trial for the treatment of small cell lung carcinoma. The trial involves the use of two different regorafenib treatments in combination with cisplatin and pemetrexed. The eligibility criteria for the trial include being over 18 years old, having a confirmed diagnosis of metastatic Stage IV or locally advanced unresectable Stage IIIB nonsquamous Non-Small Cell Lung Cancer (NSCLC), having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2, having a life expectancy of at least 12 weeks, having adequate bone marrow, liver, and renal function, having controlled blood pressure, and using adequate barrier birth control measures during the course of the study for men and women of childbearing potential. The exclusion criteria include having sensory neuropathy with sensory alterations or paresthesia, hearing impairment, persistent proteinuria of Common Toxicity Criteria (CTC) Grade 3 or higher, cardiac disease, brain metastasis, arterial or venous thrombotic or embolic events, pulmonary hemorrhage/bleeding event > Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 within 4 weeks prior to the start of study treatment, any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks prior to the start of study treatment, evidence or history of bleeding diathesis or coagulopathy, centrally located tumors with radiologic evidence of local invasion of major blood vessels, clinically significant third space fluid, and phaeochromocytoma. Prior treatment with a systemic chemotherapy for metastatic NSCLC is also an exclusion criterion, but patients who underwent prior systemic treatment or radiotherapy for NSCLC in a neoadjuvant or adjuvant setting are eligible, as long as no chemotherapy treatment was received within the last 6 months prior to study entry.",
    "The sample is a record of a clinical trial in phase 1 for the treatment of cancer. The trial involves the use of imatinib mesylate and cyclophosphamide at different dosing levels. The eligibility criteria for the trial include having a rare tumor, metastatic or locally advanced disease that is inoperable and has no standard treatment, and having measurable disease with at least one measurable lesion. The exclusion criteria include medullary insufficiency, cystitis, and hepatic porphyria. The diseases are listed as 'cancer' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 1 clinical trial for patients with type 2 diabetes mellitus who have inadequate glycemic control. The trial includes four different drugs, including a placebo, and the eligibility criteria include specific glucose level measurements and exclusion criteria such as a history of diabetic ketoacidosis or severe hypoglycemic episodes. The diseases are listed as 'diabetes mellitus, type 2' and the icd-10 codes associated with them are also provided.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on breast cancer and includes a list of ICD-10 codes associated with the disease. The trial is testing the effectiveness of three drugs - trastuzumab, paclitaxel, and myocet. The eligibility criteria for the trial includes women between the ages of 18-70 with metastatic or locally advanced breast cancer, HER2 overexpression, and at least one measurable lesion. The exclusion criteria includes prior treatment for advanced breast cancer, prior treatment with Herceptin, bone or central nervous system metastasis as the only site of disease, and a history of another malignancy within 5 years of the study.",
    "The sample is a clinical trial in the early phase 1 for the treatment of schizophrenia and cognitive deficits. The trial involves the use of the drug papaverine or a placebo. The eligibility criteria for the trial include a diagnosis of schizophrenia, stable treatment for at least 6 weeks, and no regular use of antidepressants or benzodiazepines. The trial excludes individuals with a dependence syndrome, severe physical illness, or non-removable objects above the shoulders that are incompatible with MRI. The diseases are listed as schizophrenia and cognitive deficits, and the corresponding ICD-10 codes are also provided.",
    "The sample is a phase 1 clinical trial for patients with advanced solid malignancies, specifically targeting cancer. The trial is using a drug called azd4547. The eligibility criteria for the trial includes being a Japanese patient over 25 years old with relatively good overall health, except for the cancer. The exclusion criteria includes having poor bone marrow function, poor liver or kidney function, refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the IP, or previous significant bowel resection.",
    "The sample is a phase 1 clinical trial for patients with advanced solid tumors that have failed standard therapy or for which there is no standard therapy and is indicated for treatment with anthracyclines. The trial involves the use of drugs such as doxorubicin, pazopanib (gw786034), and epirubicin. The eligibility criteria include having a confirmed diagnosis of advanced solid tumor, being at least 18 years old, having adequate organ system function, having an ECOG performance value of 0 or 1, and having measurable or evaluable disease. Exclusion criteria include prior use of pazopanib or anthracyclines, clinically significant gastrointestinal abnormalities, unstable or serious concurrent conditions, and poorly controlled hypertension. The trial also has specific criteria for women of childbearing potential and men with female partners of childbearing potential. The trial has both inclusion and exclusion criteria, and patients must provide written informed consent prior to participating.",
    "The sample is a phase 1 clinical trial for patients with metastatic or unresectable solid tumors, for which standard curative or palliative measures do not exist or are no longer effective, and there are no therapies known to prolong survival. The trial is testing the drugs XL281 and famotidine. The eligibility criteria include having a confirmed diagnosis of certain types of cancer, being at least 18 years old, having a certain performance status, having adequate organ and marrow function, and being capable of understanding and signing the informed consent document. There are also certain exclusion criteria, such as having received certain types of treatment within a certain amount of time before the trial, having an uncontrolled intercurrent illness, being pregnant or breastfeeding, and having an allergy or hypersensitivity to components of the XL281 formulation or to famotidine.",
    "The sample is a phase 1 clinical trial for patients with prostate cancer. The trial requires patients to have histologically confirmed adenocarcinoma of the prostate and meet certain criteria related to measurable or non-measurable disease, progressive systemic disease, and serum testosterone levels. Patients must also meet certain patient characteristics related to age, performance status, hematopoietic, hepatic, renal, and cardiovascular health. Prior concurrent therapy is also taken into consideration, including biologic therapy, chemotherapy, endocrine therapy, radiotherapy, and surgery. The trial involves the use of two drugs, docetaxel and epirubicin hydrochloride. The eligibility criteria are quite strict and require patients to have failed at least one prior standard endocrine therapy.",
    "The sample is a clinical trial for breast cancer patients in phases 1 and 2. The trial is testing the effectiveness of the drugs Myocet, Taxotere, and Herceptin on breast cancer tumors that overexpress HER2neu. The trial has specific eligibility criteria, including a confirmed diagnosis of breast cancer stages II and IIIA, no evidence of metastasis, and adequate cardiac, hepatic, and renal function. Patients must also be over 18 years old and have a performance status (Karnofsky index) of at least 80. Exclusion criteria include prior systemic therapy for breast cancer, prior treatment with anthracyclines or taxanes, and serious comorbidities such as congestive heart failure or uncontrolled hypertension. The trial is not open to males.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on treating advanced solid tumors, including ovarian, endometrial, cervical, and lung cancers. The trial is testing the effectiveness of two drugs, pemetrexed and topotecan. The eligibility criteria for participants include being over 18 years old, having a Karnofsky performance status of at least 80%, and having adequate liver, bone marrow, and kidney function. Exclusion criteria include having had more than three prior chemotherapy regimens in the metastatic setting, prior treatment with topotecan or pemetrexed, and the presence of active brain metastases. The sample also includes a list of icd-10 codes for the diseases being studied and the eligibility criteria for participants.",
    "The sample is a clinical trial for patients with pancreatic cancer in phase 1/phase 2. The trial is testing the effectiveness of the drugs vismodegib and gemcitabine hydrochloride. The eligibility criteria include having histologically or cytologically confirmed adenocarcinoma of the pancreas, measurable disease, and either newly diagnosed chemo-na\u00efve metastatic pancreatic cancer or recurrent disease after curative-intent surgery which has now recurred and is metastatic. Patients must also meet certain age, performance status, and blood count requirements, and have no active bleeding or pathological condition that carries high risk of bleeding. Women of child-bearing potential and men must use at least one form of contraception for the duration of study participation. The exclusion criteria include no prior chemotherapy for metastatic pancreatic cancer, known brain metastases, and clinically active liver disease.",
    "The sample is a phase 1 clinical trial for healthy male volunteers between the ages of 20 and 55 with a BMI between 18.5 and 27 kg/m2. The trial involves taking two tablets of Concor 5mg (bisoprolol hemifumarate 5mg) and one tablet of Crestor 20mg (rosuvastatin calcium 20.80mg). The eligibility criteria include being medically healthy with no clinically significant vital signs, being available for the entire study period, and understanding the requirements of the study and voluntarily consenting to participate. Exclusion criteria include a history of gastrointestinal diseases, clinically significant arrhythmic, peripheral vascular, thyroid, bronchospasm, or asthma disease, anaphylaxis to bisoprolol and/or rosuvastatin, history of drug abuse, caffeine, alcohol, or smoking abuse, clinical laboratory test values outside the accepted normal range, whole blood donation within 60 days, component blood donation within 30 days, and blood transfusion within 30 days prior to study medication dosing. Subjects considered unsuitable based on medical judgement by investigators are also excluded.",
    "The sample is a phase 1 clinical trial for patients with mantle cell lymphoma. The trial involves the use of two drugs, PD 0332991 and bortezomib. The eligibility criteria include having measurable disease, having received at least one prior chemotherapy-containing regimen and at least one prior rituximab-containing regimen, and having normal organ and marrow function. Exclusion criteria include having had chemotherapy, radiotherapy, antibodies, or investigational agents within 4 weeks prior to entering the study, and having experienced significant hematologic or neuropathic toxicities due to prior bortezomib therapy. The trial also has specific requirements for female subjects to either be post-menopausal or surgically sterilized or willing to use an acceptable method of birth control. The trial involves regular visits, treatment plans, laboratory tests, and other procedures.",
    "The sample is a record from a clinical trial table. It pertains to a phase 1 trial for the treatment of multiple myeloma, a type of cancer. The trial involves the use of three drugs: dasatinib, bortezomib, and dexamethasone. The eligibility criteria for the trial include having a confirmed diagnosis of multiple myeloma with measurable disease, evidence of relapsed or refractory disease, and having undergone at least two prior therapies for multiple myeloma. Other criteria include having a certain Eastern Cooperative Oncology Group Performance Status, not having undergone bone marrow transplant or treatment for multiple myeloma within a certain timeframe, and meeting certain hematology and chemistry parameters. The exclusion criteria include having certain medical conditions or abnormalities that may increase the risk associated with study participation, intolerance to the drugs being used, and having had certain types of cancer within a certain timeframe.",
    "The sample is a clinical trial for the treatment of diabetic macular edema. The trial is in phase 1/phase 2 and the drug being tested is ranibizumab. The eligibility criteria for the trial include being over 18 years old, having a diagnosis of diabetes mellitus, clinical evidence of retinal thickening due to macular edema involving the center of the macula, and previous history of two consecutive intravitreal bevacizumab injections for the treatment of diabetic macular edema with documented incomplete resolution of central subfield thickening by OCT. The trial also has exclusion criteria, such as pregnancy, participation in another ocular investigation or trial simultaneously, and uncontrolled glaucoma.",
    "The sample is a phase 1 trial for patients with type 2 diabetes mellitus. The trial is testing the drug canagliflozin. The inclusion criteria require patients to not be receiving any anti-hyperglycemic agents for at least 12 weeks or to be receiving a stable dose and regimen of metformin monotherapy for at least 12 weeks with a hemoglobin A1c (HbA1c) in the range of >=7% to <=10%. The exclusion criteria include a history of type 1 or \"brittle\" diabetes, severe hypoglycemic episodes, clinically significant diabetic complications, or any other clinically significant illness. The diseases and their corresponding ICD-10 codes are also listed.",
    "The sample is a clinical trial for type 1 diabetes, with a combination of phase 1 and phase 2. The trial involves the use of etanercept and placebo drugs. The eligibility criteria for the trial include subjects aged 3-18 years with T1DM, positive GAD 65 and/or islet cell antibody, HbA1c at diagnosis above 6%, insulin regimen with 3 injections of insulin daily, normal white blood count and platelets, normal ALT and AST, creatinine less than 1.8 mg/dl, and T1DM duration equal or less than 4 weeks. The exclusion criteria include infection requiring IV antibiotics at diagnosis or within the past 14 days from study entry, BMI over 85th percentile for age and gender, unstable household, unable to provide compliance with study drug, insulin and study visits, evidence of psychiatric disease in the potential study subject and/or primary care taker, and chronic diseases, including additional autoimmune disorders with the exception of euthyroid autoimmune thyroiditis.",
    "The sample is a clinical trial for patients with multiple myeloma in phase 1/phase 2. The trial is testing the drug hll1-dox, which is the doxorubicin conjugate of milatuzumab. The eligibility criteria include being at least 18 years old, having measurable disease, and having been refractory or relapsed to at least two prior standard systemic anti-myeloma treatment regimens, one of which must include either thalidomide, lenalidomide or bortezomib. Patients must also have adequate performance status, life expectancy of at least 6 months, and meet certain hematologic, cardiac, renal, and hepatic function requirements. Exclusion criteria include pregnancy or lactation, eligibility for stem cell transplant, and prior treatment with certain therapeutic agents or investigational agents within 4 weeks. Patients must also not have persistent \u2265 Grade 2 toxicity from prior treatments and must not have a history of allergic or adverse reactions to anthracycline/anthracenedione agents.",
    "The sample is a clinical trial for patients with progressive or recurrent glioblastoma, a type of brain tumor. The trial is in phase 1/phase 2 and involves the drug tandutinib. The eligibility criteria include having a confirmed diagnosis of glioblastoma, measurable disease, and a Karnofsky performance status of 60-100%. Patients must also meet various medical requirements, such as having certain blood counts and no active infections. Additionally, patients must not have any other serious medical conditions or be taking certain medications. The trial also includes a feasibility study for patients planning to undergo surgical resection or biopsy.",
    "The sample is a clinical trial for patients with non-small cell lung cancer or lung cancer in advanced stages. The trial is in phase 1/phase 2 and the treatment involves a combination of abt-751 and carboplatin. The eligibility criteria include being at least 18 years old, having a confirmed diagnosis of NSCLC, having at least one measurable lesion, and having no known curative treatment that has progressed despite therapy for recurrent/metastatic disease or prior therapy was discontinued due to intolerable toxicities. The trial also requires adequate hematologic, renal, and hepatic function, as well as an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-1. The exclusion criteria include any other malignancy within 3 years except in situ carcinoma, untreated central nervous system (CNS) metastasis, and concurrent anti-cancer therapy or radiotherapy.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on metastatic colorectal cancer and includes a list of ICD-10 codes for the disease. The trial involves the use of three drugs: azd2171, folfox (5-fluorouracil, leucovorin, oxaliplatin), and placebo cediranib. The eligibility criteria for the trial include having metastatic colorectal cancer, a WHO performance status of 0-1, and a life expectancy of 12 weeks or longer. The exclusion criteria include having uncontrolled brain metastases, inappropriate laboratory test values, and poorly controlled hypertension.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on the disease type 2 diabetes mellitus and includes a list of associated ICD-10 codes. The trial involves testing several drugs, including mk-0893 at various dosages and a placebo. The eligibility criteria for participants include being in good health, having a body mass index within a certain range, being a non-smoker, and avoiding certain foods and activities. Exclusion criteria include a history of certain diseases or surgeries, allergies to drugs or food, and drug or alcohol abuse. Participants cannot have donated blood or participated in another clinical study within four weeks prior to the trial. Additionally, participants cannot have a history of hypersensitivity to insulin, glucagon, or Sandostatine\u00ae.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1 and is studying chronic lymphocytic leukemia and small lymphocytic leukemia. The associated ICD-10 codes for these diseases are also listed. The drugs being tested are lenalidomide, fludarabine, and rituximab. The eligibility criteria for participants are also listed, including age, diagnosis, prior treatment, measurable disease, and laboratory test results. The exclusion criteria are also listed, including any serious medical conditions or psychiatric illnesses that would prevent the subject from signing the informed consent document, pregnancy or breastfeeding, and prior use of lenalidomide.",
    "The sample is a phase 1 clinical trial for HIV prevention. The trial involves testing the effectiveness of different formulations of tenofovir gel and a placebo gel. The trial is open to individuals who are at least 18 years old, willing to communicate in English, and willing to provide written informed consent. Participants must be HIV-1 negative and have natural immunity to Hepatitis B. They must also be in general good health and willing to abstain from certain sexual practices for a period of time before and after each study visit. Female participants must meet additional criteria related to contraception and vaginal insertion. There are also exclusion criteria, such as abnormal colorectal mucosa, active infections, and certain medical conditions. Female participants who are pregnant or breastfeeding are also excluded.",
    "The sample is a phase 1 clinical trial for breast cancer patients with stage IIIB, IIIC, or IV who have HER2/neu overexpression. The trial is testing the effectiveness of the drugs lonafarnib and paclitaxel as a treatment option. The eligibility criteria include various patient characteristics such as age, sex, and performance status, as well as specific medical criteria such as neutrophil count, platelet count, and creatinine clearance. Patients must also meet certain prior concurrent therapy requirements and cannot have any concurrent severe/unstable systemic disease or infection. The trial is investigating the safety and efficacy of the treatment and patients must comply with follow-up requirements.",
    "The sample is a phase 1 clinical trial for patients with locally advanced or metastatic solid malignancies, such as lung cancer, breast cancer, pancreatic cancer, head and neck cancer, and gastric cancer. The trial is testing the effectiveness of a drug called 2-deoxy-d-glucose (2dg). The eligibility criteria include being at least 18 years old, having previously received at least one chemotherapy regimen for advanced or metastatic disease, having a life expectancy of at least 3 months, and having an ECOG performance status of 0, 1, or 2. The trial also has exclusion criteria, such as having a history of cardiovascular disease, known HIV infection, or being pregnant or nursing. The trial requires patients to discontinue certain medications before and after dosing on specific days and prohibits participation in other investigational drug or device studies within 28 days of the first day of dosing.",
    "The sample is a phase 1 clinical trial for cancer patients. The trial includes patients with non-small cell lung cancer and/or pancreatic cancer with or without a KRAS mutation. The trial involves the use of multiple drugs, including trametinib, docetaxel, erlotinib, pemetrexed, carboplatin, nab-paclitaxel, and cisplatin. The eligibility criteria include having a solid tumor, tumor progression following at least one prior standard therapy, radiographically measurable tumor, ability to carry out daily life activities without difficulty, ability to swallow and retain oral medication, no significant side effects from previous anti-cancer treatment, adequate organ and blood cell counts, and use of medically acceptable methods of contraception during the study. The exclusion criteria include recent major surgery or certain types of cancer therapy, brain tumor, severe uncontrolled systemic disease, clinically significant heart, lung, or eye/vision problems, uncontrolled high blood pressure, permanent pacemaker, pregnancy or breastfeeding, and positive for Hepatitis B, Hepatitis C, or HIV.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on the treatment of central retinal vein occlusion, a disease that affects the eye. The trial is testing the effectiveness of the drug ranibizumab (lucentis) in treating the disease. The record includes a list of inclusion and exclusion criteria for participants in the trial, including age, visual acuity, and the presence of other ocular conditions. The record also includes a list of ICD-10 codes associated with the disease.",
    "The sample is a phase 1 clinical trial for patients with type 2 diabetes. The trial involves two drugs, exenatide once weekly and placebo. The eligibility criteria for the trial include having a body weight of at least 50 kg, suboptimal glycemic control, and having been treated with diet modification and exercise alone or in combination with a stable regimen of oral antidiabetic drugs for at least 2 months prior to the study start. The exclusion criteria include having donated more than 200 mL of blood within one month of study start, having received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry, and being treated with any exogenous insulin within 3 months of screening. Females who are breastfeeding are also excluded from the trial.",
    "The sample is a phase 1 clinical trial for patients with age-related macular degeneration and subfoveal choroidal neovascularization in the study eye. The trial is testing the drug pazopanib. The eligibility criteria include a best-corrected ETDRS visual acuity score between 25 and 73 letters, male or female over 50 years of age, and willingness to comply with all protocol requirements and procedures. Exclusion criteria include additional eye disease in the study eye that could compromise best-corrected visual acuity, CNV in the study eye due to other causes unrelated to age-related macular degeneration, and use of medications known to be toxic to the retina, lens, or optic nerve within 6 months prior to the screening visit. The trial also has a list of inclusion and exclusion criteria that must be met for patients to participate.",
    "The sample is for a phase 1 trial and the only disease being studied is \"healthy\". The icd-10 codes associated with the disease are \"Z76.3\" and \"Z76.2\". The drugs being tested are \"glpg0492\", \"placebo\", and \"glpg0492\" again. The eligibility criteria for the trial include being a healthy male between the ages of 18-50 or over 60, having a BMI between 18-30 kg/m\u00b2, and being a non-smoker. The exclusion criteria include having an elevated PSA or a history of drug or alcohol abuse.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on non-small-cell lung cancer and involves the use of three drugs: pemetrexed, cisplatin, and carboplatin. The trial has a set of inclusion and exclusion criteria that participants must meet in order to be eligible to participate. The inclusion criteria include having inoperable non-small-cell lung cancer, no weight loss greater than 10% in the 3 months prior to enrolling in the trial, and adequate kidney, liver, and lung function. The exclusion criteria include having had previous surgery to remove a lung tumor, previous chemotherapy or radiation therapy for lung cancer, inability to take vitamin supplementation, having had a heart attack within the past 6 months, and having an active infection.",
    "The sample is a record of a clinical trial with a combination of phase 1 and phase 2. The trial is focused on pancreatic neoplasms and adenocarcinoma, with corresponding ICD-10 codes. The trial involves the use of two drugs, gemcitabine and etanercept. The eligibility criteria for the trial include having a pathological diagnosis of recurring or metastatic pancreatic adenocarcinoma, no prior chemotherapy, immunology treatments or hormonal treatments, measurable disease, and being over 18 years old. However, there are also exclusion criteria, such as being pregnant or nursing, having psychiatric disorders that would interfere with consent ability, having known brain or leptomeningeal disease, and having a history of myocardial infarction within the previous six months. Additionally, any concurrent illness that would constitute a hazard to participation in the study, known sensitivity to gemcitabine or etanercept, and prior treatment with etanercept are also exclusion criteria.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on diabetes mellitus and involves a list of icd-10 codes for the disease. The drugs being tested are viaject\u00ae25, viaject\u00ae7, and insulin lispro. The eligibility criteria for the trial include being between the ages of 19 and 65, having a body mass index between 18 and 28 kg/m2, being diagnosed with type 1 diabetes mellitus for at least 1 year, having insulin antibody less than or equal to 10 \u00b5U/mL at screening, being a non-smoker, and providing signed and dated informed consent. The exclusion criteria include having type 2 diabetes mellitus, a C-peptide value of >1.0 ng/mL, an HbA1c value of > 10.0%, a history of hypersensitivity to any of the components in the study medication, a history of severe or multiple allergies, treatment with any other investigational drug in the last 3 months before study entry, and any systemic treatment with drugs known to interfere with glucose metabolism such as systemic corticoids, non-selective beta-blockers, and monoamine oxidase (MAO) inhibitors within 3 months prior to randomization. Other exclusion criteria include changes in concomitant medication other than insulin or insulin analogues in the last 3 weeks prior to randomization, use of non-prescription drugs within 3 weeks prior to the first dose of the test drug, progressive disease likely to prove fatal, current drug or alcohol abuse, significant cardiovascular, respiratory, gastrointestinal, hepatic, renal, neurological, psychiatric and/or hematological disease, clinically significant abnormal hematology or biochemistry screening tests, any serious systemic infectious disease during the four weeks prior to the first dose of study drug, history of any illness that might confound the results of the trial or pose a risk in administering the trial drug to the subject, blood donation within the last 30 days, lactating women, pregnant women or women intending to become pregnant during the study, sexually active women not using adequate contraceptive methods, positive serology for HIV, Hepatitis B or Hepatitis C, abnormal ECG, safety lab or physical examination results that are deemed clinically significant by the Investigator, and lack of compliance or other reasons which prevent the participation of the subject in the study.",
    "The sample is a phase 1 clinical trial for patients with malignant melanoma. The trial is testing the drug cc-5013. The eligibility criteria include being over 18 years old, having histological documentation of malignant melanoma with evidence of metastatic disease, and having an ECOG performance status of 0, 1, or 2. Patients must also have laboratory tests within certain ranges and be able to take medications orally. Women of childbearing potential must have a negative pregnancy test and agree to use at least two methods of contraception while on the study drug. Exclusion criteria include prior treatment with systemic chemotherapy, serious medical conditions, and prior use of certain drugs. Patients with certain medical conditions, such as active infection or CNS metastases, are also excluded.",
    "The sample is a clinical trial for patients with locally advanced or metastatic pancreatic adenocarcinoma. The trial is divided into two phases, phase 1 and phase 2. The patients must meet certain eligibility criteria, including having a previously unirradiated, measurable lesion and adequate hepatic and renal function. They must also have a baseline performance status of Eastern Cooperative Oncology Group (ECOG) 0, 1, or 2. The patients must not have certain exclusion criteria, such as active CNS metastases or known hypersensitivity to 5-FU. The trial involves the use of two drugs, capecitabine and PHY906, and patients must discontinue any herbal medicines or supplements at least 7 days prior to study entry. The trial aims to evaluate the safety and efficacy of the drugs in treating pancreatic cancer.",
    "The sample is a clinical trial for ovarian cancer patients in phase 1/phase 2. The trial is for patients with recurrent epithelial ovarian cancer, primary peritoneal carcinomatosis or fallopian tube cancer who have platinum-resistant or platinum refractory disease. The trial involves the drug decitabine and has eligibility criteria including measurable or detectable disease, age over 18, written informed consent, and acceptable organ function. Exclusion criteria include not having participated in any clinical trial involving conventional or investigational drugs or devices within the previous 3 weeks, having grade 2 or greater neuropathy, having additional active cancer in addition to the epithelial ovarian cancer within the last 5 years, and having an additional uncontrolled serious medical condition or psychiatric illness.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on diabetes mellitus type 2 in adults. The trial includes a list of icd-10 codes for the disease. The trial involves testing several drugs, including ertugliflozin in various doses and a placebo. The eligibility criteria for the trial include having type 2 diabetes mellitus and being either treatment-na\u00efve or on up to 2 acceptable oral anti-diabetes drugs for at least 8 weeks prior to the study. The exclusion criteria include having type 1 diabetes mellitus, having had a stroke, unstable angina, heart attack in the last 6 months, or uncontrolled blood pressure.",
    "The sample is a phase 1 clinical trial with the disease being studied being \"healthy\". The icd-10 codes associated with the disease are \"Z76.3\" and \"Z76.2\". The drug being tested is \"imatinib mesylate\". The eligibility criteria for the trial include being a healthy man or woman over the age of 18 with a BMI less than 31 kg/m2, having negative pregnancy test results for female patients of childbearing potential, and providing written informed consent. Exclusion criteria include abnormal marrow function, renal dysfunction, impaired hepatic function, taking certain medications within 2 weeks of the study, having received other investigational agents within 28 days of the study, and being pregnant or breastfeeding for female subjects.",
    "The sample is a clinical trial for kidney transplant patients with high levels of anti-HLA antibodies. The trial is in phase 1/phase 2 and involves the use of IVIG and Rituximab drugs. The eligibility criteria include having a PRA of >30%, being eligible for transplantation at Cedars-Sinai Medical Center, and having adequate liver function. Exclusion criteria include a history of severe allergic reactions, HIV, Hepatitis B and/or Hepatitis C, and significant cardiac or pulmonary disease. The patients will be monitored for anti-HLA antibody and undergo various tests throughout the trial.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on breast cancer and includes a list of ICD-10 codes associated with the disease. The trial involves the drugs panobinostat and trastuzumab. The eligibility criteria for the trial include being over 18 years old, having confirmed HER2+ ve metastatic breast cancer, having prior treatment and progression on trastuzumab, having adequate laboratory values, and having an Eastern Cooperative Oncology Group (ECOG) performance status of <2. The exclusion criteria include having active central nervous system (CNS) disease or brain metastases, impaired heart function or clinically significant heart disease, impairment of gastrointestinal (GI) function, ongoing diarrhea, liver or renal disease with impaired hepatic or renal functions, concomitant use of any anti-cancer therapy or certain drugs, being a female patient who is pregnant or breast feeding, and not being willing to use an effective method of birth control.",
    "The sample is a phase 1 clinical trial for the treatment of ulcerative colitis. The trial is testing the effectiveness of two drugs, placebo and rhumab beta7, on patients with the disease. The eligibility criteria for the trial include being between the ages of 18-70, having a diagnosis of ulcerative colitis, and being eligible to receive biologic therapy. The exclusion criteria include severe anemia, hospitalization due to the severity of the disease, and any other conditions likely to require treatment with more than 20 mg/day of prednisone. Patients must also be willing to use a reliable method of contraception and provide written informed consent.",
    "The sample is a phase 1 clinical trial for Alzheimer's disease. The trial is open to Japanese males and females between the ages of 50 and 85 who have been diagnosed with probable Alzheimer's disease and have a Mini-Mental Status Exam score of 16-26. The trial also requires participants to have a Rosen-Modified Hachinski Ischemia score of less than or equal to 4. However, individuals with a history of other dementia or neurodegenerative disorders, clinically significant cerebrovascular disease, specific findings on MRI, autoimmune disorders, or allergic or anaphylactic reactions are excluded from the trial. The drug being tested in this trial is a placebo.",
    "The sample is a phase 1 clinical trial for patients with cutaneous melanoma and clinical evidence of metastatic, non-resectable regional lymphatic, or extensive in transit recurrent disease. The trial involves the use of two drugs, bortezomib and interferon alfa-2b. The eligibility criteria include having measurable disease, normal organ and marrow function, and an ECOG performance status \u2264 2 (Karnofsky \u2265 60%). Patients with brain metastases are eligible if they have received definitive therapy and are clinically stable. Exclusion criteria include platelet count < 100 \u00d7 109/L, absolute neutrophil count < 1.0 x 109/L, calculated or measured creatinine clearance of < 30 mL/minute, history of significant brain metastases or other clinically significant central nervous system disease, \u2265Grade 2 peripheral neuropathy, hypersensitivity to bortezomib, boron or mannitol, evidence of proteinuria on urinalysis, pregnancy or breastfeeding, received other investigational drugs within 14 days before enrollment, and serious medical or psychiatric illness likely to interfere with participation in the clinical study.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for patients to participate in the trial. In this particular sample, the trial is a combination of phase 1 and phase 2, and is focused on pancreatic cancer. The drugs being tested are everolimus, cetuximab, irinotecan, and capecitabine, oxaliplatine. The eligibility criteria include factors such as patient age, performance status, blood counts, liver function, and ability to follow the treatment plan. The exclusion criteria include factors such as active or recent history of other cancers, serious medical conditions, and hypersensitivity to the treatment.",
    "The sample is a clinical trial for prostate cancer patients in phase 1/phase 2. The trial includes patients with histologically or cytologically confirmed adenocarcinoma of the prostate and androgen-independent disease progression. Patients must have a castrate testosterone level of < 40 ng/dl and a PSA level of at least 4 ng/ml, and rising on two consecutive measurements at least 2 weeks apart prior to study entry. Patients must be off anti-androgens for at least four weeks, and six weeks for bicalutamide, without evidence of response; or have evidence of progression since anti-androgen withdrawal. Patients must have adequate bone marrow, liver, and renal function, and must have recovered from acute toxicities from chemotherapy or radiotherapy administered prior to entering this study. Patients must have a MUGA scan or 2-d echocardiogram indicating an ejection fraction of > 50% within 42 days prior to first dose of study drug. Patients with reproductive potential must use an adequate contraceptive method during treatment and for three months after completing treatment. Patients must be able to understand and willing to sign a written informed consent document. Exclusion criteria include patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier, patients who have had two or more prior chemotherapy treatments, patients receiving any other investigational agent(s), patients with symptomatic brain metastases or actively receiving any therapy for brain metastasis, active second malignancy in the last 5 years except for non-melanoma skin cancer or carcinoma-in-situ, history of cardiac disease, with New York Heart Association Class II or greater, or clinical evidence of congestive heart failure, history of hypersensitivity reactions attributed to a conventional formulation of doxorubicin HCL, the components of Doxil, docetaxel or other drugs formulated with polysorbate 80, and uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on treating patients with leukemia and myelodysplastic syndromes using the drugs arsenic trioxide and azacitidine. The eligibility criteria for the trial include a confirmed diagnosis of MDS, adequate marrow iron stores, and serum creatinine or serum bilirubin levels that are less than 1.5 times the upper limit of normal. Women of childbearing potential must have a negative serum pregnancy test prior to treatment, and women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment. The exclusion criteria include active serious infections that are not controlled by antibiotics, poorly controlled hypertension, diabetes mellitus, or other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to the protocol.",
    "This sample is a phase 1 clinical trial for the respiratory syncytial virus. The trial is testing three drugs, including a placebo, and has a list of inclusion and exclusion criteria for participants. Inclusion criteria include being between 18-45 years old, healthy by medical history and physical exam, and using effective birth control methods. Exclusion criteria include having any condition that would interfere with the evaluation of the drug or interpretation of subject safety or study results, being pregnant or nursing, and having a history of alcohol or drug abuse within the past 2 years. The trial has a follow-up period of approximately 360 days.",
    "The sample is a phase 1 clinical trial for patients with acute myeloid leukemia who did not respond to first line induction therapy. The trial involves the use of three drugs: gemtuzumab ozogamicin, mitoxantrone, and etoposide. The eligibility criteria include being between 18 and 70 years old, having CD33 positive de novo AML, having an ECOG Performance Status of 0-2, and meeting certain laboratory values. Exclusion criteria include having acute promyelocytic leukemia, prior use of the three drugs, and having certain medical conditions or receiving certain treatments. Women who are pregnant or breastfeeding are also excluded.",
    "The sample is a clinical trial in phase 1 that involves patients with depression, coronary artery disease (CAD), and acute coronary syndrome (ACS). The trial is testing the effectiveness of two drugs, sertraline (Zoloft) and simvastatin (Zocor), on patients with mild depression and high levels of the inflammatory marker CRP. The eligibility criteria for the trial include being between the ages of 18 and 60, having mild depression, and having a CRP level greater than 2. Exclusion criteria include having a history of certain mental health disorders, current substance abuse, and certain medical conditions such as chronic liver or renal disease. Additionally, patients who are pregnant or lactating, have a history of coronary artery disease, or are currently using statins or regular aspirin are also excluded from the trial.",
    "The sample is a clinical trial for liver cancer patients in phase 1/phase 2. The trial involves the use of two drugs, doxorubicin-eluting beads and everolimus. The eligibility criteria for patients include having confirmed hepatocellular carcinoma, being in intermediate stage B according to the Barcelona Clinic Liver Cancer classification, having a Child-Pugh score of less than 8, and not having tumor involvement of more than 50% of the whole liver. Patients must also meet certain patient characteristics such as having a WHO performance status of 0-1, hemoglobin levels of at least 90 g/L, and platelet counts of at least 100 x 10^9/L. Patients must not have certain medical conditions such as active heart disease, hypertension, or bleeding diathesis. They must also not have any serious non-healing wounds or history of hemoptysis. Patients must not have any other prior or concurrent malignancy that is distinct in primary site or histology from HCC, except carcinoma in situ of the cervix, treated nonmelanoma skin cancer, superficial bladder tumor (Ta, Tis, T1), or any cancer curatively treated > 3 years prior to entry. The trial also has certain prior concurrent therapy requirements such as at least 4 weeks since prior transarterial embolization/chemoembolization, radiofrequency ablation, cryoablation, radiation therapy or percutaneous ethanol injection. Patients must not have any concurrent anticancer drugs or investigational drugs. They must also not have any concurrent known strong CYP3A4 inhibitors or inducers.",
    "The sample is a phase 1 clinical trial for patients with relapsed/refractory B-cell CLL or SLL. The trial involves the use of lenalidomide, rituximab, and cyclophosphamide as treatment. The eligibility criteria include being at least 18 years old, having discontinued all previous cancer therapy at least 2 weeks prior to treatment, having received at least one prior therapy, and meeting the NCI Working Group Criteria for treatment of B-CLL. Patients must also have an ECOG performance status of \u2264 2 and meet certain laboratory test result ranges. Females of childbearing potential must have a negative pregnancy test and commit to using two forms of birth control. The exclusion criteria include any serious medical condition, pregnancy or breastfeeding, and any prior use of lenalidomide.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, ICD-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying the effects of docetaxel on various types of cancer, including recurrent non-small cell lung cancer, recurrent prostate cancer, and stage III and IV prostate and non-small cell lung cancer. The eligibility criteria include having measurable disease, a performance status of ECOG 0-2 or Karnofsky 60-100%, and meeting various laboratory and medical criteria. The sample also includes a list of ICD-10 codes for the diseases being studied and a detailed list of inclusion and exclusion criteria for participants.",
    "The sample is a phase 1 clinical trial for non-small cell lung cancer. The trial involves the use of the drugs velcade and vorinostat. The eligibility criteria for the trial include having histologically confirmed NSCLC, planned surgical resection, being over 18 years old, having an ECOG performance status of 0-1, and meeting certain organ and marrow function requirements. Exclusion criteria include previous chemotherapy or radiation therapy within 5 years, prior exposure to velcade or vorinostat, and serious medical or psychiatric illness likely to interfere with participation in the trial. The trial also requires voluntary written informed consent and the use of acceptable methods of birth control.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular trial, the phase is a combination of phase 1 and phase 2, and the diseases being studied are melanoma, malignant melanoma, and experimental melanoma. The icd-10 codes associated with these diseases are also listed. The drugs being used in the trial include dmf5 melanoma reactive til, cyclophosphamide, fludarabine, and aldesleukin. The eligibility criteria for participants include having measurable metastatic melanoma that is refractory to standard treatment, being HLA-A 0201 positive, having a clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1, and meeting various hematology, serology, and chemistry requirements. There are also exclusion criteria, such as having a history of severe immediate hypersensitivity reaction to any of the agents used in the study or having a documented penicillin allergy.",
    "The sample is a phase 1 clinical trial for the treatment of schizophrenia. The trial is testing the effectiveness of aripiprazole im depot and aripiprazole tablets. The eligibility criteria for participants include a diagnosis of schizophrenia, good physical health, ability to provide informed consent, and a body mass index between 18 and 35 kg/m^2. Exclusion criteria include recent drug or alcohol abuse, use of certain medications, pregnancy or lactation, and a history of certain medical conditions. The trial aims to determine the safety and efficacy of the treatment for patients with schizophrenia.",
    "The sample is a clinical trial for patients with metastatic breast cancer in phase 1/phase 2. The trial is testing the drug amrubicin. The eligibility criteria include being a female over 18 years old with a histologic diagnosis of HER2-negative breast cancer, evidence of metastatic or locally advanced, inoperable breast cancer, and having received a minimum of 1 and maximum of 2 prior metastatic breast cancer chemotherapy regimens. Patients must also have measurable disease per RECIST criteria version 1.1 and left ventricular ejection fraction (LVEF) \u00b350% by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA). The exclusion criteria include any concurrent therapy with other investigational, chemotherapeutic, or hormonal therapy, prior treatment with >=3 regimens of cytotoxic therapy in the advanced disease setting, and major surgery or systemic therapy <=3 weeks of study treatment.",
    "The sample is a clinical trial for phase 1/phase 2 of a drug called cetuximab for the treatment of head and neck cancer. The trial is looking for patients who are over 18 years old, have histologically proven squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, and are selected for a primary surgical treatment. Patients must not have distant metastases, active second malignancy during the last 5 years, or prior or concurrent evidence of uncontrolled severe pathology precluding administration of surgery. Patients must have a life expectancy of more than 3 months, not be pregnant or nursing, and must use effective contraception if fertile. They must also have signed informed consent and have a performance status ECOG 0-1. Patients with nasopharynx cancer, past or current malignancy other than HNSCC, performance status ECOG above 2, concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not indicated in the study protocol, use of any investigational agents within 4 weeks prior to entry, previous exposure to EGFR targeting therapy, or known grade hypersensitivity to cetuximab are excluded from the trial.",
    "The sample is a clinical trial for the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) using the drugs dasatinib and bms-833923. The trial is in phase 1/phase 2 and the eligibility criteria include being over 18 years old, having a diagnosis of CML with a positive Philadelphia chromosome, and having a resistance or suboptimal response to imatinib, dasatinib, or nilotinib without a known T315I/A Abl-kinase mutation. The trial also has exclusion criteria, such as having a known Abl-kinase T315I or T315A mutation, uncontrolled medical disorders or active infections, and significant cardiovascular disease. Prior therapies for CML or Ph+ ALL are permitted with certain restrictions. The diseases are listed as 'leukemia' and the icd-10 codes are provided.",
    "The sample is a phase 1 clinical trial for patients with acute myeloid leukemia (AML). The trial is testing the effectiveness of autologous tumor cell vaccine and therapeutic autologous dendritic cells. The eligibility criteria include being newly diagnosed with AML, having adequate dendritic cells and AML blasts isolated from bone marrow and/or peripheral blood, and having no clinical evidence of CNS leukemia. Patients must be 18 years or older, have a negative pregnancy test, and use effective contraception if fertile. They must also be HIV negative and have no clinically significant autoimmune disease or other active malignancy except nonmelanoma skin cancer. Prior immunotherapy must have been more than 3 months ago. The sample does not specify any requirements for chemotherapy, endocrine therapy, radiotherapy, or surgery.",
    "The sample is a phase 1 clinical trial for patients with advanced and/or metastatic cancer that is refractory to standard therapy and/or therapies known to provide clinical benefit, or for which no standard therapy exists. The trial is testing the drug ly2584702. The eligibility criteria include having adequate organ function, a performance status of less than or equal to 2 on the Eastern Cooperative Oncology Group scale, and an estimated life expectancy of 12 weeks or greater. Exclusion criteria include having received treatment within 4 weeks of the initial dose of study drug with a drug that has not received regulatory approval for any indication, serious preexisting medical conditions or serious concomitant systemic disorders, prior clinical history of tuberculosis or positive test results in hepatitis B surface antigen or hepatitis C antibodies, symptomatic central nervous system malignancy or metastasis, and hematologic malignancies or lymphoma.",
    "The sample is a phase 1 clinical trial for patients with metastatic or unresectable solid malignancy for which standard effective antineoplastic therapy does not exist or is no longer effective. The trial is testing the drug 1-methyl-d-tryptophan. The eligibility criteria include having a confirmed solid malignancy, a performance status of 0-2, a life expectancy of more than 4 months, and meeting certain laboratory values. Patients must not have a history of gastrointestinal disease causing malabsorption or obstruction, be pregnant or nursing, have a history of allergic reactions to compounds of similar chemical or biologic composition to 1-methyl-d-tryptophan, or have active autoimmune disease or any condition requiring concurrent use of any systemic immunosuppressants or steroids for any reason. Patients must also not have uncontrolled concurrent illness, HIV-positive status, or other active malignancy. Prior therapy with approved monoclonal antibodies is allowed, but not experimental active immunotherapy consisting of targeted monoclonal antibodies or pharmaceutical compounds. Patients must have recovered from all prior therapy and not have had prior gastric bypass surgery or extensive small bowel resection. The trial does not allow concurrent supplements containing L-tryptophan or derivatives or patients with an allo-transplant of any kind.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on patients with pulmonary hypertension due to chronic obstructive pulmonary disease (COPD) and hypertension. The trial involves the use of two drugs, riociguat (adempas, bay63-2521) 1.0 mg and riociguat (adempas, bay63-2521) 2.5 mg. The eligibility criteria for the trial include patients with routine invasive measurement of hemodynamic parameters, with catheters for measurement of hemodynamic parameters in place. Exclusion criteria include acute exacerbation of COPD, pre-existing lung disease other than COPD, acute or severe chronic left heart failure, severe coronary artery disease, uncontrolled arterial hypertension, severe left ventricular hypertrophy, congenital or acquired valvular or myocardial disease, systolic blood pressure < 100 mmHg, heart rate < 55 bpm or >105 bpm, PaO2/FiO2 < 50 mmHg, PaCO2 > 55 mmHg, severe hepatic insufficiency, and severe renal insufficiency. The diseases involved in the trial are hypertension, pulmonary and chronic obstructive pulmonary disease, and the ICD-10 codes associated with these diseases are listed.",
    "The sample is a phase 1 clinical trial for patients with lung cancer or metastatic cancer. The trial involves the drug rad001 and requires patients to have radiographically confirmed brain metastases with histopathologically confirmed primary non-small cell lung cancer that will benefit from whole-brain radiotherapy. Patients must also have at least one measurable intracranial site of disease that has not been previously treated with stereotactic radiation and stable extracranial disease for 4 weeks. Eligible patients must have an ECOG performance status of 0-2, a life expectancy of at least 12 weeks, and meet various laboratory criteria. Patients must not have other malignancies within the past 3 years, except for adequately treated carcinoma in situ of the cervix or basal or squamous cell carcinomas of the skin. They must also not have severe and/or uncontrolled medical conditions or other conditions that could affect participation in the study. Prior concurrent therapy is allowed, but patients must have recovered from the acute toxicities of any prior therapy. Various prior and concurrent treatments are not allowed, and patients must not have a known history of HIV seropositivity or hypersensitivity to everolimus or other rapamycin.",
    "The sample is a clinical trial in phase 1 that aims to study the effects of Nexium and placebo on athletes with exercise-triggered asthma and gastroesophageal reflux. The trial will include athletes who experience symptoms such as choking, coughing, wheezing, shortness of breath, and chest tightness during exercise. The inclusion criteria require that the athletes exercise at least three times a week for the past six months and are at least 18 years old. The exclusion criteria include pregnancy, age less than 18 years or greater than 65 years, and abnormal methacholine challenge tests. The trial will collect data on the eligibility criteria, diseases, ICD-10 codes, drugs, and phases of the trial.",
    "The sample is a record of a clinical trial in phase 1, focused on the treatment of chronic hepatitis C. The trial involves the drug mp-424 (telaprevir) and includes a list of icd-10 codes for the disease. The eligibility criteria for the trial include being diagnosed with genotype 1b chronic hepatitis C and being naive to concomitant medications with interferon. Patients with decompensated cirrhosis or a positive HBs antigen are excluded from the trial.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on neoplasms, which are malignant tumors. The icd-10 codes associated with the diseases are listed. The drug being tested is called pt-523 for injection. The eligibility criteria for the trial are listed, including the presence of metastatic or inoperable malignancy, age greater than or equal to 18 years, and adequate organ function and bone marrow reserve. There are also exclusion criteria listed, such as the presence of uncontrolled serious medical or psychiatric illness. The sample notes that there are no limitations on the extent or type of prior therapy received by the patient, as long as they have demonstrated complete recovery from any adverse effects and fulfill all relevant inclusion criteria.",
    "The sample is a clinical trial for patients with recurrent glioblastoma multiforme, glioma, astrocytoma, or brain tumor. The trial is in phase 1/phase 2 and the treatment involves a combination of itv depocyt and temozolomide. The eligibility criteria include being between 18 and 85 years old, having a Karnofsky performance status of at least 60%, having a platelet count and ANC within a certain range, having adequate liver and renal function, and having recovered from prior therapy. Patients must also have a histological diagnosis of recurrent GBM and failed initial surgical resection followed by standard adjuvant therapy. Exclusion criteria include having received more than one other systemic or ITV adjuvant chemotherapy regimen in addition to temozolomide, having a Karnofsky performance status less than 60%, and having certain medical conditions or contraindications to the treatment. Patients or their legal guardians must sign an informed consent document.",
    "The sample is a phase 1 clinical trial for the treatment of irritable bowel syndrome. The trial includes patients who have been clinically diagnosed with IBS-C and meet the Rome III diagnostic criteria for IBS-C, are 18 years or older, and do not have certain medical conditions or take certain medications. The trial involves the use of two drugs, lubiprostone and placebo. The eligibility criteria for the trial include a list of inclusion and exclusion criteria, such as not using laxatives or prokinetics within two weeks prior to or during the study, not having a history of bowel resection except appendectomy or cholecystectomy, and not being pregnant or planning to become pregnant. The trial also involves exposure to radiation, so certain individuals who have been exposed to radiation within the past year or are currently working with radiation will be excluded.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on breast neoplasms, which is a list of diseases that includes several icd-10 codes. The trial is testing the effectiveness of two drugs, sunitinib (sutent) and taxotere. The eligibility criteria for the trial includes having breast cancer with evidence of unresectable, locally recurrent or metastatic disease and being a candidate for treatment with docetaxel. The exclusion criteria includes having prior chemotherapy in the advanced disease setting, having inflammatory breast cancer, and having HER2 positive disease.",
    "The sample is a clinical trial for the treatment of malignant melanoma. The trial is in phase 1/phase 2 and the table contains information about the diseases, icd-10 codes, drugs, and eligibility criteria. The inclusion criteria include having a confirmed diagnosis of melanoma that has been previously treated with chemotherapy or IL-2, having measurable disease, and having adequate renal, liver, and bone marrow function. The exclusion criteria include having received more than three systemic treatment regimens for malignant melanoma, having a second malignancy within the last 5 years, being pregnant or lactating, having known HIV, having acute medical problems, and having any underlying medical conditions that would contraindicate therapy with the study treatment. Patients with brain metastases are eligible if they are clinically and neurologically stable for at least 4 weeks since therapy and either off corticosteroids or on a stable dose of corticosteroids.",
    "The sample is a clinical trial for pancreatic adenocarcinoma in phase 1. The trial involves the drugs imexon and gemcitabine. The eligibility criteria include having inoperable cancer of the pancreas, normal blood cell counts and chemistries, ability to perform daily activities, a projected life expectancy of at least 2 months, and no serious illnesses or infections. Participants must not be pregnant or nursing, and must be willing to use contraceptives. Exclusion criteria include prior chemotherapy for metastatic disease and brain metastases. The icd-10 codes for the disease are also provided.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on treating advanced solid tumors, cancer, and advanced solid malignancies using the drugs azd7762 and irinotecan. The trial has a list of inclusion and exclusion criteria, which includes factors such as overall health, bone marrow function, heart conditions, and prior treatment with anthracycline. The icd-10 codes associated with the diseases being treated are also included in the record.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on pulmonary disease, specifically chronic obstructive pulmonary disease, and the associated ICD-10 codes are J44.9, J44.1, and J44.0. The drug being tested is uk-369,003. The eligibility criteria for the trial include meeting GOLD criteria 2 to 4 and having a 10 pack year history of smoking. Women of childbearing potential are excluded from the trial.",
    "The sample is a phase 1 clinical trial for patients with metastatic or unresectable melanoma. The trial involves the use of two drugs, bortezomib and sorafenib. The eligibility criteria include confirmation of malignant melanoma, measurable disease, prior treatments for the disease, age of 18 or older, life expectancy of greater than three months, ECOG performance status of 0 or 1, adequate organ and marrow function, negative pregnancy test for women of childbearing potential, and agreement to use adequate contraception. Exclusion criteria include recent chemotherapy or radiotherapy, active CNS disease, prior therapy with bortezomib or sorafenib, allergic reactions to similar compounds, and various medical conditions.",
    "The sample is a phase 1 clinical trial for the treatment of phenylketonuria using the drug ravpal-peg. The eligibility criteria include a diagnosis of PKU, a certain blood Phe concentration, willingness to provide informed consent, compliance with study procedures, and good health. Exclusion criteria include the use of investigational products, pregnancy or breastfeeding, concurrent diseases or conditions that would interfere with study participation or safety, known hypersensitivity to the drug, and certain abnormal laboratory values.",
    "The sample is a clinical trial for patients with non-small-cell lung carcinoma in phase 1. The trial involves the use of two drugs, bi 2536 and pemetrexed. The eligibility criteria for the trial include having a confirmed diagnosis of NSCLC, having measurable disease, being 18 years or older, having an ECOG performance score of 0-2, and having a life expectancy of at least 3 months. There are also exclusion criteria, such as having received more than one prior chemotherapy regimen for advanced disease, having active brain metastases, and being unable or unwilling to interrupt concomitant administration of NSAIDS 5 days prior to the day of and up to 2 days after the administration of pemetrexed. The trial requires written informed consent that is consistent with International Conference on Harmonization (ICH) - Good Clinical Practice (GCP) guidelines.",
    "The sample is a phase 1 clinical trial for patients with advanced, non-resectable, and/or metastatic solid tumors who have failed conventional treatment or for whom no proven therapy exists. The trial involves the use of the drug bi 2536 bs administered intravenously. The eligibility criteria include having evaluable tumor deposits, being 18 years or older, having a life expectancy of at least 6 months, and having an Eastern Cooperative Oncology Group (ECOG) performance score of \u2264 2. Exclusion criteria include serious illness or concomitant non-oncological disease, pregnancy or breastfeeding, active infectious disease, known brain metastases, second malignancy requiring therapy, and other factors that may interfere with the trial protocol.",
    "The sample is a clinical trial for a drug called amd3100. The trial is in phase 1/phase 2 and is focused on treating various types of leukemia, myelodysplastic syndromes, multiple myeloma, lymphoma, and Hodgkin disease. The trial involves a donor who is a 6/6 HLA-matched sibling willing to donate peripheral blood stem cells for transplant, and a recipient who must have one of the specified diagnoses and a 6/6 HLA-matched sibling willing to donate PBSC for transplant. Both the donor and recipient must meet certain eligibility criteria, including age, adequate organ function, and HIV and HTLV seronegativity. The trial also requires compliance with the study regimen and prohibits active infections or alcohol/substance abuse.",
    "The sample is a phase 1 clinical trial that involves testing the drugs ilaprazole and esomeprazole on subjects who are generally in good health and between the ages of 18 and 55. The trial includes subjects who have various diseases such as pharmacokinetics, pharmacodynamics, and ilaprazole. The eligibility criteria for the trial include having a negative pregnancy test, using a double-barrier method of birth control, having a negative breath test result for H pylori, and having a BMI within the range of 18 to 30 kg/m2. The exclusion criteria include having any current evidence of dysfunction or significant sensitivity to any drug.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation, focused on the disease glioblastoma multiforme. The icd-10 codes associated with the disease are listed as [\"['L51.0', 'L51.8', 'L51.9']\"]. The trial involves the drugs bcnu wafer, irinotecan, and bevacizumab. The eligibility criteria for the trial are listed, including requirements such as a histopathologically proven diagnosis of GBM, prior treatment with standard doses of Temodar, a KPS score greater than 50, and a predicted life expectancy of more than 3 months. The exclusion criteria are also listed, including prior exposure to VEGF inhibitors or Irinotecan, recent intracranial or GI bleeding, and uncontrolled concurrent illness that would limit compliance with study requirements.",
    "The sample is a clinical trial for lymphoma, specifically large-cell diffuse and B-cell lymphoma. It is a phase 1/phase 2 trial and includes a list of drugs such as bortezomib, cyclophosphamide, doxorubicin, vincristine, prednisolone, and lenograstim. The eligibility criteria for the trial includes confirmation of DLBCL, age 70 or younger, previously untreated, ECOG performance status of 0-2, advanced stage, measurable disease, and normal liver function. Exclusion criteria includes platelet count less than 75,000/microL, absolute neutrophil count less than 1,500/microlL, and other medical or psychiatric illnesses that may interfere with participation in the study.",
    "The sample is a clinical trial for patients with castration-resistant prostate cancer. The trial is in phase 1/phase 2 and the patients must have a rising PSA level above the androgen-deprivation therapy (ADT) nadir. The patients must have only received one prior chemotherapy regimen, which must contain docetaxel as a single agent or in combination with other agents. The trial involves treatment with cabazitaxel plus bavituximab. The eligibility criteria include being 18 years or older with a life expectancy of at least 3 months, having an Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2, and having adequate hematologic, renal, and hepatic function. The exclusion criteria include a history of bleeding diathesis or coagulopathy, ongoing therapy with oral or parenteral anticoagulants, and major surgery within 28 days of Study Day 1.",
    "The sample is a phase 1 clinical trial for patients with advanced, non-resectable, and/or metastatic solid tumors who have failed conventional treatment or for whom no proven therapy exists. The trial involves the drug bi 6727 and has eligibility criteria including confirmed diagnosis of the disease, age 18 or older, Eastern Cooperative Oncology Group (ECOG) performance score of 2 or higher, and recovery from previous therapy-related toxicities. Exclusion criteria include serious illness or non-oncological disease, pregnancy or breastfeeding, active infectious disease, and active brain or leptomeningeal disease. Patients must also meet additional criteria for measurable tumor deposits.",
    "The sample is a phase 1 clinical trial for patients aged 2 to 21 years with recurrent or progressive CNS tumors, including optic pathway and brainstem gliomas. The trial is testing the effectiveness of the drug busulfan. The eligibility criteria include having a life expectancy of at least 2 months, no limit to the number of prior therapies received, and meeting certain organ function requirements. Patients must also not be pregnant or breastfeeding, and females of childbearing potential must practice effective birth control. The trial excludes patients taking certain medications and those with certain medical conditions.",
    "The sample is a clinical trial for phase 1, with the disease being pancreatic cancer. The icd-10 code for the disease is C25.3. The drugs being tested are romidepsin and gemcitabine. The eligibility criteria for the trial include having histologically confirmed advanced solid tumors, measurable or evaluable disease, written informed consent, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. Exclusion criteria include prior treatment with romidepsin or gemcitabine, prior chemotherapy treatment within 3 weeks prior to the first day of treatment, prior radiotherapy within 4 weeks prior to the first day of treatment, and prior surgery within 3 weeks prior to the first day of treatment. Other exclusion criteria include concomitant use of any other anti-cancer therapy, any known cardiac abnormalities, serum potassium or magnesium abnormalities, concomitant use of drugs that may cause a prolongation of the QTc, clinically significant active infection, inadequate bone marrow or other organ function, pregnancy or breastfeeding, and any significant medical or psychiatric condition that might prevent the patient from complying with all study procedures.",
    "The sample is a phase 1 clinical trial for a drug called srt2104, which is being tested on ambulatory male and female subjects with type 2 diabetes or otherwise healthy cigarette smokers. The trial has eligibility criteria that include having a stable hypoglycemic therapy or dietary regimen to control diabetes, being within the age range of 18-70 years, having a BMI of 18.5-38 kg/m^2, and having a resting supine blood pressure of <160/90 mmHg. Exclusion criteria include having any major illness or injury in the past 3 months, having renal or liver impairment, and having a history of drug abuse or alcoholism. The trial also requires subjects to provide written informed consent and to be willing to use reliable contraception if they are of child-bearing potential.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on acute myelogenous leukemia, with a list of associated ICD-10 codes. The drug being tested is azd4877. The eligibility criteria for the trial are listed, including specific requirements for patients with prior allogeneic transplants. There are also exclusion criteria listed, such as patients with promyelocytic acute myelogenous leukemia or liver injury.",
    "The sample is a phase 1 clinical trial for patients with metastatic solid malignancy. The trial is testing the effectiveness of 1-methyl-d-tryptophan and docetaxel as a treatment. Patients must have measurable disease and meet certain eligibility criteria, including having an ECOG performance status of \u2264 2, a life expectancy of greater than 4 months, and normal levels of leukocytes, neutrophils, platelets, bilirubin, AST/ALT, and creatinine. Patients with known brain metastases must have their tumors treated and be neurologically stable for at least 1 month off steroids. Patients with certain gastrointestinal diseases or autoimmune diseases are not eligible. Patients must not have received chemotherapy or radiotherapy within 4 weeks prior to entering the study, and may not be concomitantly receiving any other investigational agents or standard therapies with the intent of treating their malignancy while on study.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for patients. In this particular sample, the trial is in the early phase 1 and is focused on pancreatic cancer. The icd-10 code for pancreatic cancer is C25.3. The drug being tested is pioglitazone hydrochloride. The eligibility criteria for patients include having metastatic pancreatic cancer that has progressed after first-line gemcitabine hydrochloride-based chemotherapy, having a certain performance status, blood counts, and liver function, and not having certain medical conditions or taking certain medications. Prior systemic therapy with certain drugs is allowed, but no other concurrent anticancer therapy is allowed.",
    "This is a sample from a clinical trial table that includes information about the trial phase, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1 and is studying healthy individuals. The icd-10 codes associated with the disease are \"Z76.3\" and \"Z76.2\". The drugs being tested are canagliflozin (jnj-28431754) and a placebo. The eligibility criteria for participants include having a body mass index (BMI) between 30.0 and 39.9 kg/m2, being non-diabetic, and being a non-smoker or non-tobacco user. Exclusion criteria include having a clinically significant illness, having taken anti-obesity medications within 3 months of the screening visit, having had gastric banding or other gastric-reduction surgery, and having a history of eating disorders or significant changes in body weight due to dieting or nutritional treatment.",
    "The sample is a clinical trial for Alzheimer's disease, with a combination of phase 1 and phase 2. The trial involves testing the effectiveness of the drugs ly2886721 and placebo on participants with mild Alzheimer's disease or mild cognitive impairment due to Alzheimer's disease. The eligibility criteria include meeting certain criteria for Alzheimer's disease or mild cognitive impairment, having a certain score on the Mini Mental State Examination, and having a positive scan for the presence of amyloid beta. Women must be postmenopausal, and men must use an approved barrier method of contraception if their partners are pregnant or of childbearing potential. The exclusion criteria include having certain medical conditions, being in another drug or device study, and having a history of alcohol or drug abuse.",
    "The sample is a phase 1 clinical trial for subjects with type 2 diabetes mellitus. The trial includes a list of diseases and their corresponding icd-10 codes, a list of drugs including asp1941, metformin, and placebo, and eligibility criteria for inclusion and exclusion. Inclusion criteria include stable disease under metformin monotherapy or dual therapy with metformin and a Sulfonylureum Derivative for at least 3 months, fasting serum glucose between 7-11.5 mmol/l, stable fasting blood glucose, and a BMI between 18.5 and 40.0 kg/m2. Exclusion criteria include type 1 diabetes, diabetes-related macro-complications, painful diabetic neuropathy, diabetic macular edema, diabetic proliferative retinopathy, clinical significant renal disease, recent evidence of severe hypoglycemia, pulse <40 or >90, systolic blood pressure >160 mmHg, and diastolic blood pressure >100 mmHg.",
    "The sample is a clinical trial for phase 1, with the disease being lung cancer. The trial includes patients with medically inoperable or unresectable stage II, IIIA, or IIIB disease, or post-resection intrathoracic tumor recurrence. The trial requires measurable disease by computed tomography scan, no evidence of small cell histology, no significant pleural effusion on chest x-ray or malignant pleural effusion on cytology, and no metastatic disease. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and meet certain blood count and organ function criteria. Patients must not have had a synchronous or prior invasive malignancy, myocardial infarction within the past 6 months, symptomatic heart disease, active infection or fever, known hypersensitivity to any of the components of oxaliplatin or docetaxel, prior thoracic or neck radiotherapy, or prior docetaxel or oxaliplatin.",
    "The sample is a phase 1 clinical trial for a drug called sb705498 and a placebo, aimed at treating dermatitis, atopic. The trial is looking for healthy Caucasian volunteers between the ages of 18 and 65 who are not taking any regular medication and are free from clinically significant illness or disease. The trial has a list of eligibility criteria that includes being a non-smoker, having a BMI within the range of 19.0 - 32.0 kg/m2, and having certain levels of AST, ALT, alkaline phosphatase, and bilirubin. The trial also has a list of exclusion criteria that includes having a history of sensitivity to any of the study medications, having participated in a clinical trial resulting in exposure to more than four new chemical entities within 12 months prior to the first dosing day, and being unable to refrain from use of prescription or non-prescription drugs.",
    "The sample is a phase 1 clinical trial for peripheral arterial disease. The trial includes patients who are undergoing non-emergent vascular surgery or other non-cardiac surgery. The inclusion criteria require patients to be between the ages of 21-99, have peripheral arterial disease, and be able to provide informed consent. The exclusion criteria include patients with unstable angina, myocardial infarction, stroke, or other major illnesses. Women who are lactating, pregnant, or of childbearing potential and not using a reliable contraceptive method are also excluded. Patients who have received an investigational drug within 30 days of enrollment or have a history of psychological illness or condition are also excluded. Additionally, patients with known occlusive atherosclerosis of the subclavian artery or upper extremity, or who are taking vitamin C in a dose greater than 2 times the Recommended Daily Allowance within 1 month of enrollment are excluded. The drugs being tested in the trial are atorvastatin, ascorbic acid, and placebo.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on the treatment of metastatic melanoma, with a list of associated ICD-10 codes provided. The drug being tested is rituximab. The eligibility criteria for the trial are listed, including inclusion criteria such as histologically verified non-ocular melanoma stage IIIc/IV with no evidence of disease, and exclusion criteria such as immunodeficiency syndromes, active autoimmune diseases, and treatment with immunosuppressive agents other than steroids. The sample also includes a list of exclusion criteria, such as cardiac insufficiency NYHA IV, active Hepatitis B, C, or HIV infection, and pregnancy or lactation.",
    "The sample is a phase 1 clinical trial for patients with locally recurrent or metastatic breast cancer that is resistant to trastuzumab. The trial is testing the effectiveness of a combination of the drugs grn163l and trastuzumab. The eligibility criteria include being 18 years or older, having an ECOG performance status of 0-2, having HER2+ breast cancer, and having measurable or evaluable disease according to RECIST v1.1. Patients must also have a negative pregnancy test and meet certain laboratory value requirements. Exclusion criteria include having received investigational therapy or hormonal therapy within 4 weeks or 2 weeks of study registration, respectively, and having a history of severe reaction to trastuzumab or clinically significant cardiac dysfunction.",
    "The sample is a phase 1 clinical trial for patients with relapsed or refractory leukemias, poor-risk myelodysplasia, or chronic myelomonocytic leukemia. The trial is testing the drug triciribine. The eligibility criteria include having a certain performance status, using acceptable contraceptive methods, and having specific clinical laboratory values. Patients with uncontrolled intercurrent illness, active heart disease, or receiving any other standard or investigational treatment for their hematologic malignancy are excluded.",
    "The sample is a phase 1 clinical trial for patients with advanced or metastatic breast cancer who have had progressive disease after aromatase inhibitor therapy. The trial is testing the effectiveness of lapatinib ditosylate and tamoxifen citrate as treatments. The eligibility criteria include having a confirmed diagnosis of breast cancer, being male or female, having an ECOG performance status of 0-2, and having a life expectancy of at least 12 weeks. Patients must also meet certain medical criteria, such as having normal cardiac function and no active infections. Prior concurrent therapy is also taken into consideration, with a minimum time requirement since prior treatments.",
    "The sample is a clinical trial for the treatment of multiple myeloma, a type of cancer. The trial is in phase 1/phase 2 and involves the drugs bortezomib, lenalidomide, and dexamethasone. The eligibility criteria for participants include being diagnosed with multiple myeloma, not having received prior systemic therapy for the treatment of multiple myeloma, having a Karnofsky performance status of greater than or equal to 60, and being 18 years or older. Exclusion criteria include having certain medical conditions or prior malignancies, being pregnant or breastfeeding, and having a serious medical or psychiatric illness likely to interfere with participation in the study. The trial also includes a list of ICD-10 codes for multiple myeloma and a list of diseases.",
    "The sample is a clinical trial for patients with previously treated multiple myeloma. The trial is in phase 1 and the drugs being tested are lenalidomide and dexamethasone. The eligibility criteria include measurable levels of m-protein in serum or urine, an ECOG performance status of 0-2, and willingness to follow pregnancy precautions. Exclusion criteria include recent myocardial infarction or history of deep vein thrombosis or pulmonary embolism, active infectious diseases, uncontrolled diabetes or hypertension, mental illness, and pregnancy or lactation. The sample also includes laboratory abnormalities and prior history of malignancies as exclusion criteria.",
    "The sample is a phase 1 clinical trial for various types of leukemia and myelodysplasia. The trial is testing the effectiveness of a drug called abt-348, either alone or in combination with azacitidine, in treating these diseases. The eligibility criteria for the trial include having a confirmed diagnosis of one of the specified diseases, being in a certain Eastern Cooperative Oncology Group status, having adequate hematologic and liver function, and meeting other health criteria. Exclusion criteria include having certain medical conditions or receiving certain types of therapy within a certain timeframe. The trial is approved by an Institutional Review Board and participants must provide informed consent.",
    "The sample is a phase 1 clinical trial for HIV infections using the drug lopinavir/ritonavir. The eligibility criteria for the trial include being HIV infected with a viral load greater than 10,000 copies/ml within 30 days prior to study entry, weighing more than 5.5 lbs at the time of enrollment, agreeing to take 2 nucleoside reverse transcriptase inhibitors (NRTIs) in addition to LPV/RTV, and having consent of a parent or guardian willing to provide signed informed consent and to have the infant followed at a PACTG site. Exclusion criteria include currently taking a nonnucleoside reverse transcriptase inhibitor or protease inhibitor (PI) while on study, previously used LPV/RTV, certain gestational age requirements, any laboratory toxicity of Grade 3 or greater, newly diagnosed acute opportunistic or serious bacterial infection requiring therapy at the time of enrollment, chemotherapy for active cancer, certain medications, and any other clinically significant conditions, other than HIV infection, that would interfere with the study.",
    "The sample is a phase 1 clinical trial for patients with squamous cell carcinoma that has either metastasized or recurred following surgery and/or radiation therapy. The trial is testing the effectiveness of the drugs azacitidine and cisplatin. The eligibility criteria include having a histologically proven SCCHN, having at least one lesion amenable to serial biopsy, being over 18 years old, having an ECOG performance status less than 2, having a life expectancy of greater than 3 months, having normal organ and marrow function, and not planning to receive any other concurrent therapy for SCCHN while on the study. Exclusion criteria include having known brain metastases, having a history of allergic reactions to compounds of similar chemical or biologic composition to the drugs being tested, being pregnant or nursing, having uncontrolled intercurrent illness, being HIV-positive, and having had any prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for five years.",
    "The sample is a phase 1 trial for patients with advanced non-resectable solid tumors. The trial is testing the drug combination of bez235 and mek162. The eligibility criteria include having histologically or cytologically confirmed tumors, measurable or evaluable disease, and not having primary CNS tumor or CNS tumor involvement. Exclusion criteria include having diabetes mellitus or unacceptable ocular/retinal conditions. Other inclusion/exclusion criteria may also apply. The diseases being studied are \"unspecified adult solid tumor, protocol specific\" and \"solid tumor\", and the icd-10 codes associated with these diseases are listed as well.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on neoplasms, which are a type of abnormal growth or tumor. The icd-10 codes associated with the diseases being studied are listed. The drug being tested is called bms-907351 (xl184). The eligibility criteria for the trial are also listed, including requirements for advanced or metastatic solid tumors, a life expectancy of at least 3 months, and a certain level of performance according to the Eastern Cooperative Oncology Group. There are also exclusion criteria, such as uncontrolled intercurrent illness.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on breast neoplasms and neoplasm metastasis, with corresponding ICD-10 codes provided. The drug being tested is everolimus (rad001). The eligibility criteria for the trial include patients who are 18 years or older with a WHO performance status of 1 or less, HER-2 overexpressing metastatic breast cancer cells confirmed by histology, and progressive disease on prior trastuzumab alone or in combination with other anticancer agents, or relapsed any time after completion of this therapy. Patients must also be neurologically stable with adequate bone marrow, liver, and renal function. Exclusion criteria include patients receiving endocrine therapy for breast cancer within 2 weeks prior to study treatment start, patients currently receiving chemotherapy, immunotherapy, or radiotherapy, or who have received these within 4 weeks prior to study treatment start, or patients who have received lapatinib within 2 weeks prior to study treatment start. Patients who have previously received vinorelbine or mTOR inhibitors are also excluded. Other protocol-defined inclusion/exclusion criteria may apply.",
    "The sample is a clinical trial for leukemia and lymphoma patients in phase 1/phase 2. The trial is testing the effectiveness of a drug called laromustine. The eligibility criteria for the trial includes having a diagnosis of certain hematologic malignancies, having an ECOG performance status of 0-2, and meeting certain medical requirements such as having a creatinine level of \u2264 2.0 mg/dL and no uncontrolled infections. Patients must also not be pregnant or nursing, and fertile patients must use effective contraception. The trial requires patients to have had at least 2 weeks since prior cytotoxic therapy, and they cannot be receiving any other concurrent standard or investigational treatment for this cancer.",
    "The sample is a phase 1 clinical trial for patients with Chronic Obstructive Pulmonary Disease (COPD). The trial is testing the effectiveness of the drugs salbutamol and ipratropium in treating COPD. The eligibility criteria include a diagnosis of COPD, stable symptoms and medication for at least 6 weeks prior to screening, and refraining from certain medications for a specified period of time. Other criteria include age, smoking history, and lung function. Exclusion criteria include unstable cardiac disease, other significant respiratory disorders, and sensitivity to the study medications. Patients must also be willing and able to follow the procedures outlined in the protocol.",
    "The sample is a phase 1 clinical trial for cancer patients who have been diagnosed with p-Akt positive cancer by immunohistochemistry. The trial requires patients to have measurable bi-dimensionally disease, an ECOG performance status of 0-2, and to be refractory to or intolerant of established therapy known to provide clinical benefit for their condition. Patients must also have a life expectancy of at least 3 months and be accessible for treatment and follow-up at the participating center. The trial requires four core biopsies of the primary or metastatic tumor sites prior to treatment initiation and approximately 16 days after treatment initiation. Patients must also meet certain eligibility criteria, including having a negative pregnancy test and using an adequate method of contraception if they are women of childbearing potential. The trial has exclusion criteria, including a baseline prolongation of QT/QTc interval >450 milliseconds (ms) and the use of concomitant medications that prolong the QT/QTc interval.",
    "The sample is a clinical trial for the treatment of scleroderma, a disease that affects the skin and connective tissues. The trial is in phase 1/phase 2 and involves the use of the drugs abatacept and placebo. The trial is looking for participants who have been diagnosed with diffuse systemic sclerosis, are 18 years or older, have adequate renal, pulmonary, and cardiovascular function, and are willing to use effective contraception if they are of childbearing potential. Participants cannot have other connective tissue diseases or overlap syndromes, cannot have used certain disease modifying agents or investigational agents within 90 days of the screening visit, cannot have HIV, Hepatitis B or Hepatitis C infection, cannot have used prednisone greater than 10mg daily for 28 days prior to the screening visit, and cannot be breastfeeding or pregnant.",
    "The sample is a record of a clinical trial in phase 1 for the treatment of prostate cancer using the drug mdv3100. The trial has eligibility criteria for participants, including being 18 years or older, having confirmed adenocarcinoma of the prostate, and ongoing androgen deprivation therapy. There are also exclusion criteria, such as having severe concurrent disease or a history of another malignancy within the previous 5 years. The diseases are listed as 'prostate cancer' and the icd-10 codes associated with it.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on the disease of renal impairment, which is identified by a list of ICD-10 codes. The drug being tested is denosumab. The eligibility criteria for the trial include being at least 18 years old with severe chronic kidney disease (CKD) requiring hemodialysis. The trial also has additional inclusion and exclusion criteria, such as appropriate levels of calcium, phosphate, and magnesium, and the absence of other uncontrolled co-morbidities.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on breast neoplasms, with a list of associated ICD-10 codes. The trial involves the use of two drugs, exemestane and sunitinib malate. The eligibility criteria for the trial include being at least 18 years old, having estrogen and/or progesterone receptor positive adenocarcinoma of the breast with evidence of unresectable, locally recurrent, or metastatic disease, being postmenopausal, having an ECOG score of </=1, and having evaluable and measurable disease. The exclusion criteria include having HER2 positive disease not previously treated with herceptin, having received any prior anti-angiogenic therapy, endocrine or cytotoxic anti-cancer therapy in the metastatic disease setting, and having received radiation therapy within 2 weeks of first study treatment.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on the disease ulcerative colitis, with a list of associated ICD-10 codes provided. The trial involves two drugs, avx 470 and placebo. The eligibility criteria for the trial are listed, including age range, specific diagnostic criteria, and exclusion criteria such as allergies, infections, and prior treatments. The inclusion criteria require a total Mayo score between 5-12, with endoscopic subscore of the Mayo score \u2265 2 and > 15 cm of involvement beyond the anal verge. The exclusion criteria include a positive pregnancy test, diagnosis of Crohn's disease, microscopic colitis or indeterminate colitis, and presence of ileostomy or colostomy, among others.",
    "The sample is a clinical trial for a drug called topotecan hydrochloride. The trial is in phase 1 and is testing the drug's effectiveness in treating three types of cancer: fallopian tube cancer, ovarian cancer, and peritoneal cavity cancer. The trial is looking for patients who have already received at least one course of chemotherapy and have measurable or evaluable disease or disease assessable by CA 125. The trial has specific eligibility criteria, including a Karnofsky performance status of 10-50%, certain blood counts, and normal levels of certain enzymes and bilirubin. Patients must also have a life expectancy of at least 12 weeks and cannot be pregnant or nursing. The trial has exclusion criteria, including having had another neoplasm within the past 5 years, septicemia, severe infection, or acute hepatitis, and severe gastrointestinal bleeding.",
    "The sample is a phase 1 clinical trial for advanced cancer patients. The trial involves the use of a combination of drugs called zio-201-t and doxorubicin. The eligibility criteria for the trial include being at least 18 years old, having histological or cytological documentation of cancer, having measurable disease, having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2, being ifosfamide and doxorubicin na\u00efve, having a life expectancy of at least 12 weeks, and having adequate bone marrow, liver, and renal function. Exclusion criteria include having clinically evident congestive heart failure, serious myocardial dysfunction, history of HIV infection, and substance abuse or medical, psychological, or social conditions that may interfere with the subject's participation in the study or evaluation of the study results. Written, informed consent must be obtained from potential subjects prior to the conduct of any study-specific procedures. Male and female subjects must agree to use adequate birth control measures/barrier control during the course of the trial. Women of childbearing potential must have a pregnancy test performed within 7 days of the start of treatment.",
    "The sample is a clinical trial for patients with relapsed multiple myeloma that has progressed following therapies that included bortezomib and an IMiD (thalidomide or lenalidomide) either alone or in any combination. The trial is for phase 1/phase 2 and the drug being tested is cep-18770. The eligibility criteria include having measurable disease, a life expectancy of more than 3 months, an ECOG performance status of 0, 1, or 2, adequate hepatic organ function, and meeting specific ranges for ANC, hemoglobin level, and platelet count. Patients must also have been independent of granulocyte-colony stimulating factor (G-CSF) or granulocyte macrophage-colony stimulating factor (GM-CSF) support for more than 1 week and independent of platelet transfusion for more than 1 week. Patients must have received, or may have received, an allogeneic and/or autologous transplant. There are also exclusion criteria, such as having nonmeasurable multiple myeloma, having received glucocorticoid therapy within the last 2 weeks prior to the first dose of study drug, and having plasma cell leukemia.",
    "The sample is a phase 1 clinical trial for obesity. The eligibility criteria include being a healthy adult between the ages of 20 and 55 with a BMI between 30.0 and 40.0 kg/m2, having been obese since the age of 18 or above, and having demonstrated previous sustained weight loss. Female subjects must be pre-menopausal and not pregnant or breastfeeding, and must comply with certain contraception requirements. Exclusion criteria include having certain medical conditions or diseases, such as cardiovascular disease or malignancy, and having a history of alcohol or substance abuse. The trial involves the drug sibutramine and requires adherence to protocol-stated restrictions.",
    "The sample is a clinical trial for patients with castrate-resistant prostate cancer. The trial is in phase 1/phase 2 and involves the use of three drugs: bez235, prednisone, and abiraterone acetate. The eligibility criteria include having confirmed adenocarcinoma of the prostate, radiographic evidence of disease, castrate levels of testosterone, and progressive disease. Patients must also have an Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2 and adequate bone marrow and organ function. Exclusion criteria include previous treatment with PI3K and/or mTOR inhibitors, active uncontrolled or symptomatic CNS metastases, and a concurrent malignancy or history of malignancy in the last 3 years. Patients must also not have active cardiac disease or a history of cardiac dysfunction, and must not have a history of active major depressive episodes, bipolar disorder, or other psychiatric disorders.",
    "The sample is a clinical trial for pancreatic cancer patients in phase 1/phase 2. The trial involves the use of two drugs, hydroxychloroquine and gemcitabine, and has eligibility criteria that include biopsy-proven adenocarcinoma of the pancreas, a Karnofsky performance status of 70 or greater, and normal renal, hepatic, and hematologic function. Exclusion criteria include prior chemotherapy or radiotherapy for pancreatic cancer, evidence of metastasis to distant organs, and concurrent malignancies with evidence of active or measurable disease. The trial also requires participants to use adequate contraception and excludes patients with immune deficiency or porphyria.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on diabetes mellitus type 2 and involves two drugs, placebo and ly2409021. The eligibility criteria for participants include having a hemoglobin A1c value of less than or equal to 10%, acceptable blood and urine laboratory test results, and being either healthy or having type 2 diabetes mellitus but not taking medication for it. Exclusion criteria include having a history of significant heart, lung, liver, kidney, stomach or brain disease, or any medical problems that may cause an increased risk during the study. Participants must also not have hypertension requiring more than single-agent therapy, or blood pressure greater than 140/90 millimeters of mercury (mmHg) on monotherapy. Additionally, participants must not be allergic to LY2409021 or similar drugs, have a regular alcohol intake greater than 21 units/week (male), or 14 units/week (female), or intend to use other over-the-counter or prescribed medicines during 7 or 14 days respectively before the study, or during the study. Finally, participants must not have a significant blood disorder and/or donated blood (450 ml or more) in the last 3 months.",
    "The sample is a phase 1 clinical trial for patients with pancreatic adenocarcinoma in stage IV (metastatic). The trial is testing the effectiveness of nab-paclitaxel, gemcitabine, and capecitabine as a systemic therapy. The eligibility criteria include having a confirmed diagnosis of pancreatic adenocarcinoma, being at least 18 years old, having an ECOG performance score of 0-1, and having adequate bone marrow and renal function. Patients must also have RECIST-defined measurable disease or an elevated serum CA19-9 at baseline. Exclusion criteria include prior systemic or investigational therapy for metastatic pancreatic cancer, inability to comply with study procedures, and presence of central nervous system or brain metastases.",
    "The sample is a clinical trial for advanced breast cancer patients who have not responded to available therapies. The trial is in phase 1/phase 2 and involves the drugs hki-272 and trastuzumab. The eligibility criteria include having HER2 positive breast cancer, at least one measurable target lesion, adequate performance status, and adequate cardiac, kidney, and liver function. Exclusion criteria include having extensive visceral disease, active central nervous system metastases, or significant cardiac disease or dysfunction. The trial also requires subjects to use acceptable methods of birth control and not have any other cancer within 5 years, except for certain types.",
    "The sample is a phase 1 clinical trial for a vaccine targeting infections caused by papillomavirus. The trial is open to female subjects between the ages of 9 and 25 who are healthy and meet certain eligibility criteria. The trial involves the administration of a vaccine and a placebo, and subjects must not have received any investigational or non-registered products within 30 days prior to the first dose of the study vaccine. Exclusion criteria include chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose, concurrent participation in another clinical study, and pregnancy or breastfeeding. The trial also has a list of other exclusion criteria based on medical history and physical examination.",
    "The sample is a clinical trial for a drug called PB1023 or placebo for the treatment of type 2 diabetes. The trial is a combination of phase 1 and phase 2. The trial is looking for males or post-menopausal or surgically sterile females between the ages of 18-75 who have been diagnosed with type 2 diabetes for at least 6 months and have stable glucose levels while taking one or two oral antihyperglycemic agents. The trial also requires participants to have a fasting plasma glucose level between 115 mg/dL and 269 mg/dL, a fasting C-peptide level of at least 0.8 ng/mL, and a BMI of 40 kg/m2 or less. The trial has exclusion criteria, including not currently taking a non-oral antihyperglycemic agent, having a known allergy to an approved or investigational GLP-1 receptor analog/agonist, and having a personal or family history of medullary thyroid tumors or Multiple Endocrine Neoplasia Syndrome Type 2. The trial also has other exclusion criteria based on medical or psychiatric conditions that could increase the risk for the subject.",
    "The sample is a clinical trial for ulcerative colitis, with a combination of phase 1 and phase 2. The trial involves testing the effectiveness of two drugs, placebo and he3286, on patients with mild-to-moderate ulcerative colitis. The eligibility criteria include being between 18-65 years old, having a Mayo Scoring System score of 4-9, and having a stable dose of certain medications for at least a certain period of time. Exclusion criteria include having certain medical conditions or taking certain medications. Patients must provide written consent and be able to follow instructions.",
    "The sample is a record from a clinical trial table and includes information about the trial's phase, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1 and is studying non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The ICD-10 codes associated with these diseases are also listed. The drugs being tested are polatuzumab vedotin and rituximab. The eligibility criteria for participants include having a life expectancy of at least 12 weeks, a history of one of the specified hematologic malignancies, and having at least one bi-dimensionally measurable lesion. There are also exclusion criteria listed, such as prior use of certain treatments or completion of a stem cell transplant within a certain timeframe.",
    "The sample is a phase 1 clinical trial for chronic hepatitis C infection. The trial includes adults between the ages of 18 and 70 who have documented chronic HCV infection and a positive HCV immunoglobulin G Antibody. The trial also requires participants to have HCV genotype 1, confirmed by a central laboratory test before Visit 2. Inclusion criteria also include liver biopsy results consistent with HCV infection showing minimal to mild liver fibrosis and without cirrhosis for non-cirrhotic cohorts, and previous liver biopsy or Fibroscan consistent with liver cirrhosis for cirrhotic cohorts. Exclusion criteria include patients who have been treated with at least one dose of any HCV-polymerase inhibitor for acute or chronic hepatitis C infection, any other or additional plausible cause for chronic liver disease, and decompensated liver disease within the past 12 months. The trial also excludes patients with ongoing or historical photosensitivity or recurrent rash, and those with AFP value > 100 ng/ml.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for patients. In this particular sample, the trial is in phase 1/phase 2 and is studying pancreatic cancer. The drugs being used are azd0530 and gemcitabine hydrochloride. The eligibility criteria include having a confirmed diagnosis of pancreatic adenocarcinoma, having unresectable, locally advanced, or metastatic disease, and having no known brain metastases. Patients must also meet certain performance, hematopoietic, hepatic, renal, cardiovascular, pulmonary, gastrointestinal, and immunologic criteria. Additionally, patients must not be pregnant or nursing, must have negative pregnancy test results, and must use effective contraception if fertile. Prior concurrent therapy is also listed, including restrictions on certain drugs before, during, and after the study treatment.",
    "The sample is a phase 1 clinical trial for patients with neoplastic meningitis secondary to leukemia, lymphoma, or solid tumors. The trial is testing the effectiveness of topotecan hydrochloride as a treatment option. The eligibility criteria include a diagnosis of neoplastic meningitis, refractory to conventional therapy, and no evidence of obstructive hydrocephalus or compartmentalization of CSF flow. Patients must also have a negative bone marrow aspiration within the past 2 weeks and no impending spinal cord compression or other CNS involvement. The trial is open to patients aged 3 to 21 with a performance status of Lansky 60-100% (\u2264 16 years of age) or Karnofsky 60-100% (> 16 years of age). Patients must not be pregnant or nursing, and fertile patients must use effective contraception. The trial also has specific requirements for hematopoietic, hepatic, and renal function, as well as other medical conditions. Prior concurrent therapy is allowed, but there are specific requirements for recovery time and types of chemotherapy. The trial does not allow concurrent CNS radiotherapy or other concurrent intra-CSF or systemic therapy for leptomeningeal disease.",
    "The sample is a clinical trial for a drug called imatinib, which is being tested on healthy male non-smoking subjects aged 18-55 years with a history of seasonal allergic rhinitis caused by Timothy grass pollen allergy. The trial is in phase 1/phase 2 and the subjects must meet certain inclusion criteria, such as having a positive skin prick test to Timothy grass pollen and demonstrating symptomatic worsening within one hour after nasal allergen challenge. The trial also has exclusion criteria, such as having respiratory disease other than mild stable asthma, recent nasal surgery, or use of medication that would affect the response to the allergen challenge. The trial will also monitor adverse events and non-tolerable symptoms resulting from the allergen challenge.",
    "The sample is a clinical trial for the treatment of multiple myeloma, a type of cancer. The trial is in phase 1/phase 2 and involves the use of two drugs, carfilzomib and lenalidomide, along with dexamethasone. The eligibility criteria for the trial include having newly diagnosed, previously untreated multiple myeloma, measurable disease, and a life expectancy of more than 3 months. Participants must also have adequate liver and kidney function, and meet other health requirements. Exclusion criteria include having certain types of cancer, recent surgery, or significant medical conditions that may interfere with the trial. Participants must also agree to adhere to all study requirements and undergo regular laboratory monitoring.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on the treatment of prostatic neoplasms, which are identified by a list of icd-10 codes. The drugs being tested in the trial are docetaxel, prednisone, and su011248. The eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\" and include requirements such as confirmed adenocarcinoma of the prostate, progressive hormone-refractory prostate cancer, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. The exclusion criteria include prior thalidomide or chemotherapy treatment, uncontrolled pain, and history of cardiac dysfunction or CNS involvement.",
    "The sample is a phase 1 clinical trial for patients with squamous cell carcinoma of the head and neck that is not curable by standard measures. The trial is testing the effectiveness of two drugs, fenretinide and sch66336. The eligibility criteria include having a Karnofsky performance status of at least 70%, adequate bone marrow, liver, and renal function, and having received no more than 2 prior chemotherapeutic regimens for recurrent or metastatic disease. Exclusion criteria include having received 3 or more prior chemotherapeutic regimens, having signs or symptoms of acute infection, and having a history of uncontrolled heart disease. Pregnant women and women who are currently breastfeeding are not eligible to participate. The trial requires patients to swallow the drugs daily and prohibits the use of high-dose vitamin A derivatives and antioxidants.",
    "The sample is a phase 1 clinical trial for acute pain. The trial involves testing various drugs, including trv130 and morphine, as well as a placebo. The trial is open to healthy adult males between the ages of 18 and 50 with a BMI between 19 and 32 kg/m2. Participants must also have acceptable results from a cold pain test during screening. Exclusion criteria include significant medical illness or physical exam findings, certain dermatological conditions or skin trauma, certain ophthalmic conditions, recent tobacco or nicotine use, and recent drug or alcohol abuse. Participants must provide informed consent to participate in the trial.",
    "The sample is a phase 1 clinical trial for the treatment of diabetic macular edema. The trial involves the use of two drugs, efalizumab and ranibizumab. The eligibility criteria include being 18 years or older, having a diagnosis of diabetes mellitus, having retinal thickening involving the center of the fovea, and having a best corrected visual acuity score in the study eye of 20/40 to 20/320. Exclusion criteria include having proliferative diabetic retinopathy, vitreomacular traction or epiretinal membrane in the study eye, and having uncontrolled diabetes mellitus. Participants must also demonstrate understanding of and ability to perform weekly self sub-cutaneous injections.",
    "The sample is a clinical trial for patients with myelodysplastic syndromes (MDS) or leukemia. The trial is in phase 1/phase 2 and involves the drugs azacitidine and lenalidomide. The eligibility criteria include a diagnosis of MDS meeting certain criteria, a life expectancy of at least 3 months, and an ECOG performance status of 0-2. Patients must not be pregnant or nursing, and must use effective contraception during the study. They must also meet certain medical criteria, such as having a platelet count of at least 50,000/mm^3 and no serious medical conditions that would preclude study participation. Prior concurrent therapy is also restricted.",
    "The sample is a clinical trial for patients with newly diagnosed acute myeloid leukemia who are eligible for intensive induction chemotherapy. The trial is in phase 1/phase 2 and involves the use of clofarabine, cytarabine, and idarubicin. The eligibility criteria include being at least 18 years old, having certain genetic characteristics, having adequate renal and hepatic functions, and being capable of understanding the potential risks and benefits of the study. Female patients must meet certain criteria related to menopause or contraception, and male patients must meet certain criteria related to contraception. Exclusion criteria include having certain concurrent diseases or illnesses, being pregnant or lactating, and having a known hypersensitivity to any of the investigational medical products.",
    "The sample is a clinical trial for left ventricular diastolic dysfunction, with a combination of phase 1 and phase 2. The trial involves the drugs BNP (nesiritide) and placebo. The eligibility criteria for the trial include having an ejection fraction of greater than 50% with moderate or severe diastolic dysfunction as assessed by Doppler echocardiography, and no signs or symptoms of congestive heart failure or hospitalization for heart failure. Exclusion criteria include recent myocardial infarction or unstable angina, significant valvular stenosis or cardiomyopathy, sustained ventricular tachycardia or fibrillation, and abnormal levels of various blood markers.",
    "The sample is a clinical trial for HIV infections in phase 1/phase 2. The trial is testing the effectiveness of lopinavir/ritonavir and saquinavir drugs on patients with HIV who have specific protease mutations and have been on continuous therapy with a protease inhibitor for at least 6 months. The trial has inclusion and exclusion criteria, including having a certain viral load, no change in antiretroviral therapy since genotypic resistance testing, and not having any significant diseases other than HIV that may interfere with the study. Patients must also have a telephone or other reliable method of communication with study staff and be willing to swallow study medications. Exclusion criteria include certain abnormal laboratory values, acute opportunistic or serious bacterial infections, chemotherapy for active cancer, and pregnancy or breastfeeding.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating diseases such as graft versus host disease, leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases. The trial involves the use of drugs such as busulfan, cyclophosphamide, methotrexate, and tacrolimus. The eligibility criteria for the trial include confirmed diagnosis of certain diseases, no suitable HLA genotypically identical sibling or fully matched HLA-A, -B, -C, and -DRB1 unrelated donor available, and no active CNS involvement with disease. The patient characteristics include a Karnofsky performance status of 50-100%, no symptomatic coronary artery disease or symptomatic congestive heart failure, no hepatic disease with transaminases or bilirubin > 2 times upper limit of normal except for isolated hyperbilirubinemia attributed to Gilbert's syndrome, no severe hypoxemia with room air P_AO_2 < 70, supplemental oxygen-dependence, or DLCO < 60% predicted, no impaired renal function with creatinine > 2 times upper limit of normal or creatinine clearance < 50% normal, not HIV seropositive, not pregnant or breast-feeding, and fertile patients must use effective contraception. The prior concurrent therapy includes no prior allogeneic or autologous bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation using a high-dose total-body irradiation regimen.",
    "The sample is a record of a clinical trial for a drug called tki258, which is being tested on patients with locally advanced or metastatic melanoma that is refractory to standard therapy or for which no curative standard therapy exists. The trial is in phase 1/phase 2 and the record includes a list of diseases and their corresponding icd-10 codes. The eligibility criteria for the trial are also listed, including requirements for confirmed diagnosis, measurable disease, age, laboratory requirements, and performance status. The record also includes exclusion criteria, such as concurrent therapy with other investigational agents, uncontrolled central nervous system metastases, and impaired cardiac function. Other medical or psychiatric conditions that may increase the risk associated with study participation or study-drug administration are also listed as exclusion criteria.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying non-hodgkin's lymphoma, chronic lymphocytic leukemia, and multiple myeloma. The icd-10 codes associated with these diseases are also listed. The drug being tested is gs-9219. The eligibility criteria for participants include having relapsed or refractory CLL, NHL, or MM, having an ECOG Performance Status of 0, 1, or 2, and having adequate organ function. There are also exclusion criteria listed, such as having AIDS-related lymphoma, recent anticancer therapy, or uncontrolled concurrent illness.",
    "The sample is a record of a clinical trial with a phase 1 designation, focused on the treatment of multiple myeloma. The trial involves the use of several drugs, including dasatinib and lenalidomide, in various dosages and combinations. The eligibility criteria for participants include a confirmed diagnosis of multiple myeloma, evidence of relapsed or refractory disease, and at least one prior therapy for the condition. Exclusion criteria include certain medical conditions, medication intolerances, and a history of severe reactions to prior thalidomide treatment. The sample also includes a list of disease names and corresponding ICD-10 codes.",
    "The sample is a phase 1 clinical trial for the treatment of prostate cancer using the drugs ABT-888 and temozolomide. The trial is for patients with metastatic prostate cancer that has progressed despite previous treatments. The eligibility criteria include having a confirmed diagnosis of prostate cancer, having a certain level of PSA progression, and meeting certain organ and bone marrow function requirements. Patients must also agree to use contraception during the trial. The trial has exclusion criteria, such as having uncontrolled central nervous system metastases or a history of seizure disorder.",
    "The sample is a phase 1 clinical trial for patients with advanced non-hematologic malignancies, such as breast, lung, colon, pancreatic, prostate, head and neck, or sarcoma. The trial includes patients who have failed or become intolerant to prior standard therapy and are no longer likely to respond to such therapy. The trial also includes patients diagnosed with mesothelioma who may be enrolled with no prior therapy requirements since cisplatin and pemetrexed in combination is the current standard of care 1st line therapy. The trial involves the use of drugs such as cisplatin, pemetrexed disodium, and sorafenib. The eligibility criteria include measurable or non-measurable disease, Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 2, and adequate organ function. The exclusion criteria include squamous cell of the lung, pregnant or breast-feeding women, cardiac disease, symptomatic or active brain metastases, and other medical conditions that impair the patient's ability to participate in the trial.",
    "The sample is a phase 1 clinical trial for patients with squamous cell carcinoma or poorly differentiated carcinoma of the head and neck. The trial is testing the effectiveness of a combination of drugs including bortezomib, cetuximab, and cisplatin. The eligibility criteria include having no prior treatment with bortezomib or EGFR inhibitor therapy, and having no prior head and neck radiotherapy. Patients must also have normal organ and marrow function, be over 18 years old, and have an ECOG performance status of 0-1. The trial has exclusion criteria such as having previously untreated nasopharyngeal cancer, having received chemotherapy within 4 weeks prior to the trial, and having uncontrolled intercurrent illness. Pregnant women and HIV-positive patients are also excluded from the trial.",
    "The sample is a clinical trial for patients with non-Hodgkin Lymphoma or chronic lymphocytic leukemia. The trial is in phase 1/phase 2 and involves the use of cyclophosphamide and fludarabine phosphate drugs. The eligibility criteria include having measurable disease, acceptable organ function, and being off prednisone or other immunosuppressive medications for at least 3 days prior to Day 0. The trial also requires the availability of a related HLA-haploidentical natural killer cell adult donor. The donor must be in good health and able to give informed consent. The trial has exclusion criteria such as pregnancy, lactation, active serious infection, and allergy to rituximab or IL-2. The trial also has donor selection criteria, including being HIV-1, HIV-2 negative, and Hepatitis B and C negative.",
    "The sample is a phase 1 clinical trial for the treatment of glioblastoma, gliosarcoma, and anaplastic astrocytoma. The trial involves the use of oral topotecan and temodar drugs. The eligibility criteria include having a histological diagnosis of the specified tumors, being at least 18 years old, having a Karnofsky Performance Status of at least 60%, and meeting certain laboratory parameters. Patients must also have signed informed consent and agree to practice effective birth control measures while on the study. Exclusion criteria include pregnancy or breastfeeding, active infection requiring intravenous antibiotics, and prior failure with either topotecan or temozolomide.",
    "The sample is a clinical trial for sickle cell disease, with a phase 1/phase 2 designation. The trial is testing the effectiveness of sodium nitrite injection, usp as a treatment for acute pain associated with vaso-occlusive crisis in sickle cell disease patients. The eligibility criteria include a diagnosis of sickle cell disease, sudden onset of acute pain requiring hospitalization and parenteral analgesics, and being between the ages of 8 and 23. Exclusion criteria include other complications of sickle cell disease, pregnancy or breastfeeding, and significant acute or chronic concomitant diseases. The trial will follow subjects for at least 30 days for evaluation.",
    "The sample is a phase 1 clinical trial for patients with a histologically proven solid tumor malignancy that is refractory to standard therapy and for which no curative therapy is available. The trial is testing the efficacy of a drug called hsp90 inhibitor auy922. The eligibility criteria include having at least one measurable lesion, an ECOG Performance Status of =< 1, a life expectancy of >= 12 weeks, and meeting certain laboratory values. Male participants with partners who are of childbearing potential must agree to use double barrier method of birth control or have a history of a vasectomy. Exclusion criteria include having central nervous system metastasis, prior treatment with any heat shock protein (HSP)90 or histone deacetylase (HDAC) inhibitor compounds, and impaired cardiac function. Patients must be able to understand and voluntarily sign written informed consent.",
    "The sample is a phase 1 clinical trial for patients with various hematologic malignancies that have failed standard therapy or for which no standard therapy exists. The trial is testing the effectiveness of a drug called compound 506u78. The eligibility criteria include age 18 and over, a performance status of CTC 0-2, and no history of CNS disease. Patients must also meet certain hematopoietic, hepatic, renal, neurologic, and other criteria. Prior concurrent therapy is restricted, including a minimum of 4 weeks since prior chemotherapy and at least 72 hours since prior hydroxyurea. The sample also includes a list of diseases, icd-10 codes, and eligibility criteria.",
    "The sample is a clinical trial with a phase 1/phase 2 designation, focused on treating malignant glioma (anaplastic astrocytoma or glioblastoma multiforme) that has progressed or recurred following radiation therapy and/or chemotherapy. The trial involves the use of the drugs ixabepilone and anticonvulsant. The eligibility criteria include having measurable progressive or recurrent malignant glioma by MRI or CT imaging, having recovered from severe toxicity of prior therapy, having a Karnofsky performance status of at least 60%, and meeting certain blood count and liver function requirements. Patients must also have no concurrent malignancy except for certain types of skin and breast cancer, and must be maintained on a stable corticosteroid regimen. Exclusion criteria include serious concurrent infection or medical illness, pregnancy or breastfeeding, and receiving concurrent investigational agents or certain medications that are known to be moderate to significant inhibitors of CYP3A4.",
    "The sample is a phase 1 clinical trial for patients with peritoneal neoplasms. The trial involves the use of nanoparticulate paclitaxel as a treatment option for patients who have failed all potentially curative therapy and have no other systemic treatment options available for extra-peritoneal disease. Patients with ovarian cancer that are platinum sensitive must have failed primary and at least one salvage regimen. Patients may undergo surgical debulking prior to entry into the trial. The eligibility criteria include age, diagnosis, previous treatment, performance status, blood counts, renal and hepatic function, and absence of plans for concomitant radiation therapy, hormonal therapy, or other chemotherapy. The exclusion criteria include active inflammatory bowel disease or chronic diarrhea, uncontrolled hypertension, unstable angina, symptomatic congestive heart failure, myocardial infarction within previous 6 months or serious uncontrolled cardiac arrhythmia, active infection requiring systemic therapy, pregnancy or nursing, Grade 2 or greater sensory neuropathy, taking concomitant medications demonstrated to inhibit or induce CYP3A4 or CYP2C8, and pre-existing conditions that prohibit the use of intravenous dexamethasone at the recommended dose.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on stomach neoplasms, which are tumors in the stomach. The trial includes a list of icd-10 codes associated with the disease. The trial will test the effectiveness of three drugs: cisplatin, s-1, and sunitinib. The eligibility criteria for the trial include a confirmed diagnosis of gastric cancer, being a chemonaive patient, and having adequate organ function. The exclusion criteria include patients who have previously failed chemotherapy and those who have contraindications for the drugs S-1 and Cisplatin.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being used, and eligibility criteria for participants. In this particular record, the trial is in phase 1 and is studying cancer. The icd-10 codes associated with the cancer are listed, as well as the drugs being used in the trial. The eligibility criteria for participants are also listed, including age, performance status, life expectancy, and various health measures such as liver and bone marrow function. The record also includes exclusion criteria, such as recent use of certain therapies, active brain metastases, and significant cardiovascular impairment.",
    "The sample is a phase 1 clinical trial for ovarian, peritoneal, and fallopian tube cancer patients. The trial involves the use of dasatinib, paclitaxel, and carboplatin drugs. The eligibility criteria include having measurable disease, being over 18 years old, having a GOG performance status of 0, 1, or 2, and having adequate bone marrow, renal, hepatic, and neurologic function. Patients must not have received any chemo, radiotherapy, biologic, hormonal, or investigational drug therapy within 28 days prior to study entry. They must also have had up to 3 prior cytotoxic chemo regimens, including prior treatment with carboplatin and paclitaxel. Patients must be capable of providing written informed consent and have a negative serum pregnancy test if of childbearing potential. They must also have tissue block from their tumor available for evaluation for microarray and immunoblot analyses. The exclusion criteria include having epithelial ovarian tumors of low malignant potential, a history of other invasive malignancies within the last 5 years, certain cardiac conditions, significant bleeding disorder unrelated to cancer, and certain concomitant medications.",
    "The sample is a phase 1 clinical trial for patients with recurrent ovarian carcinoma. The trial includes patients who have undergone optimal cytoreductive surgery for recurrence and have received only one prior chemotherapeutic regimen as their prior therapy. Eligible patients must have received platinum-based intravenous chemotherapy as their only prior therapy. The trial aims to evaluate the safety and efficacy of the drug cisplatin. The eligibility criteria include various factors such as the type of cancer, the stage of the disease, the absence of pleural effusions, and adequate renal function. Patients must also have appropriate hematologic parameters and sign informed consent approved by the University of Utah and institutional review board (IRB). The exclusion criteria include patients with other invasive malignancies, those who had suboptimal cytoreductive surgery at the time of first diagnosis, and those with peripheral neuropathy greater than grade 2 at baseline.",
    "The sample is a phase 1 clinical trial for patients with metastatic or unresectable solid tumors or advanced non-small cell lung cancer. The trial involves two phases: a dose escalation phase and a cohort expansion phase. The eligibility criteria include having measurable or non-measurable lesions, an ECOG performance status \u2264 2, adequate organ and marrow function, and a fasting plasma glucose \u2264 120 mg/dL at screening. The trial also requires at least 10 unstained slides of tumor tissue or a fresh tumor biopsy for central laboratory analysis. Exclusion criteria include having previously been treated with a selective PI3K inhibitor, receiving certain types of therapy within a certain timeframe, uncontrolled diabetes mellitus, and other medical conditions that would limit compliance with study requirements. The trial involves the use of XL147 (sar245408) and erlotinib as drugs.",
    "The sample is a record from a clinical trial table. It is a phase 1 trial for cancer patients who are not eligible for curative treatment. The trial involves the drug sorafenib and requires patients to have a measurable lesion in the thorax, abdomen or pelvis, normal organ and bone marrow function, and the ability to receive protocol prescribed radiation. The record also includes a list of inclusion and exclusion criteria for the trial. The diseases are listed as 'cancer' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 1 clinical trial for the treatment of obesity. The trial is looking for obese but otherwise healthy females who are not of childbearing potential and have a BMI between 30 and 45 kg/m2. The trial is testing the drugs zgn-440 and zgn-440 sterile diluent. The eligibility criteria include stable body weight for the past 2 months and exclusion criteria include a history of eating disorder, type 1 or type 2 diabetes mellitus, and current smoking.",
    "The sample is a phase 1 clinical trial for patients with recurrent glioma, high-grade meningioma, or brain metastasis. The trial involves the drug panobinostat and has eligibility criteria including age over 18, a certain performance status, and specific laboratory criteria. Patients must also have a negative pregnancy test and use contraception during the study. Exclusion criteria include prior use of certain drugs, impaired cardiac function, uncontrolled hypertension, and unresolved diarrhea. The trial has specific criteria for each arm, including prior radiation therapy and tumor size.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on non-small-cell lung carcinoma, which is listed as the disease being studied. The icd-10 codes associated with the disease are also listed. The drug being tested in the trial is celecoxib. The eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". In order to be included in the trial, subjects must have pathologically confirmed and surgically resectable non-small cell lung cancer and must be ineligible for or refuse neoadjuvant therapy. Subjects who have hypersensitivity to celecoxib or NSAIDs, previous history of GI bleeding or ulceration, chronic or concurrent use of steroids, or renal insufficiency are excluded from the trial.",
    "The sample is a clinical trial for the treatment of follicular lymphoma, a type of cancer. The trial is in phase 1/phase 2 and involves the use of three drugs: rituximab, bortezomib, and ibritumomab tiuxetan. The eligibility criteria for the trial include having histologically confirmed follicular lymphoma, being CD20+ at the time of diagnosis or subsequently, and having gone more than 4 weeks without prior rituximab treatment. Exclusion criteria include having AIDS-related lymphoma, a history or evidence of CNS involvement, being pregnant or nursing, and having serious medical or psychiatric illness that would preclude study participation.",
    "The sample is a phase 1 clinical trial for patients with non-Hodgkin's lymphoma who have achieved partial or complete response to salvage treatment for relapse or refractory disease within the past 10 weeks. The trial involves the use of drugs such as ibritumomab tiuxetan, rituximab, melphalan, and vinorelbine tartrate/g-csf, and requires patients to meet certain eligibility criteria, including having a WHO performance status of 0-1, bone marrow infiltration less than 25%, and no evidence of CNS involvement. Patients must also not have any serious underlying medical conditions that would preclude study participation and must not have had any other malignancy within the past 5 years except nonmelanoma skin cancer or adequately treated in situ cervical cancer. Prior concurrent therapy is also taken into consideration.",
    "The sample is a clinical trial for phase 1, which involves patients with metastatic breast cancer. The trial includes the use of two drugs, vinorelbine oral and capecitabine. The eligibility criteria for the trial include confirmation of metastatic breast cancer, age between 18-75 years, measurable or evaluable disease, performance status of 0-2, and adequate liver, renal, and bone marrow function. Patients must also have a life expectancy of at least 12 weeks, be able to take oral medication, and provide written informed consent. Exclusion criteria include active infection, brain metastases, significant cardiac disease, malnutrition, psychiatric illness, or pregnancy/lactation.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on studying HIV infections. The associated ICD-10 code is \"Z21\". The trial is using a combination of drugs including gpo-vir z30 tablet, lamivudine, nevirapine, and zidovudine. The eligibility criteria for participants include being between 6 and 30 kilograms, being HIV infected, receiving a specific HAART regimen, agreeing to use two forms of contraception, being able to swallow study drugs, and being willing to be hospitalized for a 12-hour intensive PK study. There are also exclusion criteria listed, such as certain abnormal laboratory values, a history of immunologic failure, and being pregnant.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying metastatic bladder cancer. The icd-10 codes associated with the disease are listed, as well as the drugs being used in the trial. The eligibility criteria for participants are also listed, including requirements for age, prior treatment, and exclusion criteria such as brain metastases and fluid collection in the lungs or abdomen.",
    "The sample is a phase 1 clinical trial for patients with metastatic neoplasms, specifically adenocarcinoma of the breast, ovary, or prostate, any NSCLC or bladder cancer. The trial involves the drugs ogx-427 and docetaxel. The eligibility criteria include being at least 18 years old, having failed potentially curative therapies or refused standard therapy, and having a Karnofsky score of at least 60%. Patients must also meet various laboratory requirements and be willing to use effective contraception during and for 3 months following treatment if of childbearing potential. Exclusion criteria include having more than three cytotoxic chemotherapy regimens, current treatment with certain anticancer agents, and serious medical conditions that would preclude protocol therapy.",
    "The sample is a phase 1 clinical trial for non-small cell lung cancer. The trial involves the use of drugs such as ipilimumab, paclitaxel, and carboplatin. The eligibility criteria include having a histologically or cytologically documented NSCLC, no prior chemotherapy or targeted-therapy-containing regimens for NSCLC, a life expectancy of at least 3 months, and an Eastern Cooperative Oncology Group performance score of 0-1. The trial also has exclusion criteria such as having symptomatic CNS metastasis, a history of severe autoimmune or immune-mediated symptomatic disease, and uncontrolled intercurrent illness.",
    "The sample is a record of a clinical trial for cervical cancer patients in phase 1. The trial involves the use of cisplatin and erlotinib hydrochloride drugs in combination with standard radiotherapy. The eligibility criteria for the trial include a diagnosis of squamous cell carcinoma of the cervix, stage IB-IVA disease, ECOG performance status 0-2, and the ability to take oral medication. Exclusion criteria include prior chemotherapy or radiotherapy, gastrointestinal surgery that limits absorption, and concurrent use of other antineoplastic or antitumor agents, chemotherapy, investigational agents, radiotherapy, immunotherapy, or anticancer hormonal therapy.",
    "The sample is a phase 1 clinical trial for patients with glioblastoma multiforme, a type of brain cancer. The trial involves the drug temodar (temozolomide) and has eligibility criteria including a confirmed diagnosis of GBM, evidence of tumor recurrence or progression, and a life expectancy of at least 8 weeks. Patients must also have recovered from the toxic effects of prior therapy and have adequate bone marrow, liver, and renal function. Exclusion criteria include a history of other cancers (except non-melanoma skin cancer or carcinoma in-situ of the cervix), active infection, pregnancy, and serious intercurrent medical illness. The trial involves dietary restriction and patients who require resection of their tumor may begin the dietary restriction component of the therapy prior to their surgery.",
    "The sample is a record of a clinical trial in phase 1, focused on neoplasms (a type of cancer). The trial is testing a drug called pf-00299804. The eligibility criteria for the trial include having a malignant solid tumor for which there is no currently approved treatment, as well as adequate bone marrow, liver, cardiac, and kidney function. Exclusion criteria include having cardiac disease, receiving anticancer therapy within 4-6 weeks (depending on the therapy), and being pregnant or breastfeeding.",
    "The sample is a phase 1 clinical trial for patients with Kaposi's sarcoma, a type of cancer that affects the skin, lymph nodes, and oral cavity. The trial is testing the effectiveness of a drug called liposomal daunorubicin citrate. To be eligible for the trial, patients must have at least 5 measurable, non-irradiated cutaneous lesions and 2 accessible lesions for biopsy. They must also be HIV positive and receiving concurrent antiretroviral therapy. Patients must have a life expectancy of at least 3 months and cannot have any other neoplasia requiring cytotoxic therapy. They must not be pregnant or nursing, and fertile patients must use effective contraception during and for 3 months after the study. Patients cannot have had prior anthracycline therapy and must have had at least 4 weeks since any prior antineoplastic treatment for KS. They also cannot have had any other concurrent investigational drugs, cytotoxic chemotherapy, or KS-specific treatment.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, ICD-10 codes associated with those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on studying graft failure. The ICD-10 codes associated with the disease are T86.831 and T86.821. The drugs being used in the trial are fludarabine, campath 1h, and fk506. The eligibility criteria for participants include a diagnosis of engraftment failure, availability of a healthy donor, age between birth and 65, and negative pregnancy test for women of childbearing potential. There are also exclusion criteria, such as uncontrolled intercurrent infection and active CNS disease from hematological disorder.",
    "The sample is a record of a clinical trial with a combination of phase 1 and phase 2. The trial is focused on acute lymphoblastic leukemia, and the table includes a list of icd-10 codes for the disease. The trial involves the use of two drugs, vincristine sulfate liposomes injection and dexamethasone. The eligibility criteria for the trial include having previously treated, relapsed or refractory ALL, having a performance status of \u22643, and having adequate liver and renal function. Patients with a prior history of stem cell transplant are also eligible. The exclusion criteria include having an active serious infection, treatment with any investigational agents or chemotherapy agents in the last 21 days before study entry, and concurrent treatment with other anti-cancer agents other than dexamethasone. Pregnant and/or lactating women, or fertile men or women not willing to use contraception are also excluded.",
    "The sample is a clinical trial for rheumatoid arthritis, in which the participants must meet certain criteria to be eligible for the study. The trial is a combination of phase 1 and phase 2. The table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being used in the trial, and the eligibility criteria for participants. The inclusion criteria include a diagnosis of rheumatoid arthritis, a positive test for rheumatoid factor or anticyclic citrullinated peptide, and active RA with at least four swollen and tender joints. The exclusion criteria include allergies to certain medications, previous exposure to certain therapies, and certain medical conditions that may place the participant at risk during the study. Participants must also be willing to adhere to the study requirements and use acceptable forms of contraception. The sample also includes a list of diseases, icd-10 codes, drugs, and eligibility criteria associated with the trial.",
    "This sample is a clinical trial for a drug called mifepristone, which is being tested on individuals with HIV-1 infection and a CD4 count of 350 cells/mm3 or more. The trial is in phase 1/phase 2 and the eligibility criteria include having a viral load of 2000 copies/ml or more, using acceptable forms of contraception during the study and for 30 days after stopping study medication, and having a body weight of at least 40 kg. There are also exclusion criteria, such as having a history of autoimmune endocrine disease, active hepatitis B or C, or current hormonal contraception or intrauterine use. The sample also includes a list of diseases (hiv infections), their corresponding icd-10 codes (Z21), and the eligibility and exclusion criteria for the trial.",
    "The sample is a phase 1 clinical trial with only healthy participants. The trial is testing the effectiveness of several drugs, including maraviroc and fosamprenavir/ritonavir, either alone or in combination. The eligibility criteria for participants include being between the ages of 21 and 55, having a BMI between 17.5 and 30.5, and weighing at least 45 kg. Exclusion criteria include a history of excessive alcohol or tobacco use, recent treatment with an investigational drug, and a known allergy to sulfonamides.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on the treatment of lymphoma, with a list of associated ICD-10 codes provided. The trial involves the use of two drugs, vorinostat and bexarotene, with the latter serving as a comparator. The eligibility criteria for the trial are also provided, including requirements for age, disease stage, prior treatment history, and Eastern Cooperative Oncology Group (ECOG) status. Exclusion criteria are also listed, including recent investigational treatment, active hepatitis B or C, prior treatment with any HDAC inhibitor, and a history of HIV. Additionally, patients must be disease-free from prior malignancies for greater than 5 years, except for curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on patients with multiple myeloma, a type of cancer. The trial is testing the effectiveness of the drug simvastatine. The eligibility criteria for the trial include patients in need of treatment with stable or progressive disease, age 18 or older, performance status less than 3, and life expectancy greater than 3 months. Exclusion criteria include pregnancy, patients incapable of giving personal consent, renal insufficiency with creatinine clearance below 25 ml/min, alanine aminotransferase levels above 2.5 times the upper reference limit, thyroxine levels below the lower reference limit, known familial muscle disease or previous myopathy, creatinine kinase levels above 10 times the upper reference limit, and medication with drugs known to interact with simvastatine.",
    "The sample is a clinical trial for Parkinson's disease, in which the phase is a combination of phase 1 and phase 2. The trial involves testing the effectiveness of two drugs, levodopa and carbidopa solution for sc administration and placebo, on subjects who experience motor fluctuations associated with LD/CD dosing. The trial has specific eligibility criteria, including a modified Hoehn and Yahr stage of less than 5, stable levodopa/dopa decarboxylase inhibitor therapy, and being age 30 or older. Women must be postmenopausal, surgically sterilized, or using adequate birth control. The trial also has exclusion criteria, such as clinically significant medical or surgical conditions, clinically significant psychiatric illness, and having undergone a neurosurgical intervention for Parkinson's disease.",
    "The sample is a phase 1 clinical trial for patients with leukemia or solid tumors. The trial involves the drug sb939 and has eligibility criteria that include having a histologically verified malignancy, no known curative therapy, and recovered from prior chemotherapy, immunotherapy, or radiotherapy. Patients must also meet certain medical criteria, such as having a certain level of platelets and hemoglobin. The trial has exclusion criteria, such as having a pathologic cardiac arrhythmia requiring active treatment or being pregnant or breastfeeding.",
    "The sample is a phase 1 clinical trial for patients with metastatic colorectal cancer or other gastrointestinal malignancies. The trial is testing the effectiveness of tivozanib (av-951) plus folfox6 chemotherapy. The eligibility criteria include being at least 18 years old, having documented progressive disease, and having no more than 2 prior chemotherapy regimens for metastatic disease. Exclusion criteria include having primary CNS malignancies or clinically active CNS metastases, hematologic malignancies, and significant cardiovascular disease. The trial also requires subjects to use effective contraception and have a signed informed consent.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on heart failure and the associated diseases and conditions. The icd-10 codes associated with the diseases are listed. The trial involves the use of two drugs, clp and spironolactone. The eligibility criteria for the trial are listed, including requirements for heart failure classification, chronic kidney disease, and cardiac ejection fraction. The inclusion and exclusion criteria are also listed, including restrictions on hospitalization, gastrointestinal conditions, and drug or alcohol abuse.",
    "The sample is a phase 1 clinical trial for patients with metastatic cancer. The trial involves the use of two drugs, carboplatin and pazopanib. The eligibility criteria include being 18 years or older, having a confirmed advanced solid tumor type that is FDA approved for treatment with carboplatin, having a life expectancy of at least 12 weeks, having an ECOG performance status of 0-2, and having adequate organ system function. Female participants must meet certain criteria related to their reproductive health. Exclusion criteria include a history of certain medical conditions, recent surgery or trauma, and ongoing toxicity from prior anti-cancer therapy.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on patients with type 2 diabetes mellitus and the icd-10 codes associated with the disease. The drug being tested is called asp1941. The eligibility criteria for the trial includes patients who have had type 2 diabetes for at least 12 weeks, have a fasting plasma glucose level of less than 240 mg/dL, have a body mass index between 20.0 and 35.0 kg/m2, and have a GFR value based on the Japanese GFR estimation equation at screening of at least 30 ml/min/1.73m2. The exclusion criteria includes patients with type 1 diabetes mellitus, those who have received insulin within 12 weeks before screening, those with diabetic ketoacidosis, dysuria and/or urinary tract infection, genital infection, significant renal, hepatic or cardiovascular diseases, and severe gastrointestinal diseases.",
    "The sample is a clinical trial for small cell lung cancer patients who have relapsed after completing their first-line chemotherapy. The trial is a combination of two drugs, topotecan and vorinostat, and is in phase 1/phase 2. The trial has specific inclusion and exclusion criteria, including age, performance status, life expectancy, and adequate organ function. Patients with certain medical conditions or prior treatment with an HDAC inhibitor are excluded from the trial. Pregnant or breastfeeding women are also excluded.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, ICD-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is a combination of phase 1 and phase 2, and the disease being studied is heart failure. The inclusion criteria for participants include being between 18 and 85 years old, having chronic systolic heart failure due to primary/idiopathic dilated cardiomyopathy, coronary artery disease or hypertension, and stable for at least 30 days prior to screening, having a left ventricular ejection fraction \u2264 40%, and being on unchanging doses of heart failure medications for 2 weeks prior to randomization. The exclusion criteria include having participated in any investigational drug study within 30 days preceding randomization, having a heart rate <50 or \u2265 90 BPM at baseline prior to randomization, and having a history of worsening heart failure within 30 days prior to screening.",
    "The sample is a phase 1 clinical trial for patients with various hematological malignancies, including leukemia, lymphoma, myelodysplastic syndromes, and multiple myeloma. The trial involves using three partially HLA matched umbilical cord blood units, with one unit serving as a source of regulatory T cells. The patients must meet certain eligibility criteria, including being between 18-45 years old, having a certain level of cryopreserved HSC graft cell dose, and being in remission from their disease. The trial also has exclusion criteria, such as being pregnant or having an available HLA matched sibling donor. The trial involves the use of drugs such as cyclophosphamide, cyclosporine, fludarabine phosphate, and mycophenolate mofetil. The eligibility criteria and exclusion criteria are detailed in the \"criteria\" column of the table.",
    "The sample is a phase 1 clinical trial for HIV-1 infection. The trial involves the drugs doravirine and placebo. The eligibility criteria include a diagnosis of HIV-1 infection at least 3 months prior to screening, a stable baseline health, and a willingness to receive no other antiretroviral therapy for the duration of the treatment phase. Exclusion criteria include a history of stroke, major neurological disorder, or clinically significant abnormalities or diseases in various bodily systems. Participants must also refrain from certain medications, excessive alcohol and caffeine consumption, and smoking more than 10 cigarettes per day. They must not have participated in another investigational study within 4 weeks prior to the screening visit and must not have a history of drug abuse within approximately 1 year.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating advanced breast cancer and advanced malignant solid tumors using the drugs HKI-272 and paclitaxel. The trial has specific eligibility criteria for participants, including good performance status, normal ejection fraction, adequate cardiac, kidney, and liver function, and adequate blood counts. Participants must also have at least one measurable target lesion and a negative pregnancy test for female subjects. The trial has exclusion criteria as well, including major surgery, radiotherapy, chemotherapy, or investigational agents within two weeks of treatment day 1, bone or skin as the only site of disease, active central nervous system metastases, significant cardiac disease or dysfunction, significant gastrointestinal disorder, inability or unwillingness to swallow HKI-272 capsules, and more. The trial has different inclusion criteria for part 1 and part 2, and part 2 has additional exclusion criteria.",
    "The sample is a phase 1 clinical trial for patients with various diseases, including chronic myelogenous leukemia and childhood solid tumors. The trial is testing the effectiveness of the drug dasatinib in treating these diseases. The eligibility criteria include having a confirmed diagnosis of one of the specified diseases, having measurable or evaluable disease, and not having received curative or survival-prolonging therapy with an acceptable quality of life. Patients must also meet various health requirements, such as having a certain level of blood counts and kidney function, and not having certain concurrent medications or conditions. The trial is not allowing concurrent investigational drugs or anticancer agents, and patients must not have received myelosuppressive chemotherapy within the past 3 weeks.",
    "The sample is a clinical trial for kidney transplantation and kidney disease patients. The trial is in phase 1/phase 2 and involves a list of drugs including alemtuzumab, sirolimus, tacrolimus, and methylprednisolone. The eligibility criteria for the trial includes having received a kidney transplant with a primary cadaveric or non-HLA-identical living donor kidney, receiving only a kidney and no other organs, being able to take medications by mouth, and being willing to use acceptable methods of contraception. Exclusion criteria include having received an HLA-identical living-donor kidney transplant, having a PRA value greater than 10%, having received a non-heart-beating donor allograft, and having a history of cancer or lymphoma.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on hematologic neoplasms, which are diseases related to abnormal growth of blood cells. The icd-10 codes associated with the diseases are listed as E70.338, E70.339, P09.3, O28.0, P61.8, P61.9, and T45.8X1A. The drug being tested is snx-5422. The eligibility criteria for the trial include being over 18 years old, having a Karnofsky performance status of over 60, having a confirmed hematological malignancy, being refractory to available therapy or for which no therapy is available, and having adequate hepatic, renal, and hematological function. The exclusion criteria include having a CNS malignancy, being at risk for prolonged QT interval, having significant GI/liver disease, or having other serious concurrent illness or medical condition.",
    "The sample is a phase 1 clinical trial for the treatment of chronic Hepatitis C virus (HCV) infection. The trial is testing the effectiveness of a drug called tmc649128 compared to a placebo. The trial is looking for treatment-naive volunteers or those who have previously been treated but stopped at least 6 months before screening. The volunteers must have chronic genotype 1a or 1b HCV infection and never received a HCV polymerase inhibitor. They must also have HCV plasma RNA levels of > 100,000 IU/mL at screening and a Body Mass Index of 18.0 to 35.0 kg/m2. The volunteers must be healthy based on a medical evaluation including medical history, physical examination, blood tests, vital signs, and electrocardiogram. The trial excludes volunteers with liver cirrhosis, decompensated liver disease, renal dysfunction, hepatocellular carcinoma, or coinfected with Human Immunodeficiency Virus-1 (HIV-1) or HIV-2, or hepatitis A or B virus infection, or clinically active tuberculosis at study screening.",
    "The sample is a phase 1 clinical trial for the treatment of HCV infection. The trial includes patients who are chronically infected with HCV genotype 1, HCV treatment-na\u00efve, and not co-infected with HIV or HBV. The patients must have a HCV RNA viral load of at least 100,000 IU/mL and a BMI between 19 to 35 kg/m2. The trial requires the use of highly effective contraception methods for female patients of childbearing potential or sexually active male patients. The trial excludes patients with a history of clinically-significant illness or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol. Patients with decompensated liver disease or cirrhosis or evidence of hepatocellular carcinoma are also excluded. Patients with serological evidence of co-infection with HIV, HBV, or another HCV genotype, and those with known, current use of amphetamines and/or cocaine, subjects taking methadone or buprenorphine (opioid replacement therapy) or ongoing alcohol abuse are also excluded. The trial involves the use of drugs such as gs-5885 and placebo.",
    "The sample is a record from a clinical trial table and includes information about the phase of the trial, which is a combination of phase 1 and phase 2. The diseases being studied are breast cancer, including male breast cancer, recurrent breast cancer, stage iiib breast cancer, stage iiic breast cancer, and stage iv breast cancer. The icd-10 codes associated with these diseases are also listed. The drugs being tested are vorinostat and trastuzumab. The eligibility criteria for participants are also included, which includes factors such as not being pregnant or nursing, having no active infections, and having no history of allergic reactions to the study drugs. The criteria also specify that participants must have measurable disease and meet certain medical criteria, such as having normal liver and heart function.",
    "The sample is a phase 1 clinical trial for the treatment of locally advanced squamous cell carcinoma of the head and neck. The trial is testing the drugs CUDC-101 and cisplatin. The eligibility criteria include having a confirmed diagnosis of the disease, having at least one measurable site of disease, being over 18 years old, having a performance status of less than 2, and meeting certain laboratory values. Exclusion criteria include prior radiotherapy or chemotherapy for the current indication, prior therapy targeting EGFR, HER2 or HDAC, and certain medical conditions such as cardiac disease or renal impairment.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on the disease \"healthy\" and has a list of icd-10 codes associated with it. The trial involves several drugs, including bazedoxifene and bazedoxifene/conjugated estrogens. The eligibility criteria for the trial include generally healthy postmenopausal women with a body mass index (BMI) between 18.0 and 35.0 kg/m2 and a body weight of at least 50 kg. Pregnant or nursing females and females of childbearing potential are excluded from the trial.",
    "The sample is a phase 1 clinical trial for patients with advanced solid tumors or lymphoma that are metastatic or unresectable. The trial is testing the effectiveness of a drug called src kinase inhibitor kx2-391. Patients must meet certain eligibility criteria, including having an ECOG performance status of 0-2, a life expectancy of at least 14 weeks, and various blood count and organ function requirements. Patients must also not have certain medical conditions or have a history of certain medical events within the past 6 months. Additionally, patients must not have received certain types of prior therapy within certain timeframes. The diseases being studied include lymphoma, lymphoproliferative disorder, small intestine cancer, and unspecified adult solid tumor, protocol specific, and their corresponding ICD-10 codes are listed.",
    "The sample is a clinical trial for patients with metastatic solid tumor malignancy, specifically prostate cancer. The trial is divided into two phases, phase 1 and phase 2. The trial involves the use of a drug called 2-deoxyglucose. The eligibility criteria for the trial include having a histologically proven metastatic solid tumor malignancy without a standard option of therapy, having prostate cancer with metastatic disease and progression after initial hormonal therapy, and having an estimated life expectancy of at least 6 months. Patients must also meet certain health criteria, such as having an ANC >1500/\u00b5l, hemoglobin > 10 g/dl, and platelet count >100,000/\u00b5l, and adequate renal function. Exclusion criteria include having a known infection with HIV, a history of glucose intolerance, ongoing coagulopathies and/or receiving oral anticoagulants, and known brain metastases. Women of childbearing potential must have a negative pregnancy test and both men and women of childbearing potential must consent to using effective contraception while on treatment and for 3 months thereafter.",
    "The sample is a record of a clinical trial in phase 1. The trial involves testing the drugs \"achn-975\" and \"placebo\" on healthy volunteers. The eligibility criteria for the trial include having a body weight between 40 and 100 kilograms, using contraception, having stable health, and testing negative for alcohol, tobacco, and drugs of abuse. The trial excludes individuals with a history of clinically significant disease or who are pregnant. The sample also includes the ICD-10 code \"Y99.2\" for the disease being studied.",
    "The sample is a phase 1 clinical trial for patients with prostate cancer that have progressed on conventional hormonal therapy. The trial requires patients to have bone metastases and evidence of disease progression. Patients must meet certain eligibility criteria, including having a minimum PSA level, a performance status of less than 2, and adequate bone marrow, hepatic, and renal function. Patients must also have fully recovered from any previous surgery and sign an informed consent. There are also exclusion criteria, such as severe intercurrent infection, uncontrolled severe hypertension or diabetes mellitus, and a history of non-compliance with medical regimens. The trial involves the use of imatinib mesylate and docetaxel drugs.",
    "The sample is a phase 1 clinical trial for patients with refractory or recurrent ovarian epithelial or fallopian tube cancer. The trial is testing the effectiveness of gemcitabine hydrochloride and topotecan hydrochloride as treatment options. The eligibility criteria include age 18 and over, a performance status of GOG 0-2, and no other active malignancy. Patients must have received at least one prior platinum- and paclitaxel-based regimen and must not be eligible for any higher priority phase II or III GOG protocol. The trial also includes various medical tests and assessments to ensure patient safety and compliance.",
    "The sample is a phase 1 clinical trial for alcohol dependence. The trial is testing the effectiveness of an opioid receptor kappa antagonist drug. The eligibility criteria for participants include being a healthy male or female with normal laboratory test results and sufficient access for blood sampling. Exclusion criteria include a history of severe allergies or adverse drug reactions, abnormal ECG or blood pressure, increased risk of seizures, current suicidal ideation, positive test for HIV or hepatitis, breastfeeding, smoking more than 10 cigarettes per day, drinking more than 5 cups of coffee per day, history of head injury, inability to undergo an MRI, and suffering from claustrophobia.",
    "The sample is a phase 1 clinical trial for non-small cell lung cancer. The trial includes patients with stage IIIB or IV NSCLC, except for those with squamous cell histology. The trial requires patients to have measurable disease per RECIST, a life expectancy of at least 12 weeks, adequate bone marrow, hepatic and renal function, and an ECOG performance status of 0, 1 or 2. Patients must have had only one prior treatment with a chemotherapy regimen, including a platinum-based regimen for advanced disease. Patients must also sign an informed consent document indicating that they have been informed of all pertinent aspects of the trial prior to enrollment. Exclusion criteria include squamous cell histology, history of untreated brain metastases, prior treatment with >1 systemic chemotherapy-based regimens for advanced disease, prior treatment with any receptor tyrosine kinase inhibitors, VEGF inhibitors, or other angiogenic inhibitors, prior chemotherapy, radiation therapy, surgery, or investigational agent within 4 weeks prior to study entry, and ongoing treatment with warfarin. Other exclusion criteria include ongoing cardiac dysrhythmias of grade >2, \u2265 grade 3 atrial fibrillation, or QTc interval of >450 msec for males and >470 msec for females, evidence of hemoptysis <4 weeks of starting study treatment, and other severe acute or chronic medical or psychiatric condition or laboratory abnormality. Women who are pregnant or breastfeeding are also excluded from the trial.",
    "The sample is a phase 1 clinical trial for patients with advanced or metastatic solid tumors that are refractory to standard therapy or have no standard therapy available. The trial allows patients with brain metastases if they have received CNS-directed treatment and have been stable for at least 8 weeks. Patients must have a life expectancy of at least 3 months, an ECOG performance status of 0-2, and meet certain laboratory criteria. They must also be able to receive vitamin B12 and folate supplementation and dexamethasone during chemotherapy. Patients cannot be pregnant or nursing and must use effective contraception during and for 3 months after the last dose of chemotherapy. Prior chemotherapy, investigational agents, or surgery must have been completed at least 4 weeks prior to the trial. Concurrent cytochrome P450/CYP3A4 inducers or inhibitors are allowed, but certain medications are not allowed. Patients assigned to group 2 cannot take enzyme-inducing antiepileptic drugs. The trial involves the use of erlotinib hydrochloride, pemetrexed disodium, and vinflunine.",
    "The sample is a phase 1 clinical trial with healthy male and non-childbearing female volunteers. The trial involves the drugs azd8418 and placebo. The eligibility criteria include being healthy and not having a history of clinically significant medical, neurologic, or psychiatric disease. Exclusion criteria include having a history of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity to drugs with a similar chemical structure or class to AZD8418.",
    "The sample is a clinical trial for a drug called vildagliptin, which is being tested on healthy volunteers and patients with type 2 diabetes. The trial is in phase 1/phase 2 and the disease being studied is diabetes mellitus, type 2. The trial is looking at the effects of the drug on patients who are already taking metformin and/or sufonylurea. The eligibility criteria include being a non-smoking, Caucasian or African American male or female between the ages of 30 and 65. Exclusion criteria include a history of type 1 diabetes or insulin use, coagulation abnormalities, abnormal heart conditions, and pregnancy or breastfeeding. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 1 clinical trial for lung cancer patients with specific disease characteristics, such as newly diagnosed single, primary, bronchogenic stage IIIA or selected stage IIIB non-small cell lung cancer. The trial involves the use of the drug docetaxel and has eligibility criteria for patient characteristics, including Zubrod performance status, absolute neutrophil count, and platelet count. Prior concurrent therapy is not allowed, and patients must not have had prior chemotherapy or curative surgery for this cancer. The trial also has specific exclusion criteria, such as brain metastases and prior therapy targeting the EGFR pathway.",
    "The sample is a phase 1 clinical trial that involves testing the effects of different drugs on individuals with varying degrees of weight, including healthy, overweight, and obese participants. The trial includes a placebo and two comparator drugs, pioglitazone and hyperinsulinemic euglycemic clamp. The eligibility criteria for the trial include having a BMI between 28 and 38 kg/m^2, being a nonsmoker or not having used nicotine-containing products for at least six months, and being willing to avoid major dietary changes during the study. Exclusion criteria include a history of diabetes, hypersensitivity to pioglitazone or other thiazolidinediones, liver disease, congestive heart failure, atherosclerotic heart disease, stroke, major neurological disorder, and neoplastic disease within the past five years.",
    "The sample is a clinical trial in phase 1 for the treatment of malignant solid tumors, biliary cancer, and pancreatic cancer. The trial involves the use of drugs such as gemcitabine, capecitabine, and zd6474. The eligibility criteria include being 18 years or older, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and having a life expectancy of at least three months. Blood samples and other testing may be required for further eligibility testing. Exclusion criteria include having uncontrolled illness, abnormal laboratory tests, and being pregnant or breastfeeding. Further exclusion criteria may also apply.",
    "The sample is a phase 1 clinical trial for the treatment of advanced or metastatic breast cancer using a combination of drugs called kw-2450, lapatinib, and letrozole. The trial is open to post-menopausal females or males over 18 years of age who have confirmed ErbB2 overexpression and estrogen receptor positive (ER+) and/or progesterone positive (PgR+) tumors. The trial has inclusion criteria such as having a life expectancy of at least 3 months for phase 1 and 6 months for phase 2, having a normal cardiac ejection fraction, and adequate hematologic, hepatic, and renal function. Exclusion criteria include having uncontrolled diabetes, abnormal free T4 values and a history or evidence of thyroid disease, and extensive symptomatic visceral disease including hepatic involvement and pulmonary lymphangitic spread of tumor. Participants must sign an IRB or EC approved informed consent.",
    "The sample is a phase 1 clinical trial for the treatment of type 2 diabetes mellitus. The trial involves the use of several drugs, including sitagliptin, saxagliptin, vildagliptin, and a placebo. The eligibility criteria for participants include having a clinically confirmed diagnosis of T2DM, not currently receiving any oral antihyperglycemic medications, and having a screening visit hemoglobin A1c (HbA1c) between 6.5% and 10% inclusive. Participants must also meet several other criteria, such as having a body mass index between 18 and 43 kg/m^2 inclusive, being a non-smoker, and agreeing to follow a specific diet and exercise program. Exclusion criteria include having a history of stroke, chronic seizures, or major neurological disorder, and having a history of neoplastic disease or myeloproliferative disease.",
    "The sample is a clinical trial for a drug called combretastatin a4 phosphate, which is being tested for its effectiveness in treating age-related macular degeneration (AMD) with choroidal neovascularization (CNV). The trial is in phase 1/phase 2 and the table includes information on the diseases being treated, the icd-10 codes associated with those diseases, the drugs being used, and the eligibility criteria for participants. The eligibility criteria include age, medical history, and ophthalmic criteria, among others. The trial has exclusion criteria as well, such as previous subfoveal thermal laser therapy and any intraocular surgery in the study eye within 12 weeks of screening for the study.",
    "The sample is a phase 1 clinical trial for patients with ovarian, fallopian tube, or peritoneal cancer who have completed adjuvant treatment and have evidence of a complete or partial response by radiological imaging. Patients with recurrent disease who have clinical or radiologic evidence of a complete or partial response or stable disease after completion of first-line chemotherapy and are not suitable for additional cytotoxic therapy are also eligible. The trial involves the use of low dose cyclophosphamide (oral) and the eligibility criteria include various medical and psychological factors such as previous courses of investigational biologic therapy, autoimmune disease, recent history of thyroiditis, and serious intercurrent chronic or acute illness. Pregnant or nursing mothers are excluded from the trial.",
    "The sample is a phase 1 clinical trial for colorectal cancer. The eligibility criteria include having a histologically confirmed primary adenocarcinoma of the rectum, with the distal border of the tumor within 12 cm of the anal verge by proctoscopic exam, and clinical stage T3-4, N1-2 (stage II or III) disease by 2 of the following tests: physical exam, transrectal ultrasound, pelvic CT scan, or pelvic MRI. Patients must also have no clinical evidence of metastatic disease and meet certain age, performance status, life expectancy, hematopoietic, hepatic, renal, cardiovascular, gastrointestinal, and other criteria. Prior to the trial, patients must not have received any immunotherapy, chemotherapy, radiotherapy, or surgery for rectal cancer, and must not have participated in another investigational drug study within the past 4 weeks. Patients must also not have any concurrent serious, uncontrolled infections, or other medical or psychiatric conditions that would preclude study participation. The drug being tested in this trial is capecitabine.",
    "The sample is a clinical trial for phase 1, focused on type 2 diabetes mellitus. The trial includes a list of icd-10 codes for the disease and a list of drugs, including asp1941 and placebo. The eligibility criteria for the trial include having type 2 diabetes for at least 12 weeks, having an HbA1c value between 7.0 and 10.0% at screening, having a fasting plasma glucose level between 126mg/dL and 240mg/dL at screening, and having a BMI between 20.0 and 45.0 kg/m2. The exclusion criteria include having type 1 diabetes mellitus, having a serum creatinine level above the upper limit of normal, having proteinuria (albumin/creatinine ratio > 300mg/g), having dysuria and/or urinary tract infection, having significant renal, hepatic or cardiovascular diseases, and having severe gastrointestinal diseases.",
    "The sample is a phase 1 clinical trial for patients with advanced malignant solid tumors or lymphoma, for which no standard therapy is available or the patient is not a candidate for standard therapy. The trial is testing the drug E7820. The eligibility criteria include having a Karnofsky Performance Status of >= 70%, a life expectancy of >= 3 months, being aged >= 18 years, having adequate renal and bone marrow function, and giving written informed consent. Exclusion criteria include having a history of hypersensitivity to sulfonamide derivatives, receiving chemotherapy or radiation within a certain timeframe, not recovering from previous chemotherapy or radiotherapy related toxicity, receiving investigational drugs or other antineoplastic therapy within 28 days of E7820 treatment, having major surgery within 4 weeks of study drug administration, being pregnant or breastfeeding, having active central nervous system metastases, being positive for certain viruses, having significant disease or any condition that would exclude the patient from the study, and having pulmonary disease that puts them at risk of hemoptysis.",
    "The sample is a phase 1 clinical trial for patients with Diamond-Blackfan anemia (DBA) who are dependent on red blood cell transfusions. The trial is testing the effectiveness of the drug lenalidomide. The eligibility criteria include being at least 18 years old, having a stable or decreasing dose of prednisone or corticosteroid equivalent, and having certain laboratory test results within normal ranges. Females of childbearing potential must have a negative pregnancy test and agree to use two forms of birth control. Exclusion criteria include having any serious medical condition or laboratory abnormality that would prevent the subject from signing the informed consent form, being pregnant or breastfeeding, and having any condition that places the subject at unacceptable risk if they were to participate in the study.",
    "The sample is a clinical trial for treating metastatic renal cell carcinoma using a combination of gefitinib and sunitinib. The trial is in phase 1/phase 2 and the eligibility criteria include having histologically confirmed renal cell carcinoma with measurable disease and having failed one prior immunotherapy or having no prior systemic therapy for metastatic RCC. The exclusion criteria include having RCC without any clear cell component, a history of or known brain metastases, and uncontrolled hypertension or other significant cardiac events within the 12 months prior to study entry. The diseases are listed as 'carcinoma, renal cell' and the icd-10 codes are listed as a string of codes.",
    "The sample is a phase 1 clinical trial for depression. The trial includes subjects who have a Hamilton Depression Rating Scale (HAM-D17) total score of 7 or less. Subjects who have previously suffered from at least two Major Depressive Episodes (MDEs) and have received prescribed treatment with an antidepressant or psychotherapy for depression for a previous MDE are also included. Control group subjects must have no history of MDEs and have never been treated with antidepressants or psychotherapy. The trial also includes inclusion and exclusion criteria, and the drugs being tested are vortioxetine (lu aa21004) and placebo.",
    "The sample is a phase 1 clinical trial for obesity. The trial is looking at the effects of the drug AZD2820 compared to a placebo. The eligibility criteria for the trial includes male subjects aged 18-45 with a body mass index (BMI) between 27 and 40 kg/m2 and suitable veins for cannulation or repeated venepuncture. The subjects must also provide signed and dated, written informed consent prior to any study specific procedures including the genetic sampling and analyses. Exclusion criteria includes a history of any clinically significant disease or disorder, prolonged QTcF >450 ms or shortened QTcF <340 ms or family history of long QT syndrome, and any clinically significant abnormalities in clinical chemistry, haematology (including eosinophilia) or urinalysis results as judged by the investigator.",
    "The sample is a phase 1 clinical trial for patients between the ages of 1 month and 21 years old who have been diagnosed with relapsed/refractory acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or acute leukemia of ambiguous lineage. The trial includes the drugs ac220, cytarabine, etoposide, and methotrexate. The eligibility criteria include having fully recovered from prior chemotherapy, immunotherapy, or radiotherapy, having adequate renal and hepatic functions, and having a shortening fraction of at least 27% by echocardiogram or an ejection fraction of at least 50% by radionuclide angiogram. Patients with uncontrolled or significant cardiovascular disease, systemic fungal, bacterial, viral or other infections, or any significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance are excluded from the trial.",
    "The sample is a clinical trial for a drug called nilotinib, which is being tested on patients with chronic myelogenous leukemia or acute lymphoblastic leukemia (philadelphia chromosome positive). The trial is in phase 1/phase 2 and the table includes information on the diseases being treated, the icd-10 codes associated with those diseases, the drugs being used, and the eligibility criteria for patients to participate in the trial. The eligibility criteria include factors such as the patient's performance status, history of cardiovascular disease, gastrointestinal function, and other medical conditions that could pose safety risks. The sample also includes exclusion criteria, such as recent chemotherapy or radiation therapy, pregnancy or breastfeeding, and a history of other primary malignancies.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on treating leukemia, specifically TdT positive acute lymphocytic leukemia or blastic chronic myelogenous leukemia, using the drugs cordycepin and deoxycoformycin. The eligibility criteria for patients include being 18 years or older, having a Karnofsky performance status greater than 70%, and a life expectancy of at least 3 months. Patients must also meet certain hematopoietic, hepatic, renal, and cardiovascular requirements, and cannot be pregnant or nursing or have any serious concurrent illness. Prior to the trial, patients must have failed at least one standard treatment and must not have received chemotherapy within the past 3 weeks. Other prior concurrent therapies are not specified. The icd-10 codes associated with the diseases being treated are also included in the record.",
    "The sample is a phase 1 clinical trial for patients with persistent, metastatic, or recurrent platinum-resistant or refractory ovarian or primary peritoneal cancer. The trial involves the use of the drug fludeoxyglucose f 18 and requires patients to meet certain eligibility criteria, such as having a life expectancy of at least 6 months, acceptable organ and marrow function, and willingness to undergo pre- and post-treatment FDG-PET/CT. Patients cannot have received radiation overlapping with the proposed treatment field, cannot be receiving chemotherapy or other investigation agents from two weeks prior to radiation through undergoing their post-therapy FDG-PET/CT, cannot be pregnant or nursing, and cannot have disease >= 8cm or greater than 3 regions of disease. Concurrent malignancy other than non-melanoma skin cancer, non-invasive bladder cancer, or carcinoma in situ of the cervix is also an exclusion criterion. The sample includes a list of diseases, their corresponding ICD-10 codes, and the eligibility criteria for the trial.",
    "The sample is a record of a clinical trial with a combination of phase 1 and phase 2. The trial is focused on type 1 diabetes and involves the use of sitagliptin and insulin as drugs. The eligibility criteria for the trial include a diagnosis of diabetes according to the WHO report of 1999, age at onset between 25-70 years, disease duration of less than 3 years, and a fasting C-peptide level of 0.2 nmol/L or more. The exclusion criteria include insulin requirements more than 0.8 units/kg/day, evidence of chronic or acute infection affecting blood glucose control, history of any malignancy, pregnancy or breastfeeding, secondary diabetes, congestive heart failure requiring pharmacologic treatment, renal disease or dysfunction, and concurrent medical conditions that may interfere with the interpretation of efficacy and safety data during the study.",
    "The sample is a clinical trial for patients with peripheral T-cell lymphomas, adult T-cell leukemia, adult T-cell lymphoma, peripheral T-cell lymphoma unspecified, angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, T/null cell systemic type, and cutaneous T-cell lymphoma with nodal/visceral disease. The trial is in the early phase 1 stage and the drug being tested is lenalidomide. The eligibility criteria include having a confirmed diagnosis of the specified lymphomas, having measurable lesions, and meeting certain laboratory test results. Patients must also be willing to comply with the requirements of the RevAssist program and must not have any serious medical conditions or psychiatric illnesses that would prevent them from participating in the trial. Exclusion criteria include being pregnant or breastfeeding, having a known hypersensitivity to thalidomide, and having prolonged QT interval on baseline EKG.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, ICD-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1 and is focused on squamous cell carcinoma of the head and neck. The trial is looking at the effectiveness of two different drug combinations. The eligibility criteria for participants include having a confirmed diagnosis of squamous cell carcinoma of the head and neck, having recurrent and/or metastatic SCCHN, and having a certain level of performance status. There are also exclusion criteria, such as prior systemic chemotherapy and relevant cardiovascular co-morbidities.",
    "The sample is a record of a clinical trial with the phase labeled as \"early phase 1\". The trial is focused on the disease \"heart failure, congestive\" and the associated ICD-10 codes. The drug being tested is \"sitagliptin\". The eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include a diagnosis of nonischemic dilated cardiomyopathy, current NYHA class I-III congestive heart failure, treatment with a stable comprehensive heart failure regimen for at least 3 months, and age over 18 years. The exclusion criteria include cardiomyopathy primarily due to ischemic heart disease, primary valvular lesion, or hypertrophic cardiomyopathy, cardiac resynchronization within the last 3 months, calculated creatinine clearance less than 30 ml/min or end-stage renal disease on dialysis, diagnosis of diabetes mellitus, history of heart transplantation, pregnancy or active breast feeding, and hospitalization for decompensated heart failure within 30 days prior to enrollment.",
    "The sample is a phase 1 clinical trial for patients with metastatic or recurrent head and neck cancer who have failed at least one prior chemotherapeutic regimen. The trial involves the use of the drugs gemcitabine and paclitaxel. The eligibility criteria include being 18 years or older, having measurable or non-measurable disease documented by CT, MRI, X-ray or nuclear exam, and having adequate hepatic function. Patients must have progressed after at least one prior chemotherapeutic regimen, and at least three weeks must have elapsed since surgery. Patients must also have an ANC of 1,500/\u00b5l and platelet count of 100,000/\u00b5l, and a Zubrod Performance Status of 0, 1, or 2. The exclusion criteria include having other prior malignancy, being pregnant or nursing, and taking drugs that are strong inducers of the enzyme CYP3A4.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on type II diabetes. The icd-10 codes associated with the disease are listed, as well as the drugs being tested, which include placebo, sitagliptin, and lez763. The eligibility criteria for participants are also listed, including age, weight, BMI, and medical history. Inclusion and exclusion criteria are also provided, such as not being a smoker and not having a history of drug or alcohol abuse.",
    "The sample is a phase 1 clinical trial for patients with advanced solid tumors. The trial is testing the drug auy922. The eligibility criteria for the trial include having an ECOG Performance Status of \u2264 2, certain laboratory values within normal limits, and not having brain metastasis or prior treatment with certain inhibitors. Patients must also be able to sign informed consent and comply with the protocol. Exclusion criteria include severe liver or renal disease, heart disease, and certain heart abnormalities. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular record, the trial is in phase 1/phase 2 and is focused on non-small cell lung cancer. The drugs being used are belinostat and erlotinib. The eligibility criteria include factors such as age, performance status, liver and kidney function, and acceptable coagulation levels. There are also exclusion criteria, such as recent treatment with experimental drugs or presence of active infection or other medical conditions that could affect the trial.",
    "The sample is a clinical trial for prostate cancer patients in phase 1/phase 2. The trial includes patients with castrate-resistant prostate cancer (CRPC) and metastatic disease. The trial involves the use of two drugs, temsirolimus and casodex (bicalutamide). The eligibility criteria include having a confirmed diagnosis of adenocarcinoma of the prostate, rising PSA levels, failure of previous treatments, and a castrate level of testosterone. Patients must also have a life expectancy of more than 6 months and meet certain performance status requirements. There are also exclusion criteria, such as prior treatment with mTOR inhibitors or chemotherapy for prostate cancer, and certain medical conditions that would make a patient ineligible for the trial.",
    "The sample is a table that contains information about a clinical trial. It includes the phase of the trial (phase I, phase II, or phase III), a list of diseases being studied, the corresponding ICD-10 codes for those diseases, a list of drugs being tested, and the eligibility criteria for participants. The eligibility criteria include age, disease stage, previous treatments, organ function, and other medical conditions. The sample also includes specific exclusion criteria, such as prior therapy with certain drugs, significant cardiovascular disease, and active infections. The sample is divided into two phases, with different inclusion and exclusion criteria for each phase.",
    "The sample is a phase 1 clinical trial for patients with metastatic or locally advanced transitional cell carcinoma of the urothelial tract who have measurable disease according to RECIST and overexpress HER1 and/or HER2 receptors. The trial involves the use of three drugs: cisplatin, gemcitabine hydrochloride, and lapatinib ditosylate. The eligibility criteria include various patient characteristics such as WHO performance status, ANC, thrombocytes, bilirubin, AST/ALT, creatinine clearance, and cardiac ejection fraction. Patients must also not have any serious cardiac illness or medical condition within the past 6 months, no peripheral neuropathy > grade 1, and must be able to swallow and retain oral medication. Additionally, patients must not have any other malignancy within the past 3 years except basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, no active or uncontrolled infections, serious illnesses, malabsorption syndrome or medical conditions, hepatitis, HIV, and/or cirrhosis, and no psychological, familial, sociological, or geographical condition potentially hampering study protocol compliance or follow-up schedule. Prior concurrent therapy is also taken into consideration.",
    "The sample is a clinical trial for patients with multiple myeloma in phase 1/phase 2. The trial includes a list of drugs such as carfilzomib, cyclophosphamide, and dexamethasone. The eligibility criteria include being a newly diagnosed MM patient, having measurable disease, being at least 18 years old, having a life expectancy of at least 3 months, and having an ECOG performance status of 0-2. The trial also has exclusion criteria such as previous treatment with anti-myeloma therapy, major surgery within 21 days prior to randomization, and significant neuropathy. The sample also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a phase 1 clinical trial for healthy female subjects between the ages of 18 and 50. The trial involves the use of multiple drugs, including tipranavir, ritonavir, and norethindrone-ethinyl estradiol. The eligibility criteria include having a BMI between 18 and 29 kg/m2, being able to swallow large capsules, and having acceptable laboratory values and medical history. Exclusion criteria include pregnancy, recent participation in another clinical trial, and a history of certain medical conditions or allergies. Participants must also abstain from certain foods and medications during the trial.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on diabetes mellitus and diabetic nephropathy. The icd-10 codes associated with these diseases are listed, as well as the drug being tested (pirfenidone). The eligibility criteria for participants are also listed, including requirements for age, kidney function, blood pressure, and a history of proteinuria. There are also exclusion criteria, such as a history of certain medical conditions or plans to receive a kidney transplant within a year of study enrollment.",
    "The sample is a phase 1 clinical trial for patients with recurrent epithelial ovarian cancer or primary peritoneal cancer. The trial is testing the effectiveness of the drug paclitaxel. The eligibility criteria include being at least 18 years old, having platinum-resistant or platinum-refractory disease, and having a treatment-free interval of at least three weeks prior to the first treatment on the protocol. Exclusion criteria include previous administration of tgDCC-E1A, progression on any taxane-containing regimen, and certain laboratory values outside of normal ranges. Patients with grade 2 or greater neurotoxicity, unstable angina, or an ejection fraction under 40% are also excluded.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on non-small cell lung cancer and includes a list of ICD-10 codes associated with the disease. The trial involves two drugs, rad001 and erlotinib, and has specific eligibility criteria for participants. Inclusion criteria include being over 18 years old, having advanced non-small cell lung cancer that is not responding to chemotherapy, and having only received 1-2 previous chemotherapy regimens for advanced disease. Exclusion criteria include chronic steroid treatment, prior treatment with EGFR inhibitors, and other severe medical conditions. There may be additional inclusion/exclusion criteria that apply.",
    "The sample is a phase 1 clinical trial for the treatment of hepatitis C. The eligibility criteria include being between the ages of 18 and 65, having confirmed genotype 1 HCV, and having a liver biopsy showing chronic hepatitis without cirrhosis within the past 2 years. Participants must also have certain blood counts and agree not to participate in a conception process while on study drugs and for 6 months following permanent discontinuation of study therapy. Exclusion criteria include previous IFN-alpha, RBV or IL2 therapy, any active viral hepatitis other than hepatitis C virus infection, and signs/symptoms of advanced liver disease. Participants must not have any severe illnesses that would make them unsuitable for the study and must not be pregnant or nursing.",
    "The sample is a phase 1 clinical trial for patients with malignant solid tumors, specifically neoplasms. The trial is testing the effectiveness of two drugs, mitoxantrone hydrochloride liposome and mitoxantrone, on patients who have failed standard chemotherapy and have no better treatment options. The eligibility criteria include being between 18-70 years old, having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2, and having an expected survival time of at least 3 months. Patients must also comply with the requirements and restrictions listed in the consent form and agree to take effective contraceptive measures during the trial. The exclusion criteria include pregnancy and breast-feeding women, patients with multiple sclerosis, patients with certain heart conditions, patients requiring other antineoplastic treatment, and patients with uncontrolled primary or metastatic brain tumors.",
    "The sample is a record from a clinical trial table. It includes information about the phase of the trial, which is a combination of phase 1 and phase 2. The trial is focused on heart failure, which is listed as the disease. The icd-10 codes associated with the disease are also included. The trial involves two drugs, trv120027 and placebo. The eligibility criteria for the trial are listed under inclusion and exclusion criteria, which include specific medical conditions and requirements for blood pressure and heart rate.",
    "The sample is a phase 1 clinical trial for the treatment of myelodysplastic syndrome, a type of blood cancer. The trial is testing the effectiveness of two drugs, ezatiostat hydrochloride and lenalidomide (Revlimid\u00ae), on patients with non-del(5q) low or Intermediate-1 risk MDS. The eligibility criteria for the trial include a histologic diagnosis of primary or de novo MDS using WHO classification, an ECOG performance status of 0-1, and documented significant cytopenia for at least 2 months. Patients must have discontinued growth factors for at least 21 days prior to study entry and must be registered into the mandatory RevAssist\u00ae program. Females of childbearing potential must have two negative serum pregnancy tests. The exclusion criteria include known hypersensitivity to Telintra\u2122, prior therapy with or hypersensitivity to thalidomide or lenalidomide, and prior allogenic bone marrow transplant for MDS. The trial also excludes patients with a history of prior malignancy, MDS evolving from a pre-existing myeloproliferative disorder, an autoimmune disease, or secondary to prior treatment with radiation or chemotherapy. Pregnant or lactating women are also excluded from the trial.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial (phase 1/phase 2), a list of diseases (lymphoma, hodgkin disease, lymphoma non-hodgkin), a list of icd-10 codes of diseases, a list of drugs (pci-24781), and eligibility criteria for the trial. The eligibility criteria include age, ability to swallow oral capsules, estimated life expectancy, ECOG performance status, and willingness to sign a written informed consent. The exclusion criteria include prior treatment with an HDAC inhibitor, creatinine clearance, total bilirubin, AST and ALT levels, platelet count, ANC, malabsorption, corticosteroids, concurrent therapeutic anticoagulation, uncontrolled illness, risk factors for or use of drugs known to prolong QTc interval, history of myocardial infarction, acute coronary syndromes, coronary angioplasty and/or stenting, known HIV infection, and other medical or psychiatric illness or organ dysfunction. Pregnant or lactating women and sexually active men who are unwilling to use adequate contraceptive protection during the course of the study are also excluded.",
    "The sample is a phase 1 clinical trial for cancer patients with HER2+ cancer or HER2+ metastatic breast cancer. The trial is testing the drug arry-380, a HER2 inhibitor taken orally. Patients must have received at least one previous therapeutic regimen and either no longer be candidates for standard therapy, have no standard therapy available, or choose not to pursue standard therapy. Patients with HER2+ breast cancer and with clinical indication for trastuzumab or lapatinib should have received prior therapy with trastuzumab and lapatinib, if available. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) between 0 and 2. The trial has key inclusion and exclusion criteria, including no uncontrolled or symptomatic brain metastases, no treatment with an investigational medicinal product or device within 30 days prior to first dose of study drug, no radiotherapy within 28 days prior to first dose of study drug (not including palliative radiotherapy at focal sites), no chemotherapy within 21 days prior to first dose of study drug, no major surgery within 30 days prior to first dose of study drug, and no known positive serology for the human immunodeficiency virus (HIV), hepatitis B and/or active hepatitis C.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on healthy subjects who are non-dependent, recreational opioid users and have experience with intranasal opioid administration. The trial involves the use of drugs such as alo-02 weight-matched placebo, crushed alo-02 30 mg/3.6 mg, oxycodone weight-matched placebo, and crushed oxycodone ir 30 mg. The eligibility criteria for the trial include being a non-dependent, recreational opioid user who has used opioids for non-therapeutic purposes at least 10 times in the past year and at least once in the 8 weeks before the screening visit. The exclusion criteria include a diagnosis of substance and/or alcohol dependence and participation in or seeking treatment for substance and/or alcohol-related disorders.",
    "The sample is a clinical trial for a drug called ana773 and its placebo, conducted in phase 1. The trial is focused on patients with HCV infection, and the table includes a list of diseases and their corresponding ICD-10 codes. The eligibility criteria for the trial are also listed, including age range, medical history, and drug/alcohol use. The trial is divided into two parts, with different inclusion and exclusion criteria for each part. The second part of the trial is specifically for patients with chronic liver disease consistent with chronic hepatitis C infection for at least 6 months, who have not received prior IFN-alpha based therapy.",
    "The sample is a phase 1 clinical trial for healthy volunteers aged 40 to 65 years with a body mass index between 18 and 35 kg/m2. The trial involves the drugs aleglitazar, aspirin, and placebo. Eligibility criteria include being a non-smoker or smoking less than 5 cigarettes per day, drinking no more than 3 cups of coffee, tea, or soft drinks per day, and having no clinically relevant abnormal laboratory test results at screening. Exclusion criteria include a history of certain medical conditions, a positive test for HIV or hepatitis, and intolerance to NSAIDs or aspirin. Females of child-bearing potential must use two acceptable methods of contraception during the study and at least 3 months before the start of the study.",
    "The sample is a clinical trial for patients with solid tumors and hematologic malignancies who have delayed methotrexate clearance. The trial is in phase 1/phase 2 and involves the drugs voraxaze (glucarpidase) and placebo. The eligibility criteria include having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and providing IRB-approved signed informed consent. Exclusion criteria include having medical or psychiatric illnesses that may interfere with participation, receiving medications that may interfere with methotrexate excretion or enhance toxicity, having uncontrolled cardiac disease, or having known hypersensitivity to any of the study drug components. The diseases are listed as 'hematologic malignancy' and 'solid tumor', and the icd-10 codes for the diseases are also provided.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying non-alcoholic steatohepatitis and increased iron storage/disturbed distribution. The icd-10 code for the disease is K75.81. The drug being used is exjade. The eligibility criteria for participants include having elevated liver enzymes and serum ferritin levels, liver histology consistent with a diagnosis of NASH, and not having certain exclusion criteria such as alcohol intake over 140 g/week, established liver cirrhosis, or anemia. There are several other exclusion criteria listed as well.",
    "The sample is a clinical trial for patients with head and neck cancer in phase 1/phase 2. The trial involves the use of two drugs, docetaxel and everolimus. The eligibility criteria include having histologically confirmed squamous cell carcinoma of the head and neck, measurable disease by RECIST criteria, and an ECOG performance status of 0-1. Patients must also meet certain medical requirements, such as having normal levels of urea and creatinine, and not having any uncontrolled infections. Additionally, patients must not have received prior chemotherapy for any cancer except for head and neck cancer, and must not have received prior therapy with any erbB inhibitors or taxanes. The trial also has certain exclusion criteria, such as not being pregnant or nursing, and not having any mental condition that would render the patient unable to understand the nature, scope, and possible consequences of the study.",
    "This sample is for a phase 1 clinical trial for the treatment of cystic fibrosis. The trial is focused on the use of amiloride solution for inhalation. The eligibility criteria for the trial includes a diagnosis of cystic fibrosis and two positive cultures for Burkholderia dolosa lung infection. The exclusion criteria includes a positive pregnancy test or currently breastfeeding, as well as a known sensitivity to amiloride. The icd-10 codes associated with cystic fibrosis are also provided.",
    "The sample is a clinical trial for patients with relapsed or resistant diffuse large B cell lymphoma. The trial is in phase 1/phase 2 and involves the use of two drugs, azacytidine and vorinostat. The eligibility criteria include having measurable disease, being over 18 years old, having a certain performance status, and having normal organ and marrow function. Women of childbearing potential must have a negative pregnancy test and agree to use contraception during the study. The exclusion criteria include having received certain previous treatments, having active CNS lymphoma, and having uncontrolled illness. Pregnant and lactating women are also excluded.",
    "The sample is a record from a table that contains information about clinical trials. It includes the phase of the trial, which can be either phase 1 or phase 2, as well as a list of diseases and their corresponding ICD-10 codes. The sample also includes a list of drugs being tested in the trial, which are lapatinib, carboplatin, and paclitaxel. Additionally, the sample provides the eligibility criteria for the trial, including inclusion criteria such as having relapsed ovarian or metastatic breast cancer and measurable disease, and exclusion criteria such as prior treatment with certain therapies and concomitant medication requirements.",
    "The sample is a record from a clinical trial table. It includes information about the phase of the trial, which is a combination of phase 1 and phase 2. The trial is focused on the disease type 2 diabetes mellitus, which is identified by a list of ICD-10 codes. The trial involves several drugs, including gk1-399 (formerly ttp399) and a placebo. The eligibility criteria for the trial include being between the ages of 18 and 75, having a diagnosis of T2DM, being on a stable dose of background medication for diabetes, and having a BMI between 20-40 kg/m2. The exclusion criteria include having type 1 diabetes, a recent heart attack or stroke, uncontrolled blood pressure, or significant kidney disease.",
    "The sample is a clinical trial for a drug called DPK-060 1% ointment and its placebo for the treatment of atopic dermatitis. The trial is in phase 1/phase 2 and the eligibility criteria include having a clinical diagnosis of atopic dermatitis, having treatable eczematous lesions of a total area of at least 25 cm2, and using an appropriate method of contraception for female patients of childbearing potential. Exclusion criteria include having significant clinical illness within the two weeks prior to the first dose, having had previous local or systemic antimicrobial therapy within the last four weeks prior to the first application of the investigational product, and having any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the drug. The trial also excludes patients who had had systemic treatment for atopic dermatitis or other topical or transdermal treatments on the site of eczema within 14 days prior to first application of DPK-060 1% or placebo ointment and/or topical treatment with tar, any corticosteroid, topical immunomodulators or oral treatment with any corticosteroids within 14 days prior to first application and/or oral antihistamines within 14 days of the first dose. Other exclusion criteria include having a diagnosis of other skin diseases likely to adversely affect the outcome of the study, having a history or evidence of significant cardiac, renal, hepatic or endocrine disease, having significant hypersensitivity or allergy, being immunocompromised, having lice or scabies, having tinea corporis, having hypersensitivity to the ingredients of the vehicle, having prominent tattoos at sites of application of DPK-060 1% or placebo ointment, having donated blood exceeding 450 mL during the three months prior to first dose, having participated in a clinical study during the 12 weeks prior to first dose, having ongoing alcohol or drug abuse, and having a positive pregnancy test or lactation.",
    "This sample is a phase 1 clinical trial for patients with unresectable or locally advanced adenocarcinoma of the pancreas or periampullary region. The trial is testing the effectiveness of gemcitabine hydrochloride as a treatment. Patients must have measurable or evaluable disease by CT scan or MRI, an ECOG performance status of 0-2, and meet various other eligibility criteria related to blood counts, liver and kidney function, and other medical conditions. Patients cannot have acute hepatitis, known HIV infection, or other active or uncontrolled infections, and must not have a significant history of uncontrolled cardiac disease. Patients cannot have had prior radiotherapy to the planned field of treatment or prior therapy that specifically and directly targets the EGFR pathway. Patients must not have had other concurrent chemotherapy within the past 5 years, and cannot be receiving any other concurrent investigational agent.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on the treatment of prostate cancer. The trial includes a list of ICD-10 codes associated with the disease. The drug being tested is an AR antagonist called BMS-641988. The eligibility criteria for the trial are listed, including requirements for advanced castration-resistant prostate carcinoma with progressive disease, adequate liver and kidney function, and adequate blood values. The exclusion criteria are also listed, including uncontrolled or significant heart disease, history of seizures, and inability to swallow tablets.",
    "The sample is a phase 1 clinical trial for the treatment of chronic hepatitis C. The trial includes subjects who have provided written consent and are deemed to be in good health by the investigator. The inclusion criteria include a creatinine clearance of greater than 50 mL/min, a specific age range, and a specific body mass index range. Female subjects must be of non-childbearing potential, and male subjects must be surgically sterile or practicing specific forms of birth control. Additional inclusion criteria are required for subjects with CHC genotype 1 infection. Exclusion criteria include various medical conditions, drug allergies, and abnormal laboratory results.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on studying primary Hepatocellular Carcinoma (HCC) and liver neoplasms. The drug being tested is talaporfin sodium. The eligibility criteria for participants include having a diagnosis of HCC, having at least 1 but no more than 3 lesions in the liver, having an ECOG performance status of 0-2, and meeting certain hematologic, liver, and renal function requirements. There are also exclusion criteria, such as having lesions larger than 8 cm in diameter and more than 40% of parenchymal disease involvement, known sensitivity to porphyrin type drugs, and concurrent participation in another clinical trial involving experimental treatment.",
    "The sample is a clinical trial for the treatment of glioblastoma multiforme, a type of brain cancer. The trial is in phase 1/phase 2 and involves the use of a combination of drugs called mpc-6827 and carboplatin. The eligibility criteria for participants include having a histologically proven WHO Grade IV glioblastoma multiforme, evidence of measurable recurrent or residual primary tumor by contrast-enhanced MRI, and a Performance Scale of Karnofsky > 60%, ECOG < 2 or WHO < 2. Exclusion criteria include hypersensitivity to Cremophor EL, evidence of current/active intratumor hemorrhage by MRI, and prior treatment with platinum-based chemotherapy.",
    "The sample is a clinical trial for patients with advanced hepatocellular carcinoma. The trial is a combination of temsirolimus and sorafenib drugs. The eligibility criteria include patients who are at least 18 years old, have a life expectancy of at least 12 weeks, have confirmed advanced HCC, and have at least one tumor lesion that can be accurately measured. Patients must have an ECOG PS of 0, 1 or 2 or a Karnofsky Performance Status > 70 %, and a cirrhotic status of Child-Pugh class A or B. Patients must also meet certain laboratory criteria, such as having white blood cells \u2265 3,000/mm\u00b3 and platelets \u2265 100,000/mm\u00b3. Exclusion criteria include patients who are currently receiving chemotherapy, immunotherapy or radiotherapy, have a known history of HIV seropositivity, or have uncontrolled diabetes. Patients must also be willing to comply with the protocol.",
    "The sample is a phase 1 clinical trial for obesity. The trial is looking for obese but otherwise healthy females who are not of childbearing potential and have a BMI between 30 and 50 kg/m2. The trial will exclude those who have used weight loss agents in the past month, have a history of eating disorder, have had gastric bypass surgery, or are current smokers. The trial will test the drugs zgn-433 and normal saline. The diseases being studied are obesity, and the icd-10 codes associated with the disease are E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, and O99.211.",
    "The sample is a phase 1 clinical trial for previously untreated metastatic pancreatic adenocarcinoma. The trial involves the use of two drugs, temsirolimus and gemcitabine. The eligibility criteria include having measurable disease by RECIST criteria, an ECOG Performance Status of 0 or 1, and a life expectancy of at least 12 weeks. Other criteria include specific laboratory values and adequate glycemic control for subjects with diabetes. Exclusion criteria include prior treatment with gemcitabine or chemoradiation, ongoing cardiac dysrhythmias, and known brain metastases or spinal cord compression. Subjects receiving other experimental or alternative therapies during the trial will also be excluded.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on treating three diseases: myelofibrosis, polycythemia vera, and thrombocytosis. The diseases are identified by their corresponding ICD-10 codes. The drug being tested is ruxolitinib. The eligibility criteria for the trial include being diagnosed with PMF or Post-PV/ET MF, requiring therapy for myelofibrosis, and having adequate bone marrow reserve. The exclusion criteria include having received anti-cancer medications or investigational therapy in the past 14 days.",
    "The sample is a record of a clinical trial in phase 1, focused on smoking cessation. The trial includes a list of ICD-10 codes for the disease, as well as a list of drugs being tested, which in this case are nicotine (2 mg) and nicotine (4 mg). The eligibility criteria for participants include being healthy smokers who usually smoke their first cigarette within 30 minutes of waking and having a body mass index within the range of 19-27 kilograms/meters^2. Participants who have used chewing tobacco or other tobacco products within 21 days of the screening visit are excluded from the trial.",
    "The sample is a record from a clinical trial table and includes information about the phase of the trial, which is phase 1, as well as the disease being studied, which is breast cancer. The ICD-10 codes associated with the disease are also listed. The drugs being tested in the trial are docetaxel, rad001, and dexamethasone. The eligibility criteria for the trial are also included, such as age requirements, disease diagnosis, and various health factors. Additionally, there are exclusion criteria listed, such as prior treatment with certain drugs or medical conditions that could interfere with the trial.",
    "The sample is a clinical trial for a drug combination of safinamide and levodopa for patients diagnosed with idiopathic Parkinson's disease. The trial is a phase 1/phase 2 trial and the eligibility criteria include being male or female, aged 30 years or older, having a BMI between 18-32 kg/m2, and being a levodopa-responsive patient with a stable dose of levodopa/carbidopa. The trial also requires a normal or non-hazardous 12-lead electrocardiogram recording, a negative beta-HCG test for females, and the ability to maintain an accurate dosing diary. The exclusion criteria include co-administration of certain drugs, being in a late stage of Parkinson's disease, having any indication of forms of Parkinsonism other than idiopathic Parkinson's disease, and having clinically relevant allergies or diseases that would exclude the subject from the study.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on treating Hodgkin's lymphoma, and the list of diseases includes only this one. The icd-10 codes associated with the disease are also listed. The trial involves the use of several drugs, including brentuximab vedotin, doxorubicin, vinblastine, dacarbazine, bleomycin, and brentuximab vedotin. The eligibility criteria for the trial are also listed, including requirements for treatment-naive Hodgkin lymphoma, measurable disease of at least 1.5 cm, and an Eastern Cooperative Oncology Group performance status of less than 3. There are also exclusion criteria, such as a history of another primary malignancy that has not been in remission for at least 3 years and known cerebral/meningeal disease.",
    "The sample is a phase 1 clinical trial for hypertension. The trial is looking for male or female participants who are at least 65 years old and have a BMI between 24 and 37 kg/m2. Participants must have a documented history of essential hypertension and be stable on treatment with an ACE inhibitor or angiotensin II receptor antagonist or renin antagonist and no more than one other antihypertensive medication at least 3 months before screening with a sitting SBP<180 mmHg and DBP<110 mmHg. All participants must be able to be safely withdrawn or down-titrated from all antihypertensive treatment(s) and transitioned to lisinopril 10 mg OD for the two-week run-in phase. The trial has a list of exclusion criteria, including any clinically relevant abnormality identified on the screening history, physical or laboratory examination, or any other medical condition or circumstance making the volunteer unsuitable for participation in the study. The trial is testing the efficacy of carvedilol cr capsules, placebo, and lisinopril as treatments for hypertension.",
    "The sample is a phase 1 clinical trial for a drug called aliskiren, along with a placebo and another drug called vtp-27999, for the treatment of renal function. The trial is open to healthy adult males and females between the ages of 18 and 75, with female subjects being postmenopausal or surgically sterilized. The trial has a list of exclusion criteria, including subjects under 18 or over 75 years of age, those with diabetes mellitus or kidney disease, and those with a history of myocardial infarction, stroke, or cardiovascular revascularization/angioplasty within the last 6 months. The trial also has a list of inclusion criteria, including subjects who are willing to use approved birth control methods for 2 weeks following completion of the study. The trial prohibits the use of any prescription drugs which may affect the renin-angiotensin-aldosterone system or with known effect on renal hemodynamics within 10 days prior to dosing or during the study. The trial also prohibits the use of any over-the-counter (OTC) medication, including herbal products, within the 14 days prior to dosing, unless approved by both the Investigator and the Sponsor. The trial has a list of other exclusion criteria, including a known hypersensitivity or contraindication to the study drugs (Aliskiren) or drugs similar to the study drugs or PAH, and inulin. The trial also prohibits the administration of any other investigational drug within 30 days of planned dosing in the study.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, ICD-10 codes associated with those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is studying prostate neoplasms and is in phase 1/phase 2. The drugs being used are abiraterone acetate, abiraterone acetate, and prednisone/prednisolone or dexamethasone. The eligibility criteria for participants include having confirmed adenocarcinoma of the prostate, no prior chemotherapy for prostate cancer, ongoing androgen deprivation therapy, and demonstrating disease progression after antiandrogen withdrawal. There are also exclusion criteria, such as having active psychiatric illnesses or uncontrolled autoimmune disease that may require corticosteroid therapy during the study.",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a trial that is in phase 1/phase 2 and involves patients with severe combined immunodeficiency disease, severe primary immunodeficiency disorder, undefined T cell deficiency disorder, or Wiskott-Aldrich syndrome. The trial requires patients to have an HLA mismatched family member or an HLA matched or mismatched unrelated donor, and they must meet certain health criteria such as having a life expectancy greater than 6 weeks and a Lansky/Karnofsky score of at least 70%. The trial excludes patients with an HLA matched related donor, symptomatic cardiac disease, known allergy to rat serum products, severe infection, HIV positive, or pregnant. The record also includes a list of icd-10 codes, drugs, and eligibility criteria.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on two diseases, B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma, which are identified by their respective ICD-10 codes. The trial is testing the effectiveness of a drug called PCI-32765. The eligibility criteria for participants include having a confirmed diagnosis of CLL or SLL and meeting at least one of several criteria for requiring treatment, such as progressive splenomegaly or lymphadenopathy. Participants must also have had one to three prior treatment regimens for CLL/SLL, an ECOG performance status of \u2264 1, and be at least 18 years old. Exclusion criteria include recent chemotherapy or radiation therapy, certain medical conditions or organ system dysfunction, and laboratory abnormalities. Participants must be willing and able to participate in all required evaluations and procedures and provide informed consent.",
    "The sample is a phase 1 clinical trial with only one disease, which is \"healthy\". The icd-10 codes associated with this disease are \"Z76.3\" and \"Z76.2\". The trial involves testing multiple drugs, including \"bi 691751\" and \"placebo\". The eligibility criteria for the trial include being a healthy male subject between the ages of 18 and 55 with a BMI range of 18.5 to 29.9 kg/m2 and a known genotype as specified in the study protocol. Any relevant deviation from healthy conditions is an exclusion criterion.",
    "The sample is a phase 1 clinical trial for the treatment of schizophrenia. The eligibility criteria include being between the ages of 18-40, having a current DSM-IV-TR diagnosis of schizophrenia, and being on a stable medication treatment regimen for at least 2 months. Exclusion criteria include having a history of poor compliance, being pregnant or breastfeeding, and having a history of Tardive dyskinesia or Neuroleptic Malignant Syndrome. The trial involves the drug PF-03654746 and requires participants to be in-patient for at least one week at the beginning of each treatment period. The study also includes various cognitive and psychiatric assessments.",
    "The sample is a record of a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating non-small cell lung cancer, specifically stage IIIA non-resectable or stage IIIB without pleural effusion. The trial drug being tested is called s-3304. The eligibility criteria for the trial includes having a performance status of 0-1, adequate organ function, and being clinically indicated and able to receive conventional chemoradiation therapy. Patients with prior history of cancer, other serious intercurrent illness including HIV/AIDS, or contraindicated for paclitaxel/carboplatin or thoracic irradiation treatment are excluded from the trial. The diseases and their corresponding ICD-10 codes are also listed in the record.",
    "The sample is a phase 1 clinical trial for the treatment of insomnia. The trial involves testing the effectiveness of drugs such as zopiclone and zolpidem tartrate sublingual tablet, as well as a placebo. The eligibility criteria for the trial include being between the ages of 21 and 64, having good health, possessing a valid driver's license for at least 3 years, and having driving experience of at least 3000 km/year. Exclusion criteria include a history of drug addiction or substance abuse, hypersensitivity to zolpidem or zopiclone, and having any additional condition that would affect sleep/wake function or prohibit the subject from completing the study. The trial requires signed informed consent from the participants.",
    "The sample is a clinical trial for phase 1, which involves testing the safety and dosage of a new drug called ziv-aflibercept in treating various types of brain tumors. The trial includes patients with diseases such as adult anaplastic astrocytoma, adult anaplastic oligodendroglioma, and recurrent adult brain tumor. The eligibility criteria for the trial include factors such as the patient's creatinine levels, pregnancy status, platelet count, and history of other cancers. Patients must also have a Karnofsky performance status of 60-100% and a life expectancy of at least 12 weeks. The trial excludes patients with a history of hypersensitivity to CHO cell products or other recombinant human antibodies, uncontrolled intercurrent illness, or clinically significant cardiovascular disease within the past 6 months.",
    "The sample is a phase 1 clinical trial for cancer patients with non-hematologic, malignant solid tumors, excluding primary brain or spinal tumors, who have no past or current involvement in the central nervous system. The trial is for Japanese patients who are at least 20 years of age and have at least one measurable lesion or evaluable disease according to RECIST (version 1.1). The trial is testing the efficacy of two drugs, bay80-6946 and bay80-6946, for advanced or refractory solid tumors that are not amenable to standard therapy. The eligibility criteria include having an Eastern Cooperative Oncology performance status (ECOG-PS) of 0 or 1, a life expectancy of at least 12 weeks, and not having received anticancer chemotherapy or immunotherapy during the study or within 4 weeks of first study treatment. The exclusion criteria include having a current diagnosis of Type I or II diabetes mellitus or fasting blood glucose level >125 mg/dL at screening, and/or HbA1c>/= 6.5%, past and current histories of cardiac disease congestive heart failure > New York Heart Association (NYHA) Class II, and being pregnant or breast feeding.",
    "The sample is a clinical trial for a drug called bi 10773, which is being tested on patients with type 2 diabetes mellitus. The trial is in phase 1 and the patients must meet certain eligibility criteria to participate. These criteria include being male or postmenopausal/hysterectomised female, having a proven diagnosis of type 2 diabetes mellitus, and being treated with diet and exercise or a maximum of two oral antidiabetic agents. The patients must also have a glycosylated haemoglobin A1 (HbA1c) level of 8.5% or less at screening, be within a certain age range, have a BMI between 18.5 and 40 kg/m2, and provide written informed consent. There are also exclusion criteria, such as not being on insulin or glitazones, having a fasted blood glucose level above 240 mg/dl, and having certain concomitant diseases or allergies. The trial aims to test the safety and efficacy of bi 10773 on patients with type 2 diabetes mellitus.",
    "The sample is a clinical trial for lupus nephritis, with a phase 1/phase 2 designation. The trial is looking at the effectiveness of the drug nkt-01 in treating the disease. The eligibility criteria for participants include being between the ages of 18-70, having a diagnosis of SLE according to the ACR criteria, having sufficient signs to diagnose active SLE nephritis, and meeting certain laboratory values. Exclusion criteria include chronic infections, liver toxicity, pregnancy or lactation, anemia, and history of malignancy. Participants cannot have major and active SLE organ involvement other than the kidney, and cannot have participated in another trial within the last 6 months.",
    "The sample is a phase 1 clinical trial for healthy volunteers aged 40 to 65 with a body mass index between 18 and 35 kg/m2. The trial involves the drugs aleglitazar, placebo, and ibuprofen. The eligibility criteria include being a non-smoker or smoking less than 5 cigarettes per day, drinking no more than 3 cups of coffee, tea, or soft drinks per day, and having no clinically relevant abnormal laboratory test results at screening. Exclusion criteria include a history of certain medical conditions, a positive test for HIV or hepatitis, and a history of intolerance to NSAIDs or aspirin.",
    "The sample is a clinical trial in the early phase 1 for patients with bladder carcinoma, infiltrative bladder carcinoma, or cystectomy. The trial involves the drug lapatinib and has specific eligibility criteria, including a life expectancy of at least 6 months, a Karnofsky performance status of at least 80%, and clinical stage T2NxM0 to T4aNxM0 bladder cancer. Patients must also have normal cardiac function and be able to swallow and retain oral medication. Female patients must have a negative pregnancy test and agree to use birth control. There are also exclusion criteria, such as prior pelvic radiation or neoadjuvant chemotherapy, pregnancy or breastfeeding, and other severe medical or psychiatric conditions.",
    "The sample is a phase 1 clinical trial for the treatment of eosinophilic esophagitis. The trial involves the use of beclomethasone dipropionate and a placebo. The eligibility criteria include being 18 years or older with a biopsy-proven diagnosis of EoE, willingness to undergo repeat EGDs with esophageal biopsies and blood work, and not having suspected or proven inflammatory bowel disease, malignancy, or collagen-vascular disease. Exclusion criteria include recent use of corticosteroids, pregnancy or breastfeeding, intolerance to beclomethasone, and history of certain medical conditions unless they have been stable in the last six months.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in both phase 1 and phase 2 and is focused on ovarian and primary peritoneal cancer. The ICD-10 codes associated with these diseases are listed, as well as the drugs being tested in each phase of the trial. The eligibility criteria for participants are also provided, including requirements for diagnosis, prior treatment, and measurable disease. Exclusion criteria are also listed, such as having received more than two lines of therapy for the cancer or being pregnant or breastfeeding.",
    "The sample is a phase 1 clinical trial for patients with locally advanced unresectable or borderline unresectable pancreatic cancer and no evidence of metastatic disease. The trial involves the use of gemcitabine and sorafenib as treatment. The eligibility criteria include confirmation of the diagnosis, age over 18, Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, measurable disease, tumor size of at least 2 cm, adequate organ function, negative pregnancy test for women of childbearing potential, and ability to understand and sign a written informed consent. Patients with a history of malignancy are eligible provided they have been curatively treated and demonstrate no evidence for recurrence of that cancer. The exclusion criteria include prior treatment with Gemcitabine within 6 months prior to registration, prior treatment with Sorafenib or other Ras or VEGF pathway inhibitors, prior radiation therapy to the upper abdomen, evidence of metastatic disease, clinical evidence of duodenal mucosal invasion by tumor, minor surgical procedure within 14 days of study registration, major surgical procedure, significant traumatic injury, or serious non-healing wound, ulcer or bone fracture within 21 days of study registration, and other severe, acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results.",
    "The sample is a clinical trial for ovarian cancer patients who have previously undergone platinum-based chemotherapy. The trial is in phase 1/phase 2 and the drug being tested is vandetanib. The eligibility criteria include having a documented invasive epithelial ovarian carcinoma, cancer of the fallopian tube or the peritoneum that is refractory to platinum-based chemotherapy or with partially platinum sensitive disease. Patients must also have received at least one previous platinum- and taxane-based chemotherapy regimen. Exclusion criteria include brain metastases or spinal cord compression, concomitant medications that may cause QTc prolongation or induce Torsades de Pointes or induce CYP3A4 function, and more than two prior lines of chemotherapy. The trial requires planned therapy with pegylated liposomal doxorubicin 50 mg/m\u00b2 for recurrent platinum-refractory ovarian cancer.",
    "The sample is a record from a clinical trial table and includes information about the trial phase, diseases being studied, ICD-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1 and is studying the effects of the drug bi 201335 on patients with liver cirrhosis and hepatitis C. The eligibility criteria include having a histologically proven liver cirrhosis, being a male patient or a female with certain medical history or conditions, being at least 18 years old, and providing written informed consent. The exclusion criteria include having active HBV, HCV or HIV infection, using any drug within 7 days prior to treatment, having decompensated liver disease within the past 12 months, and having a history of alcohol abuse within the past 3 months, among others.",
    "The sample is a phase 1 trial with only healthy participants. The trial involves the administration of multiple escalating doses of a drug called \"birt 2584 xx\" and a placebo. The eligibility criteria for the trial include being a healthy male between the ages of 18 and 63 with a BMI between 18.5 and 29.9 kg/m2. Exclusion criteria include any medical findings that deviate from normal, gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hematological, oncological, or hormonal disorders, history of orthostatic hypotension, fainting spells, or blackouts, chronic or relevant acute infections, history of allergy/hypersensitivity, intake of drugs with a long half-life, use of any drugs that might influence the results of the trial, participation in another trial with an investigational drug, smoking, alcohol abuse, drug abuse, blood donation or loss greater than 400 mL, and clinically relevant laboratory abnormalities.",
    "The sample is a phase 1 clinical trial for patients with various types of leukemia, myelodysplastic syndromes, and myeloproliferative disorders. The trial is testing the effectiveness of the drugs vorinostat, cytarabine, and etoposide. Patients must meet certain eligibility criteria, including having a confirmed diagnosis of relapsed or refractory AML, relapsed or refractory ALL, or CML in accelerated or blastic phase. Patients must also have a certain performance status, normal liver and kidney function, and not be pregnant or nursing. The trial allows for emergency leukapheresis or hydroxyurea to reduce leukemic blast count and concurrent hydroxyurea or leukapheresis to control rising leukemic blasts.",
    "The sample is a phase 1 clinical trial for patients with advanced or metastatic solid tumors, specifically bladder cancer. The trial is testing the effectiveness of gemcitabine plus carboplatin or gemcitabine plus cisplatin as a treatment option. The eligibility criteria include being at least 18 years old, having a Karnofsky Performance Status of at least 70%, and having received no more than three prior chemotherapeutic regimens. Patients must also have adequate organ function and meet certain laboratory value requirements. Exclusion criteria include having had major surgery within 30 days of starting the study treatment, having active CNS metastases, and being pregnant or breastfeeding.",
    "The sample is a record of a clinical trial in phase 1. The trial is focused on the disease \"healthy\" and the icd-10 codes associated with it are \"Z76.3\" and \"Z76.2\". The trial involves the drugs \"bi 409306\" and \"placebo\". The eligibility criteria for the trial include being a healthy male Chinese or Japanese volunteer between the ages of 20 and 45 with a BMI between 18.5 and 25 kg/m2 and a known genotype as specified in the study protocol. The subjects must also be able to understand and comply with study requirements. Any deviation from a healthy condition is an exclusion criteria.",
    "The sample is a phase 1 clinical trial for premature obstetric labor. The trial includes both male and female participants between the ages of 18 and 45 who are healthy and meet certain medical criteria. Female participants must be of child-bearing potential and agree to use contraception during the study. The trial involves the use of several drugs, including retosiban, moxifloxacin, and a placebo. The eligibility criteria for the trial are listed, including exclusion criteria such as a positive pre-study drug/alcohol screen, a positive test for HIV antibody, and a history of sensitivity to any of the study medications. The sample also includes detailed inclusion and exclusion criteria for the trial participants.",
    "The sample is a clinical trial for phase 1, with the disease being colon cancer. The trial involves the drug metformin and has a list of inclusion and exclusion criteria for participants. Inclusion criteria include having histologically documented colorectal cancer, being medically fit for resection of their primary tumor or for biopsy, and having adequate renal and hepatic function. Exclusion criteria include current use of metformin, significant medical conditions such as cardiovascular collapse or hepatic disease, and being pregnant or lactating. The trial requires participants to understand and sign a written informed consent document.",
    "The sample is a phase 1 clinical trial for patients with relapsed or refractory low or intermediate-grade B-cell lymphoma. The trial is testing the drug clofarabine. The eligibility criteria include being at least 18 years old, having measurable disease, and having a normal cardiac function. Patients must also have received at least one standard chemotherapy regimen and not have received Rituximab alone without a cytotoxic agent. Exclusion criteria include having previously untreated B-cell lymphoma, having received previous treatment with clofarabine, and having an active or untreated central nervous system lymphoma. Patients must also not have any significant concurrent disease or illness that would compromise their safety or compliance.",
    "The sample is a record of a clinical trial in phase 1, focused on neoplasms. The trial includes a list of icd-10 codes for the diseases being studied. The trial involves the use of three drugs: azd0530, carboplatin, and paclitaxel. The eligibility criteria for the trial include a life expectancy of more than 12 weeks, post-menopausal women, and male or female patients with locally advanced or metastatic cancer suitable for treatment with carboplatin and/or paclitaxel. The exclusion criteria include inadequate bone marrow reserve, inadequate liver or kidney function, and unresolved toxicity from anti-cancer therapy.",
    "The sample is a phase 1 clinical trial for patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. The trial is testing the effectiveness of oral azacitidine as a treatment. The eligibility criteria include being 18 years or older, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, and having adequate organ function. Females of childbearing potential must agree to use at least two effective contraceptive methods throughout the study. The exclusion criteria include having a known or suspected hypersensitivity to azacitidine or mannitol, being pregnant or lactating, and having any significant medical condition or psychiatric illness that would prevent participation in the study.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on neoplasms, which are cancerous growths. The icd-10 codes associated with the diseases are listed as \"C05.2\", \"C10.0\", \"C16.0\", \"C16.4\", \"C17.0\", \"C17.1\", and \"C17.2\". The trial involves the use of three drugs, all named \"rg4733\". The eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being an adult patient over 18 years of age with advanced and/or metastatic solid tumor malignancy, measurable or evaluable disease, and an ECOG performance status of 0 or 1. Exclusion criteria include having received prior chemotherapy, radiotherapy, or immunotherapy within 28 days of the first receipt of the study drug, having received prior corticosteroids as anti-cancer therapy within a minimum of 14 days of the first receipt of the study drug (except for dexamethasone as part of supportive care measures), and having undergone major surgery within 28 days of the first receipt of the study drug.",
    "The sample is a clinical trial for a vaccine for influenza. The trial is a combination of phase 1 and phase 2. The trial is looking for male or non-pregnant female participants between the ages of 18 and 40 who are in good health and able to understand and comply with the study procedures. The trial has a list of exclusion criteria, including allergies to vaccine components, immunosuppression, neoplastic disease, and long-term use of certain steroids. Participants must provide informed consent and be available for all study visits. The trial is looking to evaluate the safety and efficacy of the vaccine.",
    "The sample is a phase 1 clinical trial for patients with non-small cell lung cancer who have either metastatic or recurrent cancer and have failed at least one prior platinum-based chemotherapy. Patients who have had previous surgery and/or radiation may also participate. The trial involves the drug docetaxel and has eligibility criteria including age, disease status, brain metastases, measurable or non-measurable disease, ANC and platelet count, hepatic function, lung function, and performance status. Exclusion criteria include prior use of single-agent, weekly docetaxel chemotherapy, peripheral neuropathy, and pregnancy or nursing.",
    "The sample is a clinical trial for patients with non-small cell lung cancer in stages IIIA or IIIB. The trial is a combination of chemotherapy and thoracic conformal radiotherapy. Patients must meet certain eligibility criteria, including having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, certain blood counts, lung function, and kidney and liver function within normal limits. Patients must also not have certain medical conditions or recent surgeries, and cannot be participating in any other experimental drug studies or receiving other antineoplastic or antitumor agents.",
    "The sample is a clinical trial for patients with acute myeloid leukemia, myelodysplastic syndrome, or multiple myeloma. The trial is in phase 1/phase 2 and the drug being tested is chr-2797 (tosedostat), an aminopeptidase inhibitor. The eligibility criteria include signed informed consent, recovery from prior therapies, adequate bone marrow, hepatic and renal function, and a negative pregnancy test for female patients with reproductive potential. Exclusion criteria include concurrent illness, psychiatric disorders, and pregnancy or breastfeeding. The sample also includes lists of disease names, icd-10 codes, and drugs being studied.",
    "The sample is a phase 1 clinical trial for patients with advanced malignancy, including solid tumors and lymphoma, that are metastatic or unresectable. The trial is testing the drug XL184. The eligibility criteria include having an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less, a life expectancy of greater than 3 months, and adequate organ and marrow function. In addition, subjects must have written informed consent and use acceptable methods of contraception during the study and for 3 months after completion. The trial also has exclusion criteria, such as not having recovered from adverse events due to investigational agents or other medications administered more than 4 weeks before study enrollment, known brain metastases, uncontrolled intercurrent illness, pregnancy or breastfeeding, known HIV positive, and known allergy or hypersensitivity to any of the components of the XL184 formulation. The trial is also looking for at least 20 subjects with metastatic and/or advanced/locally recurrent Medullary Thyroid Cancer not appropriate for surgical resection with measurable disease as defined by RECIST in the MTD expanded cohort.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on prostate cancer and the icd-10 codes associated with it. The drug being tested is called odm-201. The eligibility criteria for the trial include having a confirmed diagnosis of adenocarcinoma of the prostate, ongoing androgen deprivation therapy, progressive metastatic disease, and adequate bone marrow, hepatic, and renal function. The exclusion criteria include having known metastases in the brain, a history of other malignancy within the previous 5 years, known gastrointestinal disease or procedure that affects absorption, and not being able to swallow the study drug.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on treating patients with locally advanced unresectable or metastatic gastric, gastro-oesophageal or colorectal adenocarcinoma using a combination of drugs including xeloda, oxaliplatin, and tki258. The record includes a list of diseases and their corresponding icd-10 codes, as well as eligibility criteria for patients to participate in the trial. The criteria include age, performance status, life expectancy, normal organ and marrow function, and willingness to use contraception. The record also lists exclusion criteria, such as prior history of certain medical conditions and unwillingness to provide tumor tissue for correlative studies.",
    "The sample is a phase 1 clinical trial for the treatment of cancer of the esophagus, adenocarcinoma of the gastroesophageal junction, and cancer of the stomach. The trial involves the use of drugs such as vandetanib, 5 fluorouracil (fu), carboplatin, and paclitaxel. The eligibility criteria for the trial include having a histologically documented carcinoma of the esophagus, gastroesophageal junction, or stomach for which chemo/radiation therapy is appropriate, being potentially resectable, having an Eastern Cooperative Oncology Group Performance Status of 0-2, having no evidence of distant metastases, being 18 years or older, and signing informed consent. Exclusion criteria include previous radiation therapy to chest or upper abdomen, evidence of severe or uncontrolled systemic disease, impaired cardiac function, inadequate pulmonary and cardiac function to tolerate surgery, history of arrhythmia, previous history of QTc prolongation, congenital long QT syndrome, presence of left bundle branch block, hypertension not controlled by medical therapy, being currently pregnant or breast feeding, previous or current malignancies within the last 5 years, receipt of any investigational agents within 30 days prior to commencing study treatment, and uncontrollable diarrhea that may affect the ability of the patient to absorb ZD 6474 or tolerate side-effects. The laboratory results required for eligibility include adequate bone marrow function, serum bilirubin, serum creatinine, potassium, serum calcium, magnesium, alanine aminotransferase, and aspartate aminotransferase.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on Alzheimer's disease and the ICD-10 codes associated with it. The trial involves two drugs, pf-03654746 and a placebo. The eligibility criteria for the trial include having probable Alzheimer's disease, a Mini Mental State Examination score between 18-26, and being between the ages of 55-85. The exclusion criteria include having a form of dementia other than Alzheimer's disease, clinically significant cardiovascular disease in the past 6 months prior to screening, and a creatinine clearance of less than 30 mL/min.",
    "The sample is a phase 1 clinical trial for patients with advanced or metastatic cancer, including non-small cell lung cancer, renal cell carcinoma, and neuroendocrine tumors. The trial is testing the effectiveness of the drugs ly2584702, erlotinib, and everolimus. The eligibility criteria include having measurable or nonmeasurable disease, adequate organ function, and a performance status of less than or equal to 1 on the Eastern Cooperative Oncology Group (ECOG) scale. Participants must have discontinued all previous cancer therapies for at least 2 weeks (3 weeks for myelosuppressive agents) prior to study enrollment and have recovered from the acute effects of therapy. Exclusion criteria include serious preexisting medical conditions, symptomatic central nervous system malignancy or metastasis, and concomitant treatment by strong cytochrome P450 (CYP) 3A4 inhibitors or CYP3A4 inducers.",
    "The sample is a phase 1 clinical trial for East Asian participants who are 18 years or older and have metastatic and/or advanced solid tumors or lymphomas for which no effective standard treatment is available. The trial is testing the drug alisertib. Inclusion criteria include having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, expected survival longer than 3 months from study enrollment, and having a radiographically or clinically evaluable tumor. Female participants must be post-menopausal for at least 1 year, surgically sterile, or agree to practice 2 effective methods of contraception through 30 days after the last dose of study drug or agree to abstain from heterosexual intercourse. Male participants must agree to practice effective barrier contraception through 6 months after the last dose of alisertib or agree to abstain from heterosexual intercourse. Exclusion criteria include lactating or pregnant females, treatment with any investigational products, systemic antineoplastic treatment, or antineoplastic treatment with glucocorticoids within 21 days preceding the first dose of alisertib, and major surgery within the 14 days preceding the first dose of alisertib.",
    "The sample is a clinical trial for ovarian cancer patients in phase 1/phase 2. The trial involves the use of drugs such as carboplatin, cyclophosphamide, etoposide, paclitaxel, and topotecan hydrochloride. The eligibility criteria for the trial include having histologically proven stage IIIC ovarian epithelial cancer, being chemosensitive to 6-8 courses of standard dose adjuvant chemotherapy, and having achieved at least partial response (PR) following six courses of standard dose chemotherapy. Patients must also meet certain patient characteristics such as being between the ages of 18 and 65, having a performance status of ECOG 0 or 1, and having no active infections or other malignancies within the past 5 years. The trial excludes patients who have no microscopic disease present following induction chemotherapy or who have histologically proven newly diagnosed stage IV ovarian epithelial cancer. Prior concurrent therapy is not specified, and patients must not be taking concurrent nitroglycerin preparations or antiarrhythmic drugs.",
    "The sample is a clinical trial for the treatment of metastatic malignant melanoma using the drugs karenitecin and valproic acid. The trial is divided into two phases, phase 1 and phase 2. The eligibility criteria for both phases include having cytologically/histologically-documented metastatic malignant melanoma, being at least 18 years old, having an ECOG performance status of 0-2, and being able to give informed consent and follow the study guidelines. Additionally, subjects must have no major impairment of hematological function and use an effective method of contraception during the study and three months following termination of treatment. The exclusion criteria for both phases include having evidence of significant active infection, inadequate renal or hepatic function, being pregnant or nursing, having uncontrolled CNS metastasis or a history of seizures, and having been previously treated with more than 2 prior chemotherapy regimens. The criteria for phase 2 also include having previously received any immunotherapy regimens. Subjects with stable CNS metastasis are eligible for both phases.",
    "The sample is a phase 1 clinical trial for patients with cutaneous T-cell lymphoma that is refractory to prior treatment. The trial is testing the effectiveness of forodesine hydrochloride. Patients must have stage IIA, IIB, III, IVA, or IVB disease and measurable disease. They must also meet certain eligibility criteria, including being 18 years or older, having a performance status of ECOG 0-2, and having a life expectancy of at least 3 months. Patients must not have certain medical conditions, such as impaired absorption of the gastrointestinal tract or active serious infections not controlled by antibiotics. They must also not be pregnant or nursing and must use effective contraception if fertile. Prior concurrent therapy is not specified for biologic therapy or surgery, but patients must have recovered from chemotherapy and investigational agents for more than 21 and 30 days, respectively. Patients must not have concurrent radiotherapy or tanning bed use and must not have other concurrent therapy for cutaneous T-cell lymphoma.",
    "The sample is a clinical trial for ovarian cancer patients who have previously undergone platinum-based chemotherapy. The trial is a combination of lenvatinib, carboplatin, and gemcitabine. The eligibility criteria include being a female over 18 years old, having confirmed ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer, and meeting specific laboratory values. Participants must have recovered from any major surgery within 28 days of the first dose of study treatment and have a life expectancy of at least 3 months. Exclusion criteria include being pregnant or breastfeeding, having received prior anti-angiogenic therapy with anti-VEGFR inhibitors, or having a history of bleeding diathesis or coagulopathy.",
    "The sample is a clinical trial for early phase 1 breast cancer patients who have not responded to tamoxifen treatment. The trial is testing the effectiveness of the drug panobinostat (lbh589). The eligibility criteria include being a female over 18 years old, having stage IV breast cancer, having an Eastern Cooperative Oncology Group (ECOG) performance status of \u2264 2, and meeting certain laboratory criteria. Exclusion criteria include having prior treatment with certain inhibitors, impaired cardiac function, uncontrolled hypertension, and other severe medical conditions. Women of childbearing potential must have a negative pregnancy test and use two methods of contraception during the study and for 3 months after the last study drug administration.",
    "The sample is a record of a clinical trial in phase 1, focused on treating tumors. The trial involves two drugs, azd1152 part a and azd1152 part b. The eligibility criteria for the trial include having a confirmed diagnosis of a solid, malignant tumor and having at least one measurable or non-measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Exclusion criteria include recent participation in an investigational drug study within the 21 days prior to therapy or recent major surgery within 4 weeks prior to entry into the study.",
    "The sample is a phase 1 clinical trial for patients with advanced, non-resectable, and/or metastatic solid tumors. The trial is testing the drug \"bi 6727\". The eligibility criteria for the trial include having a confirmed diagnosis of advanced solid tumor, being male, aged between 18 and 70 years, having an Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to 2, and having recovered from previous therapy-related toxicities. The exclusion criteria include having serious concomitant non-oncological disease, active infectious disease, viral hepatitis, HIV infection, clinical evidence of active brain metastasis, second malignancy currently requiring active therapy, and other medical conditions. The trial also excludes patients who are sexually active and having a partner with childbearing potential and unwilling to use a medically acceptable method of contraception, and those who have a history of allergy/hypersensitivity.",
    "The sample is a phase 1 clinical trial for HIV infections. The trial is looking at the effectiveness of two drugs, raltegravir and emtricitabine/tenofovir disoproxil fumarate, on HIV-infected individuals who have not yet received antiretroviral treatment. The trial has specific inclusion and exclusion criteria, such as having a viral load between 10,000 and 300,000 copies/ml and not having any major resistance-associated mutations. Participants must also agree to use appropriate contraception. The trial excludes individuals who have received HIV-specific immunizations within the past 6 months, have allergies to the study drugs, or have any major illnesses requiring hospitalization. Pregnant or breastfeeding individuals are also excluded.",
    "The sample is a phase 1 clinical trial for antivirals/hiv disease. The trial involves the use of two drugs, rifabutin and rifabutin + atazanavir + ritonavir. The eligibility criteria for the trial include healthy male and female subjects between the ages of 18 to 50 years old with a body mass index (BMI) of 18 to 32 kg/m\u00b2. Prior to enrollment, subjects must have physical and laboratory test findings within the normal limits, and women of childbearing potential (WOCBP) must have a negative pregnancy test. The exclusion criteria include any significant acute or chronic medical illness, evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, electrocardiogram (ECG) or clinical laboratory determinations, use of any prescription drugs or over-the-counter acid controllers within 4 weeks prior to study drug administration, and use of any other drugs, including over-the-counter medications of herbal preparations within 1 week prior to study drug administration.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating hepatocellular carcinoma, and the drugs used are mapatumumab, placebo, and sorafenib. The eligibility criteria include having Child-Pugh Class A, measurable disease demonstrating intratumoral arterial enhancement, adequate bone marrow, renal and liver function, performance status of 0, 1 or 2 on the Eastern Cooperative Oncology Group (ECOG) Scale, and age 18 years or older. The exclusion criteria include having any co-morbid condition that in the judgment of the investigator renders the subject at high risk of treatment complications or reduces the possibility of assessing clinical effect, received prior investigational or non-investigational cytotoxic chemotherapy, hormonal therapy, biological therapy, history of organ allograft, previously received mapatumumab or sorafenib, underwent resection, radiofrequency ablation, radiation or chemoembolization within 4 weeks before enrollment or not recovered from such treatments, need for concomitant anticancer therapy, major surgery within 4 weeks before enrollment, minor surgery within 2 weeks before enrollment, systemic steroids within 1 week before enrollment except steroids used as part of an antiemetic regimen or maintenance-dose steroids for non-cancerous disease, hepatic encephalopathy, per the investigator's evaluation, history of clinically significant gastrointestinal bleeding requiring procedural intervention within 4 weeks before enrollment, gastrointestinal disease resulting in an inability to take oral medication or a requirement for intravenous hyperalimentation, history of any infection requiring hospitalization or intravenous antibiotics within 2 weeks before enrollment, known brain or spinal cord metastases unless adequately treated, known human immunodeficiency virus infection, unstable angina, myocardial infarction, cerebrovascular accident, >= Class II congestive heart failure according to the New York Heart Association Classification for Congestive Heart Failure within 6 months before enrollment, cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin, uncontrolled hypertension, using and unable to discontinue use of concomitant strong CYP3A4 inducers, pregnant female or nursing mother, males who do not agree to use effective contraception during the study and for a period of 60 days following the final dose of study agent, subject is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s) or subject is receiving other investigational agents, acute or chronic severe renal insufficiency, and hepatitis B virus deoxyribonucleic acid (DNA) levels >2,000 international units/mL.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on pancreatic neoplasms, which is the only disease listed. The icd-10 code for this disease is C25.3. The trial is testing the effectiveness of two drugs, nelfinavir and gemcitabine. The eligibility criteria for the trial is listed as \"Closed to accrual.\"",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for patients to participate in the trial. In this particular sample, the trial is a combination of phase 1 and phase 2, and the disease being studied is colorectal neoplasms. The icd-10 codes associated with the disease are listed, as well as the drugs being tested, which include bevacizumab, ag-013726, and ag-013736 (axitinib). The eligibility criteria for patients to participate in the trial are also listed, including requirements for previous chemotherapy, measurable disease, and controlled hypertension. Additionally, there are exclusion criteria listed, such as prior treatment with anti-angiogenesis agents or radiation.",
    "The sample is a clinical trial for ovarian cancer patients who have failed at least one prior platinum-based chemotherapy regimen. The trial is a combination of phase 1 and phase 2, and the drugs being tested are sorafenib and topotecan. The eligibility criteria include having histologically-confirmed epithelial ovarian cancer, measurable disease according to RECIST or detectable disease by CA-125, ascites and/or pleural effusion attributed to tumor, and solid and/or cystic abnormalities on radiographic imaging. Patients must also have failed at least one prior platinum-based chemotherapeutic regimen and have no more than 3 prior treatment regimens for epithelial ovarian cancer. The exclusion criteria include no known or suspected allergy to sorafenib or any agent given in the course of this trial, no prior treatment with anti-angiogenesis therapy, no active CNS metastases, and no treatment with any investigational agent within 30 days prior to being registered for protocol therapy.",
    "The sample is a record of a clinical trial that is in phase 1/phase 2. The trial is focused on the treatment of multiple sclerosis using smoked cannabis. The eligibility criteria for the trial include a diagnosis of clinically definite multiple sclerosis, moderate or severe spasticity, and being 21 years or older. However, there are also exclusion criteria, such as preexisting pulmonary or cardiac conditions, inability to abstain from tobacco or marijuana smoking, and a history of abuse of recreational drugs. The sample also includes a list of icd-10 codes for the disease and the inclusion and exclusion criteria for the trial.",
    "The sample is a phase 1 clinical trial for patients with relapsed or refractory Acute Myeloid Leukemia (AML) or untreated AML patients who are unlikely to benefit from standard induction chemotherapy. The trial involves the drug clofarabine and has eligibility criteria including age, performance status, and satisfactory hepatic, renal, pancreatic, and cardiac function. Exclusion criteria include prior hematologic stem cell transplant, prior external beam radiation therapy to the pelvis, and other severe concurrent diseases. Patients with certain types of cancer or infections are also excluded. Patients must agree to use effective birth control during the study period and for six months after the last dose of the study drug.",
    "The sample is a phase 1 clinical trial for the treatment of chronic hepatitis C. The trial includes subjects who are either treatment-naive or treatment-experienced non-responders or relapsers. The eligibility criteria include having an HCV RNA viral load of >10^5 copies/mL, a BMI of 18 to 40 kg/m^2, and acceptable medical history and clinical laboratory evaluations. The trial also includes exclusion criteria such as having a significant acute or chronic medical illness, evidence of decompensated liver disease, or a history of any clinically significant local or systemic infectious disease within 1 week prior to screening. The trial involves the use of multiple drugs, including SCH 900518 and ritonavir, and requires subjects to practice effective contraception methods.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying urinary bladder neoplasms. The icd-10 codes associated with the disease are listed as \"['D30.3', 'C67.5', 'C67.9', 'C79.11', 'C67.0', 'C67.1', 'D41.4']\". The drug being tested is lenalidomide. The eligibility criteria for participants include being over 18 years old, having a Karnofsky Performance Status of \u2265 70%, having histological or cytological proof of transitional cell carcinoma of the urothelial tract, having measurable disease according to RECIST or unresectable disease (cT4b), and meeting certain laboratory value requirements. There are also exclusion criteria, such as having received prior treatment with systemic chemotherapy for metastatic disease or having a clinically significant infection.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on treating carcinoma, renal cell, and involves the drug topotecan. The eligibility criteria for the trial include having histologically confirmed rectal cancer, being a candidate for preoperative radiotherapy, having a primary tumor of at least 3cm and clinical stage of T2, T3, or T4, and having an Eastern Cooperative Oncology Group (ECOG) performance status less than 2. The trial also has exclusion criteria, such as having a primary tumor that has already been totally excised, having exposure to topotecan, having any concomitant malignancy within the last five years, and having severe medical problems unrelated to the malignancy which would limit compliance with the study.",
    "This sample is for a phase 1 clinical trial for patients of Chinese origin who are at least 18 years old and have metastatic renal cell carcinoma. The trial is testing the drug everolimus (rad001). The eligibility criteria include having a measurable lesion, a Karnofsky Performance Status of at least 70%, adequate bone marrow, liver, and renal function, and a negative pregnancy test for women of childbearing potential. Exclusion criteria include having received certain treatments within a certain timeframe, a history of hypersensitivity to the drug or its excipients, and certain medical conditions. Patients must provide written informed consent to participate in the trial.",
    "The sample is a phase 1 clinical trial for patients with relapsed or relapsed/refractory multiple myeloma. The trial is testing the drugs rad001 and lenalidomide. The eligibility criteria include being previously diagnosed with multiple myeloma, being 18 years or older, having an ECOG Performance Status of 0 to 2, and being able to take aspirin daily as prophylactic anticoagulation. Exclusion criteria include renal insufficiency, concurrent therapy with corticosteroids or other chemotherapy, poorly controlled diabetes mellitus, and prior therapy with RAD001. The sample also includes a list of diseases, icd-10 codes, and eligibility criteria.",
    "The sample is a phase 1 clinical trial for the treatment of overactive bladder and overactive urinary bladder. The trial involves the use of drugs such as vibegron, tolterodine er, and prophylactic antibiotic. The eligibility criteria for participants include having a clinical history of overactive bladder symptoms for at least 3 months, being non-pregnant and agreeing to use two acceptable methods of birth control, having a BMI of \u226440 kg/m^2, and being capable of completing an accurate daily diary for reporting purposes. Exclusion criteria include having other types of urinary incontinence, a history of interstitial cystitis or chronic pelvic pain, and having a history of narrow angle glaucoma, stroke, chronic seizures, or other serious and chronic organ-system health conditions. Participants must also refrain from smoking and illicit drug use throughout the study's duration.",
    "The sample is a phase 1 clinical trial for patients with ovarian, fallopian tube, or primary peritoneal cancer that has progressed or recurred in the abdomen or pelvis after salvage chemotherapy. The trial involves the use of the drug alemtuzumab. The eligibility criteria include having measurable disease or elevated CA125, being over 18 years old, having a performance status less than 2, and having adequate organ and marrow function. Patients must also be willing to sign an informed consent document. Exclusion criteria include having known immunosuppressive diseases, receiving any other agents with therapeutic intent, having a history of allergic reactions to alemtuzumab or other humanized immunotherapeutics, and having unresolved bacterial, fungal, or viral infections requiring active treatment.",
    "The sample is a phase 1 clinical trial for patients with malignant melanoma and evidence of metastatic disease. The trial involves the drugs lenalidomide and dacarbazine. The eligibility criteria include being at least 18 years old, having a histological documentation of malignant melanoma, and meeting certain laboratory test ranges. Patients must also be able to take medications orally and adhere to the study visit schedule. Exclusion criteria include pregnancy or lactation, prior treatment with systemic chemotherapy, and concurrent use of any other anti-cancer agents. The trial also has specific requirements for contraception and sexual activity for female patients of childbearing potential and male patients.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on chronic hepatitis B and involves the use of two drugs, gs-7340 and tenofovir disoproxil fumarate. The eligibility criteria for participants include being between 18 and 65 years old, having a certain level of HBV DNA in their plasma, having chronic HBV infection for at least 6 months, and having a certain level of estimated creatinine clearance. Participants must also not be pregnant or nursing, and women must have negative pregnancy tests. The trial has exclusion criteria, including not allowing pregnant or lactating subjects, those who have received anti-HBV nucleoside/nucleotide therapy, and those with co-infections or autoimmune disorders. The sample also includes a list of ICD-10 codes for the disease and the inclusion and exclusion criteria for the trial.",
    "The sample is a phase 1 clinical trial for the treatment of essential hypertension. The trial involves testing the efficacy of two drugs, qgc001 and placebo, on Caucasian male healthy subjects between the ages of 18 and 45. The subjects must have a body weight of at least 50 kg and a body mass index between 18 and 27 kg/m2. They must also be non-smokers or smoke fewer than 5 cigarettes per day and have a high probability of compliance with and completion of the study. The eligibility criteria include a medical history, physical examination, clinical laboratory test results, vital sign measurements, and digital 12 lead ECG readings. The exclusion criteria include any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatological, haematological, neurologic, psychiatric disease or history of any clinically important drug allergy, acute disease state within 7 days before study day 1, history of drug abuse within 1 year before study day 1, history of alcoholism within 1 year before day 1, positive serologic findings for human immunodeficiency virus antibodies, hepatitis B surface antigen, and/or hepatitis C virus antibodies, positive findings of urine drug screen, use of any investigational drug within 90 days or prescription drug within 30 days before investigational medical product administration, consumption of any caffeine-containing products in excess of 6 cups per day (or equivalent), of grapefruit, grapefruit-containing products, or alcoholic beverages within 24 hours before study day 1, use of any over-the-counter drugs including herbal supplements (except for the occasional use of acetaminophen [paracetamol], aspirin and vitamins \u2264100% recommended daily allowance) within 7 days before investigational medicinal product administration, and donation of blood (i.e. 450 ml) within 90 days before study day 1.",
    "The sample is a clinical trial for patients with advanced non-small cell lung cancer. The trial is in phase 1/phase 2 and involves the use of carboplatin, hydroxychloroquine, and paclitaxel as drugs. The eligibility criteria include having a confirmed diagnosis of advanced non-small cell lung cancer, with no component of squamous cell carcinoma, and measurable disease. Patients must also have an ECOG performance status of 0-1 and meet certain laboratory values. They cannot have certain medical conditions or ongoing infections, and must not be pregnant or nursing. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 1 clinical trial for patients with advanced colorectal cancer. The trial involves the use of two drugs, OSI-906 and irinotecan, and has different cohorts with specific eligibility criteria. Patients must have a histological or cytopathological diagnosis of advanced colorectal cancer with known Kirsten rat sarcoma (KRAS) mutation status and have received and progressed or be intolerable of first-line therapy with an oxaliplatin-containing regimen. Patients must also have an Eastern Co-operative oncology group (ECOG) performance status of 0-1 and a life expectancy of at least three months. The trial has various inclusion and exclusion criteria, including adequate hematological, hepatic, and renal function, and the ability to understand the requirements of the study and comply with the study protocol procedures.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on the disease of acute ischemic stroke and includes a list of ICD-10 codes associated with the disease. The trial involves the drugs mrx-801 and placebo. The eligibility criteria for the trial include having an acute ischemic stroke with occlusion demonstrated by transcranial Doppler ultrasound and being eligible for tPA. The exclusion criteria include having a right to left cardiac shunt, moderate to severe COPD, and uncontrolled hypertension.",
    "The sample is a clinical trial for type 1 diabetes mellitus, with a phase 1/phase 2 designation. The trial involves the drug lisofylline and has a list of inclusion and exclusion criteria for participants. Inclusion criteria include being between the ages of 18 and 45, having a clinical diagnosis of type 1 diabetes for at least 2 years, and being on a stable dose of insulin for at least 3 months. Exclusion criteria include having significant stomach, liver, kidney, or heart disease, a personal or family history of long QTc syndrome, and a history of drug or alcohol abuse.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial (phase 1/phase 2), the disease being studied (recurrent childhood acute lymphoblastic leukemia), the corresponding ICD-10 codes, the drugs being used in the trial (l-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone, vincristine sulfate, cytarabine, prednisone, pegaspargase, dexrazoxane hydrochloride, methotrexate, etoposide, cyclophosphamide, leucovorin calcium), and the eligibility criteria for participants. The eligibility criteria include specific requirements related to the diagnosis of B lymphoblastic leukemia, performance status, blood count, liver and kidney function, heart function, and other health factors. Participants must also have recovered from prior treatments and not be receiving any other concurrent therapies or investigational drugs.",
    "The sample is a clinical trial for asthma patients in phase 1/phase 2. The trial involves testing the effectiveness of two drugs, active and placebo, on patients with mild bronchial asthma who are currently being treated only with intermittent short-acting beta-agonist therapy by inhalation. The trial has inclusion criteria such as a BMI between 18.5 and 35 kg/m2, nonsmoking for \u2265 one year, and a pre-bronchodilator FEV1 \u2265 75% of predicted at screening. The trial also has exclusion criteria such as hypertension, respiratory tract infection and/or exacerbation of asthma within prior 4 weeks, and history of life-threatening asthma. The trial requires patients to undergo methacholine testing and have a provocation concentration of methacholine resulting in a 20% fall in FEV1 (PC20 methacholine) of \u2264 8 mg/ml at screening. The sample also includes a list of icd-10 codes of diseases associated with asthma.",
    "The sample is a phase 1 clinical trial for patients with advanced cancers that are refractory to standard treatment or for which no standard therapy is available. The trial involves the use of three drugs: azacitidine, lenalidomide, and grifola frondosa. The eligibility criteria include having an ECOG performance status of 2 or better, normal organ and marrow function, and being able to understand and sign an informed consent document. Female patients of childbearing potential must have a negative pregnancy test and commit to using two forms of birth control. Patients must be 18 years or older and have a life expectancy greater than 3 months. Exclusion criteria include uncontrolled intercurrent illness, history of stroke or transient ischemic attack, allergic reactions to the study drugs, and concurrent enrollment in another research study.",
    "The sample is a phase 1 clinical trial for asthma. The trial is looking at the effectiveness of the drugs gw870086x and placebo. The eligibility criteria for the trial includes male subjects aged 18-55 with a documented history of bronchial asthma diagnosed at least 6 months ago, who are only being treated with short-acting beta-2-agonist therapy, and who demonstrate sensitivity to adenosine mono phosphate (AMP) at the screening visit. The exclusion criteria includes subjects with any significant illness or disease, history of life-threatening asthma, history of respiratory tract infection, smokers, subjects who are oversensitive to corticosteroids, history of drug or alcohol abuse, and subjects who work night shifts or are undergoing de-sensitisation therapy.",
    "The sample is a clinical trial table that contains information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for patients to participate in the trial. The phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include advanced nonhematological malignancies, non-small cell lung cancer, small cell lung cancer, metastatic breast cancer, head and neck squamous cell carcinoma, and gastroesophageal adenocarcinoma. The icd-10 codes associated with these diseases are also listed. The drug being tested is mln8237 (alisertib). The eligibility criteria for patients to participate in the trial include being 18 years or older, having a confirmed metastatic and/or advanced solid tumor, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and meeting other specific requirements. Patients who meet any of the exclusion criteria are not eligible to participate in the trial.",
    "The sample is a phase 1 clinical trial for individuals aged 18 to 65 with a history of type 2 diabetes mellitus for at least 3 months prior to screening. The trial involves the drugs LX4211 and Januvia\u00ae and requires participants to have a body mass index (BMI) of 45 kg/sq m or less and be willing and able to self-monitor blood glucose. The eligibility criteria include exclusion criteria such as a history of type 1 diabetes mellitus, renal disease, or clinically significant abnormal liver function tests. Participants must also not have a history of major surgery within 3 months of Day -2 or any planned surgery during the study. The trial requires written informed consent and prohibits the use of tobacco products for the duration of study participation.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on pancreatic cancer and the drug being tested is vandetanib. The eligibility criteria for the trial includes a confirmed diagnosis of locally advanced unresectable or metastatic pancreatic adenocarcinoma, an ECOG performance status of less than 1, and measurable disease. The exclusion criteria includes severe or uncontrolled systemic disease, clinically significant cardiac events such as myocardial infarction, and any concomitant medication that may cause OTc prolongation, including Torsades de Pointes.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on two diseases, namely non-small cell carcinoma and neoplasm metastasis, and their corresponding ICD-10 codes. The trial is testing the effectiveness of a drug called pf-00299804. The eligibility criteria for the trial include having advanced cancer, a platelet count of over 100,000, and an ANC count of over 1500. Additionally, the patient must have an ECOG score of 0-1 and a Ccr of over 60 or a serum creatinine level of less than 1.5. The exclusion criteria include having active CNS metastases, prior IGF1-R targeted therapy, and a history of unstable angina, myocardial infarction, or symptomatic congestive heart failure.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on type 2 diabetes mellitus (t2dm) and includes a list of icd-10 codes associated with the disease. The trial involves two comparator drugs, sitagliptin phosphate and an unspecified placebo. The eligibility criteria for the trial include having poorly controlled t2dm without taking any or taking one or two oral antidiabetic medications. The exclusion criteria include a history of type 1 diabetes mellitus or ketoacidosis, requiring insulin therapy within the prior 8 weeks, and taking TZDs such as Actos\u00ae (pioglitazone) or Avandia\u00ae (rosiglitazone) within the prior 12 weeks of the screening visit.",
    "The sample is a clinical trial for patients with intermittent claudication, a symptom of peripheral artery disease (PAD). The trial is in phase 1/phase 2 and involves the use of trans sodium crocetinate (TSC) and 0.9% normal saline as drugs. The eligibility criteria include being aged 40 or older, having a 6-month history of walking limitation or symptoms of IC, and having a diagnosis of PAD secondary to atherosclerosis. Patients must also have a peak walking time of at least 1 minute but no more than 12 minutes on an exercise treadmill test. The trial has various exclusion criteria, including pregnancy or lactation, critical limb ischemia, and recent cardiovascular surgery or intervention. Patients must be willing and able to comply with all study-related procedures and provide written, signed, informed consent.",
    "The sample is a clinical trial for a drug called rm-131 and its placebo, conducted in phase 1. The trial is focused on patients with Type 1 or 2 diabetic gastroparesis, diabetes mellitus complications, and gastrointestinal motility disorder. The patients must have controlled diabetes and a body mass index between 18-40 kg/m\u00b2. The trial has a list of inclusion and exclusion criteria, including being able to provide written informed consent, not having a history of gastric surgery, and not having any acute or chronic illnesses that could pose a threat or harm to the patient. The trial also excludes patients who have participated in a clinical study within the 30 days prior to dosing in the present study.",
    "The sample is a phase 1 clinical trial for patients with relapsed or refractory multiple myeloma and plasma cell neoplasm. The trial involves the use of drugs such as dexamethasone, sorafenib tosylate, and lenalidomide. The eligibility criteria include measurable disease, ECOG performance status 0-2, life expectancy of at least 12 weeks, and various laboratory values within normal limits. Patients must not have any other active malignancy requiring treatment that would interfere with the assessments of response of the myeloma to protocol treatment. Prior concurrent therapy is allowed, but patients must not be enrolled in any other study involving a pharmacologic agent or investigative therapy.",
    "The sample is a clinical trial with a phase 1/phase 2 design, involving patients with recurrent small cell lung cancer or unspecified adult solid tumors. The trial is testing the effectiveness of obatoclax mesylate and topotecan hydrochloride as treatments for these cancers. The eligibility criteria include having a confirmed diagnosis of the cancer, not having progressive brain metastases or leptomeningeal involvement, having a certain level of performance status and blood counts, and not being pregnant or nursing. Patients must also have recovered from prior chemotherapy or radiotherapy and cannot be receiving any other investigational agents or anticancer therapy. The exclusion criteria include having a history of allergic reactions to similar compounds, having concurrent uncontrolled illnesses, and having a history of seizure disorder or other neurological dysfunction.",
    "The sample is a phase 1 clinical trial for a drug called ZYGK1 and placebo, with a focus on the treatment of diabetes. The trial is looking for male and female volunteers between the ages of 18-45 who are mentally, physically, and legally eligible to give informed consent. The inclusion criteria also require volunteers to weigh between 50-75 kg and 45-75 kg for males and females, respectively, and have the ability to communicate effectively with the study personnel. For the gender effect study, only females with a history of sterility or at least one year of menopause or use of long-acting nonhormonal contraceptive measures will be recruited. At least one panel, in single ascending dose and multiple ascending dose, will include subjects with type 2 diabetes as defined by the American Diabetes Association. The exclusion criteria include a history of hypersensitivity to any of the active or inactive ingredients of ZYGK1 formulation, pancreatitis, severe gastrointestinal disease, renal insufficiency, active liver disease, and/or liver transaminases greater than 1.5 X UNL, and other systemic disorders or diseases. The sample also excludes volunteers with abnormal bleeding time, clotting time, prothrombin time, and activated partial prothrombin time, a history or presence of any medication in the last 14 days, significant alcoholism or drug abuse within the past 1 year, significant smoking or consumption of tobacco products, difficulty with donating blood, systolic and diastolic blood pressure outside of the range of 100-140 mmHg and 60-90 mmHg, respectively, pulse rate outside of the range of 60-100/minute, any clinically significant laboratory findings during screening, any clinically significant electrocardiogram abnormalities during screening, major illness and/or major surgery in the last 3 months, volunteers who have participated in any drug research study other than the present trial within the past 3 months, and volunteers who have donated one unit of blood in the past 3 months.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on treating various types of leukemia and myelodysplastic syndromes using the drug vosaroxin. The eligibility criteria for the trial are listed, including requirements for the patient's performance status, prior treatments, and disease status. The exclusion criteria are also listed, including prior exposure to the drug, pregnancy or breastfeeding, and certain medical conditions. The sample includes lists of disease names, ICD-10 codes, and drug names.",
    "The sample is a clinical trial for the treatment of metastatic melanoma. The trial is in phase 1/phase 2 and involves the drug combination of mpc-6827 and temozolomide. The eligibility criteria for the trial include having histologically proven melanoma, measurable metastases, and a performance score of Karnofsky \u2265 60%, or Eastern Cooperative Oncology Group (ECOG) \u2264 2, or WHO \u2264 2. Exclusion criteria include having hypersensitivity to Cremophor EL, ocular melanoma, primary intradural melanoma or leptomeningeal involvement, cardiovascular disease, cerebrovascular disease, uncontrolled hypertension, and a cardiac ejection fraction < 50%. The trial requires completion of any radiation therapy for brain metastases at least 4 weeks prior to starting the study drug and a minimum of 4 weeks since prior surgical resection or major surgical procedure and a minimum of 2 weeks since chemotherapy/biochemotherapy. If steroids are needed, the subject must be on a stable or decreasing dose of steroids for at least 1 week.",
    "The sample is a clinical trial for a drug called dasatinib, which is being tested on patients with chronic myeloid leukemia who have either developed resistance to imatinib mesylate or cannot tolerate it. The trial is in phase 1/phase 2 and the patients must meet certain eligibility criteria, such as having a specific performance status and being between the ages of 20 and 75. Women of childbearing potential must use contraception throughout the study and for up to 3 months after it ends. There are also exclusion criteria, such as having uncontrolled cardiovascular disease or a history of significant bleeding disorder unrelated to CML. The sample includes a list of diseases, icd-10 codes, and drugs being studied, as well as the eligibility and exclusion criteria for the trial.",
    "The sample is a record of a clinical trial with a combination of phase 1 and phase 2. The trial is focused on the treatment of hepatitis B and liver transplantation. The diseases involved are hepatitis B and liver transplantation. The icd-10 codes associated with these diseases are also listed. The drugs used in the trial are adefovir dipivoxil and hepatitis B vaccination. The eligibility criteria for the trial are listed under inclusion and exclusion criteria. The inclusion criteria include recipients who have not tested positive for hepatitis B surface antigen, have received liver transplantation with hepatitis B core antibody positive grafts, have received adefovir treatment post transplantation, and have not reached the 18 month post transplantation time period. The exclusion criteria include recipients with hepatitis B surface antigen positivity prior to liver transplant, grafts from hepatitis B surface antigen positive patients, previous intolerance to ADV therapy, pre-transplant creatinine > 1.6 mg/dL, patients younger than 21 years of age, and patients who are pregnant or breastfeeding.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying adenocarcinoma and neoplasms. The ICD-10 codes associated with these diseases are listed. The drug being tested is torisel. The eligibility criteria for participants include having a histological diagnosis of advanced cancer that is recurrent or refractory to standard therapy or for whom standard therapy is not available. There are also exclusion criteria listed, such as subjects receiving enzyme-inducing anticonvulsants and having pulmonary hypertension or pneumonitis.",
    "The sample is a clinical trial table that contains information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for the participants. The phase of the trial can be either phase I, phase II, or phase III. The diseases being studied include brain and central nervous system tumors, melanoma, and solid tumors. The icd-10 codes associated with these diseases are also listed. The drugs being used in the trial include ps-341 (velcade) and temozolomide. The eligibility criteria for the participants are also listed, including histologically proven malignancy, no available effective therapy, adequate performance status, and adequate baseline organ system function. The inclusion and exclusion criteria for both phase I and phase II are also listed.",
    "The sample is a clinical trial for patients with leukemia that has relapsed or is refractory to prior induction therapy. The trial is in phase 1/phase 2 and involves the drugs clofarabine, cytarabine, and methotrexate. The eligibility criteria include a confirmed diagnosis of acute myeloid leukemia, acute lymphoblastic leukemia, or acute leukemia of ambiguous lineage with certain characteristics, as well as specific patient characteristics such as performance status, life expectancy, and organ function. Patients must have recovered from prior therapy and meet certain time requirements since their last treatment. The trial does not allow concurrent chemotherapy or immunomodulating agents.",
    "The sample is a clinical trial for lung cancer patients in phase 1/phase 2. The trial includes patients with selected Stage IIIB or Stage IV advanced non-small cell lung cancer or recurrent disease after previous surgery and/or radiation. The trial involves the use of two drugs, bevacizumab and bortezomib. The eligibility criteria include having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2, no history of or active brain metastases, and having received one or two prior systemic therapies, one of which contained a platinum compound. The trial also has exclusion criteria, such as patients with squamous histology, serious medical or psychiatric illness likely to interfere with participation, and pregnant or nursing women. The patients must provide voluntary written informed consent before participating in the trial.",
    "The sample is a clinical trial for HIV infections, with a phase 1/phase 2 designation. The trial involves the use of various forms of the drug raltegravir, and the eligibility criteria include documentation of HIV-1 infection, unchanged therapeutic regimen for at least 12 weeks, and HIV RNA of 1,000 copies/mL or greater at screening. Participants must also be willing to take the assigned raltegravir preparation and provide informed consent. Exclusion criteria include a history of lactic acidosis, treatment for active tuberculosis, and any clinically significant diseases that could compromise the outcome of the study. The trial also has specific exclusion criteria for participants in different stages of the trial.",
    "The sample is a phase 1 clinical trial for patients between the ages of 1 and 21 who have relapsed or refractory acute lymphoblastic leukemia with a M3 marrow. Patients must have had no more than two prior therapeutic attempts and must have a history of prior systemic allergic reaction to E. coli asparaginase. The trial involves a combination of drugs including erwinase, vincristine, dexamethasone, doxorubicin, cytarabine, methotrexate, triple intrathecal therapy, and dexrazoxane. The eligibility criteria include age, diagnosis, E. coli asparaginase allergy, performance level, prior therapy, and reproductive function. Exclusion criteria include prior stroke, Down Syndrome, prior pancreatitis, renal function, liver/pancreatic function, cardiac function, infection, planned use of other investigational agents or anti-cancer therapies, inability to comply with safety monitoring requirements, and starting protocol therapy prior to enrollment.",
    "The sample is a clinical trial for malignant pleural mesothelioma, in which patients are eligible if they are over 18 years old, have not received previous chemotherapy, and are medically suitable for limited surgical intervention. The trial involves the use of chemotherapy and allows for radiotherapy for palliation. Patients must have a WHO performance status of 2 or less and adequate organ function. Exclusion criteria include active uncontrolled infection, severe cardiac dysfunction, uncorrectable bleeding tendency, and impaired renal function. The trial also excludes patients with previous successful pleurodesis, symptomatic CNS metastases, and those with serious disabling conditions.",
    "The sample is a phase 1 clinical trial for patients with advanced solid tumors, including breast cancer, colon cancer, ovarian cancer, and endometrium cancer. The trial is testing the drug bkm120. Patients must have progressive, recurrent unresectable disease and a World Health Organization (WHO) Performance status of \u2264 2. Patients with genetic or molecular alteration of the PI3K pathway are also eligible for the MTD Expansion part of the trial. However, patients with a history of primary brain tumor or brain metastases are not eligible unless asymptomatic and clinically stable for \u2265 3 months. Patients must not have had prior treatment with a PI3K inhibitor and must not have a history of or active major depressive episode, bipolar disorder, schizophrenia, or history of suicidal attempt or ideation. Additionally, patients must not have clinically manifest diabetes mellitus, acute or chronic renal disease, acute or chronic liver disease, acute or chronic pancreatitis, unresolved diarrhea, impaired cardiac function, or clinically significant cardiac diseases such as ventricular arrhythmia, congestive heart failure, uncontrolled hypertension. Patients must not have had an acute myocardial infarction or unstable angina pectoris within the past 3 months. Pregnant or nursing patients are not eligible, and fertile patients must use barrier contraceptives. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 1 clinical trial for the treatment of subacute cutaneous lupus erythematosus (SCLE) with or without systemic lupus erythematosus (SLE). The trial is testing the effectiveness of the drugs amg 557 and amg 557 placebo. The eligibility criteria for the trial include being between the ages of 18 and 70, having a body mass index from 18 to 35 kg/m2, and having a diagnosis of SCLE with a history of skin biopsy consistent with the diagnosis. In addition, the subject must have positive SS-A and/or SS-B antibodies at screening and must have intolerance of anti-malarial therapy or residual disease activity after at least 3 months of anti-malarial therapy. The subject must also have stable disease activity for 3 months prior to screening and must not have any disorders or conditions that would interfere with the study evaluation. The exclusion criteria include drug-induced SCLE, any disorder or clinically significant disease that would interfere with the study evaluation, and a history of malignancy.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on treating CD30-positive mature T-cell and NK-cell neoplasms, including systemic anaplastic large cell lymphoma. The diseases being studied include lymphoma, large-cell, anaplastic, lymphoma, nk-cell, and lymphoma, t-cell. The icd-10 codes associated with these diseases are listed as well. The drugs being used in the trial include brentuximab vedotin, cyclophosphamide, prednisone, doxorubicin, and vincristine. The eligibility criteria for the trial are also listed, including inclusion and exclusion criteria.",
    "This sample is a phase 1 clinical trial for non-small cell lung cancer. The trial involves the use of three drugs - bortezomib, carboplatin, and docetaxel. The eligibility criteria for the trial include confirmation of stage IIIB or stage IV NSCLC, age over 18, ECOG PS less than 2, no prior chemotherapy, measurable disease, signed informed consent, adequate bone marrow, renal, and hepatic function. Exclusion criteria include untreated clinically active brain metastasis, recent radiotherapy or investigational therapy, history of other cancers, use of immunosuppressive agents, known hypersensitivity to certain drugs, and certain medical conditions. Patients must also use effective contraception while on treatment and for at least 3 months thereafter.",
    "The sample is a clinical trial for the treatment of Tourette's Syndrome using a drug called ecopipam. The trial is a combination of phase 1 and phase 2. The eligibility criteria for the trial includes having Tourette's Syndrome for at least 5 years, exhibiting both motor and vocal tics, and having a minimum score of 20 on the Yale Global Tic Severity Score. Participants must also be at least 18 years old and meet certain contraceptive requirements. Exclusion criteria includes having unstable medical illness, a history of attempted suicide, or a first-degree relative with a major depressive episode resulting in hospitalization or suicide. Participants must not have had previous treatment with ecopipam or certain other medications.",
    "The sample is a clinical trial for advanced non-small cell lung cancer patients who have progressed after treatment with at least one chemotherapy regimen. The trial is a combination of phase 1 and phase 2, and the drugs being tested are docetaxel and npi-2358 + docetaxel. The eligibility criteria include being 18 years or older, having an ECOG performance status of 1 or less, and having resolved adverse events from prior treatments to grade 2 or less. The trial excludes patients with certain medical histories, infections, or who are pregnant or breastfeeding. The sample also includes a list of diseases (cancer) and their corresponding ICD-10 codes, as well as the inclusion and exclusion criteria for the trial.",
    "The sample is a phase 1 clinical trial for patients with advanced solid tumors or recurrent/metastatic solid tumors that are easily accessible for biopsy. The trial involves the use of the drugs cisplatin and everolimus. Patients must have measurable disease and meet certain eligibility criteria, including a Karnofsky performance status of 70-100%, certain blood counts, and normal liver and kidney function. Patients must not have uncontrolled brain or leptomeningeal metastases, peripheral neuropathy \u2265 grade 2, hypertriglyceridemia \u2265 grade 2, or impaired gastrointestinal function or disease that may alter the absorption of everolimus. Patients must not have had more than 3 prior cytotoxic chemotherapy regimens for recurrent or metastatic disease and must not have had prior everolimus or other agents specifically targeting mTOR. Patients must not be receiving concurrent chronic steroid treatment (> 5 mg/day of prednisone) or immunosuppressive agents, and must not be receiving other concurrent anticancer agents or agents known to be strong inhibitors or inducers of isoenzyme CYP3A.",
    "The sample is a clinical trial in phase 1 for the treatment of non-small-cell lung carcinoma. The trial involves the use of three drugs, azd2171, paclitaxel, and carboplatin. The eligibility criteria for the trial include having confirmed NSCLC, being previously untreated for advanced/metastatic NSCLC or having postsurgery recurrent NSCLC, and having a WHO performance status of 0-1. The exclusion criteria include having untreated unstable brain or meningeal metastases, having inappropriate laboratory test values, and having poorly controlled hypertension.",
    "The sample is a phase 1 clinical trial table that includes information on various diseases, their corresponding ICD-10 codes, drugs, and eligibility criteria. The diseases listed include various types of leukemia, lymphoma, and solid tumors. The drugs being tested are vorinostat and decitabine. The eligibility criteria include a diagnosis of relapsed or refractory AML, ALL, or CML-BC, or relapsed or refractory non-Hodgkin's lymphoma, or a metastatic or unresectable solid tumor. Patients must also meet certain health criteria, such as having a normal marrow function and no ongoing infections. The trial does not allow for concurrent use of other investigational or commercial agents or therapies.",
    "The sample is a phase 1 clinical trial for patients with metastatic colorectal adenocarcinoma who may have received one prior chemotherapy regimen. The trial involves the use of drugs such as folfox-4, amg 706, and folfiri. The eligibility criteria include having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, adequate hematological, renal, and hepatic function, and a life expectancy of at least 3 months. Exclusion criteria include having more than one prior chemotherapy regimen, CNS metastases, a history of venous thrombosis, and various other medical conditions that could increase the risk of toxicity. The complete inclusion and exclusion criteria can be found in the investigator's documentation.",
    "The sample is a phase 1 clinical trial for the treatment of cancer using a drug called xl765 (sar245409). The trial is for patients with metastatic or unresectable solid tumors for which standard curative or palliative measures do not exist or are no longer effective, and there are no therapies known to prolong survival. The trial requires the subject to have a histologically confirmed disease that is assessable by tumor marker, physical, or radiologic means, be at least 18 years old, have a weight of at least 40 kg, and have an Eastern Cooperative Oncology Group performance status of 0 - 2. The subject must also have adequate organ and bone marrow function, fasting plasma glucose < 120 mg/dL at screening, and be capable of understanding the protocol and signing the informed consent. The trial has various exclusion criteria, including having received anticancer treatment within 30 days before the first dose of XL765, having uncontrolled intercurrent illness, being pregnant or breastfeeding, and having a known allergy or hypersensitivity to components of the XL765 formulation.",
    "The sample is a clinical trial for lung cancer patients in phase 1/phase 2. The trial involves the drugs everolimus and gefitinib. The eligibility criteria include having histologically confirmed non-small cell lung cancer, measurable or evaluable indicator lesions, and progressive disease after receiving at least one prior chemotherapy regimen that included cisplatin or carboplatin and docetaxel. Patients must also meet certain age, performance status, and medical criteria, and cannot have uncontrolled brain or leptomeningeal metastases. Prior concurrent therapy is also restricted. The sample includes a detailed list of eligibility criteria for the trial.",
    "The sample is a phase 1 clinical trial for patients with solid tumors or lymphoma that have failed standard therapies or for which effective therapy is not available. The trial drug is called CNF2024. The eligibility criteria include being at least 18 years old, having certain blood counts and liver and kidney function within normal limits, having a certain performance status, and having an estimated life expectancy of at least 3 months. Patients must also practice effective contraception during the study and for 3 months after their last dose of study drug. Exclusion criteria include pregnancy or nursing, recent chemotherapy or radiotherapy, active infection, and certain medical conditions.",
    "The sample is a phase 1 clinical trial for patients with gastric cancer that is unresectable and/or metastatic. The trial is testing the effectiveness of the drugs capecitabine, cisplatin, and imatinib mesylate. Patients must meet certain eligibility criteria, including having confirmed gastric cancer, having at least one evaluable site of disease, and meeting certain medical requirements such as having a certain level of white blood cells and platelets. Patients must also not have certain medical conditions or be taking certain medications. The sample includes a detailed list of eligibility criteria for both disease and patient characteristics, as well as prior concurrent therapy.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on atherosclerotic vascular disease and involves the use of two drugs, atorvastatin and placebo. The eligibility criteria for participants include being between the ages of 30 and 80 and either currently taking a low dose statin or being statin-naive. Exclusion criteria include having HIV, Hepatitis B or C, using illegal drugs, having Type I diabetes, or a history of claustrophobia.",
    "The sample is a phase 1 clinical trial for the treatment of hypercholesterolemia. The trial includes both healthy male and female subjects, as well as those with heterozygous Familial Hypercholesterolemia. The inclusion criteria include a BMI of 18-33 kg/m2, screening hematology, clinical chemistries, coagulation and urinalysis consistent with overall good health, and LDL levels of \u2265.3.24 mmol/L (\u2265 100 mg/dL). The exclusion criteria include any uncontrolled or active major systemic disease, active acute or chronic infection, use of prescription medication within 14 days prior to the planned first drug administration, and positive results on certain screening laboratory tests. The trial will involve the administration of several drugs, including spc5001 and saline 0.9%.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on the disease of type 2 diabetes mellitus. The icd-10 codes associated with the disease are listed. The trial involves two drugs, a gk activator and ethanol. The eligibility criteria for the trial are listed, including age range, type of diabetes, and hepatic function. The exclusion criteria are also listed, including other types of diabetes, diabetic complications, recent treatment with certain medications, and cardiovascular disease.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, lymphoma), the ICD-10 codes associated with the disease, the drug being tested (pegylated liposomal doxorubicin hydrochloride), and the eligibility criteria for participants. The eligibility criteria include specific disease characteristics, patient characteristics, and prior concurrent therapy restrictions. The sample also includes detailed information about the specific eligibility criteria, such as the patient's performance status, life expectancy, hematopoietic, hepatic, renal, and cardiovascular health, as well as other factors that could impact their ability to participate in the trial.",
    "The sample is a clinical trial for patients with Malignant Bowel Obstruction caused by primary ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. The trial is in phase 1/phase 2 and involves the use of cisplatin and paclitaxel as treatment. The eligibility criteria include hospital admission and diagnosis, non-surgical candidacy, understanding and willingness to sign a consent form, ECOG performance status of 0, 1, or 2, and adequate hematological, renal, and hepatic function. Exclusion criteria include other causes of MBO, recent chemotherapy, and various medical conditions that may be aggravated by treatment. The trial also requires CT confirmation of bowel obstruction and the presence of at least two of four symptoms.",
    "The sample is a clinical trial for patients with HIV infections, in which the drugs tipranavir capsules and ritonavir capsules are being tested. The trial is a combination of phase 1 and phase 2. The eligibility criteria include being between the ages of 18 and 60, having a negative pregnancy test result, being able to swallow capsules, having a BMI between 18 and 29 kg/m2, and having a documented HIV-1 RNA load of less than 50 copies/mL for at least 3 months. The trial also has exclusion criteria, such as having a positive serum pregnancy test or being co-infected with active Hepatitis B and/or C.",
    "The sample is a phase 1 clinical trial for patients with advanced cancer. The trial is testing the effectiveness of three drugs - ly2228820, midazolam, and tamoxifen. The eligibility criteria for the trial include having a diagnosis of advanced or metastatic cancer for which no higher priority therapy is available, having adequate organ function, and a performance status of less than or equal to 2 on the ECOG scale. Participants must have discontinued all previous cancer therapies for at least 14 days prior to enrollment and recovered from any acute effects of therapy. They must also have an estimated life expectancy of at least 12 weeks and be able to swallow capsules and/or tablets. Exclusion criteria include having received treatment with an unapproved drug within 14 days of the initial dose of study drug, having a history of major surgical resection involving the stomach or small bowel, or having certain preexisting medical conditions. Females who are pregnant or lactating are also excluded.",
    "The sample is a record from a clinical trial table. It is a phase 1 trial for patients with advanced cancer. The trial is testing the effectiveness of the drugs ly2090314, pemetrexed, and carboplatin. The eligibility criteria for the trial include having a performance status of less than or equal to 2 on the Eastern Cooperative Oncology Group (ECOG) scale, having a life expectancy of greater than or equal to 12 weeks, having histological or cytological evidence of a diagnosis of cancer that is advanced and/or metastatic disease for which no proven effective therapy exists, and having adequate hematologic, hepatic, and renal function. The exclusion criteria include having received treatment within 30 days of the initial dose of study drug with a drug that has not received regulatory approval for any indication, having serious preexisting medical conditions, having certain conduction abnormalities, taking any concomitant medication that may cause QTc prolongation, or induce Torsades de Pointes, having uncontrolled high blood pressure, having serious cardiac condition, having chronic atrial fibrillation and/or bradycardia, having uncorrected electrolyte disorders, having symptomatic central nervous system (CNS) malignancy or metastasis, having a hematologic malignancy, and being pregnant or lactating if female.",
    "This sample is for a phase 1 clinical trial for cancer patients who have not responded to or are refractory to available therapy or for whom no standard effective systemic therapy exists. The drug being tested is called arq197. The inclusion criteria for the trial include patients with a Karnofsky performance status (KPS) of at least 70% or an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, and adequate organ function. The exclusion criteria include patients who have received anti-cancer chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or investigational agents within 4 weeks prior to the first dose of ARQ 197, those with known symptomatic brain metastases, pregnant or breastfeeding women, and those with uncontrolled intercurrent illness. The diseases being studied and their corresponding ICD-10 codes are not specified in this sample.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the diseases being studied, the ICD-10 codes associated with those diseases, the drugs being tested, and the eligibility criteria for participants. In this particular sample, the trial is a combination of phase 1 and phase 2, and the diseases being studied are \"healthy\" and \"opioid-induced constipation\". The ICD-10 codes associated with these diseases are also listed. The drugs being tested are \"td-1211\" and \"placebo\". The eligibility criteria for participants include being between 18 and 65 years old, willingness to stop all laxatives during the screening and treatment period, and not having any clinically significant findings or medical disorders associated with diarrhea or intermittent loose stools.",
    "The sample is a clinical trial for patients with recurrent malignant glioma or metastatic brain cancer requiring craniotomy for gross total resection, subtotal resection or biopsy. The trial is in the early phase 1 and the drugs being tested are vardenafil and carboplatin. The eligibility criteria include having a Karnofsky performance status of at least 60%, normal hematologic, renal and liver function, and the ability to provide written informed consent. Exclusion criteria include serious concurrent infection or medical illness, pregnancy or breastfeeding, receiving concurrent therapy for their tumor, allergy to 5HT-(3) receptor antagonist including tropisetron, and medical conditions requiring the use of oral nitrates.",
    "The sample is a phase 1 clinical trial for patients with metastatic colorectal cancer who have progressed after first-line standard therapy that was not irinotecan-based. The trial involves the drugs cs-1008 and folfiri. The eligibility criteria include being at least 18 years old, having an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2, and having adequate organ and bone marrow function. Exclusion criteria include having a history of certain medical conditions, being pregnant or breastfeeding, and having a known hypersensitivity to certain components of the drugs being used. The trial also requires subjects to be fully informed about the study protocol and to sign an IRB-approved ICF before any study-specific procedures or tests are performed.",
    "The sample is a phase 1 clinical trial for patients with chronic lymphocytic leukemia or B-cell prolymphocytic leukemia. The trial involves the use of two drugs, alvocidib hydrochloride and cyclophosphamide. The eligibility criteria include having confirmed CLL or B-cell PLL, documented B-cell lymphocytosis, and meeting certain high-risk criteria. Patients must also have an ECOG performance status of 0-2 and meet certain laboratory values. Additionally, patients must not have any concurrent illnesses or prior treatments that would limit their survival to less than 2 years. The trial does not allow for any other concurrent hormones, chemotherapy, or radiotherapy except for steroids for new adrenal failure or hormones for nondisease-related conditions.",
    "The sample is a phase 1 clinical trial for patients with chronic hepatitis C. The trial is testing the effectiveness of peginterferon alfa 2a, a drug used to treat hepatitis C. The trial is only open to adult Caucasian patients between the ages of 18 and 70 who have not responded to previous anti-HCV therapy with peginterferon alfa and ribavirin. Patients must have compensated liver disease for at least 24 months before baseline and must test positive for anti-HCV for more than 6 months with detectable serum HCV-RNA. The trial has several exclusion criteria, including patients who are treatment-na\u00efve or have responded to previous therapy, have HCV infection other than genotype 1, have Hepatitis A, Hepatitis B or HIV infection, have chronic Hepatitis of other than HCV origin, have decompensated liver disease, have had therapy with systemic antiviral, antineoplastic or immunomodulatory agents in the 6 months prior to study, have a clinically relevant retina disorder, or are pregnant or lactating women and male partners of pregnant women.",
    "The sample is a phase 1 clinical trial for the treatment of primary insomnia in male and female subjects aged 18 to 65 years. The trial involves the use of the drugs neu-p11 and neu-p11 placebo. The eligibility criteria include having a sleep latency of more than 30 minutes and total sleep time of less than 6 hours, being in good health, and not having used BZD and non-BZD hypnotics or melatoninergic drugs for the past 2 weeks or more prior to screening. Exclusion criteria include having sleep disorders detected during the PSG inclusion/habituation night, such as sleep apnea/hypopnea and periodic leg movement syndrome, and having significant cardio-vascular, pulmonary, renal, hepatic, gastro-intestinal, neurological, psychiatric, endocrine, cancer or blood disease.",
    "The sample is a phase 1 clinical trial with only healthy participants. The trial involves the use of various drugs, including mylan fentanyl transdermal system and duragesic, along with different clinical procedures. The eligibility criteria for the trial include being 18 years or older, weighing at least 60 kg for men and 48 kg for women, and having a BMI between 19 and 30. Participants must also pass a pre-study medical evaluation, including a physical examination, laboratory tests, and a urine drug screen. Exclusion criteria include a history of significant diseases, recent medication use, and allergies to certain substances. Participants must also abstain from tobacco, alcohol, and certain foods and beverages before the trial.",
    "The sample is a phase 1 clinical trial for patients with melanoma, including recurrent, stage III, and stage IV melanoma. The trial involves the drugs sorafenib tosylate and temsirolimus. The eligibility criteria include confirmed melanoma, accessible tumor for biopsy, ECOG performance status 0-1, normal bilirubin and creatinine levels, not pregnant or nursing, negative pregnancy test, and use of effective contraception. Patients must also not have a history of allergic reactions to similar compounds, uncontrolled hypertension, bleeding diathesis or coagulopathy, or conditions that impair the ability to swallow pills. Additionally, patients must not have uncontrolled illness, traumatic injury within the past 3 weeks, or more than 1 prior systemic chemotherapy regimen for metastatic melanoma. The trial also has specific requirements for prior surgeries, chemotherapy, and radiotherapy. Patients must have measurable disease and meet certain laboratory values. Finally, patients must not have peripheral neuropathy greater than grade 2 and must have had at least 5 years since prior chemotherapy for other types of cancer.",
    "The sample is a phase 1 clinical trial for epilepsy. The trial is testing the effectiveness of three drugs - brivaracetam, levetiracetam, and lorazepam. The eligibility criteria for the trial includes healthy male or female volunteers between the ages of 18 and 50 with a BMI between 18.0 and 30.0 kg/m\u00b2. Participants must also have good physical and mental health, normal blood pressure and heart rate, and no clinically significant abnormalities in their electrocardiogram or laboratory tests. Exclusion criteria includes a low IQ, depression, allergies to pyrrolidinone derivatives, abnormalities in EEG recordings, pregnancy or lactation, and a history or presence of various disorders. The use of any hepatic enzyme-inducing drug is also prohibited.",
    "The sample is a phase 1 clinical trial for patients with leukemia, specifically chronic phase chronic myelogenous leukemia (CML) or accelerated or blastic phase CML or acute lymphoblastic leukemia. The patients must have been diagnosed with one of these hematologic malignancies and be resistant or intolerant to prior imatinib mesylate. They must have also received and benefitted from at least 3 months of prior therapy with dasatinib on protocol UCLA-0303035. The eligibility criteria include having an ECOG performance status of 0-2, not being pregnant or nursing, having a negative pregnancy test, and using effective contraception during and for 12 weeks after completion of study treatment if fertile. Patients must not have serious uncontrolled medical disorders, active infections that would preclude study participation, uncontrolled angina within the past 3 months, or diagnosed or suspected congenital long QT syndrome. They must also have a QTc \u2264 450 msec on electrocardiogram, no uncontrolled hypertension, no dementia or altered mental status that would prohibit the understanding or rendering of informed consent, and no history of clinically significant ventricular arrhythmias. The prior concurrent therapy includes no concurrent use of certain drugs that may confer risk of torsades de pointes, no other concurrent treatment for CML except for hydroxyurea for a 2-week duration, and no concurrent medications that inhibit platelet function except for hydroxyurea or anagrelide. No concurrent anticoagulants are allowed except as prophylaxis for catheter thrombosis and/or heparin flushes for IV lines.",
    "The sample is a phase 1 clinical trial that involves testing the safety and tolerability of a drug called azd3839 and its placebo on healthy male and female volunteers aged 18 to 55 years. The trial aims to measure the blood concentration of the drug and its effects on the body. The trial includes a list of diseases, their corresponding ICD-10 codes, and eligibility criteria for the volunteers. The diseases listed include Alzheimer's disease, safety, tolerability, and healthy volunteers. The eligibility criteria include having a suitable vein for cannulation or repeated venipuncture, a body mass index between 19 and 30 kg/m2, and a weight between 50 kg and 100 kg. The volunteers should also have a normal creatinine clearance and serum potassium concentration, and clinically normal findings on physical examination. The exclusion criteria include a history of clinically significant disease or disorder, psychotic disorder among first-degree relatives, significant orthostatic reaction, prolonged QTcF, or being a vegetarian/lactose intolerant.",
    "The sample is a clinical trial for patients with prostate cancer in phase 1/phase 2. The trial includes patients who are at least 18 years old and have metastatic disease with evidence of radiographic progression or serologically. Patients must have had prior treatment with bilateral orchiectomy or other primary hormonal therapy and evidence of treatment failure. Patients must have received prior therapy with docetaxel alone or in combination with either prednisone or estramustine. Patients must not have received radiotherapy < 3 weeks prior to randomization. The trial includes inclusion and exclusion criteria, such as adequate hematologic, renal and hepatic function, and no serious concurrent medical illness or active infection. The patient or the patient's legally acceptable representative must have voluntarily signed and dated an informed consent approved by an Institutional Review Board prior to any study-specific procedures.",
    "The sample is a phase 1 clinical trial for patients with advanced or metastatic malignant solid tumors or lymphoma that has progressed on standard therapy. The trial is testing the drug hydroxyurea and requires participants to meet certain eligibility criteria, such as having a Karnofsky Performance status of > 70, a predicted life expectancy of at least 3 months, and measurable or evaluable disease. Participants must also be at least 18 years old and willing to adhere to study visit schedules. The trial has exclusion criteria, such as known hypersensitivity to hydroxyurea or the study drug SCH900776, and any other medical or psychiatric condition that might interfere with participation in the trial.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on the treatment of primary open-angle glaucoma and ocular hypertension. The diseases are listed along with their corresponding ICD-10 codes. The trial involves the use of three drugs: opa-6566, placebo, and latanoprost. The eligibility criteria for the trial are also listed, including inclusion criteria such as a diagnosis of bilateral primary open-angle glaucoma and ocular hypertension, and exclusion criteria such as any form of glaucoma other than primary open-angle glaucoma in either eye and other ocular conditions as defined by the protocol.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on studying myocardial infarction. The ICD-10 codes associated with the disease are listed, as well as the drugs being tested (lovaza\u00ae and a placebo containing corn oil). The eligibility criteria for participants are also listed, including requirements such as having had an acute myocardial infarction, having undergone urgent or emergent PCI, and having the capacity for informed consent. There are also exclusion criteria listed, such as a history of drug or alcohol abuse, known pregnancy, or severe liver or renal insufficiency.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on the treatment of type 1 diabetes and includes a list of icd-10 codes associated with the disease. The trial involves the use of insulin lispro as a treatment and includes eligibility criteria for participants, such as age and body mass index, as well as exclusion criteria, such as a history of drug or alcohol abuse. The sample also includes detailed inclusion and exclusion criteria for the trial.",
    "The sample is a phase 1 clinical trial for non-small cell lung cancer. The trial is testing the effectiveness of the drugs linifanib, carboplatin, and paclitaxel. The eligibility criteria for the trial include being 20 years or older, having confirmed non-squamous NSCLC, having advanced or metastatic disease that cannot be treated with surgery or radiation, not having received prior chemotherapy for NSCLC, having measurable disease, having an ECOG Performance Score of 0-1, and having adequate bone marrow, renal, and hepatic function. Exclusion criteria include hypersensitivity to paclitaxel or other drugs formulated with polyethoxylated castor oil, having received any anti-cancer therapy for NSCLC, having a history of another active cancer within the past 5 years (except for certain types), having certain medical conditions, being pregnant or breastfeeding, and having NSCLC with a predominant squamous cell histology.",
    "The sample is a clinical trial in phase 1 for the treatment of osteosarcoma, leukemia, and lymphoma. The trial involves the use of drugs such as glucarpidase, high-dose methotrexate, and leucovorin. The eligibility criteria for the trial include patients who are receiving high-dose methotrexate with or without risk of methotrexate toxicity, impaired renal function, and delayed MTX elimination, and require intravenous leucovorin. Exclusion criteria include allergic reactions to lactose or hereditary fructose or galactose intolerance for Arm A, and delayed elimination of MTX for Arm B. The icd-10 codes for the diseases are also provided.",
    "The sample is a phase 1 clinical trial for the treatment of sepsis. The trial involves the use of two drugs, srt2379 and placebo. The eligibility criteria for the trial include being a healthy male between the ages of 18 and 35, having no major illnesses or chronic medical conditions, and agreeing to use double-barrier birth control or abstinence during the study and for 7 days following the dose of study drug. Exclusion criteria include a history of drug abuse, alcoholism, or any clinically relevant abnormality noted on the 12-lead ECG. The trial also excludes subjects who have participated in a clinical trial and received an investigational product within three months of the dosing in the current study.",
    "The sample is a clinical trial for patients with non-small cell lung cancer in phase 1/phase 2. The trial involves the use of drugs such as docetaxel, cisplatin, and sti571. The eligibility criteria for the trial include having histologically or cytologically recurrent or advanced NSCLC, having at least one measurable target lesion, and not having received prior chemotherapy treatment for this disease. Patients with brain metastasis must be neurologically stable for at least 1-2 weeks prior to study enrollment. The exclusion criteria include any prior treatment with a biologic response modifier or chemotherapeutic agent for this disease, any concomitant malignancy except non-melanoma skin cancer or in-situ carcinoma of the cervix, and uncontrolled inter-current medical illness.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating aplastic anemia, menorrhagia, and amenorrhea. The trial involves the use of two drugs, lo-ovral oral contraceptive pills and placebo - sugar pill. The eligibility criteria for the trial include women aged 12-55 years who have a uterus and at least one functioning ovary, diagnosed with bone marrow failure, and other diseases that require treatment with chemotherapy or stem cell transplantation with platelet counts less than 50,000 microliters at study entry, and do not desire pregnancy for the duration of the study. The exclusion criteria include age less than 12 years, postmenopausal women, history of liver disease that precludes OCP use, history of thrombosis, thromboembolism and/or thrombophilia, currently on 2 or more tablets of any oral contraceptive pills per day at study entry, having 2 or more depo medroxyprogesterone acetate injections in the past 12 months or having depo medroxyprogesterone acetate injection in the past 90 days, leuprolide acetate injection in the past 30 days, smoker over the age of 35, women with estrogen-dependent tumor e.g. breast cancer, pregnancy, underlying sickle cell anemia, women who are taking chemotherapeutic agents known to cause ovarian failure such as alkylating agents, and allergy to any medication in this protocol.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on treating head and neck cancer and squamous cell cancer using the drugs zalutumumab and cisplatin. The trial includes a list of inclusion and exclusion criteria for patients, such as having locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, and not having prior treatment with radiotherapy or chemotherapy in the head and neck area. The table also includes a list of icd-10 codes for the diseases being treated.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on breast cancer and involves the use of the drugs letrozole and dhea. The eligibility criteria for participants include a diagnosis of metastatic breast cancer with specific hormone receptor status, as well as certain patient characteristics such as age and blood counts. Prior concurrent therapy is also outlined, including restrictions on certain supplements and therapies.",
    "The sample is a phase 1 clinical trial for patients with advanced non-hematologic solid tumor malignancy, including breast, lung, colon, pancreatic, head and neck, kidney, or sarcoma. The trial is testing the effectiveness of the drugs pazopanib and ixabepilone. Patients must have failed or become intolerant to standard therapy and have measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST). Prior systemic chemotherapy, immunotherapy, or biological therapy is allowed, but prior use of either pazopanib or ixabepilone alone or in combination is not allowed. Patients must have recovered from the acute toxic effects of previous anti-cancer treatment prior to study enrollment. The trial has inclusion and exclusion criteria related to organ function, pregnancy, nursing, history of other malignancies, uncontrolled infection, cardiovascular conditions, hypertension, cerebrovascular accident, pulmonary embolism, untreated deep venous thrombosis, prior major surgery or trauma, active bleeding or bleeding diathesis, endobronchial lesions, involvement of large pulmonary vessels by tumor, hemoptysis, and neuropathy.",
    "The sample is a phase 1 clinical trial for type 2 diabetes. The trial includes 12 adult participants who have had type 2 diabetes for at least 6 months and are currently using oral agents (SUs, metformin, acarbose or glitinides) with or without insulin. The trial also requires participants to have an HgbA1c level between 7-12%, be between the ages of 18-70, and have a BMI between 27-40 kg/m\u00b2. The trial excludes participants with any past or present clinically relevant abnormality, medical condition, or circumstance that would make them unsuitable for participation, evidence of hepatic, renal or cardiac failure, abnormal screening test results, pregnancy or lactation, current use of TZDs, or a history of alcoholism or drug abuse within the past 12 months. The trial will test the effectiveness of various doses of insulin glargine and a placebo.",
    "The sample is a phase 1 clinical trial for patients with active rheumatoid arthritis. The trial involves the use of namilumab (mt203) and a placebo drug. The eligibility criteria include being an out-patient with low to moderate disease activity, being on stable doses of methotrexate for at least 12 weeks, and having a negative tuberculosis test. Patients must also meet certain age, weight, and BMI requirements, and follow contraceptive restrictions if they are of childbearing potential. Pregnant or lactating females are excluded from the trial. The exclusion criteria include participation in another clinical trial, use of certain medications, history or presence of certain diseases, drug abuse, and certain laboratory parameters outside a specified range.",
    "The sample is a clinical trial for patients with type 2 diabetes and incipient or overt nephropathy. The trial is in phase 1/phase 2 and involves the use of the drug aliskiren. The eligibility criteria include being between 30-80 years old, having a glomerular filtration rate of at least 40ml per minute, and having a blood pressure between 135/85 mm Hg and 170/105 mm Hg. Patients must also be on stable antihypertensive medications for at least 8 weeks prior to the trial and must be willing to discontinue any prohibited medications. Exclusion criteria include severe hypertension, kidney disease not caused by diabetes or hypertension, and a history of drug or alcohol abuse within the past 12 months. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a clinical trial for bladder cancer patients in phase 1/phase 2. The trial includes patients with initial presentation or recurrence of Stage Ta, T1 or Tis, any grade, bladder cancer after transurethral resection of bladder tumor (TURBT). The trial requires patients to have undergone TURBT within 42 days prior to Day 1/Week 1 and have a Karnofsky Performance Status greater than or equal to 80%. Patients must also have a life expectancy of at least 3 years, be 18 years or older, and have acceptable liver and renal function. The trial also requires patients to have acceptable hematologic status and a urinalysis showing no clinically significant abnormalities except those attributable to bladder cancer. Patients must agree to use an effective contraceptive method during the treatment period of the study if they are of child-producing potential. The trial has exclusion criteria, including a history or previous diagnosis of bladder fibrosis, total bladder capacity estimated at cystoscopy to be less than 150 mL, urinary incontinence of a severity that would compromise the ability of the patient to retain the study drug intravesical instillation for two hours, and severe irritative voiding symptoms such as urgency, frequency, or nocturia. Other exclusion criteria include known other malignant disease except squamous or basal cell skin cancer unless the malignancy has been in complete remission off therapy for at least 5 years, major surgery, other than TURBT and diagnostic surgery, within 28 days prior to Day 1/Week 1, and active, uncontrolled bacterial, viral, or fungal infections, including urinary tract infection. The trial also excludes patients who have received treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within one (1) month prior to Day 1/Week 1 on study (two [2] months for nitrosureas or MMC), unless given as standard treatment for bladder cancer and provided that patient is free of all treatment-related toxicities as of Day 1/Week 1. Other exclusion criteria include known infection with human immunodeficiency virus (HIV), known active infection with hepatitis B or hepatitis C, serious disease that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor (Halozyme), history of a hypersensitivity or idiosyncratic reaction to, or other contraindication to, mitomycin, known allergy to bee or vespid venom, known coagulation disorder or bleeding tendency, treatment with heparin or anticipation of heparin treatment during the treatment period in this study, and unwillingness or inability to comply with procedures required in this protocol.",
    "The sample is for a phase 1 trial and the only disease listed is \"healthy\". The icd-10 codes associated with this disease are \"Z76.3\" and \"Z76.2\". The drugs being tested are \"bi 1026706 placebo\" and \"bi 1026706\". The eligibility criteria for the trial includes only healthy male subjects, with any relevant deviation from healthy conditions being an exclusion criteria.",
    "The sample is a phase 1 clinical trial for participants with metastatic or locally advanced solid tumors that have failed to respond to standard therapy, progressed despite standard therapy, or for which standard therapy does not exist. The trial involves the use of four drugs: dalotuzumab, mk-0752, ridaforolimus, and mk-2206. The eligibility criteria include having a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (EGOG) Performance Scale, having at least one measurable metastatic or recurrent lesion according to Response Criteria in Solid Tumors (RECIST), and not having any medical conditions that may impact compliance with the protocol, limit interpretation of study results, or pose an unacceptable medical risk. The exclusion criteria include having had chemotherapy, radiotherapy, or biological therapy within 4 weeks prior to study Day 1, currently participating or having participated in a study with an investigational compound or device within 28 days, having known central nervous system (CNS) metastases and/or carcinomatous meningitis, having significant or uncontrolled cardiovascular disease, and being pregnant, breastfeeding, or expecting to conceive or father children during the study.",
    "The sample is a phase 1 clinical trial for a drug called bi 1744 cl and its placebo. The trial is for healthy male participants between the ages of 21 and 45 with a BMI between 18.5 and 30 kg/m2. The eligibility criteria include having no clinically relevant concomitant disease, no evidence of any medical findings deviating from normal, and no history of relevant orthostatic hypotension, fainting spells, or blackouts. The exclusion criteria include having any medical findings deviating from normal, evidence of a clinically relevant concomitant disease, and a history of relevant allergy/hypersensitivity to the drug or its excipients. The trial also has specific exclusion criteria due to the known class side effect profile of \u00df2-mimetics, such as asthma or history of pulmonary hyperreactivity.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1 and is studying healthy subjects. The icd-10 codes associated with the disease being studied are Z76.3 and Z76.2. The drugs being tested are clopidogrel and placebo. The eligibility criteria for participants include being in good health, having a specific body weight and BMI range, and being classified into one of four groups based on their CYP2C19 genotype. There are also exclusion criteria, such as evidence of inherited disorder of coagulation/hemostasis functions, smoking more than 10 cigarettes per day, and inability to abstain from intake of any drug affecting hemostasis throughout the whole study duration.",
    "The sample is a clinical trial with a combination of three drugs, belinostat, paclitaxel, and carboplatin, for patients with solid carcinomas that have no known curative therapy. The trial is divided into different phases, and the sample is from phase 1/phase 2. The diseases included in the trial are ovarian cancer, epithelial ovarian cancer, fallopian tube cancer, and bladder cancer, with corresponding ICD-10 codes. The eligibility criteria include signed consent, confirmed diagnosis, acceptable liver, renal, and bone marrow function, acceptable coagulation status, negative pregnancy test, and more. The exclusion criteria include recent treatment with investigational agents or anticancer therapy, active infection, concurrent second malignancy, and more.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial (phase 1/phase 2), a list of diseases (recurrent pediatric all, relapsed pediatric all, acute lymphoblastic leukemia, refractory pediatric all), a list of icd-10 codes of diseases, a list of drug names (abt-751, dexamethasone, peg-asparaginase, doxorubicin, cytarabine, methotrexate, cyclophosphamide, 6-thioguanine), and eligibility criteria for patients to participate in the trial. The eligibility criteria include age, diagnosis, performance level, prior therapy, reproductive function, and exclusion criteria such as drug allergies, renal function, liver/pancreatic function, cardiac function, and infection.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial involves testing drugs on individuals with two diseases, namely \"healthy\" and \"asthma\". The diseases are identified using ICD-10 codes. The drugs being tested include \"placebo to bi 1021958 qd\", \"bi 1021958 bid\", \"placebo to bi 1021958 bid\", and \"bi 1021958 qd\". The eligibility criteria for the trial include being a healthy male or female who is not of child-bearing potential, with the exception of individuals with mild controlled asthma.",
    "The sample is a phase 1 clinical trial for the treatment of type 2 diabetes mellitus. The trial involves the use of a drug called gsk716155 for injection and a placebo. The eligibility criteria for the trial include having a diagnosis of type 2 diabetes mellitus for at least 3 months, with a fasting plasma glucose level of no more than 240mg/dL and HbA1c between 6.5% and 10%. Participants must also have a BMI of no more than 35kg/m2, be between 20 and 70 years old, and be either diet-controlled or taking a single oral antidiabetic agent (other than thiazolidinediones) and willing to withdraw from this treatment from 2 weeks prior to the study. Women must be of non-childbearing potential. The exclusion criteria include a positive test result for syphilis, HBs antigen, HCV antibody, HIV antigen/antibody, or HTLV-1 antibody, clinically significant hepatic enzyme elevation, history of metabolic disease other than T2DM, previous use of insulin as a treatment for diabetes within 3 months, history of severe gastrointestinal disease, clinically significant cardiovascular disease, significant renal disease, history of drug allergy, history of alcohol or drug abuse, donation of blood in excess of 400mL within previous 4 months, and previous use of any GLP-1 mimetic or any other albumin-containing products.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on chronic lymphocytic leukemia, with the icd-10 codes C91.11, C91.12, and C91.10. The trial is testing the drugs gx15-070ms and gx15-070ms. The eligibility criteria for the trial include confirmation of B-CLL, previous standard systemic chemotherapy, age over 18, ECOG Performance Status of 1 or less, and a life expectancy of more than 8 weeks. Exclusion criteria include patients receiving other investigational or commercial agents, patients with a history of seizure disorders, pregnant or breastfeeding women, and HIV-positive patients receiving combination anti-retroviral therapy.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating various diseases such as leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, and others. The trial involves the use of two drugs, cyclophosphamide and fludarabine phosphate. The eligibility criteria for the trial include specific disease criteria, adequate performance status, age between 18 to 70 years, and organ function within certain limits. The trial excludes patients with an available, medically suitable, 5-6/6 HLA-A, B, DRB1 matched sibling donor, those who are eligible for autologous transplantation, and those with acquired or inherited bone marrow failure syndromes such as aplastic anemia and Fanconi anemia.",
    "The sample is a phase 1 clinical trial for the treatment of cancer using a drug called NK012. The trial is for patients with a confirmed malignant solid tumor for which there are no known regimens or protocol treatments of higher efficacy or priority, or for those who have failed conventional therapy for the cancer or have a malignancy for which a conventional therapy does not exist. The trial has inclusion and exclusion criteria, including a life expectancy of at least 12 weeks and an EOCG performance status of 0 or 1, adequate kidney, liver, and bone marrow function, and the ability to understand and sign a written informed consent document. Patients cannot have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or be receiving any other investigational agent. The trial also excludes patients with a history of brain metastases or spinal cord compression, unless irradiated a minimum of 4 weeks before study entry and stable without requirement for corticosteroids for > 1 week, and those with concurrent serious infections or uncontrolled intercurrent illness. The trial also excludes pregnant women or women of childbearing potential who are not using methods to avoid pregnancy, and those with significant cardiac disease or a history of serious ventricular arrhythmia. Patients must also test negative for anti-HbsAg, anti-HCV, anti-HIV, or anti-syphilis antibodies.",
    "The sample is a phase 1 clinical trial for advanced hematologic malignancies such as leukemia, lymphoma, myelodysplastic syndromes, and multiple myeloma. The trial involves the use of drugs such as busulfan, fludarabine phosphate, mycophenolate mofetil, and tacrolimus. The eligibility criteria include having one of the specified diseases, meeting certain disease characteristics, being between the ages of 55-70 or deemed ineligible for conventional high-dose chemotherapy, and having an available umbilical cord blood donor. Patients must also meet certain patient characteristics such as having a good performance status, normal kidney and liver function, and not being pregnant or nursing. Prior concurrent therapy is also taken into consideration.",
    "This sample is for a phase 1 clinical trial for tumors. The icd-10 codes for the diseases being studied are listed. The drug being tested is a combination of dasatinib and ketoconazole. The eligibility criteria for participants include having an ECOG status of 0-2, advanced or metastatic disease that is unresponsive to standard treatment or has no standard treatment available, and having adequate bone marrow, liver, and kidney function. Exclusion criteria include serious cardiovascular disease, bleeding disorders, gastrointestinal tract disease, and the use of platelet inhibitors, H2 blockers, or proton pump inhibitors.",
    "The sample is a clinical trial for patients with leukemia or myelodysplastic syndromes in any phase of the disease, including remission or relapse. The trial involves unmanipulated allogeneic bone marrow or peripheral blood stem cell transplantation with the use of fludarabine and treosulfan drugs. Patients must have a donor available who is either HLA-identical or HLA-matched unrelated donor by high-resolution DNA typing with a single allele mismatch allowed. Patients must also meet certain eligibility criteria, including having a performance status of Karnofsky 70-100% or Lansky 70-100%, and meeting specific hematopoietic, hepatic, renal, cardiovascular, and pulmonary requirements. Patients must not have any other disease that would severely limit life expectancy, be pregnant or nursing, have HIV positivity, or have any known hypersensitivity to the study drugs. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 1 clinical trial for patients with wild type metastatic colorectal cancer who have failed on at least two treatment regimens including a fluoropyrimidine, oxaliplatin and irinotecan with or without bevacizumab. The trial involves the drug lenalidomide and has a list of inclusion and exclusion criteria for eligibility. The table includes information on the phase of the trial, the diseases being studied, the icd-10 codes of those diseases, the drugs being used, and the eligibility criteria for the trial.",
    "The sample is a clinical trial for a drug called jnj-39393406, which is being tested on male participants between the ages of 18 and 55 who have a history of schizophrenia for at least 12 months. The trial is in phase 1 and includes patients with various diseases such as schizophrenia, Alzheimer's disease, and cognition disorders. The trial also includes a list of icd-10 codes for each disease. The eligibility criteria for the trial include stable treatment for at least 3 months, medically stable physical examination, and laboratory tests, and a BMI between 18 and 35 kg/m\u00b2. The trial has exclusion criteria such as a DSM-IV axis I diagnosis other than schizophrenia, clinically significant abnormal values for clinical chemistry, hematology or urinalysis, and treatment-resistant subjects. The trial also has a pharmacogenomic component, which requires participants to sign a separate written informed consent indicating willingness to participate in Part 1 genetic testing (mandatory), and indicate either consent or refusal for Part 2 DNA storage.",
    "The sample is a phase 1 clinical trial for participants with locally advanced and/or metastatic cancer (solid tumor or lymphoma) for which no life-prolonging therapy exists. The trial is testing the drug enzastaurin. The eligibility criteria include having given written informed consent, having a performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) scale, and having adequate organ function. Exclusion criteria include having received treatment within 28 days of the first dose of study drug with an experimental agent for non-cancer indications that has not received regulatory approval for any indication, having a serious cardiac condition, and being allergic to enzastaurin. The trial also excludes participants with glioblastoma or hematologic malignancies other than lymphoma, and those who have central nervous system (CNS) metastases.",
    "The sample is a phase 1 clinical trial for the drug aliskiren, aimed at treating end stage renal disease. The trial involves testing the drug on subjects who have been on intermittent hemodialysis three times a week for at least three months and are in relatively good health. The eligibility criteria include being a female of non-child bearing potential, having a body mass index within the range of 18 to 30 kg/m2, and being in good health as determined by past medical history, physical examination, vital signed assessments, electrocardiogram, and laboratory tests at screening. The exclusion criteria include smokers who report cigarette use of more than 5 cigarettes per day, use of aliskiren within 2 weeks prior to study entry, and a history/presence of diabetes mellitus. The trial also has other protocol-defined inclusion/exclusion criteria that may apply.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, graft versus host disease), the ICD-10 codes associated with the disease, the drugs being used in the trial (rapamycin and tacrolimus), and the eligibility criteria for participants. The eligibility criteria include age, having received a specific type of stem cell transplant, being on tacrolimus for GVHD prophylaxis, and being deemed eligible for tapering off of tacrolimus by the primary BMT physician. There are also exclusion criteria, such as ongoing GVHD and allergy to rapamycin. Women of childbearing potential must have a negative pregnancy test before starting treatment.",
    "The sample is a clinical trial for the treatment of multiple myeloma, a type of cancer. The trial is in phase 1/phase 2 and involves the use of two drugs, bortezomib and sorafenib. The eligibility criteria for participants include having received no more than 2 prior regimens for the treatment of multiple myeloma, being defined as Relapsed or Refractory Disease, having an ECOG performance status of 0, 1, or 2, and meeting certain laboratory values for blood counts, kidney function, and liver function. Participants must also have measurable or evaluable disease. Exclusion criteria include having > grade 1 peripheral neuropathy, recent thrombolic or embolic events, and other medical conditions that could interfere with participation in the trial. Women who are pregnant or lactating are ineligible, and all patients of childbearing potential must use adequate contraception while receiving study treatment.",
    "The sample is a phase 1 clinical trial for a drug called gsk573719, which is being tested on individuals with pulmonary disease, chronic obstructive. The trial includes a list of eligibility criteria, such as being between 18 and 65 years old, having a normal spirometry, and being a non-smoker. The trial also has a list of exclusion criteria, such as having a positive pre-study drug/alcohol screen, being pregnant or lactating, and having a history of asthma or bronchoconstriction. The sample includes a detailed list of inclusion and exclusion criteria, as well as information on the diseases being studied, the drugs being tested, and the icd-10 codes associated with the diseases.",
    "The sample is a phase 1 clinical trial that involves patients with various types of cancer, including melanoma, soft tissue sarcoma, parathyroid carcinoma, small cell carcinoma of the lung, and carcinoid tumors. The trial is testing the effectiveness of a combination of drugs, dacarbazine and bortezomib, in treating these cancers. The eligibility criteria for the trial include having a histologic diagnosis of one of the specified cancers, having measurable or evaluable disease that cannot be treated with surgery or radiation, being at least 18 years old, and having an ECOG Performance Status of 0 or 1. There are also exclusion criteria, such as having uncontrolled brain metastatic disease, low platelet or neutrophil counts, or hypersensitivity to the drugs being tested. The trial is not open to pregnant or nursing women, and patients cannot have received other investigational drugs within 14 days of enrollment.",
    "The sample is a phase 1 clinical trial for kidney transplantation. The trial is testing the effectiveness of the drugs bleselumab and placebo. The eligibility criteria for the trial include having received a de novo kidney transplant from a living or deceased donor, having a post-transplant serum creatinine value that is at least 30% decreased from the pre-transplant value and requiring no dialysis, and being willing and able to comply with the study requirements. Exclusion criteria include having received antibody induction therapy, having previously received or currently receiving an organ transplant other than a kidney, having a positive T or B cell crossmatch, and having a current malignancy or a history of any malignancy within the past 5 years, except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully. The sample also includes a list of icd-10 codes for the diseases being studied and the eligibility criteria for the trial.",
    "The sample is a clinical trial for patients with metastatic prostate cancer in phase 1/phase 2. The trial involves the use of two drugs, dasatinib and docetaxel, and has specific eligibility criteria for patients to participate. These criteria include having confirmed adenocarcinoma of the prostate that is clinically refractory to hormone therapy, evidence of progressive metastatic disease, and measurable disease on imaging or bone scan with a certain level of serum prostate specific antigen (PSA). Patients must also have a certain Eastern Cooperative Oncology Group performance status and testosterone levels, and must not have certain exclusion criteria such as known brain metastases or clinically-significant cardiovascular disease. The trial has restrictions on prior therapy for metastatic disease, including limitations on prior chemotherapy and radiotherapy.",
    "The sample is a phase 1 clinical trial for ovarian cancer, epithelial ovarian cancer, fallopian tube carcinoma, and primary peritoneal carcinoma. The trial involves the use of drugs such as lenalidomide, liposomal doxorubicin, bevacizumab, and revlimid, doxil, avastin. The eligibility criteria for the trial include being platinum resistant/refractory, having measurable or evaluable disease, not having prior anthracycline or lenalidomide use, having a calculated creatinine clearance above a certain level, and being willing to comply with the requirements of the RevAssist program. The trial also has exclusion criteria such as being pregnant or breastfeeding, having a concurrent use of other anti-cancer agents or treatments, and having a known hypersensitivity to any component of Avastin.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on the disease \"graft versus host disease\" and the associated ICD-10 codes are listed as \"D89.810\", \"D89.811\", \"D89.813\", and \"D89.812\". The drug being studied is \"everolimus\". The eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". In order to be included in the trial, patients must have given written informed consent, undergone allogeneic HSCT from HLA-identical related or unrelated donors, have clinically confirmed acute GVHD \u2265 grade II, be between the ages of 18 and 70, have a Karnofsky performance status > 60%, and meet other criteria. Patients who meet any of the exclusion criteria, such as having severe hepatic impairment or being unwilling to undergo study procedures, will not be included in the trial.",
    "The sample is a phase 1 clinical trial for various types of leukemia and other blood disorders. The trial is testing the effectiveness of the drugs clofarabine and cyclophosphamide. The eligibility criteria include having a certain performance status, normal laboratory values, and normal cardiac function. Patients who have had a stem cell transplant or have certain medical conditions are excluded from the trial. The trial also excludes patients who have received certain types of therapy within the past two weeks. Female patients of childbearing potential must have a negative pregnancy test before entering the trial.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is a combination of phase 1 and phase 2, and the disease being studied is obesity. The icd-10 codes associated with obesity are listed, as well as the drug being tested, which is tesofensine. The eligibility criteria for participants are also listed, including age, BMI, and various medical conditions that would exclude someone from participating in the trial.",
    "The sample is a clinical trial for patients with metastatic castration-resistant prostate cancer. The trial is in phase 1/phase 2 and the drug being tested is temsirolimus. The eligibility criteria include having evidence of chemotherapy-refractory metastatic CRPC, having received prior Docetaxel-based or Mitoxantrone-based chemotherapy, and having an ECOG performance status of 0-2. Patients must also meet various medical criteria such as having certain blood counts, liver function, and cholesterol levels. Patients with a history of a prior malignancy are eligible provided they were treated with curative intent and have been disease-free for the appropriate time period. Patients must not have received prior treatment with AVASTIN, temsirolimus, everolimus or sirolimus. The trial excludes patients with certain medical conditions such as significant cardiovascular disease, history of stroke or transient ischemic attack, and known pulmonary hypertension or pneumonitis. Patients must also not be taking certain medications or supplements.",
    "This sample is a record of a clinical trial in phase 1 for the treatment of breast neoplasms. The trial involves the use of two drugs, lapatinib and docetaxel. The eligibility criteria for participants include having advanced solid tumors and being able to swallow oral medication. The icd-10 codes associated with the disease are also listed.",
    "The sample is a phase 1 clinical trial for patients with metastatic renal cell carcinoma or other advanced refractory solid tumors. The trial is testing the effectiveness of the combination of bevacizumab and pazopanib. The eligibility criteria include being over 18 years old, having a certain performance status, having measurable disease, and meeting certain laboratory values. Patients must also not have received certain prior treatments and must not have certain medical conditions. The trial also has exclusion criteria, such as ongoing toxicity from prior anti-cancer therapy and pregnancy or breastfeeding.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on HIV-1 infection and involves a list of drugs, including tbr-652 and its various dosages. The eligibility criteria for the trial include having no clinically significant findings on screening evaluations, being antiretroviral treatment-experienced, having a CD4 cell count of at least 250 cells/mm3, and having two separate qualifying plasma HIV 1 RNA levels of at least 5,000 copies/mL within 45 days prior to the first dose. The trial also has a list of exclusion criteria, including the presence of CXCR4- or dual/mixed-tropic HIV 1 virus, active CDC category C disease, and history of infection with hepatitis B or hepatitis C virus. The trial also prohibits the use of certain medications, including immunomodulating agents and experimental medications, within a certain timeframe prior to the first dose of study medication.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is for patients with hepatocellular carcinoma and the drug being tested is rad001. The inclusion criteria include having measurable disease, a prior core biopsy confirming the diagnosis of HCC, and having archived tissues available for correlative studies. Exclusion criteria include prior treatment with an mTor inhibitor, uncontrolled brain or leptomeningeal metastases, and known hypersensitivity to RAD001 or other rapamycins or its excipients.",
    "The sample is a phase 1 clinical trial for patients with advanced, persistent or recurrent squamous cell carcinoma of the uterine cervix. The trial is testing the effectiveness of carboplatin and docetaxel as a treatment option for patients who have no other curative options available. The eligibility criteria include having measurable disease, being over 18 years old with a performance status of GOG 0-2, and having a life expectancy of more than 6 months. Patients must also meet certain hematopoietic, hepatic, and renal requirements, and cannot have any other invasive malignancy within the past 5 years. Additionally, patients cannot have prior severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80, no peripheral neuropathy > grade 1, and no other concurrent malignancy except curatively treated non-melanoma skin cancer. The sample also includes information on prior concurrent therapy, including biologic therapy, chemotherapy, endocrine therapy, radiotherapy, and surgery.",
    "The sample is a phase 1 clinical trial for patients with B-cell chronic lymphocytic leukemia. The trial is open to patients who have received up to 2 previous lines of treatment, one of which was fludarabine based. Patients must be at least 18 years old, have a life expectancy of more than 6 months, and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. Female patients must not be pregnant and both male and female patients must be willing to use effective contraception for the entire duration of treatment and 2 months thereafter. Patients who have received more than 2 previous lines of treatment, are pregnant or nursing, on corticosteroid treatment, have active or severe infection, have total bilirubin > 2 \u00d7 ULN, calculated creatinine clearance <70 mL/min, seropositivity for human immunodeficiency virus, hepatitis B virus, or hepatitis C virus, have any coexisting medical or psychological condition that would preclude participation in the required study procedures, have participated in another clinical study <6 weeks prior to this study, or have a known hypersensitivity to the study medication are excluded from the trial.",
    "The sample is a phase 1 clinical trial for patients with locally recurrent breast cancer involving the chest wall and/or its overlying skin, with distant metastasis allowed. The trial is testing the effectiveness of lyso-thermosensitive liposomal doxorubicin (thermodox) as a treatment option. The eligibility criteria include various disease characteristics such as tumor size and thickness, prior radiotherapy, and progression on hormonal and chemotherapy treatments. Patient characteristics include being female, having a certain performance status, and meeting various laboratory and physical examination requirements. Prior and concurrent therapies are also specified, and certain drugs and conditions that may interfere with the trial are not allowed.",
    "The sample is a clinical trial for patients with myeloma, a type of cancer. The trial is in phase 1/phase 2 and involves the use of four different drugs: trisenox (arsenic trioxide), velcade (bortezomib), melphalan, and vitamin c (ascorbic acid). The eligibility criteria for the trial include having primary refractory disease, consolidation of a partial remission, or relapsing after prior therapy. Patients must also be under 75 years old, have a Zubrod performance status of <2, and meet certain medical criteria such as having a left ventricular ejection fraction >40% and no uncontrolled arrhythmias or symptomatic cardiac disease. Patients must also be HIV-negative and have a negative Beta human chorionic gonadotrophin (hCG) test in a woman with child bearing potential. The trial has exclusion criteria as well, such as having a corrected QT interval greater than 470 msec or being in complete remission.",
    "The sample is a phase 1 clinical trial for various types of hematologic malignancies, including relapsed or refractory acute myelogenous leukemia, pre-B-cell or T-cell acute lymphoblastic leukemia, and chronic myelogenous leukemia. The trial also includes patients with myelodysplastic syndromes and myeloproliferative disorders. The eligibility criteria include having received or being ineligible for established curative regimens, having no active CNS leukemia, and having a certain level of performance status and organ function. The trial involves the use of two drugs, 7-hydroxystaurosporine and perifosine, and patients must not have a history of allergic reactions to similar compounds. The trial excludes patients with poorly controlled diabetes, psychiatric illness, or HIV positivity, and patients must not be receiving any other concurrent anticancer therapy.",
    "The sample is a clinical trial for a combination treatment of HKI-272 and vinorelbine for patients with advanced malignant solid tumors or stage IV ErbB-2-positive breast cancer. The trial is divided into two parts, with different eligibility criteria for each part. The inclusion criteria for both parts include a confirmed diagnosis of the respective cancer type, prior treatment with at least one antineoplastic chemotherapy regimen for metastatic disease, and at least one measurable lesion. The exclusion criteria include prior treatment with certain drugs or cumulative doses of certain drugs, as well as having received more than a certain number of prior antineoplastic treatment regimens.",
    "The sample is a phase 1 clinical trial for patients with intracranial malignant glioma, including glioblastoma multiforme, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed oligoastrocytoma, or malignant astrocytoma NOS. The trial involves the use of the drugs temozolomide and vorinostat. The eligibility criteria include having a Karnofsky performance status of at least 60, a life expectancy of more than 8 weeks, and meeting certain blood count and liver function requirements. Patients must also have recovered from the toxic effects of prior therapy and not be receiving any other investigational agents. The trial has specific eligibility criteria for patients in part 1 and part 2 of the study. Exclusion criteria include having progressed on temozolomide, having any significant medical illnesses that cannot be controlled with therapy, and being pregnant or breastfeeding.",
    "The sample is a phase 1 clinical trial for cancer patients who have no effective standard therapeutic options. The trial involves the use of two drugs, vintafolide iv bolus and vintafolide iv infusion. The eligibility criteria include having a histological or cytological diagnosis of neoplasm, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and adequate bone marrow reserve, renal, and hepatic function. Exclusion criteria include concurrent hematological malignancies, pregnancy or lactation, symptomatic brain metastases, receiving concomitant anticancer therapy (excluding supportive care), and requiring palliative radiotherapy at the time of study entry.",
    "The sample is a phase 1 clinical trial for the treatment of ulcerative colitis using the drug adalimumab. The trial is open to both male and female participants over the age of 18 who have been diagnosed with ulcerative colitis for at least 3 months and have confirmed the diagnosis through endoscopy. Participants must have moderately-to-severely active disease despite concurrent treatment with corticosteroids, azathioprine or 6 mercaptopurine, and/or 5-aminosalicylate-containing medications. They must also have a Mayo Clinic Score of 6 to 12 points and an endoscopic subscore of at least 2. Participants who have not responded to or could not tolerate corticosteroids, azathioprine or 6 mercaptopurine, or 5-aminosalicylate-containing medications will not be required to be taking concurrent therapy at enrollment. Participants must be either anti-TNF agent na\u00efve or have had previous clinical response to infliximab therapy for UC with subsequent loss of response and/or are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions. They must be able and willing to give written informed consent and to comply with the requirements of the study protocol. Participants must also have adequate cardiac, renal, and hepatic function as determined by the principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits. Exclusion criteria include a history of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin, a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB, Crohn's Disease, symptomatic obstructive strictures, subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication, currently receiving total parenteral nutrition (TPN), any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer), antibiotic treatment for any systemic infection within 3 weeks prior to screening, female subjects who are pregnant or breast-feeding, history of clinically significant drug or alcohol abuse in the prior year, poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months), subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening, and subjects who have been on methotrexate within 4 weeks of screening.",
    "The sample is a phase 1 trial with only one disease, which is \"healthy\". The icd-10 codes associated with this disease are \"Z76.3\" and \"Z76.2\". The trial involves two drugs, \"ides\" and \"placebo\". The eligibility criteria for the trial include having the ability to understand and sign informed consent, having a BMI between 19 and 30, and not having any clinically significant disease. The exclusion criteria include having a positive HIV, hepatitis B or C, drug abuse, smoking, and use of medication except paracetamol.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on patients with type 2 diabetes and includes a list of icd-10 codes for the disease. The trial involves testing the effectiveness of four different drugs, including a placebo. The eligibility criteria for the trial are listed, including age, BMI, and exclusion criteria such as current use of certain medications and high blood glucose levels.",
    "The sample is a clinical trial for breast cancer patients in phase 1/phase 2. The trial is testing the effectiveness of the drugs docetaxel and epirubicin hydrochloride. The eligibility criteria for the trial include having histologically confirmed invasive adenocarcinoma of the breast, meeting certain criteria such as T4, NX, M0 or any T, N2-N3, M0, and having no evidence of metastatic disease. Patients must also meet certain patient characteristics such as being female, having a certain performance status, and meeting certain hematopoietic, hepatic, renal, and cardiovascular criteria. Patients must not have had prior chemotherapy, hormonal therapy, or radiotherapy for breast cancer, and must not have any other concurrent investigational drugs or anticancer treatment.",
    "The sample is a phase 1 clinical trial for patients with melanoma (skin cancer) that has spread to the extremities. The trial is testing the effectiveness of a combination of two drugs, buthionine sulfoximine and melphalan, as a regional therapy for the disease. Patients must meet certain eligibility criteria, including having stage IIIB or IIIC disease, having previously undergone melphalan-based regional therapy with persistent disease or recurrence within 6 months, and having distal disease to the planned site of tourniquet placement. Patients must also meet certain patient characteristics, such as having a certain performance status, blood counts, and no history of other malignancies. Prior concurrent therapy is also taken into consideration. The eligibility criteria and patient characteristics are described in detail in the criteria section.",
    "The sample is a phase 1 clinical trial for chronic hepatitis B. The trial is testing the drug adefovir and the eligibility criteria includes having a positive HBsAg for at least 3 months, positive HBeAg, and not having been treated with interferon alpha, lamivudine or adefovir within 3 months before study entry. The trial also requires a certain level of HBV DNA and ALT value, and patients must give written consent. Exclusion criteria includes uncompensated liver disease, positive for Hepatitis C, hepatitis D or HIV infection, previous liver or bone marrow transplant, taking immunosuppressant or immune modulatory drugs, pregnant or breastfeeding women, and patients with severe diseases affecting the study.",
    "The sample is a record from a clinical trial table. It includes information about the trial phase, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1 and is studying the effects of fondaparinux on morbid obesity. The eligibility criteria include age, BMI, negative pregnancy test, and exclusion criteria such as certain medical conditions, medications, and laboratory values. The sample also includes specific details about the laboratory values that would exclude a participant from the trial.",
    "The sample is a phase 1 clinical trial for children with recurrent or refractory solid tumors. The trial allows for bone marrow metastases and involves the use of carboplatin, cyclophosphamide, etoposide, thiotepa, and topotecan hydrochloride. The eligibility criteria include age between 1 and 30, a performance status of 0-2, a life expectancy of at least 2 months, and various hematopoietic, hepatic, renal, cardiovascular, and neurologic requirements. Patients must also have recovered from prior immunotherapy and chemotherapy, and must not have any uncontrolled infections or allergies to platinum compounds or etoposide. The trial does not allow for concurrent immunomodulators, cytokines, or other chemotherapy, and patients must have recovered from prior radiotherapy.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, kidney transplantation), the ICD-10 codes associated with the disease, the drug being tested (aeb071), and the eligibility criteria for participants. The eligibility criteria include requirements for age, type of kidney transplant, and exclusion criteria such as certain medical conditions or infections. The sample also notes that there may be additional inclusion/exclusion criteria defined by the protocol.",
    "The sample is a clinical trial for a vaginal gel called dapivirine (tmc120) for HIV-negative women who are willing to use the experimental gel and be randomized to a study group that includes the possibility of being assigned to a placebo group. The trial is in phase 1/phase 2 and the disease being studied is HIV infections. The inclusion criteria include being willing to undergo pelvic examinations with colposcopy and photographic documentation, having a regular menstrual cycle, and being sexually abstinent from randomization until completion of Day 7 evaluations. The exclusion criteria include being currently pregnant or breast-feeding, having laboratory confirmed gonorrhea, chlamydia, trichomonas, syphilis, or vaginal candidiasis or clinically diagnosed genital ulcer disease or active HSV-2 lesions, and requiring treatment for tuberculosis (TB) within 21 days prior to randomization.",
    "The sample is a phase 1 clinical trial for cancer patients. The trial is testing a drug called aee788. The eligibility criteria for the trial include having a confirmed solid tumor, adequate hematologic, renal and hepatic function, being at least 18 years old, having a Karnofsky performance status score of at least 70%, and having a life expectancy of at least 12 weeks. The exclusion criteria include having active brain metastases, peripheral neuropathy greater than grade 2, diarrhea greater than grade 1, gastrointestinal dysfunction, compromised cardiac function, and concurrent severe and/or uncontrolled medical conditions. The icd-10 codes for the diseases being studied are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2.",
    "The sample is a clinical trial for small cell lung cancer patients in phase 1/phase 2. The trial involves the use of three drugs, vorinostat, carboplatin, and etoposide. The eligibility criteria include having measurable disease, being chemotherapy naive, having a life expectancy of greater than 3 months, and having adequate organ and marrow function. Patients with known brain metastases, peripheral neuropathy CTC grade >2, uncontrolled intercurrent illness, and other malignancies in the last 5 years are excluded. Pregnant women and patients with known HIV, Hepatitis B, Hepatitis C, or active Hepatitis A are also excluded. The trial requires patients to sign a written informed consent document and use adequate contraception during the study.",
    "The sample is a clinical trial for lung cancer patients in phase 1/phase 2. The trial is testing the effectiveness of the drug celecoxib. The eligibility criteria for patients include having non-small cell lung cancer that is inoperable stage IIB or unresectable stage IIIA or IIIB, with no evidence of hematogenous metastases. Patients must also meet certain age and performance status requirements, have a certain life expectancy, and meet specific hematopoietic, hepatic, and renal criteria. Patients cannot have active gastrointestinal ulcers or bleeding within the past 3 months, no other malignancy within the past 3 years except nonmelanoma skin cancer, no known hypersensitivity to celecoxib, and no prior allergic-type reactions to sulfonamides or aspirin. Patients cannot be pregnant or nursing, must have a negative pregnancy test, and fertile patients must use effective contraception. The trial excludes patients who have had prior neoadjuvant chemotherapy, prior thoracic radiotherapy, or prior complete or subtotal tumor resection. Patients cannot take concurrent chemotherapy, corticosteroids, NSAIDs, lithium, furosemide, or angiotensin-converting enzyme inhibitors, but concurrent aspirin (325 mg/day) for cardioprotection is allowed.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on the treatment of neoplasms, which are cancerous growths. The trial includes a list of ICD-10 codes associated with the diseases being studied. The drugs being tested in the trial are sunitinib, pemetrexed, cisplatin, and carboplatin. The eligibility criteria for the trial include having a solid cancer that is not responsive to standard therapy or for which no standard therapy exists, and having a good performance status. The exclusion criteria include prior treatment with either pemetrexed or SU011248, coughing up blood within 4 weeks before starting study treatment (small amounts okay), and hypertension that cannot be controlled by medications.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on treating non-Hodgkin's lymphoma and B-cell lymphoma using a combination of drugs including velcade (bortezomib), rituximab, ifosfamide, carboplatin, and etoposide. The eligibility criteria for the trial include having aggressive B-cell non-Hodgkin lymphoma, being CD-20 positive, and being in first relapse or refractory to first- or second-line chemotherapy (non-platinum). Other criteria include being between the ages of 18-70, having an ECOG performance status of 0-2, and having measurable disease on CT scan by international working group response criteria. The sample also includes a list of exclusion criteria, such as having a platelet count of less than 75,000 or having received other investigational drugs within 14 days before enrollment.",
    "The sample is a phase 1 trial that focuses on the development of follicles in the ovaries and the use of oral contraceptives. The trial includes premenopausal women between the ages of 18 and 35 who have a regular menstrual cycle and a BMI between 18 and 30 kg/m\u00b2. The trial also has specific inclusion and exclusion criteria, as dictated by the FDA-approved protocol. The inclusion criteria include being non-pregnant and non-lactating, while the exclusion criteria include conditions that contraindicate the use of combination oral contraceptives, known thrombophlebitis or thromboembolic disorders, and migraine headaches with focal neurological symptoms.",
    "The sample is a clinical trial for breast cancer patients in phase 1 and phase 2. The trial is testing the effectiveness of two drug combinations, bez235 + trastuzumab and lapatinib + capecitabine. The trial is open to female patients over the age of 18 with HER2-positive invasive breast cancer that is either locally advanced or metastatic. Patients must have adequate bone marrow and organ function, and have recovered from any significant toxicities related to prior anti-neoplastic therapies. Patients must also meet a number of other eligibility criteria, including having received prior trastuzumab but no more than three prior cytotoxic chemotherapy lines. The trial has additional inclusion criteria for phase 2, including available tumor tissue for biomarker analysis and at least one measurable lesion as per RECIST 1.1. There are also exclusion criteria, such as previous treatment with PI3K and/or mTOR inhibitors, symptomatic/uncontrolled CNS metastases, and concurrent malignancy or malignancy in the last 3 years prior to enrollment.",
    "The sample is a clinical trial for patients with active rheumatoid arthritis in combination with a stable dose of methotrexate. The trial is in phase 1/phase 2 and the only drug being tested is a placebo. The eligibility criteria include patients aged 18-75 years with a diagnosis of active rheumatoid arthritis of stages I, II or III, and a disease duration of at least 6 months prior to randomization. Patients with congestive heart failure or poorly controlled diabetes mellitus, as well as those with major chronic inflammatory autoimmune diseases like psoriasis, psoriatic arthritis, spondyloarthropathy, inflammatory bowel disease or SLE, will be excluded. Pregnant or breastfeeding women will also be excluded. Other protocol-defined inclusion/exclusion criteria may apply.",
    "The sample is a clinical trial for sickle cell disease, with a phase 1/phase 2 designation. The trial involves the drugs eptifibatide and placebo. The eligibility criteria include being between the ages of 18 and 55, having a confirmed diagnosis of sickle cell anemia or sickle beta zero thalassemia, having certain laboratory values within normal ranges, experiencing sudden onset of pain, having adequate intravenous access, and being willing to give informed consent. Exclusion criteria include having certain medical conditions or histories, being pregnant or breastfeeding, being on certain medications, or having received investigational drugs within the past 4 weeks.",
    "The sample is a clinical trial for patients with juvenile myelomonocytic leukemia (JMML) who have relapsed or have residual disease after allogeneic hematopoietic cell transplant (HCT). The trial is in phase 1/phase 2 and involves the use of drugs such as cyclosporine, cytarabine, and methotrexate. The eligibility criteria include patients aged 0-18 with JMML, who are at least 6 months from their first HCT if clinically stable, and have adequate major organ function. The trial requires written informed consent and excludes patients with active uncontrolled infection within one week of HCT.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on sickle cell disease and involves the use of the drug propranolol. The eligibility criteria for participants include a diagnosis of HbSS or HbSBeta0Thal, age between 10-17 years, weight of 30kg or greater, and Hb levels of 7mg/dL or greater. Exclusion criteria include recent vaso-occlusive crisis or transfusion, pregnancy, history of certain medical conditions or medications, and allergy to sulfonamides. The sample also includes a list of icd-10 codes associated with sickle cell disease.",
    "The sample is a clinical trial for the treatment of multiple myeloma, a type of cancer. The trial is in phase 1/phase 2 and involves the drugs kw-2478 and bortezomib. The eligibility criteria include having a confirmed diagnosis of multiple myeloma and having had one to three prior unsuccessful treatments. Participants must also have an ECOG performance status of \u2264 2, a life expectancy of at least 3 months, and adequate hematologic status, liver and renal function. Exclusion criteria include no anti-cancer treatment for \u2265 4 weeks and no bortezomib treatment \u2265 60 days prior to receiving study drug, any other severe, acute or chronic illness, no other prior or concurrent malignancy, and no immunosuppressant therapy.",
    "The sample is a phase 1 clinical trial for patients with brain neoplasms. The trial is testing the effectiveness of temsirolimus (torisel) as a treatment for supratentorial grade III or IV astrocytoma (anaplastic astrocytoma, anaplastic oligodendroglioma, glioblastoma multiforme). Patients must have had prior radiation therapy and be a candidate for temsirolimus as the next therapy for their tumor. The eligibility criteria include being at least 18 years old, having a Karnofsky performance status \u2265 50%, and having adequate bone marrow, liver, and renal function. Patients must also not be allergic to temsirolimus or rapamycin. Exclusion criteria include serious concurrent infection or medical illness, pregnancy or breastfeeding, and not having MRI or CT evidence of measurable, contrast-enhancing residual disease.",
    "The sample is a phase 1 clinical trial for the treatment of rubeosis iridis and proliferative diabetic retinopathy using the drug ranibizumab. The trial has eligibility criteria for subjects with diabetes mellitus and proliferative diabetic retinopathy induced rubeosis who are willing to undergo cataract surgery and have an HgbA1c level below 12%. The exclusion criteria include a history of glaucoma surgery, active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis, intraocular surgery in the study eye within 60 days preceding Day 0, history of prior pars plana vitrectomy in the study eye, positive pregnancy test, and HbA1c level above 12.",
    "The sample is a phase 1 clinical trial for the treatment of rheumatoid arthritis. The trial involves the drug methotrexate (metoject\u00ae prefilled pen) and the eligibility criteria include being a suitable candidate for treatment with methotrexate, being 16 years of age or older, and not having any history of hypersensitivity to the drug. The exclusion criteria include being pregnant, having a history of or current inflammatory arthritis or rheumatic autoimmune disease other than rheumatoid arthritis, and being unable to comprehend written labeling and training materials.",
    "The sample is a phase 1 clinical trial for patients undergoing major cardiac or vascular surgery requiring the use of a cardiopulmonary bypass machine. The trial is focused on patients with acute renal failure or acute kidney injury and aims to test the effectiveness of the drugs i5np and placebo. The eligibility criteria include patient age between 21 and 85 years old, capability of giving consent, willingness to comply with the visit schedule and study procedures, and a cumulative score of \u2265 5 on the Cleveland Clinic Foundation (CCF) Acute Kidney Injury (AKI) risk factor scale OR an estimated GFR (eGFR) <60 mL/min/1.73 m2. The trial also has exclusion criteria, such as a history of cancer or abnormality on chest X-ray that could represent a malignancy, elevated pancreatic and/or hepatic enzyme level, and participation in a study of an experimental therapy in the last 30 days. The trial has different inclusion and exclusion criteria for before, during, and after surgery.",
    "The sample is a phase 1 clinical trial for patients with metastatic/unresectable adrenocortical carcinoma or melanoma that cannot be treated with surgery or radiation therapy. The trial is testing the drug sunitinib malate. The eligibility criteria include various medical and laboratory requirements, as well as restrictions on prior treatments and concurrent therapies. Patients must also not have certain medical conditions or histories within the past 12 months. The trial does not allow concurrent treatment on another clinical trial or other concurrent anticancer agents or therapies.",
    "The sample is a phase 1 clinical trial for patients with advanced solid tumors who have failed or are intolerant to standard therapy or for whom standard therapy does not exist. The trial is testing the drug px-866. The eligibility criteria include being 18 years or older, having an ECOG performance status of 0 to 1, and having a predicted life expectancy of at least 12 weeks. Patients must have discontinued prior chemotherapy or other investigational agents for at least three weeks prior to receiving the first dose of study drug and recovered from the toxic effects of the prior treatment. Adequate hematologic, hepatic, and renal function is also required. Exclusion criteria include any active infection, known diabetes or fasting blood glucose >160 mg/dL, known HIV, and any serious concomitant systemic disorders that would place the patient at excessive or unacceptable risk of toxicity.",
    "The sample is a phase 1 clinical trial for the treatment of obesity and lipid disorders. The trial involves the use of a drug called ZYT1 and placebo tablets. The eligibility criteria for the trial include being between the ages of 18-45, mentally and physically capable of giving informed consent, and having normal thyroid function tests. In addition, participants must meet certain lipid criteria and have no history of certain medical conditions. Exclusion criteria include a history of hypersensitivity to the drug, liver or renal disease, and certain cardiovascular conditions. Female participants must meet additional criteria related to pregnancy and contraception. The sample includes a detailed list of inclusion and exclusion criteria.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on chronic lymphocytic leukemia and leukemia, with corresponding ICD-10 codes. The drug being tested is clofarabine. The eligibility criteria for the trial include having relapsed from or being refractory to at least one fludarabine-based regimen, having adequate liver and renal function, and an ECOG performance status of 2 or lower. Exclusion criteria include having NYHA grade 3 heart disease, being pregnant or breastfeeding, having received chemotherapy within 4 weeks of starting therapy, having another malignancy within 3 years, being unwilling or unable to provide informed consent, having hypersensitivity to nucleoside analogues, and having other significant medical conditions that compromise safety, compliance, or study conduct.",
    "The sample is a clinical trial for colorectal cancer patients in phase 1/phase 2. The trial is testing the effectiveness of three drugs, (folpi) picoplatin with 5-fu and leucovorin, folpi, and folfox. The eligibility criteria for the trial include having metastatic colorectal adenocarcinoma, not having received prior systemic therapy for metastatic cancer, having an ECOG performance score of 0 or 1, and having a life expectancy of more than 3 months. The trial also requires measurable disease, defined by the RECIST criteria, and certain blood count levels. Women of childbearing potential must have a negative pregnancy test and agree to use appropriate birth control methods while on the study. The exclusion criteria include having concurrent use of EGFR inhibitors or anti-VEGF agents, having clinically significant obstructive symptoms or intestinal bleeding, and having a history of serious cardiac disease.",
    "The sample is a clinical trial for a drug called xpf-002 and a placebo, for patients with primary or inherited erythromelalgia. The trial is a combination of phase 1 and phase 2. The table includes information about the diseases being studied, the icd-10 codes associated with them, the drugs being tested, and the eligibility criteria for participants. The eligibility criteria include having a BMI between 18-40 kg/m2, experiencing flares of pain in the feet or hands caused by erythromelalgia, being generally healthy apart from the pain, and being willing to comply with all study procedures and restrictions. The exclusion criteria include not being in constant pain, having coexistent pain from other conditions, having HIV, Hepatitis B or C, having a history of major psychiatric disturbance, and using any other investigational drug in the 30 days prior to dosing.",
    "The sample is a clinical trial for patients with metastatic colorectal cancer in phase 1/phase 2. The trial involves the use of three drugs: capecitabine, gefitinib, and oxaliplatin. The eligibility criteria include confirmation of the colorectal cancer diagnosis, measurable disease, no CNS metastases, and certain hematopoietic, hepatic, renal, cardiovascular, and pulmonary requirements. Patients must also meet certain age and performance status requirements, have a life expectancy of more than 3 months, and not have any other significant clinical disorder or laboratory finding that would preclude study participation. Prior concurrent therapy is also specified.",
    "The sample is a clinical trial for a drug called rose-010 and a placebo, aimed at treating constipation-predominant irritable bowel syndrome (IBS) in females aged 18-65 years old. The trial is a combination of phase 1 and phase 2. The eligibility criteria include a previous diagnosis of IBS according to Rome III criteria, with symptoms of recurrent abdominal pain or discomfort for at least six months prior to diagnosis, and currently at least three days per month in the last three months associated with two or more symptoms. The symptoms include improvement with defecation, onset associated with a change in the frequency of stool, and onset associated with a change in form (appearance) of stool. The trial also requires constipation-predominant type IBS, with fewer than three spontaneous complete bowel movements per week, hard or lumpy stools more than 25% of the time, and straining during a bowel movement more than 25% of the time. The trial excludes patients who are pregnant or breastfeeding, have structural or metabolic diseases/conditions that affect the gastrointestinal system, or functional gastrointestinal disorders other than C-IBS. Patients who are considered by the Investigator to be alcoholics not in remission or known substance abusers, and those who have participated in another clinical study within the past 30 days are also excluded.",
    "The sample is a phase 1 clinical trial for non-small cell lung cancer. The trial includes patients with unresectable stage II, stage III, and Mx, and those who are being considered as surgical candidates after induction chemoradiation. Patients with pleural effusion that is transudative, cytologically negative and non-bloody are eligible if the radiation oncologist feels that the tumor can be encompassed within a reasonable field of radiotherapy. Patients with malignant pleural or pericardial effusions are not eligible. Patients will be eligible with or without measurable or evaluable disease. Patients with both measurable and evaluable disease will be evaluated for criteria for measurable disease. The trial has inclusion and exclusion criteria, including adequate lung, bone marrow, liver, and renal function, and fasting serum cholesterol and triglycerides levels. Patients who have received prior radiation or chemotherapy for the current diagnosis of NSCLC, patients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, and patients who have not recovered from the side effects of any major surgery are excluded. The trial also excludes patients with other malignancies within the past 3 years except for adequately treated carcinoma of the cervix, basal or squamous cell carcinomas of the skin, or breast DCIS, who may be included if the diagnosis was within 3 years. Patients with any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study are also excluded.",
    "The sample is a phase 1 clinical trial for patients with type 2 diabetes who have been treated with metformin for two years or less and have reached a stable dose between 1000-2550 mg per day for at least two months. The trial is testing the effectiveness of chromium picolinate as a treatment for type 2 diabetes. The eligibility criteria include having an ICD-9 diagnosis of type 2 diabetes, HbA1c levels between 7.0-10.5%, and not having a history of certain medical conditions such as myocardial infarction or congestive heart failure. Women of child-bearing age must be using standard birth control measures. There are also certain laboratory values that must be within a certain range for eligibility. Participants must discontinue any nutritional supplements and certain lipid-lowering medications prior to the study.",
    "The sample is a phase 1 clinical trial for patients with metastatic breast cancer. The trial is testing the drug icaritin. The eligibility criteria include being a female between the ages of 18 and 65, having advanced breast tumors confirmed through histologic or cytologic diagnosis with ER positive or investigator think that subjects will benefit from the trial, having relapsed or failed from previous standard treatment, having a BMI index between 19 and 30, having no serious heart, liver, lung, or kidney diseases, having received at least one anti-cancer treatment, having a life expectancy of at least 12 weeks, having an ECOG Performance Status of 0 or 1, and having no concurrent anti-cancer treatment. The exclusion criteria include having a known hypersensitivity to flavonoid drugs, having abnormal liver, renal, or bone marrow function, having a PT/APTT greater than 1.25 times the upper limit of normal, having suffered from thrombotic disease, having serum Ca greater than the upper limit of normal, not having recovered from toxic effects of previous anti-cancer treatments or surgery, having any serious or uncontrollable concomitant systemic disorder or active infection which will influence the clinical trial, having CNS metastases or invade requiring treatment for unstable status or various psychiatric disorders, having malabsorption or other disease which will affect the drug absorption, distribution, metabolism, and excretion, and having concurrent other malignancies with the exception of cervical cancer in situ or squamous Cell Carcinoma of the Skin.",
    "The sample is a phase 1 clinical trial for the treatment of acute leukemia using a drug called ly2523355. The trial includes two periods: a dose escalation period and a dose confirmation period. The inclusion criteria for both periods require participants to have a confirmed diagnosis of acute leukemia, be at least 18 years old, have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale, and have a negative pregnancy test if female and of childbearing potential. The exclusion criteria include having received treatment with an unapproved drug within 28 days of the initial dose, having other active malignancy (except for basal and squamous cell skin cancer), having had a bone marrow transplant within 3 months, having evidence of graft-versus-host disease, having uncontrolled systemic infection, being pregnant or lactating, and having positive test results for HIV, hepatitis B surface antigen, or hepatitis C antibodies.",
    "The sample is a phase 1 clinical trial for patients with multiple myeloma and plasma cell neoplasm. The trial involves the use of three drugs - arsenic trioxide, bortezomib, and melphalan. The eligibility criteria for the trial include confirmed diagnosis of multiple myeloma, indication for therapy based on symptoms, stable disease or achieved partial or complete remission to pre-transplant cyto-reductive therapy, and being a candidate for high-dose chemotherapy with autologous stem cell transplantation. Patients must also meet certain patient characteristics such as having a Karnofsky performance status of 60-100%, creatinine levels below 3.0 mg/dL, and platelet count above 50,000/mm\u00b3. Exclusion criteria include evidence of active plasma cell leukemia, relapsed refractory disease, and progressive disease on their last therapy. Prior concurrent therapy is allowed if it meets certain criteria, while previous autologous or allogeneic transplantation and other investigational or experimental drug or therapy are excluded.",
    "The sample is a phase 1 clinical trial for breast cancer patients with stage IV disease. The trial is testing the effectiveness of lapatinib, docetaxel, and trastuzumab, as well as docetaxel and trastuzumab, as treatments. The eligibility criteria include being 18 years or older, having a confirmed diagnosis of invasive breast cancer with stage IV disease, having measurable or evaluable lesions according to RECIST criteria, and having documentation of ErbB2 over-expression. The trial also requires subjects to have adequate haematological, hepatic, and renal function, and a cardiac ejection fraction within the institutional range of normal. Exclusion criteria include having peripheral neuropathy of grade 2 or higher, having had prior systemic therapy for metastatic disease, and having uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure.",
    "The sample is a phase 1 clinical trial for patients with refractory solid tumors or leukemia. The trial involves the use of drugs such as bevacizumab, sorafenib, and cyclophosphamide. The eligibility criteria include a diagnosis of recurrent or refractory tumors, age less than or equal to 21 years at the time of diagnosis, a life expectancy of at least 8 weeks, adequate organ and marrow function, and fully recovered from the acute toxic effects of prior therapy. Patients must not have a deep venous or arterial thrombosis within the last three months prior to study entry, and must not have a known thrombophilic condition. The trial also has exclusion criteria such as body surface area less than 0.3 m2, presence of a known bleeding diathesis or coagulopathy, and uncontrolled infection.",
    "The sample is a phase 1 clinical trial for individuals with type 1 diabetes mellitus. The trial is looking at the effects of two different formulations of insulin glargine on eligible participants. The inclusion criteria for the trial include being between 20 and 65 years old, having a stable insulin regimen for at least 2 months prior to the study, and being certified as otherwise healthy for type 1 diabetes mellitus. Women of childbearing potential must have a negative pregnancy test and use two independent methods of contraception throughout the study. The exclusion criteria include having a history or presence of certain diseases or conditions, such as cardiovascular or infectious diseases, and having a known hypersensitivity to insulin glargine or its excipients.",
    "The sample is a phase 1 clinical trial for the treatment of metastatic triple negative breast cancer using the drugs azd2281 and paclitaxel. The trial is looking for patients who have normal organ and bone marrow function, an ECOG performance status of no more than 2, and a histologically or cytologically diagnosed metastatic triple negative breast cancer. Patients must also have a formalin fixed, paraffin embedded tumor sample from the primary or recurrent cancer available for central testing. The trial has exclusion criteria such as recent chemotherapy or radiotherapy, major surgery within 4 weeks of starting the study, and certain medications. Patients with second primary cancer are also excluded unless they have been adequately treated. The diseases and their corresponding ICD-10 codes are listed as well.",
    "The sample is a record from a clinical trial table. It pertains to a phase 1 trial for the treatment of melanoma. The record includes information about the diseases being treated, the icd-10 codes associated with those diseases, the drugs being used in the trial, and the eligibility criteria for participants. The eligibility criteria include requirements such as having a measurable tumor and a certain performance status, as well as exclusion criteria such as having an autoimmune disease or having received prior therapy with immune stimulating agents.",
    "The sample is a clinical trial for a drug called \"human secretin\" for the treatment of chronic pancreatitis. The trial is a combination of phase 1 and phase 2. The eligibility criteria for the trial include being between the ages of 18-70, having documented chronic pancreatitis, and using opioid analgesics for chronic pain from CP. The exclusion criteria include having abnormal serum amylase and/or lipase indicative of acute pancreatitis within 30 days of study enrollment, exhibiting signs and/or symptoms of an episode of acute pancreatitis, and having severe cardiac, pulmonary, or renal disease. Pregnant women, nursing mothers, or women of childbearing potential not employing appropriate contraception are also excluded. The sample includes a detailed list of inclusion and exclusion criteria for the trial.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on treating advanced solid tumors, excluding breast cancer, that have progressed despite standard therapy or for which no standard therapy exists. The trial drug being tested is tki258 (dovitinib). The eligibility criteria for the trial include having a World Health Organization (WHO) performance status of \u2264 2 and meeting protocol-specified laboratory values. Exclusion criteria include having brain cancer, concurrent severe and/or uncontrolled medical conditions, not having recovered from previous anti-cancer therapies, and being pregnant, breastfeeding, or not willing to use an effective method of birth control. The record also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a record of a clinical trial for phase 1, which is focused on stomach neoplasms. The trial includes a list of icd-10 codes for the diseases, and a list of drugs that will be used in the trial, including 5-fluorouracil, cisplatin, and sunitinib malate. The eligibility criteria for the trial are also listed, including confirmed diagnosis of stomach cancer, advanced stage IV stomach cancer, adequate blood chemistry, blood counts, and kidney function, and willingness to participate and sign an informed consent document. The exclusion criteria include prior chemotherapy for stomach cancer in its advanced stage, excessive toxicities related to prior therapies, and being pregnant or breastfeeding.",
    "The sample is a phase 1 clinical trial for healthy male volunteers of Caucasian ethnicity, aged between 21 and 50 years, with a body mass index (BMI) between 19 and 29.9 kg/m2. The trial involves the administration of four drugs: bi 207127 na, bi 201335 na, midazolam, and tolbutamide. The eligibility criteria include being willing to complete all study-related activities and giving written informed consent prior to admission to the study. Exclusion criteria include any medical findings deviating from normal and of clinical relevance, as well as various medical conditions and drug use that may affect the results of the trial. The trial also excludes vulnerable subjects, smokers, alcohol and drug abusers, and those with a marked baseline prolongation of QT/QTc interval.",
    "The sample is a clinical trial table that includes information about the phase of the trial (phase I, phase II, or phase III), a list of diseases, a list of ICD-10 codes of diseases, a list of drug names, and eligibility criteria. The diseases listed in the sample include recurrent childhood anaplastic astrocytoma, recurrent childhood brain stem glioma, recurrent childhood ependymoma, recurrent childhood giant cell glioblastoma, recurrent childhood glioblastoma, recurrent childhood gliosarcoma, and recurrent childhood medulloblastoma. The eligibility criteria include requirements for patients to have a histological diagnosis of malignant CNS tumor, measurable disease, and adequate general condition for the study. Patients with uncontrolled infection or any significant medical illnesses that cannot be adequately controlled with appropriate therapy are excluded from the study.",
    "The sample is a record of a clinical trial that is in phase 1/phase 2. The trial is focused on treating proliferative diabetic retinopathy using the drug ranibizumab. The eligibility criteria for the trial include being 18 years or older, having diabetic neovascularization that was previously treated with full panretinal photocoagulation and has persisted for at least three months, and having no known sensitivity to ranibizumab or other anti-VEGF injections. Patients must also not be pregnant and must provide evidence of using two types of birth control while enrolled in the study. The trial has exclusion criteria such as uncontrolled glaucoma, prior enrollment in the study, and any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on Parkinson's disease and the associated symptoms. The trial includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being tested. The eligibility criteria for the trial are also listed, including age range, general health, medication use, and other factors. The exclusion criteria are also listed, including specific medical conditions and medication use. Overall, the sample provides a detailed overview of the clinical trial and the requirements for participation.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, ICD-10 codes for those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is for melanoma and is in phase 1/phase 2. The eligibility criteria include having stage IV or unresectable stage III melanoma, adequate organ function, and measurable disease by RECIST criteria. There are also exclusion criteria, such as having had major surgery or radiation therapy within 4 weeks of starting the study treatment, and having a history of active CHF or LVEF<50% at screening echocardiogram.",
    "The sample is a phase 1 clinical trial for patients with platinum-resistant or refractory epithelial cancer of the ovary, fallopian tube cancer, or gynecologic primary peritoneal cancer. The trial involves the drugs perifosine and docetaxel, and requires patients to have accessible tumors for biopsy and another tumor for imaging studies. Patients must also meet certain eligibility criteria, such as having an ECOG performance status of 0-2, being at least 18 years old, and having adequate liver and renal function. Exclusion criteria include any concurrent chemotherapy, underlying medical conditions that cannot be controlled, and known hypersensitivity to the study drugs.",
    "The sample is a phase 1 clinical trial for patients with advanced solid tumors that are refractory to standard therapies. The trial is testing the drug darinaparsin. The eligibility criteria include confirmation of advanced cancer, ECOG performance score \u22642, at least one measurable lesion, life expectancy \u226512 weeks, and adequate bone marrow, liver, and renal function. Exclusion criteria include allergies to arsenic, uncontrolled cardiac arrhythmia, pregnancy or lactation, metastatic brain or meningeal tumors, and substance abuse or medical conditions that could interfere with participation in the study. The trial requires written informed consent and compliance with ZIOPHARM policies and the Human Investigation Review Committee.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, corresponding ICD-10 codes, drugs being used, and eligibility criteria for patients. In this particular sample, the trial is in phase 1/phase 2 and is studying leukemia and lymphoma. The ICD-10 codes associated with these diseases are listed. The drugs being used in the trial are pentostatin, tacrolimus, and methotrexate. The eligibility criteria for patients include receiving allogeneic hematopoietic transplants from an unrelated or one antigen mismatched related donor, having certain types of cancer, meeting certain health criteria, and not having certain exclusions such as HIV seropositivity or uncontrolled infection.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on breast cancer patients who have undergone a unilateral segmental mastectomy. The trial is testing the effectiveness of melatonin versus a placebo in treating insomnia in these patients. The record includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being tested. The eligibility criteria for the trial are also listed, including age, physical status, and willingness to participate in the trial. The exclusion criteria are also listed, including certain medical conditions and medications that would disqualify a patient from participating in the trial.",
    "The sample is a phase 1 clinical trial for the treatment of cystic fibrosis. The trial is looking at the effectiveness of sodium chloride (7%) as a treatment. The eligibility criteria for the trial include having a confirmed diagnosis of cystic fibrosis, with a sweat chloride level greater than 60 mEq/l or 2 disease-causing CFTR mutations. Patients must also have a FEV1 of greater than or equal to 50% of predicted at the screening visit and an oxygen saturation of >92% on room air. Patients must be willing to participate in the study and sign an informed consent form. Exclusion criteria include unstable lung disease, use of certain medications, and recent radiation exposure.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, ICD-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying metastatic melanoma. The ICD-10 codes associated with the disease are listed, as well as the drug being tested (temozolomide). The eligibility criteria for participants are also listed, including requirements such as having had at least one prior systemic therapy, negative pregnancy test, and recovered from all toxic effects of prior therapy. Exclusion criteria are also listed, such as having a life expectancy of less than 4 months or being pregnant or nursing.",
    "The sample is a phase 1 clinical trial for the treatment of secondary hyperparathyroidism. The trial involves the use of two drugs, etelcalcetide and placebo. The eligibility criteria for the trial include being a male between the ages of 18 and 45 who is in good health and has provided written informed consent. Exclusion criteria include having a history or presence of any significant acute or chronic illness, ongoing medical conditions requiring prescription medication, asthma or severe allergies, clinically significant abnormalities on screening tests, and a history of drug or alcohol abuse.",
    "The sample is a phase 1 clinical trial for patients with metastatic or unresectable cancer. The trial involves the use of decitabine and pegylated interferon-alfa 2b drugs. The eligibility criteria include having measurable disease by RECIST criteria, a Zubrod performance status of 0-2, and adequate liver and renal function. Patients must not have untreated brain metastasis and must not have received chemotherapy, radiotherapy, surgery, biologic therapy, or any other investigational drug for any reason within 28 days prior to registration. The trial also has exclusion criteria, such as severe and/or uncontrolled concurrent medical disease and pregnancy or nursing mothers.",
    "The sample is a clinical trial for phase 1/phase 2 of treatment for head and neck cancer. The trial involves the use of drugs such as carboplatin, rad001, and paclitaxel. The eligibility criteria for patients include having locally advanced disease, no known brain metastases, and a WHO performance status of 0-2. Patients must also meet certain medical requirements such as having a platelet count of at least 100,000/mm\u00b3 and a creatinine clearance of at least 60 mL/min. Additionally, patients must not have any preexisting neuropathy \u2265 grade 2 or uncontrolled diseases such as diabetes or hypertension. Prior therapy for this cancer is not allowed, and patients must not be receiving concurrent CYP3A4 strong inhibitors or anti-coagulant therapy.",
    "The sample is a phase 1 clinical trial for patients with metastatic breast cancer that is HER-2 negative. The trial is testing the effectiveness of the drug paclitaxel. The eligibility criteria include having a life expectancy of at least 3 months, measurable or evaluable disease, and an Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 or less. Patients must also have adequate hematologic, renal, and hepatic function, and meet other specific criteria. Exclusion criteria include a history of bleeding diathesis or coagulopathy, concurrent hormone therapy, and more than one prior chemotherapy regimen for metastatic disease. Patients must agree to use appropriate non-hormonal contraception and cannot be pregnant or nursing.",
    "The sample is a phase 1 clinical trial for patients who have received a BEAM-conditioned autologous stem cell transplantation for high-risk lymphomas, follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, or T-cell non-Hodgkin lymphoma. The trial is testing the effectiveness of the drug vorinostat. The eligibility criteria include specific disease characteristics and patient characteristics, such as performance status, blood counts, and organ function. Patients must not have received prior treatment with a histone deacetylase inhibitor and must not be taking certain medications or undergoing certain therapies during the trial. The sample includes detailed information on the eligibility criteria, patient characteristics, and prior concurrent therapy.",
    "The sample is a clinical trial for patients with adult glioblastoma or gliosarcoma, or recurrent adult brain neoplasm. The trial is in phase 1/phase 2 and involves the drugs sorafenib tosylate and temsirolimus. The eligibility criteria include having had no more than two prior systemic chemotherapy regimens, evidence of tumor progression following radiation therapy or the most recent anti-tumor therapy, and a performance status of 0, 1, or 2. Patients must also meet various medical criteria, such as having certain blood counts and no uncontrolled infections. The trial has exclusion criteria, such as prior intratumoral chemotherapy or evidence of bleeding diathesis or coagulopathy.",
    "The sample is a phase 1 clinical trial for patients with renal cell carcinoma. The trial involves the use of a combination of tivozanib and temsirolimus drugs. The eligibility criteria include being at least 18 years old, having histologically confirmed renal cell carcinoma with a clear cell component, documented progressive disease, and measurable disease by RECIST criteria. Patients must not have had more than one prior VEGF receptor targeted therapy and no prior treatment with temsirolimus or other drugs targeting the mTOR pathway. Other criteria include a Karnofsky performance status of over 70%, a life expectancy of at least 3 months, and the ability to give written informed consent. The trial has various exclusion criteria, including known hypersensitivity to temsirolimus or its metabolites, primary CNS malignancies, hematologic malignancies, and significant cardiovascular disease. Prohibited medications include VEGF receptor targeted therapy, other signal transduction inhibitors, monoclonal antibodies, and immunotherapy or biological response modifiers. The trial also prohibits the use of herbal preparations/supplements and any experimental therapy. Patients must not have had radiotherapy involving \u2265 25% of bone marrow within the last 4 weeks prior to the study.",
    "The sample is a phase 1 clinical trial for patients with advanced, non-resectable and/or metastatic solid tumors who have failed conventional treatment or for whom no therapy of proven efficacy exists. The trial involves the use of two drugs, bibw 2992 and bibf 1120. The eligibility criteria include confirmed diagnosis of the disease, age 18 years or older, life expectancy of at least three months, Eastern Cooperative Oncology Group performance score 0, 1 or 2, and recovery from any therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapies to CTC <= Grade 1. The exclusion criteria include active infectious disease, gastrointestinal disorders that may interfere with the absorption of the study drug or chronic diarrhea, serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol, and others. Patients who meet the eligibility criteria and do not meet the exclusion criteria will be enrolled in the trial.",
    "The sample is a phase 1 clinical trial for patients with metastatic cancer or unspecified adult solid tumors. The trial involves the drug riluzole and requires patients to have at least 2 brain metastases that are too large for radiosurgery or surgical resection. Patients must also meet certain eligibility criteria, including having an ECOG performance status of 0-2, normal blood counts and liver function, and no history of allergic reactions to riluzole. Patients cannot have received prior whole-brain radiotherapy or systemic chemotherapy within 2 weeks of the trial. The trial allows for radiosurgical boosts to up to 3 metastases, at the discretion of the treating radiation oncologist.",
    "This sample is for a phase 1 clinical trial for cancer patients with advanced or metastatic solid tumors. The trial is testing the drug bms-690514. The eligibility criteria for the trial includes having inadequate response to standard care and having adequate kidney, liver, and cardiac function. The icd-10 codes associated with the disease are also provided.",
    "The sample is a clinical trial for head and neck cancer patients in phase 1/phase 2. The trial involves the use of drugs such as carboplatin, cisplatin, docetaxel, fluorouracil, and lapatinib ditosylate. The eligibility criteria include having newly diagnosed squamous cell carcinoma of the larynx or hypopharynx, being in a certain stage of the disease, having no distant metastasis, and meeting certain patient characteristics such as having normal cardiac function and being able to swallow oral agents. Patients must not have received any other anticancer therapy or investigational agents while on the study. The sample also includes a list of icd-10 codes for the diseases being studied and the eligibility criteria in detail.",
    "The sample is a clinical trial for rheumatoid arthritis, in which the phase is a combination of phase 1 and phase 2. The trial includes a list of icd-10 codes for the disease, a drug called ccx 354-c, and eligibility criteria for participants. The inclusion criteria include being between the ages of 18-75, having stable RA for at least 3 months, being on a stable dose of methotrexate, and being willing to comply with the study protocol. The exclusion criteria include having a history of alcohol or drug abuse, being pregnant or breastfeeding, having a history of cancer within the past 10 years, and having any medical or psychiatric condition that may prevent the subject from completing the study.",
    "The sample is a clinical trial for non-small cell lung cancer patients in phase 1/phase 2. The trial includes patients with stage II or III non-small cell lung cancer, or stage IV non-small cell lung cancer that will be treated with curative intent. The trial will use the drugs etoposide and cisplatin. The eligibility criteria include having measurable disease, being evaluated by a surgeon and deemed inoperable, having no active malignancy within the past 5 years (except for non-melanoma skin cancers or carcinoma in situ of the cervix), being 18 years or older, having a life expectancy of greater than 6 months, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2, having normal organ and marrow function, and having a Forced expiratory volume (FEV1) of 1 L or greater OR 50% or greater of predicted. The exclusion criteria include having a primary tumor size greater than 6cm, having a prior history of thoracic radiotherapy, not being able to receive any other study agents, having a history of pulmonary fibrosis, having a history of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin or etoposide, having a primary tumor less than 1.5 cm beyond hilar lymphadenopathy (if any) and 1.5 cm from proximal bronchial tree, having uncontrolled intercurrent illness, being pregnant or breast feeding, having a history of a different malignancy (except for certain circumstances), being HIV-positive individuals on combination antiretroviral therapy, and planned to receive certain medications.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on the treatment of multiple sclerosis, with a list of icd-10 codes provided. The trial involves the use of inhaled cannabis, oral THC, oral placebo, and inhaled placebo as potential treatments. The eligibility criteria for participants include a diagnosis of clinically definite multiple sclerosis, moderate or severe spasticity, age 21 or older, and living close to the Sacramento, CA area. Exclusion criteria include preexisting pulmonary or cardiac conditions, inability to abstain from tobacco or marijuana smoking, history of abuse of recreational drugs, and poorly controlled psychiatric illness. The trial also requires participants to provide informed consent and comply with adequate contraception if female and of childbearing potential.",
    "The sample is a clinical trial for patients with metastatic pancreatic cancer. The trial is in phase 1/phase 2 and involves two groups of patients: one group receiving ipi-926 plus gemcitabine and the other group receiving placebo plus gemcitabine. The eligibility criteria include being 18 years or older, having pathologically confirmed metastatic pancreatic adenocarcinoma, having at least one radiologically evaluable metastatic lesion, having an ECOG score of 0 or 1, having a life expectancy of at least 3 months, agreeing to use adequate methods of birth control, being able to adhere to the study visit schedule, and voluntarily signing an informed consent form. The exclusion criteria include having islet cell, acinar cell carcinoma, non-adenocarcinoma, adenocarcinoma originated from biliary tree or cystadenocarcinoma, having prior treatment with chemotherapy for pancreatic cancer, having known central nervous system metastases, having inadequate hematologic, hepatic, or renal function, having an external biliary drain, having a history of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months, having a venous thromboembolic event requiring anticoagulation not appropriately anticoagulated or have NCI CTCAE Grade 2 or greater bleeding episode in the 3 weeks prior to administration of IPI-926, having concurrent administration of medications or foods known to inhibit CYP3A activity to a clinically relevant degree, having presence of active infection or systemic use of antibiotics within 72 hours of treatment, having significant co-morbid condition or disease which in the judgment of the Investigator would place the patient at undue risk or interfere with the study, having known human immunodeficiency virus (HIV) positivity, being known hypersensitive to gemcitabine, IPI-926, or their excipients, or being pregnant or lactating women.",
    "The sample is a phase 1 clinical trial for patients with type 2 diabetes mellitus. The trial involves the drugs azd1656 and placebo. The eligibility criteria include being a male patient aged 20-60 years, having been treated with 1 to 2 OADs for at least 30 days prior to enrollment, and not having been treated with glitazones within 6 months prior to enrollment. Patients with known cardiovascular disease are excluded, except for those with Grade 1 hypertension without secondary organ involvement. Other exclusion criteria include a history of ischemic heart disease, heart failure, stroke, transitory ischemic attack, or peripheral vascular disease, as well as certain abnormalities in rhythm, conduction, or morphology of resting ECG, and high blood pressure. Patients must provide signed and dated, written informed consent prior to any study-specific procedures.",
    "The sample is a phase 1 clinical trial for atherosclerosis, with the drugs darapladib and diltiazem being tested. The eligibility criteria include being between 18 and 65 years old, healthy, having a BMI between 19-37 kg/m2, and having a corrected QT duration below 450 msec. Female participants must either be of non-childbearing potential or agree to use contraception during the study. Exclusion criteria include a history of liver disease, sensitivity to study medications, and certain medical conditions that may pose a risk. Participants must also refrain from using certain medications and follow the study procedures outlined in the protocol.",
    "The sample is a phase 1 clinical trial for patients with kidney cancer. The trial is testing the effectiveness of the drug sorafenib. The eligibility criteria for the trial include having histologically or cytologically confirmed clear cell renal cell carcinoma, measurable disease, and no prior treatment except for sunitinib malate. Patients must also meet certain patient characteristics, such as having an ECOG performance status of 0-1 and a life expectancy of more than 6 months. The trial excludes patients with certain medical conditions, such as uncontrolled hypertension or a history of major cardiac arrhythmias. Prior concurrent therapy is also restricted, and patients must not have received systemic treatment for metastatic disease other than sunitinib malate.",
    "The sample is a record from a clinical trial table. It includes information about the phase of the trial, which is a combination of phase 1 and phase 2. The disease being studied is malignant melanoma, and the icd-10 codes associated with it are listed. The drugs being tested are imexon and dtic. The eligibility criteria for the trial are also listed, including requirements for the patient's health status, ability to perform daily activities, and projected life expectancy. The exclusion criteria are also listed, which include prior chemotherapy for the stage III or IV disease and brain metastases.",
    "The sample is a clinical trial for patients with leukemia or myelodysplastic syndromes in phase 1/phase 2. The trial is testing the effectiveness of the drug cytarabine for patients who are not suitable for intensive chemotherapy regimens. The eligibility criteria include having a diagnosis of AML or high-risk myelodysplastic syndromes, being in good health with no serious medical conditions, and not having any other concurrent experimental drugs or anticancer therapy. Patients must also have a negative pregnancy test and use effective contraception if they are fertile. The trial excludes patients with a history of significant neurologic or psychiatric disorder, active uncontrolled serious infections, active peptic ulcer disease, or evidence of bleeding diathesis. Prior concurrent therapy is limited to hydroxyurea and prophylactic doses of anticoagulants.",
    "The sample is a phase 1 clinical trial for patients with invasive breast cancer and HER2 overexpression who also have at least one brain metastasis. The trial is testing the effectiveness of the drugs lapatinib and herceptin. The eligibility criteria include having a life expectancy of greater than 12 weeks, normal organ and marrow function, and an ECOG performance status of 0-2. Exclusion criteria include prior whole brain radiation therapy, receiving any other investigational agents, and concurrent chemotherapy, immunotherapy, biologic therapy or hormonal therapy for treatment of their cancer. Pregnant or breastfeeding women are also excluded.",
    "The sample is a clinical trial for patients with metastatic pancreatic cancer in phase 1/phase 2. The trial is testing the effectiveness of gemcitabine and albumin-bound paclitaxel as a treatment for the disease. The eligibility criteria for the trial include having no prior therapy for metastatic disease, acceptable blood counts and chemistry levels, acceptable coagulation status, a Karnofsky performance status of 70 or higher, and one or more measurable metastatic tumors. Patients must also have no clinically significant abnormalities in urinalysis results and must be willing to comply with study procedures. Exclusion criteria include having known brain metastases, using therapeutic coumadin for a history of pulmonary emboli and deep vein thrombosis, having active, uncontrolled bacterial, viral, or fungal infections, and having serious medical risk factors involving any of the major organ systems.",
    "The sample is a clinical trial for rheumatoid arthritis, with a combination of phase 1 and phase 2. The trial involves the drugs ocrelizumab and placebo. The eligibility criteria for the trial include having moderate to severe RA for at least 6 months, a positive serum rheumatoid factor, and current treatment with RA on an outpatient basis. In addition, the participant must have failed treatment with one disease modifying anti-rheumatic drug (DMARD) or biologic, but not more than six of these agents including methotrexate. The participant must also be currently taking methotrexate for at least 12 weeks at a stable dose and using highly effective contraception. The exclusion criteria include having any other rheumatic autoimmune disease or inflammatory joint disease, concurrent treatment with any DMARD or anti-tumor necrosis factor (TNF)-alfa or other biologic therapy, and previous treatment with cell-depleting therapies, IV gamma-globulin, intra-articular or parenteral corticosteroids, and receipt of live/attenuated vaccine prior to screening. The participant must not have a history of severe allergic or anaphylactic reactions to humanized monoclonal antibodies, known active bacterial, viral or fungal infections, history of active tuberculosis and primary or secondary immunodeficiency, and concomitant diseases such as cardiovascular disease, nervous system, pulmonary disease, renal, hepatic, endocrine or gastrointestinal disorders. The participant must not be pregnant or lactating.",
    "The sample is a clinical trial for patients with persistent or recurrent ovarian epithelial, primary peritoneal, or fallopian tube cancer. The trial is in phase 1/phase 2 and involves the use of the drug docetaxel. The trial requires patients to have received 1 prior platinum-based chemotherapy regimen containing carboplatin, cisplatin, or other organoplatinum compound. Patients must also meet a number of eligibility criteria, including having measurable disease, a Zubrod performance status of 0-2, and various blood count and organ function requirements. The trial excludes patients with certain medical conditions, such as active bleeding or pathologic conditions that carry a high risk of bleeding, and those with a history of allergic reactions to certain compounds. The trial also requires patients to undergo an MRI scan and prohibits concurrent use of other anticancer therapies or investigational agents.",
    "The sample is a phase 1 clinical trial for the treatment of chronic hepatitis B. The trial is testing the effectiveness of two drugs, dv-601 and entecavir, on patients with the disease. The eligibility criteria for the trial include being between 18 and 65 years old, having a diagnosis of chronic hepatitis B, and having normal renal function. Women of childbearing potential must have a negative pregnancy test and agree to use dual methods of contraception. Exclusion criteria include liver disease other than chronic hepatitis B, co-infection with hepatitis A, C, or HIV, previous therapy with interferon alpha, and any other antiviral therapy for chronic hepatitis B within the previous 3 months. The trial also excludes patients with evidence of cirrhosis, a Child-Turcotte-Pugh score of 7 or higher, and any clinically significant acute or chronic illnesses. Additionally, patients with a history of substance or alcohol abuse are excluded from the trial.",
    "The sample is a clinical trial for patients with non-small-cell lung carcinoma that is unresectable and locally advanced or metastatic. The trial is in phase 1/phase 2 and the drug being tested is patupilone. The eligibility criteria include prior treatment with a platinum-containing regimen, age \u226518 years, performance status of 0-1 on the WHO scale, life expectancy of \u22653 months, and adequate hematologic parameters. Patients with brain metastases are eligible if they are neurologically stable and have at least one bidimensionally measurable intracranial lesion of minimum diameter 2 cm. Patients with brain metastases must show evidence of residual disease or progression of disease since prior radiological or surgical therapy. Patients with brain metastases who have extracranial metastases in more than two organs are excluded. The trial has other protocol-dependent inclusion/exclusion criteria that may apply.",
    "The sample is a phase 1 clinical trial for individuals with type 2 diabetes mellitus. The trial includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs including placebo, insulin, glucose, and glucagon. The eligibility criteria for the trial include various medical and health-related factors such as age, BMI, blood pressure, and medical history. The trial also includes exclusion criteria such as allergies to certain compounds, history of cardiovascular or respiratory disorders, and regular use of drugs of abuse. The trial requires participants to be reliable and willing to follow study procedures, and to have given written informed consent approved by the ethical review board governing the site.",
    "The sample is a clinical trial for pre-hypertension, with a phase 1/phase 2 design. The trial includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being tested. The eligibility criteria for the trial includes individuals who are over 18 years old with pre-hypertensive or borderline blood pressures, and have at least one additional risk factor for cardiovascular disease. Exclusion criteria include patients with a history of cardiac, cerebral or other vascular events within the previous 6 months, background therapy with a beta blocker or ACE inhibitor therapy, known or suspected intolerance to beta blockers or ACE inhibitors, angiotensin receptor blocker therapy, or diabetes. Pregnant or lactating women, and women of child-bearing age who are not using an acceptable form of contraception are also excluded from this study.",
    "The sample is a phase 1 clinical trial for cancer patients. The trial is testing the drug gsk1120212. The eligibility criteria for the trial includes being a male over 18 years old, having a confirmed diagnosis of a solid tumor, and having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. In addition, participants must meet certain physical requirements such as having a body weight greater than or equal to 45 kg and a BMI greater than or equal to 19 kg/m2 and less than or equal to 35 kg/m2. Participants must also agree to use one of the contraception methods listed in the protocol from the time of the first dose of study medication until sixteen weeks after the last dose of study medication. There are also exclusion criteria, such as currently receiving cancer therapy, having a serious pre-existing medical or psychiatric disorder, or having a history of interstitial lung disease or pneumonitis.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on the disease of allergic asthma and includes a list of associated ICD-10 codes. The trial involves the use of three drugs: qge031, omalizumab, and placebo. The eligibility criteria for the trial includes adult patients between the ages of 18 and 65 who have a positive skin prick test to one or more common airborne allergens, airway hyperresponsiveness, and an early asthmatic response. Patients must also meet certain weight and IgE requirements for omalizumab. Exclusion criteria include pregnant or nursing women, smokers, and patients with poorly controlled asthma or who have had an asthma exacerbation within the past year. Other inclusion/exclusion criteria may also apply.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is for patients with intracranial glioblastoma multiforme or gliosarcoma, who have evidence of tumor progression by MRI or CT scan within the past 14 days and are on a stable steroid dose for at least 5 days. Patients who underwent prior therapy that included interstitial brachytherapy or stereotactic radiosurgery must have confirmation of true progressive disease. The trial allows treatment for any number of prior relapses, defined as disease progression after initial therapy. Patients must meet certain eligibility criteria, including having a Karnofsky performance status of 60-100%, certain blood counts, and no significant medical illnesses that would preclude study treatment. Patients must also not have any other active cancer, HIV disease, or allergies to certain compounds. The trial involves the use of several drugs, including sorafenib tosylate, erlotinib hydrochloride, tipifarnib, and temsirolimus. Patients must not have received these drugs before and must meet other criteria specific to each drug. The trial also has certain exclusion criteria, such as concurrent use of certain medications and concurrent prophylactic filgrastim.",
    "The sample is a phase 1 clinical trial with only healthy subjects. The trial is testing the effects of various drugs, including a placebo and different doses of alo-02 and oxycodone ir, on non-dependent, recreational opioid users. The eligibility criteria include using opioids for non-therapeutic purposes at least 10 times in the past year and at least once in the 8 weeks before the screening visit. Exclusion criteria include a diagnosis of substance or alcohol dependence, participation in or seeking treatment for substance or alcohol-related disorders, a history of sleep apnea, and testing positive for Hepatitis B or C and HIV during screening.",
    "This sample is a phase 1 clinical trial for patients with advanced solid tumors. The trial is testing the drug lcl161. The eligibility criteria for the trial include having a solid tumor, a certain performance status, a life expectancy of at least 12 weeks, meeting certain blood laboratory values, and meeting criteria for time since the last dose of prior therapy. There are also exclusion criteria, such as having active brain tumors or brain metastases, unresolved nausea, vomiting, or diarrhea, and certain medical conditions that could compromise participation in the study. Women who are pregnant or breastfeeding and patients with HIV or chronic active hepatitis B or C are also excluded. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a clinical trial for breast cancer patients in the phase 1/phase 2 stage. The trial is testing the effectiveness of the drugs docetaxel, epirubicin, and bevacizumab. The eligibility criteria for the trial include having confirmed metastatic breast adenocarcinoma, no HER2 overexpression or gene amplification, and no previous therapy for metastatic breast cancer. Patients must also be between the ages of 18-75 and have measurable disease as defined by the presence of at least one measurable lesion. Additionally, patients must have a performance status (WHO) of 0-2 and adequate liver, renal, and bone marrow function. Exclusion criteria include active infection, brain metastases, significant cardiac disease, history of stroke, and other invasive malignancy except nonmelanoma skin cancer. Pregnant or lactating women are also excluded from the trial.",
    "The sample is a clinical trial for small cell lung cancer patients in phase 1/phase 2. The trial includes patients with extensive stage or recurrent lung small cell carcinoma. The trial involves the use of drugs such as carboplatin, cisplatin, etoposide, and sunitinib malate. The eligibility criteria include having measurable disease, no prior chemotherapy for small cell lung cancer, completed radiation therapy at least one week before the trial, and a Common Toxicity Criteria (CTC) performance status of 0-1 for phase IB and 0-2 for phase II. Patients with certain medical conditions such as ongoing cardiac dysrhythmias, atrial fibrillation, or QTc interval >= 500 msec are not eligible. The trial also has specific requirements for blood counts, liver and kidney function, and coagulation parameters.",
    "The sample is a clinical trial for lung cancer patients in phase 1/phase 2. The trial involves the drugs rad001 and docetaxel. The eligibility criteria include having histologically confirmed non-small cell lung cancer, an ECOG Performance Status of 0, 1, or 2, and a life expectancy greater than 12 weeks. Patients must also have adequate bone marrow, renal and hepatic function, and completed all prior therapy at least 3 weeks prior to registration. Exclusion criteria include chronic treatment with systemic steroids or other immunosuppressive agents, uncontrolled brain or leptomeningeal metastases, and a known history of HIV seropositivity. Final eligibility for the trial is determined by the health professionals conducting the trial.",
    "The sample is a phase 1 clinical trial for patients with advanced or recurrent non-small-cell lung cancer. The trial is testing the effectiveness of a combination of drugs called arq 197 and erlotinib. The eligibility criteria for the trial include having a confirmed diagnosis of non-small-cell lung cancer, having received at least one prior chemotherapy regimen (with EGFR tyrosine kinase inhibitors counting as one regimen), having an ECOG performance status of 0 or 1, and having a life expectancy of at least 3 months. Exclusion criteria include recent anti-cancer therapy, surgery for cancer, active double cancer, symptomatic brain metastases, uncontrolled intercurrent illness, pregnancy or lactation, and unwillingness to use contraceptive measures.",
    "The sample is a clinical trial for patients with Richter's transformation, leukemia, or relapsed/refractory B-cell chronic lymphocytic leukemia. The trial is in phase 1/phase 2 and involves the use of oxaliplatin, fludarabine, cytarabine, rituximab, and pegfilgrastim. The eligibility criteria include confirmation of the disease, age of 18 or older, performance status of 0-2, adequate renal and hepatic function, and agreement to use contraception. Exclusion criteria include untreated or uncontrolled life-threatening infection, intolerance to the drugs, pregnancy or lactation, recent chemotherapy or radiation therapy, and medical conditions that may interfere with the study.",
    "The sample is a record of a clinical trial in phase 1, focused on the disease of type 2 diabetes mellitus. The trial involves the drug rosiglitazone maleate and includes a list of ICD-10 codes for the disease. The eligibility criteria for the trial include age requirements, female contraception use, and the absence of certain medical conditions or abnormalities. The sample also includes exclusion criteria for the trial.",
    "The sample is a phase 1 clinical trial for the treatment of cachexia. The trial is testing the drugs gsk2849466 and placebo. The eligibility criteria for the trial includes males between 18 and 50 years of age, with a body weight of at least 50 kilograms and a BMI within the range of 19-32 kg/meter squared. The subjects must be healthy as determined by a physician, and must not have a history of certain diseases or abnormalities. They must also be willing to use contraception if they have female partners of child-bearing potential. The trial has a list of exclusion criteria, including a history of drug or alcohol abuse, liver disease, or sensitivity to the study medications. The trial also has specific laboratory test ranges that subjects must fall within to be eligible. The sample includes the inclusion and exclusion criteria for the trial.",
    "The sample is a table with information about clinical trials for various types of non-Hodgkin lymphoma. The table includes the phase of the trial (phase I, II, or III), a list of diseases, their corresponding ICD-10 codes, the drug being tested (lenalidomide), and eligibility criteria for participants. The eligibility criteria include factors such as previous cancer therapy, performance status, blood counts, and liver and kidney function. The table also lists exclusion criteria, such as pregnancy or breastfeeding, use of other experimental drugs, and certain medical conditions.",
    "The sample is a phase 1 clinical trial for healthy males and females between the ages of 18 and 55. The trial involves the use of dabigatran etexilate capsules, quinidine sulfate tablets, and fexofenadine tablets. The eligibility criteria include having a BMI between 18.5 and 30 kg/m2, passing a medical examination, having a negative pregnancy test (if female), and using adequate contraception (if female and of child-bearing potential). Exclusion criteria include having any clinically relevant concomitant disease, a history of relevant allergy/hypersensitivity, and taking drugs that might influence the results of the trial or prolong the QT/QTc interval.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is a combination of phase 1 and phase 2, and it is focused on studying esophagus cancer. The trial is testing the effectiveness of three drugs - oxaliplatin, docetaxel, and capecitabine. The eligibility criteria for participants include having adenocarcinoma or squamous cell carcinoma of the esophagus or G/E junction, being a surgical candidate, having no previous treatment for esophageal cancer, having measurable or evaluable disease, being able to perform daily activities with minimal assistance, having adequate bone marrow, liver, and kidney function, and providing written informed consent. There are also exclusion criteria, such as having tumor location in the proximal esophagus, having metastatic disease or locally advanced cancer, having moderate to severe peripheral neuropathy, having serious pre-existing medical illnesses, having significant heart disease, being treated for an invasive cancer within the previous 5 years, being pregnant or breastfeeding, or being under 18 years of age. The study center will determine if a participant meets all of the criteria, and if they do not qualify, the study personnel will explain the reasons.",
    "The sample is a clinical trial for patients with B- or T-cell non-Hodgkin's lymphoma (NHL) who have relapsed or refractory disease. The trial is in phase 1/phase 2 and the patients must have received 1-3 prior therapeutic regimens. The trial is testing the effectiveness of bortezomib and gemcitabine hydrochloride as a treatment for NHL. The eligibility criteria include specific disease characteristics, patient characteristics, and prior concurrent therapy. Patients must meet certain criteria related to their performance status, life expectancy, blood counts, liver and kidney function, and other medical conditions. They must also not have received prior treatment with bortezomib or gemcitabine hydrochloride, and cannot be receiving other systemic cytotoxic chemotherapy or investigational agents during the trial.",
    "The sample is a phase 1 clinical trial for patients with leukemia or myelodysplastic syndromes. The trial is testing the effectiveness of cyclophosphamide as a treatment option for patients who have failed or are ineligible for other treatments such as azacitidine or lenalidomide. Patients must meet certain eligibility criteria, including having a partially mismatched related donor available and meeting certain health requirements such as having a good performance status and normal liver and kidney function. The sample includes detailed information on the disease characteristics and patient characteristics required for participation in the trial.",
    "The sample is a clinical trial for patients with chronic lymphocytic leukemia in need of treatment. The trial is a combination of bendamustine, rituximab, and lenalidomide. The trial is in phase 1/phase 2. The eligibility criteria include being 18 years or older, having a confirmed diagnosis of CLL, having a life expectancy of more than 12 weeks, and having relapsed or refractory disease after at least one but no more than three prior regimens. The exclusion criteria include having previously been treated with more than three prior regimens for CLL, having known central nervous system involvement of CLL, and having other severe concurrent diseases that could interfere with the patient's ability to participate in the study.",
    "This sample is a phase 1 clinical trial for patients with acute myeloid leukemia who are not eligible for standard induction or have relapsed/refractory AML. The trial involves a combination therapy using decitabine and midostaurin. The eligibility criteria include being at least 60 years old with newly diagnosed AML or at least 18 years old with relapsed/refractory AML, having histologically documented AML, a Karnofsky performance status of at least 70, and meeting certain lab value requirements. Exclusion criteria include prior bone marrow or stem cell transplant, uncontrolled active infection, and certain medical conditions that could compromise participation in the study. Patients must also give written informed consent.",
    "The sample is a phase 1 clinical trial for patients with active multiple myeloma who have experienced disease progression after at least 2 cycles of anti-myeloma treatment or have relapsed with progressive disease after treatment. The trial involves the drug CC-5013 and requires patients to meet certain eligibility criteria, such as having measurable myeloma paraprotein levels in serum or urine, a certain Eastern Cooperative Group Performance Status, and adequate bone marrow and renal function. Women of childbearing potential must have a negative pregnancy test and agree to use adequate contraceptive methods while on the drug. The trial also has exclusion criteria, such as severe infection, prior malignancy, and uncontrolled medical problems.",
    "The sample is a phase 1 clinical trial for patients with non-small cell lung cancer. The trial is testing the effectiveness of the drug gefitinib on patients with a high likelihood of sensitivity to the drug, as determined by previous response to similar treatments or a known somatic mutation. The trial includes eligibility criteria such as a confirmed diagnosis of non-small cell lung cancer, recurrent or persistent disease, and adequate hematologic, renal, and/or hepatic function. Exclusion criteria include previous Grade 4 toxicity on gefitinib or erlotinib, uncontrolled brain metastases, and any other malignancy within the past five years. The trial also includes various other criteria related to medical history, current medical conditions, and ongoing treatments.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on treating non-small cell lung cancer using the drugs lapatinib and pemetrexed. The eligibility criteria for the trial include having stage IIIB or IV NSCLC, having previously received one line of cytotoxic chemotherapy, and having an ECOG performance status of 0-2. The trial also has exclusion criteria, such as having a history of other malignancies or concurrent cancer therapy. The record includes the list of diseases being studied, their corresponding ICD-10 codes, and the eligibility criteria for the trial.",
    "The sample is a clinical trial for phase 1 of a drug called pemetrexed disodium, which is being tested on patients with pancreatic cancer. The trial has eligibility criteria for patients, including having confirmed carcinoma arising from the pancreas, meeting certain disease stage criteria, and having certain blood counts and performance status. Patients must also not have certain conditions, such as brain metastasis or significant cardiovascular disease. Prior to the trial, patients cannot have received chemotherapy for pancreatic cancer and must be able to discontinue certain medications. The trial also requires patients to take folic acid and vitamin B12 supplementation.",
    "The sample is a phase 1 clinical trial for the treatment of high-risk FIGO Stage I or Stages II-IV epithelial ovarian, primary peritoneal and fallopian tube cancer using a combination of amg 386, paclitaxel and carboplatin. The trial has eligibility criteria for female subjects over 18 years of age, with specific disease types and stages, who have not undergone certain prior treatments or have certain medical conditions. The trial also has exclusion criteria for subjects with certain medical conditions or prior treatments. The trial requires adequate organ and hematological function as evidenced by laboratory studies prior to enrollment. The sample includes the eligibility and exclusion criteria in detail.",
    "The sample is a phase 1 clinical trial for the treatment of advanced stage ovarian cancer using a combination of pegylated liposomal doxorubicin and sb-485232 (interleukin 18). The trial is open to female patients aged 18 or older with a confirmed diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Patients must have measurable lesions according to RECIST v1.0 and an ECOG performance status of 0, 1, or 2. They must also have a predicted life expectancy of at least 4 months and have not received chemotherapy, immunotherapy, hormonal therapy, or biological therapy for cancer, radiotherapy, or surgical procedures (except for minor surgical procedures) within four weeks before beginning treatment with SB-485232. Patients must have recovered from toxicities incurred as a result of previous therapy sufficiently to be entered into a Phase I study. The trial has a list of exclusion criteria, including significant cardiac, pulmonary, metabolic, renal, hepatic, gastrointestinal or autoimmune conditions that in the opinion of the investigator and/or GSK medical monitor, places the subject at an unacceptable risk as participant in this trial.",
    "The sample is a phase 1 clinical trial for the treatment of rheumatoid arthritis. The trial is testing the effectiveness of a drug called otelixizumab, along with a matching placebo. The eligibility criteria for participants include being between 18 and 75 years old, having a diagnosis of rheumatoid arthritis, and having active disease despite previous treatment with at least one DMARD. Participants must also meet a number of other criteria related to their health and medical history. The trial will last for 6 months and will involve regular assessments and monitoring of participants' health.",
    "The sample is a phase 1 clinical trial for the treatment of thrombosis and heparin-induced thrombocytopenia using the drug fondaparinux. The trial is open to children between the ages of 1 and 18 who have documented venous or arterial thrombosis confirmed by diagnostic imaging and weigh more than 8.3 kg. The trial has a set of inclusion and exclusion criteria, including no active bleeding, no planned invasive procedures within 2 weeks of enrollment, no contraindication to anticoagulation, and no use of thrombolytic agents. The trial also excludes patients with an INR>1.5 or an activated partial thromboplastin time (PTT)>40 seconds, a creatinine level above 1.2 times the upper limit of normal expected for age, and children under 1 year of age. Signed informed consent/assent is required for participation in the trial.",
    "The sample is a clinical trial for phase 1, which includes patients with advanced breast, gastric, head and neck, liver, and non-small cell lung cancer. The trial requires patients to have no further standard of care options or have refused standard therapy. Patients must also have measurable or evaluable disease, be at least 18 years old, have an ECOG performance score of less than 2, and a life expectancy of at least 3 months. Female patients must not be pregnant or lactating, and if of childbearing potential, must use adequate birth control. Patients must also meet certain laboratory criteria, including having an absolute neutrophil count of at least 1,500/\u00b5L and platelets of at least 100,000/\u00b5L. The trial also has exclusion criteria, such as recent anticancer therapy or use of investigational agents within 30 days of study entry, and a history of certain cardiac diseases or infections with HIV, hepatitis B, or hepatitis C.",
    "The sample is a clinical trial for kidney diseases and kidney transplantation, with a focus on patients who have received a kidney transplant. The trial is in phase 1/phase 2 and involves several drugs, including daclizumab, mycophenolate mofetil, prednisone, tacrolimus, ganciclovir, valganciclovir, and trimethoprim and sulfamethoxazole. The eligibility criteria include being the primary recipient of a kidney transplant, meeting site-specific transplant criteria, having a Panel Reactive Antibody (PRA) of 20% or less, and being willing to use acceptable forms of contraception. Exclusion criteria include previous treatment with steroids within 6 months prior to transplantation, receiving an organ that does not meet protocol-specified requirements, receiving an organ from an HLA identical donor or a non-heart-beating donor, receiving a solid organ other than a kidney, receiving a bone marrow or hematopoietic stem cell transplant, receiving a repeat kidney transplant, currently receiving an investigational pharmacologic or biologic agent, being HIV infected or infected with another immunodeficiency virus, having hypersensitivity to murine products or the study drugs or their formulations, being unable to measure height accurately, and being pregnant or breastfeeding.",
    "The sample is a clinical trial for patients with non-small-cell lung carcinoma. The trial is in phase 1/phase 2 and includes patients with Stage IIIB or Stage IV disease or recurrent metastatic disease. Patients must have had disease progression or relapse following failure of platinum-based chemotherapy. The trial involves two drugs, chr-2797 (tosedostat) and erlotinib. The eligibility criteria include various medical and laboratory requirements, as well as the absence of certain medical conditions and prior treatments. Patients must also be willing to use contraception or be abstinent during the treatment period and for 3 months after discontinuation of treatment. The trial has exclusion criteria, including certain medical conditions, prior treatments, and allergies to study medication.",
    "The sample is a phase 1 clinical trial for patients with type 2 diabetes mellitus. The trial includes the drugs canagliflozin and placebo. The eligibility criteria include having a stable anti-hyperglycemic agent regimen for at least 2 months prior to the screening visit, having a diagnosis of T2DM for at least 1 year but not more than 12 years prior to the study, and having fasting plasma glucose concentrations between 7.8 mM and 15 mM on Day -2. Patients with a history of clinically significant diabetic complications, type 1 diabetes mellitus, or repeated severe hypoglycemic episodes before screening are excluded from the trial.",
    "The sample is a record from a clinical trial database. It includes information about the phase of the trial, which is a combination of phase 1 and phase 2. The trial is focused on treating multiple myeloma, a type of cancer. The record lists the icd-10 codes associated with the disease, as well as the drugs being used in the trial, which are ixazomib, lenalidomide, and dexamethasone. The record also includes the eligibility criteria for patients to participate in the trial, such as being 18 years or older, having measurable disease, and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. The record also lists exclusion criteria, such as having peripheral neuropathy greater than or equal to Grade 2, being pregnant or lactating, and having a serious medical or psychiatric illness that could interfere with treatment.",
    "The sample is a phase 1 clinical trial for the treatment of hepatitis C. The trial involves the use of two drugs, imo-2125 and a saline placebo. The eligibility criteria for the trial include being HCV-positive and a non-responder to standard-dose pegylated interferon-\u03b1-2a or -\u03b1-2b in combination with standard-dose ribavirin. Exclusion criteria include having HIV or hepatitis B surface antigen, inadequate bone marrow, liver, and renal function, treatment with any IFN-based or other experimental or antiviral therapies within 30 days, other significant medical diseases, and known alcohol or drug abuse within the past 12 months.",
    "The sample is a clinical trial for a drug called ro5024048, which is being tested on individuals with chronic hepatitis C infection. The trial is in phase 1/phase 2 and includes both healthy volunteers and individuals with hepatitis C virus. The trial requires participants to meet certain eligibility criteria, such as being between the ages of 18 and 65, having a certain genotype of hepatitis C, and having a certain level of serum HCV RNA. Participants must also have a BMI between 18 and 36 and be able to abstain from alcohol and limit caffeine consumption. The trial also has exclusion criteria, such as a positive test for HAV, HBV, or HIV, and a history of certain medical conditions. Participants must be willing to give written informed consent and comply with the study restrictions.",
    "The sample is a phase 1 clinical trial for the treatment of Autistic Disorder. The trial is for male adults between the ages of 18 and 45 with an IQ greater than 70 and a body mass index between 18 and 35 kg/m2. The trial involves the use of two drugs, placebo and ro5028442. The eligibility criteria include a confirmed diagnosis of Autistic Disorder, a score of 13 or less on the Irritability subscale of the Aberrant Behavior Checklist, and no history of drug or alcohol abuse, among other factors. The trial excludes individuals with certain medical conditions or disorders, as well as those who have recently undergone psychosocial intervention or treatment with an investigational agent.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on male and female breast cancer patients with stage IIIB, IIIC, or IV disease. The trial involves the use of two drugs, vorinostat and paclitaxel. The eligibility criteria include having histologically or cytologically confirmed adenocarcinoma of the breast, accessible disease for biopsy, and consent to serial biopsy. Patients must also have at least one measurable indicator lesion, ECOG performance status of <=1, and meet certain laboratory values. Exclusion criteria include recent chemotherapy or radiotherapy, use of other investigational agents, and uncontrolled intercurrent illness.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on the disease Friedreich ataxia, which is caused by homozygosity for the GAA repeat expansion in intron 1 of the FXN gene. The trial is testing the drug resveratrol. The eligibility criteria for the trial include being an adult with Friedreich ataxia and having a functional stage on the Ataxia subscale of the FARS of 1 or higher. Exclusion criteria include being pregnant or lactating, having active arrhythmias or significant cardiac insufficiency, using idebenone, Coenzyme Q or vitamin E within 30 days prior to enrollment, and using amiodarone or other medications which may have clinically significant drug interactions that cannot be safely monitored.",
    "The sample is a clinical trial for phase 1/phase 2 of a drug called tipifarnib. The trial is for patients with newly diagnosed non-disseminated intrinsic diffuse brainstem glioma. The eligibility criteria include a Karnofsky performance scale (KPS) or Lansky performance score of at least 50, no prior chemo or radiation therapy, and certain blood count and liver function requirements. Patients must not have any significant medical illnesses that cannot be controlled with appropriate therapy or any disease that will obscure toxicity or dangerously alter drug metabolism. Patients with disseminated intrinsic diffuse brainstem glioma, taking enzyme-inducing anticonvulsant drugs, known allergy to certain imidazoles, receiving any other anticancer or experimental drug therapy, or with uncontrolled infection are excluded from the trial.",
    "The sample is a clinical trial for patients with hormone refractory prostate cancer that has progressed after at least two prior hormonal manipulations. The trial is in phase 1/phase 2 and involves the drugs docetaxel and imatinib mesylate. The eligibility criteria include being at least 18 years old, having a histologically documented diagnosis of adenocarcinoma of the prostate gland, and having PSA levels of at least 5 ng/ml. Patients must have recovered from previous therapies and have adequate end organ function. Exclusion criteria include having received other investigational agents within 28 days of the trial, having severe and/or uncontrolled medical disease, and having a known diagnosis of HIV infection.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on hypertension and renal transplant patients. The trial involves the use of two drugs, placebo and allopurinol. The eligibility criteria for the trial include males or females aged 6 to 18 years who are renal transplant recipients taking cyclosporin, with a weight greater than 20kg, and with SBP or DBP greater than 95th percentile for age, gender, and height. Exclusion criteria include severe or poorly controlled hypertension, taking certain medications, laboratory abnormalities, history of heart disease, pregnancy or lactation, and non-compliance with study procedures.",
    "The sample is a clinical trial for a combination of drugs (cetuximab, oxaliplatin, capecitabine, and diphenhydramine hydrochloride) for the treatment of rectal and colorectal cancer. The trial is in phase 1/phase 2 and the eligibility criteria include having histologically-confirmed adenocarcinoma of the rectum, being at least 18 years old, having a Karnofsky performance status of at least 70, and meeting certain blood count and liver function requirements. Patients with metastatic or stage IV disease, a history of treatment with cetuximab or other therapy targeting EGFR, or certain other medical conditions are excluded from the trial. Women of child-bearing potential must have a negative pregnancy test and use adequate contraception throughout the treatment.",
    "The sample is a clinical trial for patients with anaplastic or poorly differentiated variant thyroid carcinoma. The trial is in phase 1/phase 2 and the patients must have original/diagnostic tumor blocks available to confirm histopathology and for tumor microvessel density immunohistochemistry. The trial involves the use of drugs such as cisplatin, doxorubicin hydrochloride, and fosbretabulin disodium. The eligibility criteria include age 18 and over, ECOG 0-2 performance status, and a life expectancy of at least 12 weeks. Patients must also meet certain hematopoietic, hepatic, renal, and cardiovascular requirements. Prior concurrent therapy is not allowed, and patients must not have certain medical conditions or take certain medications known to prolong the QTc interval.",
    "The sample is a clinical trial for phase 1, with the disease being rectal cancer. The trial involves the use of two drugs, azd6244 and cediranib (azd2171). The eligibility criteria include having histologically confirmed rectal adenocarcinoma, defined locally advanced rectal cancer, and being fit to receive all study treatments. Patients who have concurrent uncontrolled medical illness, metastatic disease, or uncontrolled cardiac, respiratory, or other disease are excluded from the trial. Additionally, patients who have had recent major thoracic or abdominal surgery or have a surgical incision that is not fully healed are also excluded. The trial also has specific exclusion criteria for each drug being tested.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on breakthrough nausea and vomiting and unspecified adult solid tumors. The trial involves the use of fosaprepitant dimeglumine and systemic chemotherapy drugs. The eligibility criteria for the trial include a diagnosis of cancer, scheduled to receive inpatient chemotherapy containing at least moderately emetogenic agents, and scheduled to receive 5-HT3 receptor antagonist antiemetic on the day of chemotherapy. The patient must also have self-reported at least mild nausea or moderate nausea, or have had at least one episode of emesis since receiving chemotherapy. The patient must not have a history of chronic nausea and/or vomiting, anticipatory nausea and/or vomiting, or emesis within 24 hours before chemotherapy. The patient must also be able to understand English, not be pregnant or nursing, have no clinical evidence of current or impending bowel obstruction, and have no allergy or intolerance to study drugs. Prior chemotherapy is allowed, but aprepitant as prophylaxis or rescue treatment during the current course of chemotherapy is not allowed, and the patient is not scheduled to receive a dopamine antagonist after chemotherapy.",
    "The sample is a clinical trial for a drug called mk-0941, along with a placebo and lantus insulin, for the treatment of type 2 diabetes mellitus. The trial is in phase 1 and the participants must be between 18 to 70 years of age and diagnosed with type 2 diabetes and currently being treated with basal insulin. Smokers are allowed to participate but are limited to 10 cigarettes per day while at the clinic and must follow clinic smoking rules. The exclusion criteria include a history of type 1 diabetes, treatment with peroxisome proliferator-activated receptor (PPAR) agonists within 12 weeks prior to study start, history of severe hypoglycemia, and allergy to insulin.",
    "The sample is a phase 1 clinical trial for the treatment of chronic hepatitis C infection. The trial is for males and females who are 18 years or older and have not received treatment for hepatitis C before. The trial requires participants to have a clinical diagnosis of hepatitis C with genotype 1b, IL28B genotype CC, and HCV RNA levels greater than 10,000 IU/mL at screening. The trial involves the use of two drugs, ach-0143102 and ribavirin. Female participants must use two effective methods of contraception during the dosing period and for six months after the last dose of ribavirin, while male participants must use an effective barrier method of contraception throughout the dosing period and for six months after the last dose of ribavirin. The trial has inclusion and exclusion criteria, and participants must be willing to participate in all study activities and requirements.",
    "The sample is a phase 1 clinical trial for patients with non-small cell lung cancer. The trial involves the use of the drugs sunitinib and rapamycin, but patients who have not received prior therapy are also eligible if they are not good candidates for standard treatment with cytotoxic chemotherapy or do not wish to receive it. The eligibility criteria include having a histologically or cytologically proven NSCLC, being at least 18 years old, having an ECOG score of 0-2, and having a life expectancy of at least 3 months. Patients must have recovered from any uncontrolled intercurrent illness and may not have had certain medical conditions or complications within a certain timeframe. Adequate bone marrow, liver, and renal function are also required. Patients must give written consent and use adequate contraception if they have reproductive potential. The trial is open to both men and women of all racial and ethnic subgroups.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on the treatment of renal cell carcinoma, and the table includes a list of disease names and corresponding ICD-10 codes. The trial involves the use of drugs such as cp-675,206 and su011248. The eligibility criteria for the trial include a histologically proven diagnosis of renal cell carcinoma with metastases and an Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1. The exclusion criteria include prior treatment with more than one systemic therapy for metastatic renal cell carcinoma and a history of or known brain metastases, spinal cord compression or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease on screening Computed Axial Tomography (CT) or Magnetic Resonance Imaging (MRI) scan.",
    "The sample is a phase 1 clinical trial for the treatment of type 2 diabetes. The trial is testing a drug called pf-05161704, or a placebo, on healthy male and female subjects between the ages of 18 and 55 with a BMI of 24.5 to 35.5 kg/m2 and a total body weight of over 50 kg. The trial has inclusion and exclusion criteria, including the absence of certain medical conditions and habits such as regular alcohol consumption and tobacco use. The trial is investigating the safety and efficacy of the drug in treating type 2 diabetes.",
    "The sample is for a phase 1 clinical trial and involves only healthy individuals. The trial is testing the effectiveness of three drugs - darifenacin, tolterodine, and placebo - on individuals who are at least 50 years old and have a body mass index between 18.5 and 35.0 kg/m2. The eligibility criteria include being in good health, not having any allergies to the drugs being tested, not having any irregular day and night patterns, not having any significant medical problems that affect heart rate, not taking any medication that affects heart rate, not having had any malignancy within the past 5 years (except for localized basal cell carcinoma of the skin), not being pregnant or nursing, and not having certain diseases such as urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, or severe renal insufficiency. There may be other inclusion/exclusion criteria that apply as well.",
    "The sample is a phase 1 clinical trial for patients with amyloidosis, a condition where abnormal proteins build up in tissues and organs. The trial is testing the effectiveness and safety of the drugs amifostine trihydrate and melphalan. The eligibility criteria include having histologically confirmed amyloidosis, presence of monoclonal protein, and no secondary familial or localized amyloidosis. Patients must also meet certain age, performance status, and health requirements. Prior to the trial, patients must not have received certain treatments such as radiotherapy or high doses of melphalan.",
    "The sample is a clinical trial for patients with stage IV pancreatic cancer that is unresectable. The trial is in phase 1/phase 2 and involves the drugs erlotinib hydrochloride and gemcitabine hydrochloride. The eligibility criteria include having measurable and/or nonmeasurable disease, a Zubrod performance status of 0-1, and meeting various laboratory values. Patients must not have endocrine or neuroendocrine tumors, lymphoma of the pancreas, or ampullary cancer, and must not have macroscopic residual disease post-resection as the only site of disease. They must also not have clinically significant ascites or known brain metastases. Other exclusion criteria include having a history of allergic reaction to compounds of similar chemical or biological composition to anti-IGF-1R recombinant monoclonal antibody IMC-A12, active acute or chronic infections requiring antibiotics, significant ongoing cardiac problems, and plans to receive concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or any other type of therapy for treatment of cancer. Patients must also not have received prior chemotherapy, hormonal therapy, immunotherapy, or chemoradiotherapy for advanced or locally advanced pancreatic cancer, including drugs that target either EGFR or IGFR, and must not have received prior gemcitabine hydrochloride or chimerized or murine monoclonal antibody therapy. Concurrent CYP3A4 inducers or inhibitors are also not allowed, but concurrent prophylactic low-dose coumadin or low molecular weight heparin is allowed provided coagulation criteria are met. Full-dose anticoagulation is allowed provided coagulation criteria are met and are under strict control and monitoring.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on diabetes, specifically type 1 diabetes mellitus. The trial includes two drugs, liraglutide and placebo. The eligibility criteria for the trial includes having a clinical diagnosis of type 1 diabetes mellitus for at least 12 months prior to randomization and having a body mass index (BMI) between 20.0 and 28.0 kg/m^2. The exclusion criteria includes having used liraglutide or exenatide within 3 months of randomization, having experienced recurrent severe hypoglycemia or hypoglycemic unawareness, and having donated blood or plasma within the past month or more than 500 mL within 3 months prior to screening. The icd-10 codes associated with the diseases being studied are also included in the record.",
    "The sample is a phase 1 clinical trial for patients with advanced non-small cell lung cancer that has failed standard therapy or for which there is no standard therapy. The trial is testing the effectiveness of three drugs - pazopanib, erlotinib, and pemetrexed. The eligibility criteria include a confirmed diagnosis of advanced solid tumor, age over 18, ECOG performance status of 1 or less, and adequate organ system function. The trial also requires measurable disease on CT scan and specific laboratory values for hematologic, hepatic, and renal function. Exclusion criteria include prior use of the drugs being tested, history of central nervous system metastases, and certain medical conditions that could interfere with the study. The trial is also testing the ability of patients to discontinue certain medications and avoid certain foods during the study period.",
    "The sample is a phase 1 clinical trial for the treatment of type 2 diabetes mellitus using insulin degludec. The trial is for Japanese subjects aged 20-70 who have been diagnosed with type 2 diabetes for at least 12 months and have been treated with insulin for at least 3 months. The inclusion criteria also include a maximum BMI of 33.0 kg/m^2, a maximum HbA1c of 10.0%, and a fasting C-peptide below 1.0 nmol/L. The exclusion criteria include the use of oral antidiabetic drugs or GLP-1 receptor agonists within 3 months prior to screening, recent blood or plasma donation, smoking or use of nicotine gum or patches during the inpatient period, and high blood pressure. The diseases listed are diabetes and diabetes mellitus, type 2, and the icd-10 codes associated with these diseases are also provided.",
    "The sample is a clinical trial for ovarian cancer patients in phase 1/phase 2. The trial is testing the effectiveness of two drugs, cc-5013 and topotecan, on patients who have already undergone chemotherapy with platinum and paclitaxel but have progressed. The trial requires patients to have measurable metastatic advanced ovarian or primary peritoneal carcinoma, be at least 18 years old, and have an ECOG performance status of 0 or 1. The eligibility criteria also include exclusion criteria such as laboratory abnormalities, serious medical conditions or psychiatric illnesses, prior history of malignancy, and concurrent use of any other anti-cancer agents. The trial prohibits the use of any standard or experimental anti-cancer drug therapy within 28 days of the initiation of study drug therapy and known active Hepatitis C.",
    "The sample is a clinical trial for chronic plaque type psoriasis, with a combination of phase 1 and phase 2. The trial involves testing the effectiveness of various drugs, including ciclosporin, betamethasone, and calcipotriol, on the disease. The trial has specific inclusion and exclusion criteria, such as excluding subjects with erythrodermic psoriasis or acute virus infections. Sexually active females of childbearing potential must use contraception or be surgically sterile. The trial also excludes subjects who have received certain treatments or medications in the past few weeks or months.",
    "The sample is a clinical trial for patients with intracranial malignant glioma or recurrent or progressive benign or malignant meningioma. The trial is in phase 1/phase 2 and the drug being tested is erlotinib hydrochloride. The eligibility criteria include having measurable or evaluable disease, a performance status of Karnofsky 60-100%, and meeting certain medical requirements such as having a WBC of at least 3,000/mm^3 and a platelet count of at least 100,000/mm^3. Patients must also not have any other serious concurrent medical illness or other malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix. They must not be pregnant or nursing and must use effective barrier contraception during and for 12 weeks after study participation if they are fertile. The trial also has various exclusion criteria, such as having prior chemotherapy for stable GBM or concurrent combination antiretroviral therapy for HIV-positive patients.",
    "The sample is a phase 1 clinical trial for the treatment of neuropathic pain. The trial involves testing the efficacy and safety of three drugs - gabapentin lower dose, donepezil, and gabapentin higher dose. The eligibility criteria for the trial include being a male between 18 and 55 years of age, having a body weight of at least 50 kilograms and a BMI within the range of 18.5-29.9 kilograms per square meter, being healthy as determined by a medical evaluation, and having certain laboratory test results within normal limits. The trial also has exclusion criteria, such as having a previous disease or medical condition that may compromise safety or affect the interpretation of efficacy data, having a history of seizures or abnormal electrocardiogram results, and being unable to follow the procedures outlined in the protocol.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes associated with those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on studying multiple myeloma. The icd-10 codes associated with this disease are listed as \"C90.01\", \"C90.02\", and \"C90.00\". The drugs being used in the trial are cci-779 and bortezomib. The eligibility criteria for participants include being 18 years or older, having received prior therapy for myeloma and having relapsed and/or relapsed/refractory multiple myeloma, having certain levels of monoclonal protein or light chain in the serum or urine, having an ECOG Performance Status of 0, 1 or 2, and meeting certain laboratory values as outlined in the protocol. There are also exclusion criteria listed, such as uncontrolled infection, recent chemotherapy or biologic therapy, pregnancy or nursing, and serious medical or psychiatric illness likely to interfere with participation in the trial.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on the treatment of sarcoma, a type of soft tissue cancer. The trial includes a list of ICD-10 codes for the disease, as well as a list of eligible drugs, in this case chemotherapy. The eligibility criteria for patients include a biopsy-proven diagnosis of soft tissue sarcoma, as well as specific disease characteristics such as tumor size and location. Patient characteristics such as age and medical history are also taken into account. The trial requires that patients have not received any other therapy for sarcoma within the past 30 days.",
    "The sample is a phase 1 clinical trial for patients with an unspecified adult solid tumor. The trial involves the use of two drugs, cyclophosphamide and imatinib, and has specific eligibility criteria that patients must meet in order to participate. These criteria include having a diagnosis of advanced or metastatic solid tumor, being refractory to standard therapy or having no standard therapy available, and having certain medical characteristics such as a platelet count of at least 100,000/mm^3 and a creatinine level of less than 2 mg/dL. Patients must also not have certain medical conditions or histories, such as uncontrolled hypertension or a history of noncompliance with medical regimens. The trial does not allow for patients with certain types of cancer, such as advanced ovarian cancer or lung malignancy with certain characteristics, to participate. Prior concurrent therapy is also restricted, with no major surgical procedures allowed within the past 28 days or anticipated during the study treatment.",
    "The sample is a phase 1 clinical trial that involves testing the drug dacomitinib on healthy individuals and those with mild or moderate hepatic dysfunction. The trial includes a list of diseases and their corresponding ICD-10 codes. The eligibility criteria for the trial include being between the ages of 18 and 75, having a BMI between 18 and 35 kg/m2, and having no clinically relevant abnormalities identified by medical history, physical examination, and laboratory tests. The trial also includes exclusion criteria such as having a positive urine drug screen or a history of gastrointestinal hemorrhage due to esophageal varices or peptic ulcers less than one month prior to study entry. The trial is divided into three groups: normal hepatic function group (Group 1), hepatic impairment group 2, and hepatic impairment group 3. The inclusion criteria for the hepatic impairment groups include satisfying the criteria for Class A or B of the modified Child-Pugh classification, having a diagnosis of hepatic dysfunction due to hepatocellular disease, and being on a stable dose of medication and/or treatment regimen. The trial also includes exclusion criteria for subjects in the hepatic impairment groups, such as having hepatic carcinoma and hepatorenal syndrome or a life expectancy of less than one year.",
    "The sample is a record of a clinical trial in phase 1, which involves testing the drug cetuximab on patients with non-small-cell lung carcinoma and metastatic tumors. The trial requires patients to have measurable tumors available for biopsies and a life expectancy of at least 3 months. However, patients with known or documented brain metastases prior to cetuximab therapy are excluded from the trial. The sample also includes the ICD-10 codes for the diseases being studied and the eligibility criteria for the trial.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on non-Hodgkin's lymphoma and includes a list of ICD-10 codes for the disease. The trial involves the use of bortezomib, chop, and rituximab drugs. The eligibility criteria for the trial include a confirmed diagnosis of diffuse large B cell or mantle cell Non-Hodgkin's Lymphoma, no prior anti-cancer therapy for lymphoma, measurable disease, and specific blood count and organ function requirements. The exclusion criteria include known central nervous system involvement by lymphoma, HIV disease, pregnancy or nursing, recent major surgery, and known peripheral neuropathy.",
    "The sample is a phase 1 clinical trial for patients with extracranial primary malignancy and multiple brain metastases or less than 3 metastases with at least 1 metastasis greater than 4.0 cm in diameter. The trial is testing the effectiveness of lithium carbonate as a treatment option. The eligibility criteria include various medical conditions and laboratory values, and patients must not have certain medical illnesses or psychiatric conditions that would prevent them from completing the study treatment. Additionally, patients must not have prior or concurrent chemotherapy, radiotherapy to the head and neck area, or concurrent anticonvulsants or psychoactive drugs. The trial also requires patients to use effective contraception if they are fertile.",
    "The sample is a phase 1 clinical trial for patients with advanced solid tumors or lymphoma that may be metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. The trial is testing the drug kx2-391. The eligibility criteria include being over 18 years old, having an ECOG performance status of 0-2, having a life expectancy of at least 14 weeks, having adequate bone marrow reserve, liver function, and renal function, and having a normal coagulation profile. Patients must also be willing to abstain from sexual activity or practice physical barrier contraception for a certain period of time. The exclusion criteria include unresolved toxicity from previous anti-cancer treatment or investigational agents, receiving or having received investigational agents or systemic anti-cancer agents within a certain time frame, and having received extensive radiation therapy within a certain time frame. Patients must also not be pregnant or breastfeeding, have had major surgery within a certain time frame, or have certain medical conditions that could interfere with the study or compliance with the protocol.",
    "The sample is a phase 1 clinical trial for individuals with type 1 diabetes. The trial is testing the effectiveness of three drugs, sar341402 and two types of insulin aspart. The eligibility criteria for participants include having type 1 diabetes for at least one year, a total insulin dose of less than 1.2 U/kg/day, and a fasting negative serum C-peptide. Participants must also have a stable insulin regimen for at least two months prior to the study and have normal findings in their medical history and physical examination. Exclusion criteria include a history of certain diseases or illnesses, frequent episodes of severe hypoglycemia, and certain medication use within a certain timeframe. The information provided is not intended to cover all considerations relevant to a patient's potential participation in the trial.",
    "The sample is a phase 1 clinical trial for the treatment of tumors using the drug fruquintinib. The eligibility criteria include being between 18 and 70 years old, having a confirmed solid malignant tumor, having an ECOG performance status of 0-1, and having failed standard treatment or having no standard treatment available. Other criteria include having a life expectancy of more than 12 weeks, adequate organ function, and at least one measurable lesion. Exclusion criteria include factors such as pregnancy or lactation, uncontrolled CNS metastasis, and previous treatment with VEGF/VEGFR inhibition. The sample also includes a list of icd-10 codes for the disease being treated.",
    "The sample is a phase 1 clinical trial for patients with various types of solid tumors, including breast cancer, ovarian cancer, pancreatic cancer, and non-small cell lung cancer. The trial is testing the effectiveness of a drug called ati-1123 (active drug = docetaxel). The eligibility criteria for the trial include having a confirmed solid tumor, having progressive disease following standard/approved chemotherapy or having no appropriate alternative therapy available, having measurable or evaluable tumors, having an ECOG performance status of \u2264 2, having a life expectancy of at least 3 months, being \u2265 18 years old, having acceptable hepatic, renal, hematologic, and coagulation function, having recovered from prior treatments, and agreeing to use an effective contraceptive method. Exclusion criteria include having certain cardiac, pulmonary, or infectious conditions, being pregnant or nursing, having undergone certain treatments within a certain timeframe, having a known history of certain infections, having a serious nonmalignant disease, currently receiving any other investigational agent, or having exhibited allergic reactions to docetaxel or similar compounds.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on treating tumors, with a list of associated ICD-10 codes provided. The drug being tested is gefitinib. The eligibility criteria for participants include having a confirmed solid tumor that is refractory to conventional treatment or for which no standard treatment exists, a life expectancy of more than 12 weeks, and a World Health Organization performance status of less than 2. Exclusion criteria include severe hypersensitivity to gefitinib or any of its excipients, having completed chemotherapy or radiation therapy less than 4 weeks prior (except for nitrosoureas or mitomycin-C, which require a 6-week washout period), and incomplete healing from previous oncologic or major surgery.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying the effectiveness of imatinib mesylate in treating recurrent melanoma, stage iii melanoma, stage iv melanoma, and unspecified adult solid tumor. The eligibility criteria include having measurable disease, a performance status of ECOG 0-1, and meeting various medical requirements such as having no history of stroke, uncontrolled hypertension, or significant traumatic injury within the past 28 days. Participants must also not be pregnant or nursing, and must use effective contraception during and for at least 3 months after study participation.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for study subjects. In this particular sample, the trial is in phase 1/phase 2 and is focused on cystic fibrosis. The icd-10 codes associated with the disease are listed, as well as the names of the drugs being tested. The eligibility criteria for study subjects are also provided, including requirements such as a confirmed diagnosis of CF, a history of chronic infection with P.aeruginosa, and the ability to comply with study medication use and procedures. The exclusion criteria are also listed, which include factors such as recent use of investigational drugs, hospitalization for respiratory-related illness, and history of alcohol or drug abuse.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, ICD-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is a phase 1/phase 2 trial for patients with multiple myeloma who have not responded to previous treatments. The trial is testing the effectiveness of two drugs, obatoclax mesylate and bortezomib. The eligibility criteria include specific requirements related to the patient's medical history, disease progression, and current health status. The criteria also exclude patients with certain medical conditions or who are taking certain medications.",
    "The sample is a clinical trial for the treatment of Fanconi Anemia and severe aplastic anemia. The trial is in phase 1/phase 2 and involves the use of the drug fludarabine. The eligibility criteria include a diagnosis of Fanconi Anemia or other DNA breakage/chromosomal instability syndromes, severe aplastic anemia, availability of an HLA matched or mismatched family member or unrelated donor, and certain health requirements such as a Karnofsky score of 70% or more. Exclusion criteria include symptomatic cardiac disease, severe infection, severe personality disorder or mental illness, and HIV positivity. The protocol allows for some flexibility in including patients with laboratory abnormalities at the investigator's discretion.",
    "This sample is a phase 1 clinical trial for patients with non-small cell lung cancer. The trial is testing the effectiveness of the drugs erlotinib and hydroxychloroquine. The eligibility criteria include having a confirmed diagnosis of non-small cell lung cancer, being at stage IIIB with pleural effusion or stage IV, having had at least 12 weeks of prior treatment with erlotinib or another EGFR small molecule TKI agent, being at least 18 years old, having measurable disease, and having a performance status of 0, 1, or 2. Exclusion criteria include current use of hydroxychloroquine for any reason, known hypersensitivity to chloroquine, erlotinib, or gefitinib, glucose-6-phosphate dehydrogenase deficiency, and any evidence of clinically active interstitial lung disease.",
    "The sample is a clinical trial for kidney transplantation, with a phase 1/phase 2 designation. The trial is looking at the use of c1 esterase inhibitor and placebos as potential therapies. The eligibility criteria include having end-stage renal disease, being between the ages of 18-65, having a high level of HLA sensitization, and having a donor-specific antibody/cross match + non-HLA identical donor at the time of transplant. Exclusion criteria include being pregnant or lactating, having certain infections or medical conditions, and having received certain vaccines or investigational agents within a certain timeframe. The trial requires informed consent from the subject/parent/guardian.",
    "The sample is a phase 1 clinical trial for patients with advanced solid tumors. The trial is testing the effectiveness of the drug combination of temsirolimus and capecitabine. The eligibility criteria for the trial include having histologically proven adenocarcinoma with measurable or evaluable disease, having advanced unresectable and/or metastatic disease for which there is no known curative therapy, and having a performance status of 0-2. The exclusion criteria include having brain metastases not under control for at least 3 months, having active severe infection or known chronic infection with HIV, hepatitis B virus, or hepatitis C virus, having cardiovascular disease problems, having life-threatening visceral disease or other severe concurrent disease, being pregnant or breastfeeding, and having an anticipated patient survival under 3 months.",
    "The sample is a phase 1 clinical trial for pancreatic cancer. The eligibility criteria include having histologically proven adenocarcinoma of the pancreas, complete resection by standard pancreaticoduodenectomy or distal pancreatectomy, no measurable disease, ECOG performance status 0-1, being at least 18 years old, and having the ability to start adjuvant therapy within 8 weeks after pancreatic cancer surgery. Other criteria include having a CA 19-9 level \u2264 2.5 times the upper limit of normal, ANC \u2265 1500/\u03bcL, hemoglobin \u2265 9 gm/dL, platelet count \u2265 100,000/\u03bcL, INR \u2264 1.5, total bilirubin \u2264 2.0 mg/dL, AST and ALT \u2264 2.5 times the upper limit of normal, serum creatinine \u2264 2.0, and negative pregnancy test for women of childbearing potential. Patients must also have at least one paraffin block from their pancreatic cancer surgery available for analysis. Exclusion criteria include any prior systemic or investigational therapy for pancreatic cancer, grossly positive surgical margins, and any post-operative complications such as wound dehiscence or infection. Patients with a \"currently active\" second malignancy other than non-melanoma skin cancer are also excluded.",
    "The sample is a phase 1 clinical trial for postmenopausal women with osteopenia. The trial is testing the effectiveness of the drugs romosozumab and placebo. The eligibility criteria include being between 45 to 80 years of age, having low bone mineral density, and having a 25-hydroxyvitamin D level of at least 20 ng/mL. Exclusion criteria include having osteoporosis, any condition that affects bone metabolism, and previous exposure to AMG 785.",
    "The sample is a clinical trial for a drug called PCI-32765 and ofatumumab for patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), prolymphocytic leukemia (PLL), or Richter's transformation arising out of CLL/SLL. The trial is in phase 1/phase 2 and the table includes information on the diseases being treated, the icd-10 codes of the diseases, the drugs being used, and the eligibility criteria for patients to participate in the trial. The eligibility criteria include factors such as previous treatments, organ and marrow function, and exclusion criteria such as significant cardiovascular disease or active systemic infection. The sample also includes the inclusion and exclusion criteria for the trial.",
    "The sample is a clinical trial for rheumatoid arthritis, with a combination of phase 1 and phase 2. The trial involves testing the effectiveness of a drug called he3286, and the eligibility criteria include being between 18-75 years old, having stable or active disease on a stable dose of methotrexate for at least 30 days prior to Day 1, having normal thyroid stimulating hormone (TSH) levels, and not having experienced renal or liver disease or acute cardiac disease within 6 months prior to screening. The trial also has exclusion criteria, such as having a history of clinically significant cardiovascular disease or active tuberculosis. The sample includes a list of diseases and their corresponding icd-10 codes, as well as the eligibility criteria for the trial.",
    "The sample is a clinical trial for phase 1, which involves patients with various types of malignant gliomas that have progressed or recurred after radiation therapy and chemotherapy. The trial aims to test the effectiveness of erlotinib hydrochloride and isotretinoin drugs in treating the disease. The eligibility criteria include having a Karnofsky performance status of at least 60%, being registered and meeting the requirements of iPLEDGE, having a Mini Mental Status Exam score of at least 15, and meeting certain laboratory test results. Patients must also have recovered from the toxicity of prior therapy and must not have any uncontrolled intercurrent illness or history of certain disorders. The trial excludes pregnant or breastfeeding women, patients receiving concurrent therapy for their tumor (with the exception of steroids), and those with a history of allergic reactions to certain compounds.",
    "The sample is a phase 1 clinical trial for the treatment of multiple myeloma using the drug lbh589. The eligibility criteria include having a diagnosis of active multiple myeloma, having received at least one prior line of therapy, being suitable for treatment with BTZ, and having certain laboratory values within normal limits. Exclusion criteria include prior exposure to a HDAC inhibitor compound used in the treatment of MM, refractory MM, and certain medical conditions that could cause safety risks or compromise compliance with the protocol. Patients must also be willing to undergo bone marrow aspirate sampling and sign informed consent.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on treating metastatic non-small cell lung cancer and metastatic breast cancer using the drugs pazopanib and vinorelbine. The eligibility criteria for the trial include being over 18 years old, having a diagnosis of breast cancer or non-small cell lung cancer, having evaluable disease, and committing to the use of effective contraception while on the study. Exclusion criteria include not being pregnant or lactating, not receiving any other investigational agents, and not having received more than 2 prior chemotherapy regimens for lung cancer or 3 prior chemotherapy regimens for breast cancer. The trial also has a list of icd-10 codes for the diseases being treated.",
    "The sample is a phase 1 clinical trial for patients with advanced solid tumors or lymphoma who have failed or are intolerant to standard therapy. The trial is testing the drug PX-478. The eligibility criteria include being at least 18 years old, having a predicted life expectancy of at least 12 weeks, and having adequate hematologic, hepatic, and renal function. Patients must have discontinued prior chemotherapy or other investigational agents for at least three weeks prior to receiving the first dose of study drug and recovered from the toxic effects of that treatment. Exclusion criteria include any serious concomitant systemic disorders that would place the patient at excessive or unacceptable risk of toxicity, surgery within the four weeks prior to the first dose of PX 478, and significant central nervous system or psychiatric disorder(s) that preclude the ability of the patient to provide informed consent.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on prostate cancer and involves the use of drugs such as bicalutamide and cp-675,206 (tremelimumab). The eligibility criteria for the trial include being at least 18 years old with a histologic diagnosis of adenocarcinoma of the prostate, having completed surgery or radiation at least 8 weeks prior to entry, having clinical Stage D0 prostate cancer with rising PSA and PSA >2ng/ml, having an ECOG performance of <2, and having normal hematologic, renal, and liver function. Exclusion criteria include not having evidence of immunosuppression or having been treated with immunosuppressive therapy, not having prior treatment with an LHRH agonist or nonsteroidal antiandrogen such as casodex or flutamide, not having evidence for metastatic disease per bone scan or CT scan of the abdomen and pelvis, not having prior treatment with anti-CTLA 4 monoclonal antibody, not having a history of known autoimmune disorder or HIV, hepatitis B or hepatitis C, not having known brain metastases, and not having a history of inflammatory bowel conditions including diverticulitis, ulcerative colitis, etc.",
    "The sample is a phase 1 clinical trial for patients with \u03b2-thalassemia and transfusional iron overload. The trial is testing the drug deferasirox. The inclusion criteria for the trial are male or female patients over 18 years old who have not previously been treated with deferasirox, have received regular transfusions every 2-5 weeks, and have a transfusion history of at least 20 units of packed red blood cells. The exclusion criteria include abnormal renal function, ALT greater than 5 x ULN at screening, and underlying cardiac disease requiring continuous iron chelation therapy. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 1 clinical trial for patients with advanced, non-resectable and/or metastatic solid tumors, of types historically known to express EGFR and/or HER2. The trial is testing the drug bibw 2992. The eligibility criteria include confirmed diagnosis of the specified tumors, failed conventional treatment or no therapy of proven efficacy, age 18 or older, life expectancy of at least three months, and Eastern Cooperative Oncology Group (ECOG) performance score 0, 1 or 2. The trial also has exclusion criteria, such as active infectious disease, serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol, and treatment with other investigational drugs. The sample includes detailed inclusion and exclusion criteria, as well as criteria for re-treatment after the previous course is finished.",
    "The sample is a phase 1 clinical trial for patients with metastatic renal cell cancer. The trial involves the use of drugs such as interleukin-2, okt3, cyclophosphamide, fludarabine, and mesna. The eligibility criteria for the trial include having a clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1, being seronegative for HIV and hepatitis B antigen, having a life expectancy of greater than three months, and meeting certain medical requirements such as having a normal stress cardiac test and pulmonary function testing. Patients must also have measurable metastatic renal cell cancer and have tumor progression after therapy with interleukin-2 (IL-2) to be eligible for the cell infusion phase of the trial. There are also exclusion criteria, such as having active systemic infections or coagulation disorders, requiring steroid therapy, or being pregnant or nursing.",
    "The sample is a phase 1 clinical trial for patients with advanced solid tumors that are refractory to standard therapies or for which no standard therapies exist. The trial involves the use of the drugs bevacizumab, everolimus, and lbh589. The eligibility criteria include having at least one measurable site of disease, being at least 18 years old, having a Karnofsky Performance status of at least 80%, and having adequate bone marrow, liver, and renal function. Exclusion criteria include receiving anticancer therapies within 4 weeks of the trial, having a known hypersensitivity to experimental drugs, and having severe or uncontrolled medical conditions that could affect participation in the trial. Women of childbearing potential must have a negative pregnancy test and use two forms of contraception during the trial and for 3 months after the last study drug administration.",
    "The sample is a clinical trial for chronic hepatitis C, in which the phase is a combination of phase 1 and phase 2. The trial involves testing the drugs daclatasvir and placebo on patients who are chronically infected with hepatitis C virus genotype 1 and have not received treatment before or have not responded to previous treatment. Patients who are co-infected with HIV or hepatitis B virus are excluded from the trial. The trial also requires patients to have a hepatitis C virus RNA viral load of at least 10*5* IU/mL and a BMI between 18 to 35 kg/m\u00b2. The eligibility criteria include key inclusion criteria and key exclusion criteria, which are listed in detail.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on Crohn's Disease. The icd-10 codes associated with the disease are listed, as well as the specific drugs being tested. The eligibility criteria for participants are also listed, including age range, disease severity, and exclusion criteria such as previous use of certain medications or a history of certain medical conditions.",
    "The sample is a phase 1 clinical trial for breast cancer patients. The trial involves the drugs paclitaxel and neratinib. The eligibility criteria include having a confirmed diagnosis of invasive adenocarcinoma of the breast with evidence of metastatic breast cancer, being of reproductive potential and agreeing to use non-hormonal contraception during therapy and for at least 6 months after the last dose of study therapy, having an ECOG performance status of 0, 1, or 2, and being able to swallow oral medication. Exclusion criteria include having a history of or active cardiac disease that would preclude the use of any of the drugs included in the treatment regimen, chronic daily treatment with corticosteroids with a dose of greater than or equal to 10 mg/day methylprednisolone equivalent, and use of any investigational agent within 4 weeks prior to study entry.",
    "The sample is a clinical trial for breast cancer patients with HER-2 positive and ER positive or PR positive (HR+) metastatic or resistant locally advanced breast cancer. The trial is in phase 1/phase 2 and the drug being tested is auy922. The eligibility criteria include being 18 years or older, having certain laboratory values within normal limits, having a negative pregnancy test, having at least one measurable lesion, and having a World Health Organization (WHO) Performance Status of less than 1. Exclusion criteria include unresolved diarrhea, pregnancy or lactation, impaired cardiac function, HIV positive status, known hypersensitivity to any of the study drugs or their excipients, and participation in another clinical study within 30 days before first study treatment.",
    "The sample is a phase 1 clinical trial for patients diagnosed with cancer and experiencing chronic neuropathic pain syndrome. The trial is testing the effectiveness of methadone hydrochloride as a treatment for pain related to cancer or its treatment. Patients must meet certain eligibility criteria, including experiencing pain for at least 4 weeks with an average pain score of 4 or higher, and requiring strong opioids to control pain. They must also have a Karnofsky performance status of 40-100%, and meet various other patient characteristics. The trial excludes patients with certain medical conditions or histories of substance abuse, and those who live alone without access to a caregiver. Prior concurrent therapy is allowed under certain conditions.",
    "The sample is a record of a clinical trial with a combination of phase 1 and phase 2. The trial is focused on rheumatoid arthritis, and the icd-10 codes associated with the disease are listed. The trial involves the use of two drugs, ask8007 and placebo. The eligibility criteria for the trial are also listed, including the requirement that participants meet the American Rheumatism Association's criteria for the classification of RA and have been treated with an adequate dose of either MTX, leflunomide, or sulfasalazine for at least 4 months prior to baseline. The exclusion criteria are also listed, including recent treatment with investigational drugs or TNF\u03b1-blockers, and the presence of certain medical illnesses that could put the patient at safety risk or mask measures of efficacy.",
    "The sample is a clinical trial for patients with hematological malignancies who have undergone either ablative or non-myeloablative allogeneic stem cell transplantation. The trial is in phase 1/phase 2 and the drugs being tested are rituximab and 375 mg/m2 rrituximab. The eligibility criteria include being 18 years or older, having a performance status of 0-2, and having a life expectancy of over 100 days. Patients must have received transplantation from donors who are identical at 6 HLA loci, or mismatched at no more than 1 locus. Patients who have undergone a non-myeloablative stem cell transplant must have > 80% donor hematopoiesis within 30 days of study enrollment. Patients with CLL are eligible if there is no more than 20% residual leukemia in the bone marrow at the time of study entry. The exclusion criteria include evidence of relapsed or residual malignancy within 30 days of trial entry, highly aggressive B cell malignancy, evidence of any active uncontrolled infection, evidence of ongoing gastrointestinal or hepatic acute GVHD, or evidence of greater than ongoing Stage I cutaneous acute GVHD, among others.",
    "The sample is a phase 1 clinical trial for patients with recurrent advanced ovarian, fallopian tube, or primary peritoneal cavity cancer. The trial is testing the effectiveness of the drugs docetaxel and idronoxil. The eligibility criteria include having received platinum and taxane combination chemotherapy as first-line treatment with disease recurrence more than 6 months after conclusion of therapy, and meeting certain disease and patient characteristics such as having a Karnofsky performance score of at least 60%, no active CNS metastases, and no concurrent severe and/or uncontrolled medical disease. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 1 clinical trial for asthma. The trial includes male participants between the ages of 18 and 55 who are healthy and meet certain criteria, such as having a body weight greater than or equal to 55kg and BMI within the range of 18-31 kg/m2. The trial also includes additional inclusion criteria for healthy smokers. The trial excludes participants with certain medical conditions, such as liver disease or a history of congestive heart failure, as well as those who have participated in a clinical trial within a certain time period prior to the current study. Participants must also avoid certain medications and substances, such as red wine and grapefruit juice, prior to the first dose of study medication.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on kidney diseases and the associated ICD-10 codes. The drugs being tested are yspsl and placebo. The eligibility criteria for the trial include patients undergoing primary cadaver renal transplants, while exclusion criteria include patients with planned transplants from non-heart beating donors, donors < 6 years of age, or donors who have received investigational therapies to reduce the impact of ischemia/reperfusion injury, DGF, or other donor-related immune events. Patients planned to receive a living donor kidney or an ABO-incompatible donor kidney are also excluded.",
    "The sample is a clinical trial for Alzheimer's disease in phase 1. The trial includes patients with a clinical diagnosis of mild to moderate Alzheimer's disease and a Mini Mental State Examination (MMSE) score of 16 to 28. The patients must be on stable treatment for at least 12 weeks prior to the screening visit. The trial excludes patients with any neurological condition that could contribute to cognitive impairment, any psychiatric diagnosis or symptoms that could interfere with assessment of cognition, history of TIA, stroke, or seizures within 12 months of screening, evidence of infection, tumor, stroke, or other clinically significant lesions that could indicate a dementia diagnosis other than AD on brain MRI at screening, and other significant pathological findings on brain MRI at screening. The trial will test the efficacy of different drugs, including active and placebo comparators.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on non-small-cell lung cancer and involves the drug gefitinib. The trial has eligibility criteria for patients, including a requirement for written informed consent, a need for low dose palliative thoracic irradiation, and a confirmed diagnosis of non-small cell lung cancer. There are also exclusion criteria, such as previous thoracic radiotherapy and known hypersensitivity to any component of the study medication. The sample includes a list of icd-10 codes associated with the disease.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on ulcerative colitis, and the patients must be between the ages of 5 and 17 years old. The trial involves the use of mesalamine as part of the treatment for ulcerative colitis. The eligibility criteria include being in good health, able to swallow Asacol tablets, and willing to participate in the study. The exclusion criteria include a history of cancer, renal insufficiency, or allergy to salicylates or aminosalicylates. The patients must also not be using proton pump inhibitors or antacids and must not have participated in another clinical trial involving active intervention within 30 days prior to randomization.",
    "The sample is a phase 1 clinical trial for the treatment of cutaneous T-cell lymphoma. The trial involves the use of a drug called \"shape (shp-141)\" at different concentrations and a placebo. The eligibility criteria for the trial include confirmed diagnosis of CTCL, specific clinical stage of the disease, skin lesion involvement of at least 3% of BSA, and a certain performance status. Exclusion criteria include certain types of CTCL, severe pruritus, palpable lymph nodes, coexistent second malignancy, and various medical conditions. The trial also excludes individuals with active Hepatitis B or C or HIV, and those with circulating atypical cells greater than 5%.",
    "The sample is a clinical trial for phase 1, which involves patients with leukemia, lymphoma, or myeloma. The trial uses drugs such as rituximab, cyclophosphamide, fludarabine, mesna, and sirolimus. The eligibility criteria for the trial include being between the ages of 18-70, having a confirmed diagnosis of follicular lymphoma, mantle cell lymphoma, chronic lymphocyte leukemia/small lymphocytic lymphoma, or multiple myeloma, and having persistent or progressive disease despite initial chemotherapy. Patients must have achieved a partial or complete response to their most recent chemotherapy. Other criteria include having an HLA matched related donor, a Zubrod Performance Scale of 0 or 1, and meeting certain medical requirements such as having a creatinine level below 1.8 mg/dl and an ejection fraction of at least 40%. Exclusion criteria include uncontrolled infection, being HIV or hepatitis B/C positive, having a serum glutamic-pyruvic transaminase level above 200 IU/ml, and being pregnant or lactating.",
    "The sample is a phase 1 clinical trial for the treatment of gastroparesis. The trial involves testing the drugs \"gsk1322888\" and \"placebo\" on male and female participants between the ages of 18 and 65. The participants must be healthy and meet certain criteria, such as having a body weight of at least 50 kg and a BMI within the range of 18.5 to 29.9 kg/m2. They must also have an average QTc, QTcB or QTcF of less than 430 msec. The trial has exclusion criteria, such as being pregnant, having a history of liver disease, or being mentally or legally incapacitated. Participants must also avoid certain foods and substances, such as red wine and tobacco products, during the trial.",
    "The sample is a clinical trial for non-small-cell lung carcinoma and carcinoma, non-small cell lung. The trial is in phase 1/phase 2 and involves the drugs entinostat, sndx-275, and erlotinib. The eligibility criteria include having confirmed NSCLC of stage IIIb or IV, having received at least 1 but no more than 2 prior chemotherapy or chemoradiotherapy regimens for advanced NSCLC, having at least 1 measurable lesion by conventional or spiral CT scan, having an ECOG performance score of 0, 1, or 2 and life expectancy of at least 6 months, and meeting various other medical criteria. The exclusion criteria include having prior stem cell transplant, clinical evidence of CNS involvement, prior treatment with an HDAC inhibitor or an EGFR inhibitor, and various other medical conditions. Patients must also be willing to use accepted and effective methods of contraception during the study and for 3 months after the last dose of SNDX-275.",
    "The sample is a clinical trial for the treatment of chronic hepatitis C, genotype 1, in non-responders or relapsers. The trial is in the early phase 1. The trial involves the use of betaine, peginterferon alpha 2a, and ribavirin. The eligibility criteria include having a history of chronic hepatitis C, genotype 1, and meeting certain hematologic, biochemical, and serologic criteria. In addition, subjects must be willing to give informed consent and adhere to dose and visit schedules. Exclusion criteria include pregnancy or nursing, prior response to therapy and failure to achieve SVR, and participation in any clinical trial of a HCV protease inhibitor of any duration.",
    "The sample is a clinical trial for breast cancer patients in phase 1/phase 2. The trial is testing the effectiveness of two drugs, bibf and paclitaxel, on patients with localized breast cancer with a primary tumor over 2 cm in diameter. The patients must be HER2 negative and have measurable disease with a primary lesion over 2 cm. The trial has a set of inclusion and exclusion criteria, including adequate hematologic, renal, and hepatic function, and a life expectancy of over 6 months. Patients with metastatic or non-surgical breast cancer, locally breast cancer with a primary lesion under 2 cm, or previous or concurrent treatment for breast cancer are excluded from the trial. The trial also excludes male patients, pregnant or breastfeeding women, and patients with active malignancy at any other site. The trial has a total of 17 exclusion criteria.",
    "The sample is a clinical trial for patients with type 2 diabetes and incipient or overt diabetic nephropathy. The trial is in phase 1/phase 2 and the drug being tested is aliskiren. The eligibility criteria include having a BMI within the range of 20 and 32, a GFR of at least 40 ml/min, and being on stable hypoglycemic medications for at least 8 weeks prior to the trial. Patients must also be willing and medically able to discontinue certain medications for the duration of the study. Exclusion criteria include severe hypertension, kidney disease not caused by diabetes or hypertension, and a history of malignancy within the past five years. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a clinical trial for pancreatic cancer patients in phase 1/phase 2. The trial is testing the effectiveness of gemcitabine hydrochloride as a treatment option. The eligibility criteria for patients include having histologically or cytologically confirmed adenocarcinoma of the pancreas, completely resected disease, and no grossly positive surgical margins. Patients must also have an ECOG performance status of 0-1, be not pregnant or nursing, and have no known CNS disease. Other criteria include having certain blood counts and levels within normal ranges, no postoperative complications, and no history of major psychiatric disorder or other chronic medical illness that contraindicates the use of the study drugs. Patients must not have had prior chemotherapy or radiotherapy for pancreatic cancer, no prior systemic or investigational therapy for pancreatic cancer, and no major surgical procedure (except for resection of pancreatic cancer) or open biopsy within the past 28 days. The trial does not allow concurrent newly prescribed nonsteroidal anti-inflammatory drugs (NSAIDs), but concurrent chronic-dose NSAIDs for analgesia are allowed.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is a combination of phase 1 and phase 2, and is focused on metastatic breast cancer. The drugs being tested are lapatinib and docetaxel. The eligibility criteria include age, performance status, HER positivity, prior treatment history, cardiac function, and adequate organ function. There are also exclusion criteria, such as certain medical conditions, prior treatments, and pregnancy.",
    "The sample is a phase 1 clinical trial for a vaccine against plasmodium falciparum malaria. The eligibility criteria include being between 18 and 40 years old, not having been exposed to or infected with malaria, being in good health, and agreeing to not donate blood until 6 months after the last blood draw in the protocol. Women of childbearing potential must have a negative pregnancy test and agree to practice adequate contraception. Exclusion criteria include a history of travel to a malaria-endemic area, hypersensitivity to components of the vaccine, immunosuppression, significant cardiac abnormality, seizure disorder, hemophilia, thrombocytopenia, bleeding or clotting disorders, implanted electronic stimulation device, and active neoplastic disease. The sample also includes various other exclusion criteria related to medical conditions, medication use, and psychiatric history.",
    "The sample is a clinical trial for a drug called Velcade, which is being tested on patients with peripheral T-cell lymphomas and non-Hodgkin lymphoma. The trial is in phase 1/phase 2 and has specific eligibility criteria for patients to be included, such as having a confirmed diagnosis of PTCLs or NK/T cell lymphomas (excluding ALK-positive anaplastic large cell T-cell lymphomas), being under the age of 65, and having measurable lesions. The trial also has exclusion criteria, such as having any other malignancies within the past 5 years (except for basal cell skin cancer or carcinoma in situ of the cervix) and serious comorbid diseases. Any waiver of these criteria must be approved by the investigator and sponsor on a case-by-case basis.",
    "The sample is a phase 1 clinical trial for patients with advanced solid tumors. The trial is testing the drug Osi-906 and the eligibility criteria includes having a documented malignancy that is now advanced and/or metastatic and refractory to established forms of therapy or for which no effective therapy exists. Patients must also have an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2 and a life expectancy of at least 12 weeks. Prior chemotherapy and tyrosine kinase inhibitor therapy is permitted, provided that a minimum of 3 weeks has elapsed and patients have recovered from any treatment-related toxicities. Patients must also have normal levels of potassium, calcium, and magnesium, and their fasting glucose levels must be within a certain range. The trial has exclusion criteria, including a history of any kind of stroke, any type of active seizure disorder, previously diagnosed brain metastases, and concurrent anticancer therapy.",
    "The sample is a phase 1 clinical trial for hypertension and metabolic syndrome. The trial includes African American men and women between the ages of 18 and 80 who are currently taking no more than two antihypertensive medications. Patients must have at least one marker of metabolic syndrome, such as low HDL cholesterol or high triglycerides. Exclusion criteria include uncontrolled hypertension, recent cardiovascular events, and severe renal impairment. Women who are pregnant or nursing or who are of childbearing potential must use reliable contraception throughout the study and for one week after the study ends.",
    "The sample is a clinical trial for phase 1, with the disease being melanoma (skin). The trial requires patients to have a biopsy-proven relapsed malignant melanoma that has failed prior standard regimen for metastatic disease and must have an HLA-matched or related bone marrow donor. Patients must also meet certain criteria such as age, performance status, life expectancy, and various health conditions. The trial involves the use of drugs such as busulfan, cyclophosphamide, cyclosporine, and methotrexate. The eligibility criteria also include prior concurrent therapy with at least one prior standard regimen for metastatic disease. The icd-10 codes for the disease are also provided.",
    "The sample is a clinical trial for the treatment of multiple myeloma, a type of cancer. The trial is in phase 1/phase 2 and involves the use of drugs such as lenalidomide, bortezomib, dexamethasone, and doxil. The eligibility criteria for participants include being at least 18 years old, having measurable disease, completing necessary baseline studies, and having a left ventricular ejection fraction greater than or equal to 50 percent. Exclusion criteria include having grade 2 or higher peripheral neuropathy, renal insufficiency, evidence of bleeding or platelet refractory, and other medical conditions that place the subject at unacceptable risk. The trial also excludes pregnant or breastfeeding women and those who have received other investigational drugs within 14 days of enrollment.",
    "The sample is a clinical trial for lung cancer patients in phase 1/phase 2. The trial includes patients with non-small-cell lung cancer and other related diseases. The trial involves the use of drugs such as abt-751, pemetrexed, and placebo. The eligibility criteria for the trial include having only one prior anti-tumor treatment regimen, measurable disease by RECIST criteria, and an ECOG performance score of 0-2. The trial also has exclusion criteria such as allergy to sulfa medications, previous treatment with ABT-751 or pemetrexed, and significant systemic disease that would adversely affect participation.",
    "The sample is a phase 1 clinical trial for the treatment of prostate cancer using the drug dasatinib. The eligibility criteria for patients to participate in the trial include having histologically or pathologically confirmed adenocarcinoma of the prostate, being at intermediate, high, or very high risk for the disease, having no prior pelvic or prostate radiation or chemotherapy, and meeting certain laboratory parameters. Patients must also have a life expectancy of at least 1 year, no concurrent anticancer therapy, and must be able to take oral medication. Patients meeting any of the exclusion criteria, such as evidence of distant metastases or prior radical prostatectomy, are not eligible to participate in the trial.",
    "The sample is a clinical trial for patients with metastatic breast cancer who have received at least two prior chemotherapy regimens. The trial is in phase 1/phase 2 and involves the drugs hydroxychloroquine and ixabepilone. The eligibility criteria include having measurable disease according to RECIST criteria, being anthracycline-resistant and taxane-resistant, and having a known hormone receptor status. Patients must also meet certain patient characteristics, such as having an ECOG performance status of 0-2 and no serious uncontrolled medical disorder or active infection. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 1 clinical trial for patients with relapsed or refractory multiple myeloma or other plasma cell disorders. The trial is testing the effectiveness of paricalcitol and zoledronic acid as treatments. The eligibility criteria include having had at least one previous treatment for the disease, a performance status of ECOG 0-2 or Karnofsky 60-100%, a life expectancy of at least 3 months, and meeting certain medical requirements such as having a calcium level of \u2264 10.5 mg/dL and no history of certain cardiac or renal conditions. Patients must also not be pregnant or nursing, have no ongoing or active infections, and have no psychiatric illness or social situation that may preclude study compliance. Prior concurrent therapy is also taken into consideration.",
    "The sample is a clinical trial for patients with uveitis or glaucoma who have recently received a Retisert implant. The trial is in phase 1 and involves the use of anecortave acetate. The eligibility criteria include being at least 12 years old, having received the implant within the last 12 weeks, and being able to make required study visits and follow instructions. Exclusion criteria include having certain medical conditions or allergies, having a scleral buckle in the study eye, being on certain medications, or having clinical evidence of scleral thinning.",
    "The sample is a clinical trial for non-Hodgkin's lymphoma patients in phase 1/phase 2. The trial involves the use of rituximab, dhap, tec, and autologous stem cell transplantation as drugs. The eligibility criteria include being between 18-65 years old, having first relapse or primary refractory disease of aggressive Non-Hodgkin's lymphoma stage I-IV, and having pretreatment with systemic therapy. The exclusion criteria include having a second neoplasia in history or existing, CNS-involvement by lymphoma, respiratory partial- or global insufficiency, cardiac insufficiency, severe neurological or psychiatric disease, pregnancy, HIV positivity, active virus hepatitis, bacterial infection, and no follow-up procedures ensured.",
    "The sample is a clinical trial with a combination of drugs, paclitaxel, carboplatin, and vorinostat, for patients with stage IIIA, IIIB, or IV non-small cell lung cancer. The trial is in phase 1/phase 2 and the eligibility criteria include having no prior chemotherapy for advanced or metastatic disease, measurable disease, and an ECOG performance status of 0 or 1. Patients must also meet certain laboratory values and have a life expectancy of greater than 12 weeks. Exclusion criteria include prior therapy with paclitaxel, uncontrolled intercurrent illness, and pregnancy.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on neoplasms, which are a type of abnormal growth or tumor. The icd-10 codes associated with the diseases being studied are listed. The drug being tested is called jnj-38877605. The eligibility criteria for the trial are listed, including requirements for confirmed advanced or refractory solid tumors, a certain performance status test score, and meeting certain lab criteria. There are also exclusion criteria listed, such as recent major surgery or chemotherapy, brain metastases, and certain medical conditions.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on heart failure and asymptomatic systolic dysfunction. The trial involves the use of nesiritide and placebo drugs. The eligibility criteria for the trial include having an ejection fraction of less than 45%, no clinical signs or symptoms of congestive heart failure, ability to walk a minimal distance of more than 450 meters on a 6-minute walk, and being on stable doses of an angiotensin converting enzyme (ACE) inhibitor for two weeks prior to the active study date. The exclusion criteria include having a recent myocardial infarction, unstable angina, significant valvular stenosis, hypertrophic, restrictive or obstructive cardiomyopathy, and other medical conditions.",
    "This sample is for a phase 1 clinical trial for patients with advanced cancer. The trial is testing a drug called RDEA119. The eligibility criteria include having a confirmed solid tumor, advanced metastatic or locally recurrent disease for which no proven effective therapy exists, an ECOG performance status of 0-1, and a life expectancy of at least 3 months. Patients must also have acceptable hematology, clinical chemistry, and coagulation laboratory values, and be acceptable for treatment and follow-up according to the investigator. Exclusion criteria include use of investigational agents or devices within the last 28 days, major surgery within 30 days of the start of the study, and other serious medical or psychiatric illness. Patients with known hypersensitivity to any of the drugs or components given in this protocol, pregnancy, and women or men of childbearing potential not willing to use effective contraception are also excluded. Patients with abdominal fistula, GI perforation, intra-abdominal abscess, or small bowel resection, any of which is within 6 months of study entry, and patients with abdominal radiation resulting in chronic diarrhea are also excluded. Patients with known HIV infection will be excluded.",
    "The sample is a phase 1 clinical trial for the treatment of myelodysplastic syndrome (MDS) using the drug txa127. The trial has eligibility criteria for inclusion, such as a diagnosis of MDS using the World Health Organization classification and Low or Intermediate-1 risk MDS using the IPSS, a mean platelet count of \u226450 x 109/L, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Exclusion criteria include currently receiving any treatment for MDS other than transfusions, concurrent active malignancy (other than controlled prostate cancer, in situ cervical cancer, or basal cell cancer of the skin), and a history of arterial thrombosis or venous thrombosis that currently requires anti-coagulation therapy. Women of childbearing potential are required to have a positive HCG serum or urine pregnancy test performed 7 days prior to the first study drug dose and must use an adequate form of contraception during the course of the study.",
    "The sample is a phase 1 clinical trial for patients with advanced cancer. The trial is testing the effectiveness of a drug called sgx523 capsules. Patients must have failed standard therapy and be deemed suitable for the trial by the investigator. They must also have certain laboratory values within normal ranges and have no residual toxic effects from previous therapy. In addition, they must have IHC evidence of phospho-MET expression on tumor material no more than 12 months old. Patients must not be pregnant or have cardiac disease requiring medical therapy, and must not have had major surgery within 4 weeks prior to the start of the study. They must also not have an active, uncontrolled bacterial, viral, or fungal infection that requires ongoing systemic therapy, or a known active infection with HIV, hepatitis B or C. Patients with psychiatric or seizure disorders that would require therapy or interfere with study participation, or other severe concurrent nonmalignant disease that could compromise protocol objectives, including malabsorptive conditions, are also excluded. Patients receiving prohibited medications as listed in Appendix E, including drugs categorized as strong inhibitors of CYP3A4 and A5 and drugs known to have a high potential risk of liver toxicity, or those with known allergy to SGX523 formulation or its excipients (croscarmellose sodium, lactose monohydrate and magnesium stearate), or those receiving anti-coagulant therapy are also excluded.",
    "The sample is a phase 1 clinical trial for patients with non-small cell lung cancer or recurrent disease following locoregional treatment. The trial is testing the effectiveness of drugs such as cetuximab and bibw 2992 on tumors that have an Epidermal Growth Factor Receptor (EGFR) mutation known to be associated with drug sensitivity. Patients must have either had a documented partial or complete response to previous treatment with an EGFR Tyrosine Kinase Inhibitor (EGFR TKI) or stable disease for at least 6 months. Patients must also have adequate tumor-derived material available for EGFR mutation analyses. Exclusion criteria include prior treatment with EGFR targeting antibodies, adverse events due to major surgery, and brain metastases that are symptomatic. Women of childbearing potential and men who are able to father a child must use a medically acceptable method of contraception during the trial.",
    "The sample is a phase 1 clinical trial for patients with symptomatic Multiple Myeloma, Salmon-Durie Stage II or III or International Staging System II or III that has been previously treated with at least one cycle of a specific therapy. The trial involves the use of bendamustine, lenalidomide, dexamethasone, aspirin, prophylaxis, and antibiotic drugs. The eligibility criteria include having measurable levels of monoclonal protein, bone marrow plasmacytosis, or lytic bone disease, as well as meeting certain organ and marrow function requirements. Patients must not be pregnant or breastfeeding, and sexually active participants must agree to avoid conception while participating in the study. The trial has exclusion criteria, including patients with a history of allergic reactions to compounds of similar chemical or biologic composition to lenalidomide and/or Bendamustine or other agents used in the study, and patients with a serious cardiac condition.",
    "The sample is a clinical trial for patients with rectal cancer in phase 1/phase 2. The trial involves the drug capecitabine and has a list of inclusion and exclusion criteria. Inclusion criteria include having clinical stage T4 or recurrent adenocarcinoma of the rectum, confirmed histology, no distant metastatic disease, a performance status of 70% or greater, and being able to tolerate the proposed radiation and chemotherapy regimen. Exclusion criteria include prior radiotherapy to the pelvis, pregnancy or lactation, treatment for other carcinomas within the last five years (except cured non-melanoma skin and treated in-situ cervical cancer), uncontrolled intercurrent illness, major surgery within 4 weeks of the start of study treatment, and prior severe reaction to fluoropyrimidine therapy or known hypersensitivity to 5-fluorouracil or capecitabine. The sample also includes a list of diseases and their corresponding icd-10 codes.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on treating soft tissue sarcoma, including locally advanced or metastatic, unresectable disease. The trial involves the use of two drugs, amg 655 and doxorubicin. The eligibility criteria for the trial include having a confirmed diagnosis of soft tissue sarcoma, measurable disease according to modified RECIST, an ECOG performance status of 0 or 1, and adequate hematological, renal, hepatic, and coagulation function. The exclusion criteria include prior treatment with anthracyclines and uncontrolled cardiovascular disease.",
    "The sample is a clinical trial with a phase 1 designation, focusing on diabetes and healthy individuals. The trial involves the use of the drug semaglutide and a placebo. The eligibility criteria for participants include being male, between the ages of 18-65, having a BMI below 35.0 kg/m^2, and being in good general health based on medical history, physical examination, ECG, and laboratory analysis. Exclusion criteria include previous participation in a clinical trial involving investigational products within the last 3 months, recent myocardial infarction, use of certain medications, clinically significant gastrointestinal disease, and history of drug or alcohol abuse. Participants must also use effective contraception if sexually active and not surgically sterilized. The trial involves a variety of tests and measurements to evaluate the safety and efficacy of the drug.",
    "The sample is a clinical trial for patients with acute lymphoblastic leukemia. The trial is in phase 1/phase 2 and involves the drug clofarabine. The eligibility criteria include having received therapy with at least 1 but not more than 3 prior different induction regimens and having been deemed to have relapse or refractory disease. Patients must also have adequate renal and hepatic functions, be at least 16 years old, and have an ECOG PS of 0-2. Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment, and both male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment. The exclusion criteria include current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol, lack of bone marrow or blood involvement by leukemia, and any other severe concurrent disease or history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment.",
    "The sample is a phase 1 clinical trial for patients with advanced solid tumors. The trial is testing the drug g-202. Patients must have a confirmed metastatic or unresectable malignancy that cannot be treated with standard measures. They must also have acceptable liver and renal function, hematologic status, and coagulation profile. Patients with brain metastases that have been treated and are clinically stable for at least 30 days may be enrolled. Patients with pre-existing cardiac conditions, corrected QTc prolongation value > 450 msec, or active uncontrolled infection are excluded. Patients must also meet other eligibility criteria and agree to use an effective method of birth control. The trial requires patients to have at least 4 weeks since prior chemotherapy or surgery, with recovery to Grade 1 or baseline of significant toxicities felt related to prior drug(s). Women of childbearing potential must have a negative serum pregnancy test at screening. Patients must also be able to understand and sign a written informed consent document.",
    "The sample is a phase 1 clinical trial for patients with solid tumors who have progressed after receiving approved therapies for their disease and for whom no effective therapies are available. The trial is testing the drug E7107. Patients must meet certain inclusion criteria, such as having completed surgery and radiotherapy at least four weeks prior to study entry, having an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, and having a life expectancy of more than three months. Patients must also meet certain exclusion criteria, such as having symptomatic or progressive brain tumors or brain or leptomeningeal (CNS) metastases requiring clinical intervention, having laboratory parameters outside of certain ranges, having a positive history of HIV, active hepatitis B or active hepatitis C, or having clinically significant cardiac impairment or unstable ischemic heart disease. Women who are pregnant or breastfeeding are also excluded from the trial.",
    "The sample is a clinical trial in phase 1 for patients with moderate to severe chronic obstructive pulmonary disease (COPD). The trial includes patients who are current or ex-smokers with at least 10 pack-year smoking history and have a post-bronchodilator FEV1 (forced expiratory volume in one second) between 35% and 80% of predicted normal value. The trial also includes patients with a post-bronchodilator FEV1/FVC (forced vital capacity) ratio less than 0.70 and a post-bronchodilator improvement in FEV1 of at least 100 mL. The trial excludes patients with current evidence or recent history of clinically significant or unstable disease (other than COPD), current diagnosis of asthma, or a history of clinically significant allergy requiring treatment. Other exclusion criteria include recent COPD exacerbation, use of daily oxygen therapy for more than 10 hours, thoracotomy with pulmonary resection, use of systemic steroids within 3 months, lower respiratory tract infection within 30 days, upper respiratory tract infection within 30 days requiring treatment with antibiotics, history of tuberculosis, bronchiectasis, or other non-specific pulmonary disease, and prolonged corrected QT (QTc) interval or history of long QT syndrome. The trial includes the drugs pur0200, pur0200 placebo, and an active comparator.",
    "The sample is a clinical trial for metastatic colorectal cancer patients who have received one prior line of chemotherapy. The trial is in phase 1/phase 2 and involves the drugs tivantinib, placebo, cetuximab, and irinotecan. The eligibility criteria include having measurable disease, expressing the wild-type form of the gene KRAS, having an ECOG performance status of 0 or 1, and meeting certain bone marrow, liver, and renal function requirements. Participants must also agree to use double-barrier contraceptive measures or avoid intercourse during the study and for 90 days after the last investigational drug dose received. Exclusion criteria include prior therapy with an Epidermal Growth Factor Receptor (EGFR) inhibitor, history of malignancy other than CRC, and certain cardiac diseases. Participants must be fully informed about the study and sign an Independent Ethics Committee (IEC) or Institutional Review Board (IRB)-approved informed consent form (ICF) before participating.",
    "The sample is a clinical trial for multiple sclerosis patients in phase 1. The trial involves the use of two drugs, acth and methylprednisolone. The eligibility criteria include being between 18-65 years old, having clinically definite multiple sclerosis, having at least one MS relapse within the last year and/or at least one new T2 or Gadolinium-enhanced lesion on MRI while on stable interferon therapy, and having an EDSS score of 3.0 - 6.5. Exclusion criteria include being pregnant or breastfeeding, having uncontrolled hypertension, clinically significant cardiac arrhythmias, gastrointestinal ulcer, uncontrolled diabetes mellitus, osteoporosis, any stage of renal failure, psychiatric disorders, or any other clinically significant general health conditions that may interfere with the trial participation. The sample also includes a list of icd-10 codes for the disease and a list of inclusion and exclusion criteria.",
    "The sample is a clinical trial in phase 1 for the treatment of inflammation and rheumatoid arthritis. The trial involves the use of two drugs, nnc0215-0384 and placebo, and requires participants to meet certain eligibility criteria, such as having active RA and being on a stable dose of MTX for at least 6 weeks prior to dosing. The trial also has exclusion criteria, such as having a history of other inflammatory joint diseases or chronic infectious diseases. The sample includes a list of disease names, icd-10 codes, and eligibility criteria for the trial.",
    "The sample is a phase 1 clinical trial for the treatment of obesity. The trial is looking for obese, otherwise healthy females who are post-menopausal or infertile, weigh at least 50 kg, and have a BMI between 32 and 45 kg/m2. The trial is testing the drug zgn-433. The eligibility criteria include exclusion of individuals who have used weight loss agents in the past month, have a history of eating disorder, diabetes or other endocrine disorder, gastric bypass, or are current smokers. Additionally, individuals with unstable body weight during the past 3 months are also excluded.",
    "The sample is a clinical trial for pancreatic cancer patients in phase 1/phase 2. The trial involves the drugs gefitinib and gemcitabine. The eligibility criteria include being diagnosed with pancreatic cancer, having a tumor volume less than 500 cc, being between the ages of 18 and 75, having an ECOG performance status of 1 or less, having a life expectancy of more than 12 weeks, and being willing to practice reliable methods of birth control if a woman of child-bearing potential. Exclusion criteria include having received previous radiotherapy or chemotherapy for malignant disease, having other co-existing malignancies or malignancies diagnosed within the last 5 years (with the exception of basal cell carcinoma or cervical cancer in situ), having evidence of severe or uncontrolled systemic disease, having certain blood counts or liver function tests outside of normal range, having active dermatoses, using certain medications, or having a severe hypersensitivity to ZD1839 or any of its excipients.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on the treatment of hepatocellular carcinoma, a type of liver cancer. The trial involves the use of drugs such as ro5323441 and sorafenib. The eligibility criteria for the trial include being an adult patient over the age of 21 with advanced or metastatic and/or unresectable hepatocellular carcinoma, having at least one measurable lesion according to RECIST criteria, and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. The exclusion criteria include having prior systemic treatment for metastatic hepatocellular carcinoma, major surgery within the previous 4 weeks or planned major surgical procedure during the course of the study, and a history of uncontrolled seizures or encephalopathy within the last 6 months, among others.",
    "The sample is a phase 1 clinical trial for healthy individuals. The trial is testing the drugs Advagraf\u00ae and Prograf\u00ae. The eligibility criteria for participants include being Caucasian, having no history of certain diseases or disorders, having a normal ECG, and not smoking within the past 3 months. Participants must also have a systolic blood pressure below 140 mm Hg and a diastolic blood pressure below 90 mm Hg, and must be willing to abstain from alcohol during the study. Exclusion criteria include a positive screen for illicit drugs or alcohol consumption, a history of certain diseases or disorders, a positive tuberculin skin test, and a history of certain medical conditions or procedures. Participants must also not have a body mass index below 18.0 or above 30.0, and must not have donated plasma or blood within certain timeframes prior to the study. Additionally, participants must not have a history of drug or alcohol abuse within the past year, and must not have received steroid injections or live vaccines within certain timeframes prior to the study.",
    "The sample is a phase 1 clinical trial for patients with metastatic or unresectable solid tumor malignancy or lymphoma. The trial is testing the drug batracylin and the eligibility criteria includes having completed any prior chemotherapy or biologic therapy, having normal organ and marrow function, and having a slow acetylator NAT2 genotype. Women of child-bearing potential and men must agree to use adequate contraception during the study and for 2 months after discontinuation. Patients with known brain metastases or clinically significant illnesses are excluded. Both men and women of all races and ethnic groups are eligible for the trial.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for patients. In this particular sample, the trial is in phase 1 and is studying various types of tumors including sarcoma, neuroblastoma, wilms tumor, osteosarcoma, and brain tumor. The ICD-10 codes associated with these diseases are also listed. The drug being tested is pazopanib (gw786034). The eligibility criteria for patients include age restrictions, measurable or evaluable relapsed or refractory solid tumors, and specific performance scores and organ function requirements.",
    "The sample is a clinical trial for a drug called pt-523 for injection, aimed at treating non-small-cell lung carcinoma in patients who have failed standard first and second line chemotherapy regimens or are intolerant to them. The trial is in phase 1/phase 2 and the eligibility criteria include being over 18 years old, having confirmed NSCLC which is stage III or stage IV, or recurrent disease, and having adequate organ function and bone marrow reserve. Patients must also have a performance status of 0-2 on the ECOG scale and use appropriate contraceptive methods. The trial excludes patients who have received nitrosoureas or mitomycin-C within 6 weeks or other chemotherapy or radiation therapy within 3 weeks before study entry, as well as those with uncontrolled intercurrent illness, symptomatic or uncontrolled brain metastases, or uncontrolled pleural effusions. Patients must provide signed informed consent to participate in the trial.",
    "The sample is a phase 1 clinical trial for patients with advanced stage malignancies who have failed treatment, including at least one, but no more than two, prior regimens of chemotherapy for breast cancer, ovarian cancer, prostate cancer, colon cancer, and renal cancer. The trial involves the use of cyclophosphamide & zyc300 (zyc300 with cyclophosphamide pre-dosing) as a treatment. The eligibility criteria include having evidence of measurable disease, being at least 18 years old, having a baseline Eastern Cooperative Oncology Group Performance Status of 0 or 1, and having a life expectancy of more than 6 months. The trial also has exclusion criteria, such as having a history of parenchymal brain metastases, receiving chemotherapy, radiation therapy, immunotherapy, systemic immunosuppressive drugs, or investigational agent or experimental therapy within 28 days prior to receiving the first dose of cyclophosphamide, and having a history of bone marrow or stem cell transplantation. The study center will determine if patients meet all of the criteria, and if they do, study personnel will explain the trial in detail using an IRB-approved informed consent, and answer any questions.",
    "This is a sample from a table that contains information about clinical trials. The trial is in phase 1/phase 2 and is focused on chronic lymphocytic leukemia. The trial includes patients who have received at least one prior chemotherapy regimen and have certain blood cell counts and ECOG scores. The trial excludes patients with certain medical conditions or concurrent malignancies. The sample also includes a list of drugs being used in the trial and the eligibility criteria for patients to participate.",
    "The sample is a phase 1 clinical trial for various types of cancer, including breast, colorectal, gastric, lung, ovarian, pancreatic, and unspecified adult solid tumors. The trial involves the use of two drugs, cyclophosphamide and fludarabine phosphate. The eligibility criteria for patients include having a confirmed malignancy that is metastatic or unresectable, no primary brain tumor or brain metastases, and a CEA-positive tumor. Patients must also meet certain health criteria, such as having a WHO performance status of 0-1, a life expectancy of at least 3 months, and normal levels of various blood tests. Patients cannot have certain medical conditions, such as autoimmune disease or inflammatory bowel disease, and cannot be pregnant or nursing. Patients must also not have participated in another clinical trial within the past 30 days and must not have received certain types of therapy within the past 4-6 weeks.",
    "The sample is a phase 1 clinical trial for patients with incurable metastatic lung or colorectal cancer. The trial involves the use of recombinant fowlpox-cea(6d)/tricom vaccine, recombinant vaccinia-cea(6d)-tricom vaccine, docetaxel, and sargramostim. The eligibility criteria include having a life expectancy of at least 4 months, meeting certain blood count and liver function requirements, and having no clinically active brain metastases. Patients must also have had first- and second-line treatment or declined second-line treatment. Additionally, patients must not have certain medical conditions or be taking certain medications. The trial requires patients to avoid close contact with certain individuals after receiving the recombinant vaccinia vaccination.",
    "The sample is a phase 1 clinical trial for patients with central nervous system neoplasms or neoplasm metastasis. The trial involves the use of the drug temozolomide and eligibility criteria include having a left ventricular ejection fraction greater than or equal to 45%, adequate pulmonary function, and an ECOG performance status between 0 and 2. Patients must also be at least 4 weeks from their last cytoreductive chemotherapy and have an expected survival of at least 3 months. Exclusion criteria include uncontrolled metastatic disease outside of the CNS, uncontrolled seizures, and pregnancy or lactation.",
    "The sample is a phase 1 clinical trial for the treatment of metastatic melanoma using the drug LBH589. The trial is open to patients who are 18 years or older, have measurable disease, and have an ECOG performance status of 0, 1, or 2. Patients must also have normal organ and marrow function, be clinically euthyroid, and have biopsiable disease. Women of childbearing potential must have a negative pregnancy test and use two methods of contraception during the study and for 3 months after the last study drug administration. Patients with brain metastases, a history of allergic reactions to similar compounds, or certain medical conditions are excluded from the trial. The trial also excludes patients who have received chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.",
    "The sample is a clinical trial for patients with high-risk myelodysplastic syndrome or acute myelogenous leukemia. The trial is in phase 1/phase 2 and the drug being tested is mgcd0103. The eligibility criteria include having a certain level of BM blasts, a certain ECOG performance status, being at least 18 years old, and meeting certain laboratory requirements. Patients with other active cancers, uncontrolled illnesses, or serious medical conditions are excluded. Patients must also be able to read, understand, and sign a written informed consent. The trial has both inclusion and exclusion criteria, and patients who meet the criteria will be enrolled in the study.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on colorectal cancer and includes a list of ICD-10 codes for the disease. The trial involves the use of three drugs: bevacizumab, oxaliplatin, and capecitabine. The eligibility criteria for the trial include patients between the ages of 20-74 with histologically confirmed colorectal cancer that has not been previously treated with chemotherapy for metastatic disease. Patients must also have at least one measurable lesion according to RECIST. The exclusion criteria include evidence of clinically detectable ascites, recent major surgical procedures or biopsies, bleeding diathesis or coagulopathy, serious wounds or fractures, and the use of certain medications known to predispose to gastrointestinal ulceration.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on two diseases, \"metabolism and nutrition disorder\" and \"obesity\", which are identified by a list of ICD-10 codes. The trial involves testing three drugs, \"nnc 0070-0002-0453\", \"'2-0453\", and \"placebo\". The eligibility criteria for the trial are listed, including requirements for BMI and general health, as well as exclusion criteria such as recent weight changes, history of eating disorders, and substance abuse. The sample also includes instructions for obtaining informed consent before any trial-related activities.",
    "The sample is a phase 1 clinical trial for patients with squamous cell carcinoma of the head and neck, including variants or undifferentiated/poorly differentiated carcinoma. The trial is testing the effectiveness of the drugs bortezomib and cisplatin in treating previously untreated stage IV disease or residual disease or regionally recurrent disease after prior surgery and/or chemotherapy. Patients must be eligible to receive full-dose radiotherapy and be evaluated and accepted for treatment by a Radiation Oncologist. Patients with clinically measurable distant disease or previously untreated nasopharyngeal cancer are not eligible. The trial also has specific patient eligibility criteria, including ECOG performance status, ANC, platelet count, total bilirubin, AST and ALT levels, creatinine clearance, and cognitive and neurologic function. Patients must not have a history of allergic reactions to compounds of similar chemical or biologic composition to bortezomib, cetuximab, cisplatin, or other agents used in the study, and must not have peripheral sensory neuropathy \u2265 grade 2 or concurrent uncontrolled illness. Prior concurrent therapy is also taken into consideration.",
    "The sample is a record of a clinical trial with a combination of phase 1 and phase 2. The trial is focused on the treatment of prostatic neoplasms, and the icd-10 codes associated with the disease are listed. The drug being tested is a combination of samarium sm-153 lexidronam and docetaxel. The eligibility criteria for the trial are listed under inclusion criteria, which includes having histological evidence of adenocarcinoma of the prostate, progressive castrate metastatic disease, and evidence of at least 3 bone metastases on bone scan. The exclusion criteria are also listed, which includes patients with small cell carcinoma, clinically significant cardiac disease, and those who have participated in a research study or clinical trial protocol within 30 days of the baseline visit.",
    "The sample is a phase 1 trial for psoriasis, a skin condition. The trial involves testing the effectiveness of several drugs, including mapracorat, prednicarbate, clobetasol, calcipotriene, and betamethasone dipropionate, on plaques of psoriasis. The eligibility criteria for the trial include being between 18 and 65 years old, having stable plaque-type psoriasis, and having plaques of adequate size for evaluation. Exclusion criteria include a positive urine drug screening, pregnancy or lactation, severe kidney or liver disease, and a history of relevant diseases. The trial also excludes volunteers with certain types of psoriasis, such as guttate or pustular psoriasis, and those with known allergies to any of the trial medication's excipients.",
    "The sample is a record from a clinical trial table. It includes information about the phase of the trial, which can be either phase 1 or phase 2, a list of diseases, their corresponding ICD-10 codes, and a list of drugs used in the trial. The eligibility criteria for the trial are also included, which specify the requirements for participants to be included or excluded from the trial. These criteria include factors such as ethnicity, performance status, tumor type, and medical history. The sample also includes exclusion criteria, which specify conditions that would prevent a participant from being included in the trial.",
    "The sample is a phase 1 clinical trial for the treatment of type 1 diabetes using the drug pramlintide acetate. The trial is open to individuals between the ages of 18 and 70 who have been diagnosed with type 1 diabetes for at least one year and are not achieving glycemic goals while on MDI of insulin. The trial requires participants to have an HbA1c between 7.0% and 9.0%, a BMI less than 30 kg/m2, and to have been on MDI of regular insulin or continuous subcutaneous insulin infusion for at least three months. The eligibility criteria also includes exclusion criteria such as a history of hypoglycemia unawareness, confirmed diagnosis of gastroparesis, and treatment with certain medications. The trial is not open to individuals who have been treated with SYMLIN/pramlintide or have participated in a SYMLIN/pramlintide clinical study within three months of screening. The trial also excludes individuals with certain medical conditions and those who have donated blood within two months or have had major surgery or a blood transfusion within two months.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on the disease \"essential tremor\" and the associated ICD-10 code is \"G25.0\". The trial involves two drugs, \"levetiracetam\" and \"placebo\". The eligibility criteria for the trial include having a history of tremor for 5 or more years and having no other neurological problems. The exclusion criteria include having a prior stroke or other neurological disease, psychiatric problems, a history of renal disease, and being pregnant.",
    "The sample is a phase 1 clinical trial for hypertension. The trial includes patients between the ages of 18 and 65 who weigh at least 50 kg and have a body mass index (BMI) between 18.5 and 24.9. The trial involves testing the effectiveness of different drug treatments, including a reference treatment of 5 mg amlodipine + 50 mg losartan and a combination of amlodipine and losartan. The eligibility criteria include normal liver function, a normal electrocardiogram, and being in good health as determined by a physician. Exclusion criteria include a positive drug or alcohol screen, a history of liver disease, and inability to follow the procedures outlined in the protocol.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on treating tumors and neoplasm metastasis using the drug brivanib. The trial is open to men and women over the age of 18 who have been diagnosed with advanced or metastatic colorectal, hepatocellular, or renal cancer and have measurable disease on scans. In order to be eligible for the trial, participants must have no tumor spread to the brain, be feeling well other than their cancer diagnosis, have a tumor tissue sample available from prior surgery, and have recovered from prior therapy. Women who are pregnant or breastfeeding are not eligible for the trial. The diseases and their corresponding ICD-10 codes are also listed in the record.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on non-Hodgkin B-cell lymphoma and the drug being tested is aflibercept. The eligibility criteria for the trial include being in good condition and not having been previously treated for the disease. There are also exclusion criteria, such as having a contraindication to any of the drugs contained in the R-CHOP regimen, having had major surgery within the past 42 days, or having cerebral or leptomeningeal involvement. Other exclusion criteria include having a history of another neoplasm, participating in another clinical trial, or having any acute or chronic medical condition that could impair participation in the study or interfere with interpretation of the results. Additionally, patients who are pregnant or breastfeeding, or who have reproductive potential without an effective method of contraception, are excluded from the trial.",
    "The sample is a clinical trial for patients with colorectal cancer that has spread and cannot be cured by surgery or radiotherapy. The trial is for patients who have received at least one prior chemotherapy regimen and have had disease progression or intolerable toxicity during or within 3 months of receiving a cetuximab-containing regimen. The trial involves the drug irinotecan hydrochloride and requires patients to meet a number of eligibility criteria, including having a KRAS wild-type tumor, measurable disease, and an ECOG performance status of 0-1. The trial also excludes patients with certain medical conditions or prior treatments, and requires patients to undergo various tests and screenings.",
    "The sample is a record of a clinical trial that is in phase 1/phase 2. The trial is focused on arthritis and rheumatoid arthritis, and the icd-10 codes associated with these diseases are listed. The drugs being tested are cdp 6038 sc and methotrexate. The eligibility criteria for the trial are also listed, including requirements for RA duration, joint count, and CRP levels. There are also exclusion criteria, such as previous participation in studies with defined agents, certain medical conditions, pregnancy, and drug addiction or alcohol abuse.",
    "The sample is a phase 1 clinical trial with only healthy subjects. The trial is testing the effectiveness of three different treatments: pf-03654764 2.5mg plus fexofenadine 60mg, pf-03654764 5mg plus fexofenadine 60mg, and a placebo. The eligibility criteria for the trial includes being healthy with no clinically relevant abnormalities, as determined by a detailed medical history, physical examination, and clinical laboratory tests. The exclusion criteria includes having any clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (excluding untreated, asymptomatic, seasonal allergies at the time of dosing), a positive urine drug screen, or having been treated with an investigational drug within 30 days or 5 half-lives preceding the first dose of study medication.",
    "The sample is a clinical trial for relapsing multiple sclerosis, in which the phase is a combination of phase 1 and phase 2. The trial involves the use of drugs such as cdp323 and placebo. The eligibility criteria for the trial include being between the ages of 18-65, having a relapsing form of MS with at least one clinical relapse in the 24 months before screening, having a screening EDSS score of 0-6.5, being fully immunocompetent, and female subjects of childbearing potential must agree to practice contraception methods. The exclusion criteria include any conditions that could interfere with the contrast-enhanced MRI, any clinically significant disease state or findings other than MS, any clinically significant deviation from the pre-defined ranges for laboratory tests, and concomitant treatment with MS disease modifying drugs.",
    "The sample is a clinical trial for a drug called ta-7284 and its placebo, conducted on patients with type 2 diabetes mellitus. The trial is a combination of phase 1 and phase 2. The table contains information about the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The eligibility criteria include factors such as stable diabetes, specific BMI and blood glucose levels, and blood pressure within a certain range. Patients who have not been administered anti-diabetic medication within 2 weeks prior to dosing are eligible. The exclusion criteria include patients with type 1 diabetes mellitus or secondary diabetic mellitus, history of diabetic complications, and treatment with certain medications within 3 months prior to informed consent. Patients with significant complications or serum creatinine levels above the upper limit of the normal range are also excluded.",
    "The sample is a phase 1 clinical trial for individuals with essential hypertension. The trial is testing the effectiveness of the drugs vasomera (pb1046) and 0.9% sodium chloride. The eligibility criteria include being between the ages of 18-70, having a diagnosis of essential hypertension with a systolic blood pressure between 140-169 mmHg (between 130-169 mmHg if subject has type 2 diabetes mellitus) or diastolic blood pressure 90-109 mmHg (between 85 - 109 if subject has T2DM) who is not currently on antihypertensive therapy, having a BMI between 20 and 40 kg/m2, and meeting other health criteria. Exclusion criteria include having unstable or underlying cardiovascular disease, uncontrolled type 2 diabetes mellitus, and other medical or psychiatric conditions that would place the subject at increased risk or interfere with the interpretation of the study results.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on prostate cancer and includes a list of ICD-10 codes associated with the disease. The trial involves testing three different formulations of a drug called ODM-201, which participants must be able to swallow whole. The eligibility criteria for the trial include having a confirmed diagnosis of adenocarcinoma of the prostate, ongoing androgen deprivation therapy, and adequate bone marrow, hepatic, and renal function. Participants cannot have previously undergone chemotherapy for prostate cancer, have known brain metastases, or have a history of other malignancies within the past 5 years, except for basal cell carcinoma of the skin. Additionally, participants cannot have a known gastrointestinal condition that could significantly affect the absorption of the study treatment.",
    "The sample is a phase 1 clinical trial for cancer patients. The trial is testing a drug called npi-2358. The eligibility criteria for the trial include having an ECOG performance status of 2 or less, having a confirmed solid tumor malignancy, not being a candidate for regimens known to provide clinical benefit, having resolved adverse events from prior chemotherapy, surgery, or radiotherapy to a certain grade, having adequate bone marrow reserve, hepatic and renal function, and signing informed consent. Exclusion criteria include recent administration of chemotherapy, biological, immunotherapy or investigational agent, significant cardiac history or findings, underlying conditions or medications associated with bleeding diathesis, disorders associated with significant vascular pathology, lung cancer with central chest tumors, prior treatment with vascular disruptive agents, seizure disorder requiring anticonvulsant therapy, brain metastases, severe chronic obstructive pulmonary disease (COPD) with hypoxemia, active uncontrolled bacterial, viral, or fungal infection, known infection with human immunodeficiency virus (HIV), active hepatitis A, B, or C, prior hypersensitivity reaction to any product containing Solutol and/or propylene glycol, pregnancy or breastfeeding, and concurrent, active second malignancy for which the patient is receiving therapy.",
    "The sample is a phase 1 clinical trial for patients with an unspecified childhood solid tumor. The trial includes patients who have had histologic verification of malignancy at original diagnosis or relapse, and have either measurable or evaluable disease. Patients must have fully recovered from the acute toxic effects of all prior anti-cancer chemotherapy. The trial includes a list of drugs such as temsirolimus, temozolomide, and irinotecan hydrochloride. The eligibility criteria include various medical conditions such as Karnofsky score, peripheral absolute neutrophil count, platelet count, creatinine clearance, bilirubin, serum glutamate pyruvate transaminase, serum albumin, prothrombin time, serum triglyceride level, serum cholesterol, and blood glucose. Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and if seizures are well controlled. The trial has exclusion criteria such as pregnant or breast-feeding women, patients receiving chronic systemic corticosteroids, patients who are currently receiving another investigational drug, and patients who have an uncontrolled infection.",
    "The sample is a clinical trial for patients with multiple myeloma in phase 1/phase 2. The trial includes patients who have been previously diagnosed with multiple myeloma and have received at least one but less than four lines of therapy. The patients must currently require further treatment due to relapse from CR or PD. The trial also includes patients who have been previously treated with bortezomib and had a duration of response of more than 6 months from the completion of therapy. Patients must be over 18 years old and willing and able to comply with the protocol requirements. Female patients of child-bearing potential and male patients with female partners of child-bearing potential must agree to use 2 simultaneous methods of contraception. Patients must have measurable disease and a Karnofsky performance status of at least 80%. Patients must have a life-expectancy of more than 3 months and meet certain laboratory values within 14 days before study drug administration. Patients with prior severe allergic reactions to bortezomib, romidepsin, boron, or mannitol, neuropathy of grade 3 or higher, or certain cardiac risk factors will be excluded from the study. Pregnant female patients will also be excluded.",
    "The sample is a phase 1 clinical trial for the treatment of migraine. The trial is looking at the effectiveness of a placebo drug. The eligibility criteria for participants include being diagnosed with migraine at or before the age of 50, having a history of migraine for at least 12 months, and having between 5 and 14 migraine days in each 28-day period in the 3 months prior to screening. Participants must also agree to use adequate contraception if they are of child-bearing potential. Exclusion criteria include having other pain syndromes, certain types of migraine, regular use of prophylactic headache medication, and ongoing co-morbidities that may interfere with participation in the trial. Participants must also not be pregnant, breastfeeding, or planning to become pregnant during the trial.",
    "The sample is a phase 1 clinical trial for the treatment of pain. The trial includes postmenopausal women or women who have undergone hysterectomy, and males between 18 and 70 years of age who experience pain intensity during pain attack that is greater than 5 on the GSRS questionnaire. The trial involves the use of the drugs ppc-5650 and placebo. The eligibility criteria include signed informed consent, patients able to co-operate and tolerate the experimental procedures, and patients on stable medication. The exclusion criteria include any history of, or current condition or medication that may affect gastrointestinal function and the interpretation of the clinical data, chronic extraintestinal pain dominating the clinical history, and any known biochemical or structural abnormality of the digestive tract.",
    "The sample is a phase 1 clinical trial for participants who have been diagnosed with either essential thrombocythemia or acute myeloid leukemia that is relapsed or refractory to at least one prior standard treatment. The trial is testing the drug LY573636-sodium. The eligibility criteria include being at least 18 years old, having adequate hepatic and renal function, and having discontinued all previous cancer therapies for a certain period of time. Participants with certain medical conditions or serious concomitant disorders are excluded from the trial. Females of childbearing potential must have a negative pregnancy test and agree to use medically approved contraceptive precautions during the trial and for 6 months following the last dose of study drug.",
    "The sample is a phase 1 clinical trial for patients with chronic renal insufficiency. The trial involves the use of dabigatran etexilate as a single medication for patients who are either taking aspirin or Vitamin K Antagonists. The inclusion criteria for the trial include patients who are 18 years or older, have stable impaired renal function, and provide informed consent. The exclusion criteria include patients with unstable renal function, those treated with two or more platelet aggregation inhibitors, those with prosthetic heart valves, and those with bleeding disorders or low platelet counts. Additionally, patients who have participated in another drug trial in the last 30 days before screening are also excluded.",
    "The sample is a phase 1 clinical trial for patients with small cell carcinoma or lung cancer. The trial involves the use of two drugs, topotecan and sorafenib. The eligibility criteria include having received one course of systemic chemotherapy, having radiographically documented disease recurrence or progression, and having an ECOG performance status of 0 to 2. Patients must also have adequate organ function and meet certain laboratory values. Women of childbearing potential and sexually active males must use an effective method of contraception during the study and for 3 months after the last dose of study drug. The exclusion criteria include pregnancy or breastfeeding, recent myocardial infarction or cerebrovascular accident, uncontrolled hypertension, and history of other active invasive malignancy within 12 months.",
    "The sample is a phase 1 clinical trial for Parkinson's disease. The trial includes a list of drugs, such as BIA 9-1067, levodopa/carbidopa, and placebo, and a list of inclusion and exclusion criteria for participants. Inclusion criteria include being between the ages of 18 and 45, having a BMI between 18 and 30, and being in good health. Exclusion criteria include having a history of drug abuse or alcoholism, having certain medical conditions, and being pregnant or breastfeeding. The trial aims to test the safety and efficacy of the drugs in treating Parkinson's disease.",
    "The sample is a record of a clinical trial in phase 1, focused on the disease of ischemic stroke. The trial includes a list of ICD-10 codes related to the disease. The trial involves the use of two drugs, aspirin and warfarin. The eligibility criteria for the trial include a clinical and imaging diagnosis of cervicocephalic arterial dissection within 3 months, while the exclusion criteria include any contraindication to aspirin or warfarin.",
    "The sample is a phase 1 clinical trial for patients with non-small cell lung cancer who have not received chemotherapy before and have stage IIIB or IV disease. The trial is testing the drugs mk0683 and vorinostat. The eligibility criteria include having normal organ and bone marrow function, and exclusion criteria include having received radiation treatment within the past 3 weeks, having peripheral neuropathy above grade 2, and having certain types of fluid buildup or uncontrolled illnesses. Pregnant or breastfeeding individuals are also excluded from the trial. The diseases being studied are neoplasms, and the associated ICD-10 codes are listed as C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2.",
    "The sample is a phase 1 clinical trial for patients with type 2 diabetes mellitus who are taking metformin only. The trial is testing the effectiveness of the drugs pf-04991532 and placebo. The eligibility criteria include having a BMI between 18.5 and 45.0 kg/m2, a total body weight of over 50 kg, and a fasting C-peptide level of over 0.8 ng/mL. Patients must also have an HbA1c level of at least 7% and at most 10%, and must not have evidence or history of certain medical conditions or complications. Exclusion criteria include a history of stroke, myocardial infarction, or congestive heart failure, as well as certain laboratory values and pregnancy or nursing.",
    "This sample is for a phase 1 clinical trial with the disease being 'healthy'. The icd-10 codes associated with the disease are 'Z76.3' and 'Z76.2'. The trial will test the drugs 'glpg0778' and 'placebo'. The eligibility criteria for the trial includes being a healthy male between the ages of 18-50 with a BMI between 18-30 kg/m\u00b2. Exclusion criteria includes having abnormal platelet function or coagulopathy, smoking, drug or alcohol abuse, and hypersensitivity to any of the test substances.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1 and is studying an unspecified adult solid tumor that is protocol specific. The icd-10 codes associated with the disease are listed. The drug being used in the trial is decitabine. The eligibility criteria for participants include having a biopsy-proven solid tumor that is metastatic or unresectable, having measurable disease by scans, and meeting various medical and psychological conditions. The sample also includes information about prior treatments and medical history that may exclude a patient from participating in the trial.",
    "The sample is a phase 1 trial for children between the ages of 3 and 8 who have been diagnosed with autism spectrum disorder and have a serum copper/zinc ratio greater than 2.0 or as determined in phase 1 of the study. The trial involves taking oral zinc and vitamin C supplements. The inclusion criteria include the age range and diagnosis, while the exclusion criteria include any known chromosomal or neurological disorders other than autism.",
    "The sample is a phase 1 clinical trial for the treatment of hepatitis C. The trial involves the use of the drugs mk-3281 and a placebo. The eligibility criteria for participants include being in good health, having no significant abnormalities on an ECG, and having a clinical diagnosis of chronic HCV infection. Exclusion criteria include a history of certain neurological, gastrointestinal, cardiovascular, hematological, immunological, renal, respiratory, or genitourinary abnormalities or diseases, as well as a history of neoplastic disease or HIV infection. Participants with female partners of childbearing potential must agree to use contraception during the study and for 90 days after the last dose of study drug.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on treating lymphoma, specifically B-cell lymphoma. The trial involves the use of two drugs, inotuzumab ozogamicin and rituximab, and has a list of eligibility criteria for patients to participate. These criteria include having CD20 and CD22-positive B-cell NHL that has progressed after one or two prior therapies, having an ECOG performance status of 0/1, and not having received previous radioimmunotherapy or certain other treatments within 28 days before the first dose of the test article. The sample also includes a list of exclusion criteria, such as being a candidate for potentially curative therapies or having received previous radioimmunotherapy.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on non-small cell lung cancer. The drug being tested is irinotecan. The eligibility criteria include being 18 years or older, having received prior chemotherapy for advanced non-small cell lung cancer, displaying high ISG15, having a life expectancy of at least 12 weeks, and having an ECOG/Zubrod performance status of 0-2. Adequate bone marrow, hepatic, and renal function are also required. Exclusion criteria include symptomatic brain metastases, pregnancy or nursing, concurrent chemotherapy or radiation therapy, severe medical problems, and previous hypersensitivity reaction to camptothecins.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on neoplasms, which are cancerous growths. The icd-10 codes associated with the diseases are listed as \"C05.2\", \"C10.0\", \"C16.0\", \"C16.4\", \"C17.0\", \"C17.1\", and \"C17.2\". The trial involves the use of two drugs, afatinib (in 20mg and 40mg doses) and vinorelbine (in 25 or 20mg/m2 doses) administered intravenously. The eligibility criteria for the trial include a confirmed diagnosis of advanced malignancy, a life expectancy of at least 12 weeks, an Eastern Cooperative Oncology Group Performance Status of 0 or 1, adequate organ function, and written informed consent. The exclusion criteria include recent chemotherapy, immunotherapy, surgery, or radiotherapy, prior treatment with afatinib or vinorelbine, and clinically significant active infectious disease.",
    "The sample is a phase 1 clinical trial for patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) who have no curative treatment options. The trial is testing the drug pralatrexate. The eligibility criteria include confirmed CTCL, progression or relapse of disease after at least one previous systemic therapy, and adequate blood, liver, and kidney function. Patients must also have an Eastern Cooperative Oncology Group (ECOG) Performance Status of \u2264 2 and a life expectancy of \u2265 3 months. Women of childbearing potential must use a medically acceptable contraceptive regimen, and men who are not surgically sterile must also use a medically acceptable contraceptive regimen. The exclusion criteria include active concurrent malignancy (except non-melanoma skin cancer or carcinoma in situ of the cervix), congestive heart failure Class III/IV, uncontrolled hypertension, and active uncontrolled infection. Patients must also not have received previous exposure to pralatrexate, unless they were on this study, achieved a complete or partial response, and were taken off study treatment because of investigator decision, and subsequently experienced disease recurrence or progressive disease.",
    "The sample is a record from a clinical trial table and contains information about a phase 1 trial for pancreatic cancer. The eligibility criteria for the trial include having a confirmed diagnosis of measurable or assessable malignancy, being at least 18 years old with a life expectancy of at least 3 months, having an Eastern Cooperative Oncology Group (ECOG) Performance Status of less than 2, and having no more than 3 prior chemotherapy regimens for advanced/metastatic disease. The sample also includes a list of drugs, which in this case are as703569/gemcitabine, and a list of icd-10 codes for the disease, which is C25.3.",
    "The sample is a phase 1 clinical trial for HIV-1 infection. The trial is testing the effectiveness of interleukin-2, gm-csf, and growth hormone as a therapeutic vaccine. The eligibility criteria include being over 18 years old, having a documented HIV-1 positive result, being stable on HAART, having a CD4 T cell count of >400 cells/ul, and having a nadir CD4 T cell count of >200 cells/ul. Exclusion criteria include prior therapeutic vaccination, acute illness within 2 weeks of the start of the study, and pre-existing autoimmune disease. The trial is not open to patients with diabetes mellitus type 2, cardiac abnormalities, active neoplasia, or evidence of any progression or recurrence of an underlying intra-cranial lesion.",
    "The sample is a record of a clinical trial with the phase labeled as \"early phase 1\". The trial is focused on two diseases, \"injuries\" and \"shock, traumatic\", which are identified by their corresponding ICD-10 codes. The trial involves two drugs, \"normal saline control\" and \"vasopressin\". The eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The criteria include factors such as age, blood pressure, evidence of acute traumatic injury, and exclusion of patients who have received more than 4 liters of fluid since the time of injury. The trial also excludes patients who are pregnant, have \"Do Not Resuscitate\" orders, or have an identifiable method of objection to participation.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying metastatic melanoma. The icd-10 codes associated with the disease are listed, as well as the drug being tested (raf265). The eligibility criteria for participants are also listed, including requirements for diagnosis, measurable disease, performance status, and restrictions on concurrent therapy or recent surgery. Exclusion criteria are also listed, including restrictions on certain medical conditions and previous therapy with certain molecularly targeted agents.",
    "The sample is a clinical trial for HIV infections in phase 1/phase 2. The trial is testing the effectiveness of two drugs, tenofovir df and tenofovir alafenamide. The eligibility criteria for participants include having HIV-1 RNA levels greater than or equal to 30,000 copies/mL, a CD4 count greater than or equal to 200 cells/mm3, and adequate hematologic function. Participants must also have a serum creatinine level less than 1.5 mg/dl, hepatic transaminases less than or equal to 2.5 times the upper limit of normal, and a total bilirubin less than or equal to 1.5 mg/dL. Additionally, participants must have a serum amylase less than or equal to 1.5 times the upper limit of normal, serum phosphate greater than or equal to 2.2 mg/dL, and not be pregnant. Exclusion criteria include prior treatment with antiretroviral therapy, immunization within 30 days of study entry, a new AIDS defining condition within 30 days of study entry, and receiving nephrotoxic agents, probenecid, chemotherapeutic agents, corticosteroids, or interleukin-2.",
    "The sample is a phase 1 clinical trial for patients with advanced-stage cancer and anxiety. The trial involves the use of psilocybin (drug) and takes place in Los Angeles, California. The trial has specific inclusion and exclusion criteria, including age range, medical history, and medication restrictions. Patients may take PRN benzodiazepines up to 3 days before the session, but must not consume alcohol the day before, the day of, and the day after a session. Female subjects of childbearing potential must have a negative pregnancy test and agree to use an effective form of birth control.",
    "The sample is a clinical trial for prostate cancer patients who have not responded to hormone therapy. The trial is a combination of phase 1 and phase 2. The trial involves the use of drugs such as abiraterone acetate and dexamethasone. The eligibility criteria for the trial include having histologically documented adenocarcinoma of the prostate, evidence of progressive prostate cancer, and an ECOG performance status score of 0 or 1. Exclusion criteria include having central nervous system disease or brain metastases, active autoimmune disease, and having had major surgery or significant traumatic injury within 4 weeks of the start of the study.",
    "The sample is a record of a clinical trial for pancreatic cancer treatment. The trial is in phase 1/phase 2 and involves the use of four drugs: gemcitabine, capecitabine, erlotinib, and bevacizumab. The eligibility criteria for patients include having histologically or cytologically confirmed adenocarcinoma of the pancreas, locally advanced or metastatic disease, and not being amenable to curative resection. Patients must also meet certain age, performance status, and life expectancy requirements, as well as have specific hematopoietic, hepatic, renal, and cardiovascular health. Additionally, patients must not be pregnant or breastfeeding, have any serious wounds or infections, or have a history of certain medical conditions or treatments. Prior to the trial, patients must not have received chemotherapy, radiotherapy, or other investigational drug treatment for metastatic disease, and must not be on full dose anti-coagulation or certain medications known to predispose to gastrointestinal ulceration.",
    "The sample is a clinical trial for small cell lung cancer patients who have progressed after only one prior platinum-containing chemotherapy regimen. The trial is in phase 1/phase 2 and the drugs being tested are at-101 and topotecan. The eligibility criteria include confirmed SCLC, measurable disease, ECOG performance status 0-1, adequate hematologic, liver and renal function, and ability to swallow oral medication. Exclusion criteria include more than one prior chemotherapy regimen, prior chemotherapy regimen containing irinotecan, active secondary malignancy, unstable or progressive brain metastases, and uncontrolled concurrent illness. The trial also requires patients to have recovered from all treatment-related toxicities.",
    "The sample is a phase 1 clinical trial for patients with advanced solid tumors. The trial is testing the drug tki258. The eligibility criteria include having a life expectancy of at least 3 months, an ECOG performance status of 0 or 1, and agreeing to remain hospitalized. Patients must also meet specific hematological/blood chemistry laboratory values and agree to employ an effective method of birth control if of reproductive potential. Exclusion criteria include having received any investigational compound within 28 days prior to the first dose of study drug, having CNS and/or leptomeningeal disease metastases, and having impaired cardiac function or clinically significant cardiac disease. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 1 clinical trial for chronic obstructive pulmonary disease (COPD) using the drug MN-221 in three different dose groups. The trial is open to both male and female participants between the ages of 40 and 65 who have been diagnosed with COPD and have been treated for at least 3 months. Participants must also have a FEV1 (forced expiratory volume in one second) of at least 30% but less than 80% and a FEV1/FVC (forced vital capacity) ratio of less than 0.7 at screening. In addition, participants must have a negative urine pregnancy test (unless post-menopausal or surgically sterile), negative urine drug screen for cocaine, PCP, and methamphetamine, and a normal ECG with no evidence of ischemic heart disease or dysrhythmias. Participants must also meet several other inclusion and exclusion criteria, including not having taken certain medications within a certain time frame and not having certain medical conditions. Legally effective written informed consent must be obtained prior to starting any study procedures.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on non-small-cell lung cancer. The drugs being tested are vorinostat and erlotinib, and the eligibility criteria include having failed at least one prior treatment for NSCLC, being at least 4 weeks from any chemotherapy or surgeries, and having normal lab results. The sample also includes exclusion criteria, such as prior treatment with vorinostat or erlotinib, active infections, and pregnancy.",
    "The sample is a record from a clinical trial table. It pertains to a phase 1 trial for the treatment of relapsed or refractory solid tumors or non-Hodgkin's lymphoma using a drug called cep-18770. The eligibility criteria for the trial are listed, including the patient's diagnosis, expected survival, performance score, and previous treatments. The exclusion criteria are also listed, including certain medical conditions and medications that would make the patient unsuitable for the trial. The diseases and icd-10 codes associated with the trial are also provided.",
    "The sample is a phase 1 clinical trial for acute coronary syndrome. The trial includes healthy male subjects between the ages of 20 and 50 years with a BMI between 18.0 and 27.0 kg/m2 and a total body weight between 55 kg and 90 kg. The trial involves the use of three drugs: lc23-1306, placebo, and ticagrelor. The eligibility criteria include informed consent, acceptable medical history and physical examination findings, and laboratory results within the reference ranges.",
    "The sample is a phase 1 clinical trial for the treatment of cystic fibrosis. The trial involves the use of tiotropium bromide at low, medium, and high doses, as well as a placebo. The eligibility criteria include having a documented diagnosis of CF, being able to perform acceptable spirometric maneuvers, having an FEV1 greater than 25% of predicted values, and being clinically stable. Patients must also be able to inhale medication in a reproducible manner and must be willing to continue any chronic medication they are currently taking. Exclusion criteria include having a significant history of allergy or hypersensitivity, being pregnant or lactating, having documented persistent colonization with B. cepacia, and having a clinically significant disease or medical condition other than CF that would compromise the safety of the patient or the quality of the data.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, ICD-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1 and is studying choroidal neovascularization. The ICD-10 codes associated with this disease are listed, as well as the drugs being tested (ranibizumab). The eligibility criteria for participants are also listed, including age requirements, visual acuity, and exclusion criteria such as allergies to certain substances or previous participation in clinical trials involving anti-angiogenic drugs.",
    "The sample is a clinical trial with a phase 1 designation, focusing on the treatment of inflammation, rheumatoid arthritis, and healthy subjects. The trial involves the use of drugs such as nnc0114-0000-0005 and a placebo. The eligibility criteria for the trial include various factors such as age, health status, and medical history. For example, male subjects must use two acceptable methods of contraception, and females must be post-menopausal or surgically sterile. The trial also has exclusion criteria, such as a history of regular alcohol consumption exceeding a certain amount and a positive pregnancy test for females.",
    "The sample is a phase 1 clinical trial for the treatment of metastatic melanoma using the drug vemurafenib. The trial is open to Chinese male or female participants who are at least 18 years old and have histologically confirmed metastatic melanoma that is surgically unresectable Stage IIIC or Stage IV. Participants must have a positive BRAF V600 mutation result and measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. They must also have completed previous chemotherapy, immunotherapy, or radiation therapy at least 2 weeks prior to study drug administration, and all associated toxicity must be resolved. Participants must have adequate hematologic, renal, and liver function as defined by the protocol, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Exclusion criteria include active central nervous system (CNS) lesions, history of or known spinal cord compression or carcinomatous meningitis, and previous treatment with a BRAF inhibitor or MEK inhibitor.",
    "The sample is a clinical trial for patients with stage IV non-small cell lung cancer that has spread and cannot be surgically removed. The trial is in phase 1/phase 2 and involves the use of a drug called paclitaxel albumin-stabilized nanoparticle formulation. The trial is looking to determine the safety and effectiveness of the drug in treating this type of cancer. The eligibility criteria for the trial include having measurable disease documented radiographically, no evidence of active brain metastases or leptomeningeal involvement, and meeting certain hematopoietic, hepatic, renal, and other health requirements. Patients must also not have any concurrent active malignancy, pre-existing peripheral neuropathy grade 1 or greater, or other concurrent clinically significant illness. Prior chemotherapy for metastatic disease is not allowed, and patients must not be concurrently enrolled in another clinical trial involving investigational drugs or procedures.",
    "The sample is a phase 1 clinical trial for asthma. The trial includes men and women between the ages of 18 and 60 who are non-smokers and have a stable asthma condition. The trial involves the use of two drugs, gw805858 and placebo. The eligibility criteria include a BMI within the range of 19.0-30.0 kg/m2, a body weight of at least 50 kg for men and 45 kg for women, and a signed informed consent. Exclusion criteria include a history of allergy to the inhaler ingredients, recent use of prescription or non-prescription drugs, and ongoing respiratory tract infections or worsening of asthma.",
    "The sample is a clinical trial with a phase 1 designation. The trial is focused on treating patients with advanced solid tumors, recurrent glioblastoma multiforme, or recurrent or metastatic melanoma. The trial involves the use of two drugs, mk-4827 and temozolomide. The eligibility criteria include having failed standard therapy or not having a standard therapy available, having a performance status of 0 or 1, and having adequate organ function. Participants must also agree to use contraception during the trial. Exclusion criteria include having received chemotherapy, radiotherapy, or biological therapy within four weeks prior to the trial, having symptomatic or progressive central nervous system metastases, and having prior exposure to PARP inhibitors.",
    "The sample is a clinical trial for non-small cell lung cancer patients in phase 1/phase 2. The trial is testing the effectiveness of the drugs docetaxel and pemetrexed. The eligibility criteria include having inoperable stage IIIB-IV NSCLC, being previously untreated with docetaxel and pemetrexed, and having measurable disease according to RECIST criteria. Patients must also have a WHO performance status of 0-2, a life expectancy of at least 12 weeks, and meet certain laboratory values. Exclusion criteria include having other co-existing malignancies, severe uncontrolled concomitant disease, unresolved chronic toxicity from previous anticancer therapy, unstable central nervous system metastases, malnutrition, performance status of 4, psychiatric illness or social situation that would preclude study compliance, and being pregnant or lactating.",
    "The sample is a phase 1 clinical trial for patients with malignant glioma, specifically anaplastic astrocytoma, anaplastic oligodendroglioma, glioblastoma multiforme, or recurrent brain tumor. The trial is testing the effectiveness of the drug sorafenib tosylate. Patients must have measurable progressive or recurrent malignant glioma by MRI or CT imaging and have recovered from toxicity of prior therapy. They must also meet certain eligibility criteria, including having a Karnofsky performance status of at least 60%, certain blood counts and liver function tests within normal limits, and a Mini Mental State Exam score of at least 15. Patients with serious concurrent infection or medical illness, those who are pregnant or breastfeeding, and those who have received more than two prior treatments are excluded from the trial.",
    "The sample is a phase 1 clinical trial for the treatment of type 2 diabetes mellitus. The trial involves testing the drugs asp1941 and placebo on healthy subjects and those with T2DM. The eligibility criteria for inclusion in the trial vary depending on whether the subject is healthy or has T2DM. For healthy subjects, they must have a fasted plasma glucose (FPG) of less than 5.6 mmol/l at screening, a BMI between 18.5 and 28.0 kg/m2, and normal serum creatinine levels. For T2DM subjects, they must have been diagnosed with T2DM for at least 6 months, have a BMI between 20.0 and 35.0 kg/m2, and meet certain HbA1c and FPG levels. Exclusion criteria include abnormal liver function tests, a history of cardiac arrhythmias or structural heart disease, and uncontrolled hypertension.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, ICD-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1 and is focused on knee osteoarthritis. The ICD-10 codes associated with the disease are listed, as well as the drugs being tested (sar113945 and placebo). The eligibility criteria for participants are also listed, including inclusion criteria such as a diagnosis of primary knee osteoarthritis and exclusion criteria such as being younger than 40 years old or having a secondary form of osteoarthritis.",
    "The sample is a phase 1 clinical trial for various types of leukemia, myelodysplastic syndrome, and myelofibrosis. The trial is testing the drug th-302 as a potential treatment option for patients who have relapsed or are refractory to standard chemotherapy, or are unsuitable or unwilling to undergo standard chemotherapy. The eligibility criteria include being at least 18 years old, having certain types of leukemia or myelodysplastic syndrome, having adequate organ function, and agreeing to use effective contraception. Exclusion criteria include having certain medical conditions or allergies, being pregnant or breastfeeding, and being unwilling or unable to comply with the study protocol.",
    "The sample is a phase 1 clinical trial for patients with unresectable hepatocellular carcinoma (HCC) using the drugs lenalidomide and sorafenib. The eligibility criteria include a clinical or pathological diagnosis of HCC, discontinuation of previous cancer therapy at least 28 days prior to treatment, Child-Pugh Liver Function Class A/B9, Eastern Cooperative Oncology Group (ECOG) performance status of </= 2 at study entry, and laboratory test results within protocol-specific ranges. Patients must also be registered into the mandatory RevAssist\u00ae program and be willing and able to comply with its requirements. Females of childbearing potential must have two negative pregnancy tests before starting lenalidomide and must agree to use two methods of birth control and submit to pregnancy tests throughout the study. Exclusion criteria include serious medical conditions, pregnancy or breastfeeding, recent surgical resection or chemotherapy, and known hypersensitivity to thalidomide.",
    "The sample is a clinical trial for patients with acute myeloid leukemia. The trial is in phase 1/phase 2 and the patients must meet certain eligibility criteria to participate. These criteria include having primary refractory AML, relapsed AML, and not having received a high-dose cytarabine containing regimen within 3 months prior to registration. The trial involves the use of cytarabine and lovastatin as drugs. The sample also includes exclusion criteria, such as having other serious illnesses or a currently active second malignancy.",
    "The sample is a phase 1 trial for HIV-1 infection and HIV infection, as well as healthy volunteers. The trial involves the use of the drugs dcvax-001, poly-iclc, and placebo. The eligibility criteria include being a healthy adult between the ages of 18 and 60, willing to comply with the protocol and available for follow-up for 15 months, and assessed as being at \"low risk\" for HIV infection. Exclusion criteria include confirmed HIV-1 or HIV-2 infection, any clinically significant abnormality on history or examination, and any laboratory value outside of reference range. The trial also excludes those who have had excessive daily alcohol use or frequent binge drinking, or any other use of illicit drugs within the 12 months prior to enrollment. Additionally, the trial excludes those who are pregnant, planning a pregnancy during the trial period, or lactating.",
    "The sample is a clinical trial for patients with relapsed or refractory multiple myeloma. The trial is in phase 1 and the treatment involves a combination of arsenic trioxide, ascorbic acid, and bortezomib. The eligibility criteria include having measurable disease, adequate organ function, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. The exclusion criteria include not receiving any other investigational agents, having a history of allergic reactions to similar compounds, and having certain cardiac conditions. The sample also includes a list of disease names, icd-10 codes, and eligibility criteria for the trial.",
    "The sample is a record from a clinical trial table and includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1 and is focused on prostate cancer. The ICD-10 codes associated with the disease are listed, as well as the drugs being used in the trial. The eligibility criteria for participants are also listed, including requirements for confirmed adenocarcinoma of the prostate, no prior radiation or chemotherapy, acceptable lab values, and willingness to use contraception. The exclusion criteria are also listed, including a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with Polysorbate 80.",
    "The sample is a phase 1 clinical trial for the drug GSK1265744 in individuals with HIV infection. The eligibility criteria include being healthy, between 18 and 55 years old, and having a CD4 cell count of at least 200 cells/mm3 and plasma HIV-1 RNA of at least 5,000 copies/mL. Exclusion criteria include having a positive pre-study Hepatitis B surface antigen, positive hepatitis C (HCV) antibody or detectable HCV ribonucleic acid (RNA), or positive HIV-1 antibody result (except for those entering the study as an HIV-1 infected subject). Other exclusion criteria include regular alcohol consumption, use of illicit drugs, participation in another research trial within 30 days, and history of allergy or intolerance to the study drug or its components. The sample also includes specific exclusion criteria for screening ECG and 24-hour screening Holter.",
    "The sample is a clinical trial with a phase 1/phase 2 designation, focused on small cell lung cancer and small cell lung carcinoma. The trial includes a list of icd-10 codes for the diseases being studied, as well as a list of drugs being used in the trial. The eligibility criteria for the trial include being at least 18 years old, having a documented diagnosis of small cell lung cancer or other non-hematological malignancy, having received prior chemotherapy treatment, and meeting certain medical criteria related to bone marrow, renal, and hepatic function. The trial also includes exclusion criteria, such as a history of bleeding or active immune thrombocytopenic purpura, and a requirement for archived diagnostic tissue for assessment of Bcl-2 family protein expression.",
    "The sample is a clinical trial for major depressive disorder, with a phase 1/phase 2 designation. The trial involves the drugs alks 5461 and placebo. The eligibility criteria include being between 18 and 65 years old, meeting DSM-IV-TR criteria for MDD, and having an inadequate/partial response to a stable dose of an SSRI or SNRI. Exclusion criteria include having certain Axis I or II diagnoses, experiencing psychotic symptoms, using certain medications or supplements, having received electroconvulsive therapy during the current MDD episode, and having a history of intolerance or hypersensitivity to buprenorphine or opioid antagonists/quinine. The trial also includes specific scoring criteria for depressive symptom severity and suicide risk.",
    "The sample is a phase 1 clinical trial for breast cancer patients with confirmed HER2 adenocarcinoma. The trial includes two groups of patients who have had disease progression on at least one standard hormonal or chemotherapy regimen for advanced breast cancer or who have refused standard therapies. The trial aims to evaluate the safety and efficacy of two drugs, cnf2024 and cnf2024 + trastuzumab. The eligibility criteria for both groups include age over 18, evaluable disease, ECOG score of 2 or less, and required laboratory values. The exclusion criteria for both groups include prior antitumor therapies within 1 month, active infection requiring IV antibiotic treatment, and history of prior malignancies within the past 5 years. The trial also has specific exclusion criteria for each group, such as prior treatment with Hsp90 inhibitors for Group A and history of CNS metastasis for Group B.",
    "The sample is a phase 1 clinical trial for the treatment of chronic hepatitis C. The trial includes both healthy volunteers and subjects with chronic hepatitis C genotype 1 infection. The trial involves the use of two drugs, als-002158 and placebo. The eligibility criteria include being in good health, having a creatinine clearance of greater than 50 mL/min, and meeting certain age and BMI requirements. Additional inclusion criteria are specified for subjects with chronic hepatitis C genotype 1 infection, including having a positive HCV antibody and a positive HCV RNA at screening, and absence of hepatocellular carcinoma. Exclusion criteria include having certain medical illnesses or psychiatric disorders, abnormal screening laboratory results, and participation in other investigational drug trials.",
    "The sample is a clinical trial for patients with various hematologic diseases, including myelodysplastic and myeloproliferative disorders, acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, multiple myeloma, plasma cell dyscrasia, lymphoproliferative disorders, and other non-malignant hematologic diseases. The trial is in phase 1/phase 2 and involves the use of drugs such as campath, busulfan, fludarabine, and fk-506. The eligibility criteria include a diagnosis of one of the specified diseases, a performance status of 0-2 on the Zubrod scale, and various other medical conditions such as a certain ejection fraction, AST/ALT and bilirubin levels, and lung function. Patients must also have a healthy donor available for donation and be able to understand and sign consent. Exclusion criteria include pregnancy, HIV positivity, uncontrolled infections, and various other medical conditions.",
    "The sample is a phase 1 clinical trial for patients with advanced solid tumors. The trial is testing the effectiveness of a combination of drugs called osi-930 and erlotinib. The eligibility criteria for the trial include having a documented malignancy that is now advanced and/or metastatic and refractory to established forms of therapy or for which no effective therapy exists, being at least 18 years old, having an ECOG PS score of 0-2, and meeting certain laboratory values. Patients must also have recovered from any treatment-related toxicities and use effective contraceptive measures throughout the study. The exclusion criteria include having significant cardiac disease, active or uncontrolled infections, and history of unacceptable toxicity with previous EGFR inhibitor therapy.",
    "The sample is a clinical trial for the treatment of colorectal cancer and other solid tumors. The trial is divided into three phases, and the table contains information about the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The eligibility criteria include patient characteristics such as performance status, blood counts, and organ function, as well as prior treatments and concurrent medications. The criteria also specify the types of diseases and tumors that are eligible for the trial, as well as the stage and extent of the disease. The sample provides detailed information about the criteria for each phase of the trial, including the types of tumors and diseases that are eligible, the required performance status and blood counts, and the prior treatments that are allowed or not allowed.",
    "The sample is a phase 1 clinical trial for cancer and lymphoma patients who have metastatic or unresectable tumors and have exhausted standard treatments. The trial is testing the effectiveness of a drug called XL147 (sar245408). The eligibility criteria include having a confirmed diagnosis of cancer or lymphoma, being at least 18 years old, having an ECOG performance status \u22642, and having adequate organ and marrow function. The trial also requires tumor tissue amenable to serial biopsy for some subjects. Exclusion criteria include having previously been treated with a selective PI3K inhibitor, having a primary brain tumor, and having an uncontrolled intercurrent illness.",
    "The sample is a phase 1 clinical trial for patients with advanced, non-resectable and/or metastatic solid tumors who have failed conventional treatment and for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment. The trial involves the drugs bi 6727 and bibf 1120. The eligibility criteria include confirmed diagnosis of advanced, non-resectable and/or metastatic solid tumors, age greater than or equal to 18 years, European Cooperative Oncology Group performance status less than or equal to 2, written informed consent, and recovery from Common Terminology Criteria for Adverse Events grade 2-4 therapy-related toxicities from previous systemic anti-cancer therapies or radiotherapy (except alopecia). The exclusion criteria include serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the trial, known hypersensitivity to the trial drugs or their excipients, treatment with any other investigational drug or participation in any other interventional trial within 28 days before first administration of trial drug (BIBF 1120) or concomitantly with this trial, systemic anti-cancer therapy or radiotherapy within 28 days before start of therapy or concomitantly with this trial, active infectious disease infection or HIV I/II, other malignancy currently requiring another anti-cancer therapy, clinical evidence of symptomatic progressive brain or leptomeningeal disease during the past 6 months, known inherited predisposition to bleeding or thrombosis, radiographic evidence of cavitary or necrotic tumors, history of clinically significant hemoptysis within the past 3 months, centrally located tumors with radiographic evidence (Computed Tomography or Magnetic Resonance Imaging) of local invasion of major blood vessels, absolute neutrophil count (ANC) less than 1.5 x 1000000000/L, platelets count (PLT) less than 100 x 1000000000/L, total bilirubin greater than upper limit of normal (ULN), alaninaminotransferase (ALT) and/or aspartateaminotransferase (AST) greater than or equal to 1.5 x ULN (in case of liver metastases: ALT and AST greater than or equal to 2.5 x ULN), serum creatinine greater than 1.5 mg/dl, major injuries and/or surgery or bone fracture within 28 days before first administration of trial drug (BIBF 1120), or planned surgical procedures during the trial period, known history of clinically relevant QT prolongation (e.g. long QT syndrome), history of severe hemorrhagic or thromboembolic event in the past 6 months (excluding central venous catheter thrombosis and peripheral deep vein thrombosis), therapeutic anticoagulation (except low dose heparin and/or heparin flush as needed for maintenance of an indwelling intravenous device) or antiplatelet therapy (except for chronic low-dose therapy with acetylsalicylic acid less than or equal to 325mg per day), active alcohol or drug abuse, women and men who are sexually active and unwilling to use a medically acceptable method of contraception during the trial, pregnancy or breast-feeding, patients unable to comply with the protocol, and uncontrolled hypertension.",
    "The sample is a clinical trial for cystic fibrosis patients in phase 1/phase 2. The trial is testing the effectiveness of two drugs, oligog cf-5/20 and saline. The eligibility criteria for participants include being 18 years or older, having a confirmed diagnosis of cystic fibrosis, and having a positive microbiological finding of Pseudomonas aeruginosa in expectorated sputum or cough swab documented within 24 months prior to screening. Participants must also have an FEV1 between 35%-80% of the predicted normal value and no clinical or laboratory findings suggestive of significant pulmonary illness, other than CF, which in the opinion of the investigator would preclude participation in the study. The trial has exclusion criteria such as changes in underlying therapy, pulmonary exacerbation within 28 days of screening, and current malignant disease.",
    "The sample is a phase 1 trial for a drug called varespladib methyl. The trial is focused on patients with renal impairment, which is classified as mild, moderate, or severe using the MDRD and Cockcroft-Gault formulae. The trial is open to both males and non-pregnant, non-lactating females who are 18 years or older and have a BMI of 18-40 kg/m2. The eligibility criteria include no chronic medications that might compromise the hematologic, cardiovascular, pulmonary renal, gastrointestinal, hepatic, or central nervous system. The exclusion criteria include evidence of significant respiratory, gastrointestinal, or hepatic disease, positive screen for hepatitis B surface antigen or HIV, and positive test in drugs of abuse screens or alcohol on admission to the clinic.",
    "The sample is a phase 1 clinical trial with healthy male volunteers between the ages of 20 to 45 years old. The trial involves investigating the effects of the drug yh4808 at various doses, as well as a placebo and esomeprazole 40mg. The eligibility criteria include being within a certain weight range, having no significant medical history or disorders, and signing a written consent form. Exclusion criteria include having a history of drug abuse, recent use of prescription or over-the-counter drugs, and certain medical conditions. The trial also involves using a pH meter catheter and conducting various tests to ensure the safety of the participants.",
    "The sample is a phase 1 clinical trial for patients with various types of central nervous system (CNS) malignancies, including brain stem gliomas, optic pathway gliomas, and pineal tumors. Patients must have measurable or evaluable disease and no known curative therapy or therapy proven to prolong survival with an acceptable quality of life. They must also have a Karnofsky performance status (PS) of 50-100% (for patients > 16 years of age) or Lansky PS of 50-100% (for patients \u2264 16 years of age). Other eligibility criteria include specific laboratory values, no uncontrolled infection, and no concurrent enzyme-inducing anticonvulsants. The trial involves the use of the drugs vorinostat and temozolomide, and patients must meet various prior treatment requirements.",
    "The sample is a phase 1 clinical trial for HIV infections. The trial includes patients between the ages of 18 and 65 with a plasma HIV-1 RNA level of at least 5000 copies/mL and a CD4+ cell count of at least 100 cells/mm\u00b3. Patients must also meet certain laboratory parameters, including a lymphocyte count of at least 1000 cells/mm\u00b3, hemoglobin of at least 9.0 g/dl, and platelet count of at least 75000 cells/mm3. Patients must be willing to use a reliable method of double-barrier contraception and must sign a written consent form. Exclusion criteria include pregnancy or breastfeeding, use of certain medications, and certain medical conditions such as hepatic or renal insufficiency.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on the treatment of prostatic neoplasms, and the icd-10 codes associated with the disease are listed. The trial involves the use of radium-223 dichloride (xofigo, bay88-8223) as a treatment, and the eligibility criteria for participants are listed. Inclusion criteria include being male, having confirmed adenocarcinoma of the prostate, presenting with at least 2 bone metastases, and having progressive castration resistant metastatic disease. Exclusion criteria include having received an investigational drug in the 4 weeks before or after study drug administration, having received chemo-, immuno-, or radiotherapy within the last 4 weeks prior to entry in the study, and having received prior hemibody external radiotherapy.",
    "The sample is a clinical trial for patients with acute myeloid leukemia or acute promyelocytic leukemia. The trial is in phase 1/phase 2 and involves the drugs clofarabine and cytarabine. The eligibility criteria include having an ECOG performance status of 0-2, understanding the potential risks and benefits of the study, and providing valid informed consent. Patients must also have a negative pregnancy test (if female), use effective contraception, and meet certain laboratory criteria. Exclusion criteria include having a significant concurrent disease or illness, being pregnant or lactating, and having a history of serious organ dysfunction. The trial does not allow concomitant cytotoxic therapy or investigational therapy, except for intrathecal therapy for leukemic meningitis.",
    "The sample is a clinical trial for the treatment of chronic hepatitis C. The trial is in phase 1/phase 2 and the diseases being studied are limited to chronic hepatitis C. The icd-10 codes associated with the disease are listed. The drugs being tested are bilb 1941 zw and a placebo. The eligibility criteria for the trial are listed, including age, HCV infection, genotype, liver biopsy results, and RNA load. The exclusion criteria are also listed, including other causes of liver disease, decompensated liver disease, HIV or HBs antigen positivity, alcohol or drug abuse, concurrent medical illness or disease, and laboratory abnormalities. Patients must also be willing to abstain from alcohol during the trial period.",
    "The sample is a phase 1 clinical trial for Alzheimer's disease. The trial includes healthy males and females aged 30 to 55 years for cohorts 1 through 5, and aged 65 to 85 years for cohort 6. The trial requires a body mass index (BMI) of 18 to 32kg/m^2 at screening. Cohort 6 has additional inclusion criteria for healthy elderly subjects. Females of child-bearing potential are excluded from the trial, as well as those with personal or family history of neurological abnormalities, any clinical abnormality of the electrocardiogram (ECG) at screening and check-in, a family history of cardiac abnormalities, and thyroid abnormalities. The trial involves the use of the drug e2609 and a placebo.",
    "The sample is a record from a clinical trial table. It includes information about the phase of the trial, which is phase 1, and a list of diseases being studied, which are central nervous system lymphoma and intraocular lymphoma. The icd-10 codes associated with these diseases are also provided. The drugs being tested are intraventricular rituximab plus mtx. The eligibility criteria for the trial are also listed, including requirements for CD20+ tumors, an Ommaya reservoir, and sufficient hematologic function. There are also exclusion criteria, such as a history of whole brain or craniospinal irradiation or intrathecal chemotherapy less than 4 days before initiation of intra-CSF administration of rituximab, anticipated survival of less than one month, and HIV infection.",
    "The sample is a record from a clinical trial database. It includes information about the phase of the trial, which is a combination of phase 1 and phase 2. The diseases being studied are small cell lung cancer and carcinoma, small cell, both of which are represented by ICD-10 codes. The drugs being tested are pemetrexed and cisplatin. The eligibility criteria for the trial are listed under inclusion and exclusion criteria, which include factors such as measurable disease, performance status, age, prior treatment history, and organ function.",
    "The sample is a phase 1 trial with only healthy participants. The trial is testing two drugs, trv130a and dextrose in water. The eligibility criteria for the trial includes being a healthy adult male between the ages of 19 and 50, having a body weight of at least 50 kg, and being able to provide written informed consent. The exclusion criteria includes having any clinically significant diseases or conditions that may put the participant at risk or interfere with the study's safety, tolerability, or pharmacodynamic evaluations. Additionally, participants with positive laboratory tests for HIV, Hepatitis B virus surface antigen, or Hepatitis C virus antibody, as well as those with positive drug or alcohol tests or positive urine tests for cotinine, are excluded. Participants who have had major surgery within 4 weeks of screening are also excluded.",
    "The sample is a phase 1 clinical trial for patients with unresectable hepatocellular carcinoma, liver mets with no evidence of extrahepatic disease, or cholangiocarcinoma. The trial is testing the drug capecitabine (xeloda). The eligibility criteria include being over 18 years old, having a Karnofsky performance status of >60, having at least one measurable lesion according to the RECIST criteria, and meeting specific laboratory values. Exclusion criteria include being pregnant or lactating, having a life expectancy of less than 3 months, having serious uncontrolled concurrent infections, and having a history of uncontrolled seizures or psychiatric disability. The sample also includes a list of diseases, icd-10 codes, and eligibility criteria.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on treating advanced solid tumor cancers, medulloblastoma, and basal cell carcinoma. The icd-10 codes associated with these diseases are also listed. The drug being tested is called lde225. The eligibility criteria for the trial are listed, including inclusion criteria such as a confirmed diagnosis of the specified cancers and meeting certain blood work criteria, and exclusion criteria such as a history of brain tumors or brain metastases, positive HIV or hepatitis B or C, impaired intestinal or heart function, and pregnancy or breastfeeding. The sample also notes that there may be other protocol-defined inclusion/exclusion criteria that apply.",
    "The sample is a clinical trial for patients with non-small-cell lung carcinoma in phase 1/phase 2. The trial involves the use of cisplatinum and docetaxel drugs. The eligibility criteria include patients with a confirmed diagnosis of NSCLC, aged between 18 and 75 years, with a life expectancy of at least 12 weeks, and an ECOG performance status of 0, 1, or 2. Patients must also meet certain laboratory and lung function test requirements. Exclusion criteria include patients with small cell lung cancer, stage IIIB NSCLC, pregnant or lactating women, and those with prior systemic chemotherapy, immunotherapy, or biological therapy. Patients with certain medical conditions or illnesses are also excluded.",
    "The sample is a phase 1 clinical trial for patients with relapsed multiple myeloma. The trial involves the use of the drugs carfilzomib, lenalidomide, and dexamethasone. The eligibility criteria include having symptomatic multiple myeloma, having relapsed or progressive disease after one to three prior treatments, and having measurable disease. Other criteria include being at least 18 years old, having a life expectancy of more than three months, and having adequate hepatic and laboratory function. Exclusion criteria include having non-secretory or hyposecretory multiple myeloma, having received corticosteroid therapy within three weeks prior to the trial, and having a history of allergy to boron or mannitol.",
    "The sample is a phase 1 clinical trial for hypertension. The trial includes participants with a diagnosis of essential hypertension and a body mass index (BMI) of 35 kg/m^2 or less, who are in general good health and have no history of clinically significant cardiac disease or arrhythmias. Participants must be treatment-na\u00efve or taking up to 2 antihypertensive therapeutic agents and must not be smokers or have used nicotine-containing products for at least 6 months. The trial has a list of exclusion criteria, including a history of stroke, chronic seizures, or major neurological disorder, and a history of clinically significant abnormalities or diseases in various body systems. Participants must also refrain from using certain prescription and non-prescription drugs and must not consume excessive amounts of alcohol or caffeine. The trial also excludes participants who have had major surgery or participated in another investigational study within 4 weeks prior to the screening.",
    "The sample is a phase 1 clinical trial for various types of leukemia and other blood disorders. The trial is testing the effectiveness of two drugs, belinostat and azacitidine, on patients who have relapsed or refractory disease, or for whom no standard therapy exists. The trial also includes patients with myelodysplastic syndromes and chronic myeloproliferative disorders. Patients must meet certain eligibility criteria, including having a confirmed diagnosis of one of the eligible diseases, having a certain performance status, and not having any concurrent uncontrolled illnesses. The trial requires patients to have recovered from prior therapy and to not be receiving any other concurrent anticancer therapy.",
    "The sample is a phase 1 clinical trial for chronic obstructive pulmonary disease (COPD) using the drugs mn-221 and placebo. The trial is for males and females between the ages of 40-75 who have been diagnosed with COPD and have been treated for at least 3 months prior to the pre-screening visit. The trial requires a FEV1 (forced expiratory volume in one second) of at least 30% and less than 80% predicted and a FEV1/FVC (forced vital capacity) ratio of less than 0.7. The trial also requires negative urine pregnancy tests for females unless they are post-menopausal or surgically sterile, negative urine drug screens for cocaine, phencyclidine (PCP), and methamphetamine, and a negative alcohol breath test. The trial also requires an ECG without serious abnormality and with QTcB and QTcF less than 460 milliseconds (msec). The trial requires the ability to wash-out of concomitant LABA (long-acting beta agonist) and Theophylline for 7-8 days. The trial has various exclusion criteria, including recent antibiotic therapy for respiratory infection, presence of active respiratory disease, significant clinical laboratory abnormality, significant renal, hepatic, endocrine, neurologic or other systemic disease, uncontrolled hypertension, uncontrolled angina, uncontrolled diabetes, uncontrolled congestive heart failure (CHF), uncontrolled serious arrhythmia, myocardial infarction within 6 months of treatment start, pregnancy or lactation, participation in another clinical study with an investigational drug within 30 days of pre-screening, home oxygen requirements, known allergy to excipients of the MN-221 drug product, known allergy to other beta agonists, and currently on medication/s that are recognized to have risk of Torsades de Pointes.",
    "The sample is a phase 1 clinical trial for a drug called gsk1322322, which is being tested for its effectiveness in treating bacterial infections. The trial involves male and female participants between the ages of 18 and 65 who are healthy and meet certain eligibility criteria, such as having normal liver function and a BMI within a certain range. The trial also has exclusion criteria, such as a history of liver disease or drug/alcohol abuse. Participants will be randomly assigned to receive either the drug or a placebo, and their health will be monitored throughout the trial. The trial will also involve Japanese participants who consume a typical Japanese diet. The eligibility criteria include various medical tests and evaluations, and participants must give written informed consent to participate.",
    "The sample is a clinical trial for patients with multiple myeloma that is progressing or has relapsed after at least two different anti-myeloma treatments. The trial is divided into two phases, phase 1 and phase 2. The patients must be at least 18 years old and able to adhere to the study visit schedule and other protocol requirements. They must have sufficient bone marrow function and a performance status score of 0, 1, or 2. The trial requires patients to discontinue all anti-myeloma drug or non-drug therapy prior to the first dose of study drug. The trial also requires patients to have normal cardiac function and prior thromboembolic event with adequate anticoagulation. The trial has a list of inclusion and exclusion criteria that patients must meet to participate.",
    "The sample is a clinical trial for patients with hepatocellular carcinoma, a type of liver cancer. The trial is in phase 1/phase 2 and includes patients with a history of cirrhosis or chronic hepatitis B or C infection. The trial is testing the drug denspm. Patients must meet certain eligibility criteria, including having measurable disease and meeting certain laboratory values. Patients who have received certain types of therapy within a certain timeframe or who have certain medical conditions are excluded from the trial. Female patients of childbearing potential must use effective contraception and all patients must provide written informed consent.",
    "The sample is a phase 1 clinical trial for patients with gastrointestinal stromal tumor. The trial involves the use of two drugs, imatinib mesylate and sunitinib malate. The eligibility criteria include having a biopsy-proven gastrointestinal stromal tumor, measurable lesions, and a performance status of 0-2. Patients must also meet certain laboratory and medical criteria, such as having no history of brain metastases or symptomatic brain disease, and not having any severe medical or psychiatric conditions that may increase the risk associated with study participation. Prior concurrent therapy is also taken into consideration.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on neoplastic diseases, specifically those with advanced metastatic or locally advanced disease. The trial is testing the efficacy of the drug ombrabulin (ave8062) as a treatment option. The eligibility criteria for the trial include having an Eastern cooperative oncology group (ECOG) performance status of 0 to 1 and not receiving any other anticancer therapy during the study. The sample also includes exclusion criteria such as absence of histologically or cytologically proven cancer at the first diagnosis and a negative serum/urinary pregnancy test. The record concludes with a disclaimer that the information provided is not exhaustive and other considerations may be relevant to a patient's potential participation in the trial.",
    "The sample is a record of a clinical trial in phase 1, focused on treating depressive disorder. The trial involves the drug extended-release bupropion hydrochloride. The eligibility criteria for the trial include having a history of Major Depressive Disorder with a seasonal pattern, while exclusion criteria include having a seizure disorder or brain injury, a history or current diagnosis of anorexia nervosa or bulimia, and other psychiatric disorders. Additionally, participants cannot have initiated psychotherapy within the last 3 months. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 1 clinical trial for colorectal carcinoma. The trial includes participants who are Japanese and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Participants must have metastatic disease that is not amenable to potentially curative resection and have received no more than 2 prior systemic chemotherapy regimens in any setting. The trial involves the use of irinotecan, levofolinate, and 5-fluorouracil (5-fu) drugs. The eligibility criteria include adequate hepatic, renal, hematologic, and coagulation function, and urinary protein \u22641+. The exclusion criteria include previous bevacizumab therapy, chemotherapy, and any previous systemic therapy for first-line treatment of metastatic CRC. Participants must not have experienced any arterial thrombotic/thromboembolic event, Grade 4 hypertension, Grade 4 proteinuria, a Grade 3-4 bleeding event, or bowel perforation during first-line therapy with a bevacizumab-containing regimen. The trial also excludes participants who have undergone major surgery within 28 days or subcutaneous venous access device placement within 7 days prior to study registration, or have elective or planned surgery to be conducted during the trial. Other exclusion criteria include a history of deep vein thrombosis or pulmonary embolism within the past 12 months, symptomatic congestive heart failure, unstable angina pectoris, or symptomatic or poorly controlled cardiac arrhythmia, and uncontrolled arterial hypertension despite standard medical management.",
    "The sample is a clinical trial for a drug called Proellex, which is being tested on healthy adult females between the ages of 18 and 50 who have excessive menstrual bleeding, menstrual pain, uterine fibroids, or endometriosis. The trial is in phase 1/phase 2 and the eligibility criteria include having a normal menstrual cycle, agreeing not to attempt to become pregnant, and being willing to discontinue hormonal contraceptives and use double barrier contraceptive techniques. The exclusion criteria include being post-menopausal, pregnant, lactating, or attempting to become pregnant during the study period, having abnormal liver enzymes or liver disease, and having previously participated in Proellex clinical trials. The sample also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a phase 1 clinical trial for patients with hematologic malignancies, multiple myeloma, lymphoma, or Hodgkin lymphoma. The trial is testing the drug mln4924 and the eligibility criteria includes having a confirmed diagnosis of one of the listed diseases that is relapsed and/or refractory after at least 2 prior standard chemotherapeutic regimens and for which no curative option exists. Patients must also have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and suitable venous access for blood sampling. Exclusion criteria includes recent systemic antineoplastic therapy, treatment with corticosteroids, prior radiation therapy involving >25% of bone marrow, and low blood counts or kidney function.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on the disease uveitis, which is associated with vision loss. The icd-10 codes associated with the disease are listed as \"H44.133\", \"H44.131\", \"H44.132\", and \"H44.139\". The drug being tested is apremilast. The eligibility criteria for the trial include having failed to respond to prednisone and at least one other systemic immunosuppressive medication, or being unable to tolerate such medications due to side effects. Exclusion criteria include having a serious concomitant illness that could interfere with participation, previous or current use of an alkylating agent, use of CYP3A4 inhibitors during the trial, and TNF blocker use within the 8 weeks prior to enrollment.",
    "The sample is a table with information about clinical trials for prostate cancer. It includes the phase of the trial (phase I, II, or III), a list of diseases, a list of ICD-10 codes for those diseases, a list of drug names, and eligibility criteria for the trial. The eligibility criteria include inclusion and exclusion criteria for different types of prostate cancer, such as non-metastatic CRPC, metastatic CRPC (treatment-naive), and metastatic CRPC (chemotherapy-naive, post-abiraterone). The criteria specify requirements such as PSA levels, ongoing androgen depletion therapy, ECOG performance status, and life expectancy, as well as exclusion criteria such as prior treatment with certain drugs, concurrent treatment with medications known to have seizure potential, and evidence of severe or uncontrolled systemic disease or HIV infection.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, mesothelioma), the ICD-10 codes associated with the disease, the drugs being used in the trial (carboplatin, bevacizumab, and pemetrexed), and the eligibility criteria for patients to participate in the trial. The eligibility criteria include requirements for the patient's diagnosis, performance status, renal and hepatic function, bone marrow function, and ability to take certain medications. The sample also includes exclusion criteria, such as a history of certain medical conditions or recent surgeries, and laboratory values that must be met for a patient to be eligible for the trial.",
    "The sample is a clinical trial for patients with non-small cell lung cancer in phase 1/phase 2. The trial is testing the effectiveness of the drug erlotinib hcl. The eligibility criteria include having confirmed NSCLC, having received at least one chemotherapy regimen for advanced or metastatic NSCLC, and having an ECOG performance status of 0, 1, or 2. Patients must also be at least 18 years old, have recovered from prior anti-cancer therapy, and have measurable disease on CT and at least one detectable lesion on FDG-PET scan and/or FLT-PET scan. Patients must be able to comply with the study and follow-up procedures, including all specified imaging studies, and be able to take oral medication. Exclusion criteria include prior treatment with an investigational or marketed agent for the purpose of inhibiting epidermal growth factor receptor (EGFR), chemotherapy, radiotherapy, or investigational treatment within 14 days or within 5 half-lives of the active molecules in the chemotherapy or investigational treatment, whichever is longer, prior to study entry or from which patients have not yet recovered, and any unstable systemic disease.",
    "The sample is a phase 1 clinical trial for patients with unresectable or metastatic cancer that is refractory to standard therapies or for which no standard therapy exists. The trial is testing the drug ridaforolimus. The eligibility criteria include being at least 18 years old, having measurable or nonmeasurable lesions assessable using an appropriate radiographical procedure, having adequate renal and hepatic function, and having an anticipated life expectancy of at least 3 months. Patients with active central nervous system metastases or leptomeningeal disease, prior therapy with rapamycin or rapamycin analogs, or known hypersensitivity to any excipient contained in the study drug are excluded.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on the disease hepatitis C, with a list of associated ICD-10 codes. The trial involves the use of multiple drugs, including pf-00868554 and a placebo. The eligibility criteria for the trial include having a HCV RNA level of at least 100,000 IU/mL at screening and having genotype 1a or 1b. The exclusion criteria include having received prior treatment with IFN and/or RBV and having evidence of decompensated liver disease.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is a combination of phase 1 and phase 2, and is focused on prostate cancer. The icd-10 codes associated with the disease are listed, as well as the drugs being used in the trial (tak-700, docetaxel, and prednisone). The eligibility criteria for participants are also listed, including requirements such as a confirmed diagnosis of prostate adenocarcinoma, radiograph-documented metastatic disease, and an estimated life expectancy of 6 months or more. The sample also includes exclusion criteria, such as known hypersensitivity to the drugs being used, prior therapy with investigational compounds or radiation therapy for prostate cancer within 30 days prior to the trial, and uncontrolled cardiovascular conditions.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying metastatic or relapsed locally advanced breast cancer that is HER2-positive by FISH. The drugs being used are bevacizumab and herceptin. The eligibility criteria include various requirements such as bidimensionally measurable disease, normal left ventricular ejection fraction, and no prior chemotherapy for metastatic disease. There are also exclusion criteria such as more than 3 different metastatic sites and clinically significant cardiovascular disease.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on the treatment of esophageal neoplasms, which are listed under the \"diseases\" column. The corresponding ICD-10 codes for these diseases are listed under the \"icdcodes\" column. The drug being tested is capecitabine (xeloda), which is listed under the \"drugs\" column. The eligibility criteria for the trial are listed under the \"criteria\" column, with inclusion criteria including locally advanced and surgically resectable esophageal or gastroesophageal junction cancer, no prior therapy, and adequate organ function. Exclusion criteria include evidence of metastasis, cervical esophageal tumors, and peripheral or auditory neuropathy grade >= 2.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on the disease glioblastoma multiforme, which is identified by a list of icd-10 codes. The drug being tested is aee788. The record includes the eligibility criteria for the trial, including requirements for confirmed GBM diagnosis, adequate hematologic, hepatic and renal function, age over 18, Karnofsky performance status score of at least 70%, and a life expectancy of at least 12 weeks. The record also includes exclusion criteria, such as peripheral neuropathy greater than grade 1, diarrhea greater than grade 1, gastrointestinal dysfunction, compromised cardiac function, and concurrent severe and/or uncontrolled medical conditions.",
    "The sample is a phase 1 clinical trial for patients with non-resectable and/or metastatic cancer, preferably squamous cell carcinomas of head and neck, oesophagus, lung or cervix. The trial involves the use of two drugs, bibw 2992 and bibw 2992, and patients must meet certain eligibility criteria, including having a confirmed diagnosis of cancer, being at least 18 years old, having a life expectancy of at least three months, and having an Eastern Cooperative Oncology Group (ECOG) performance score less than or equal to 2. Patients must also have recovered from any therapy-related toxicity from previous chemo-, hormone-, immuno-, or radiotherapies, and must not have any active infectious disease or serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol. There are also several exclusion criteria, including untreated or symptomatic brain metastases, cardiac left ventricular function with resting ejection fraction less than 50%, and active alcohol or drug abuse.",
    "The sample is a clinical trial for patients with symptomatic multiple myeloma requiring treatment. The trial is in phase 1/phase 2 and the drug being tested is busulfan. The eligibility criteria include being approved for single or tandem autologous transplant, being over 65 years of age or diagnosed with renal insufficiency, having adequate pulmonary function, having an ECHO or MUGA performed within 60 days prior to registration, and having evaluable myeloma marker for response. Patients must also be able to receive full doses of DT-PACE, in the opinion of the treating investigator, with the exception of cisplatin. Exclusion criteria include having serum transaminases or direct bilirubin levels above a certain threshold, being HIV positive or having active Hepatitis B or C infection, having a prior malignancy in which life expectancy is more likely to be determined by the prior malignancy than the myeloma, and being pregnant or nursing.",
    "The sample is a record of a clinical trial with a combination of phase 1 and phase 2. The trial is focused on the treatment of osteoarthritis, and the icd-10 codes associated with the disease are listed. The drug being tested is normal saline. The eligibility criteria for the trial are also listed, including inclusion criteria such as having painful osteoarthritis in the study knee and being able to walk without assistive devices, and exclusion criteria such as having chronic pain conditions other than knee osteoarthritis or having had surgery to the study knee within 24 weeks.",
    "The sample is a clinical trial for a drug called tmc278la, which is being tested on individuals with HIV infections. The trial is a combination of phase 1 and phase 2. The eligibility criteria for the trial include being between the ages of 18 and 50, having a BMI between 16 and 35, and not having any significant health problems. Participants must also be willing to undergo HIV testing and use contraception if sexually active. Exclusion criteria include having a significant medical illness, being pregnant or lactating, and having a history of severe drug allergy. The trial is being conducted in the UK and participants must be registered with a GP.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying mantle cell lymphoma. The icd-10 codes associated with the disease are listed, as well as the drugs being used in the trial. The eligibility criteria for participants are also listed, including age, disease classification, previous treatments, bone marrow function, performance status, and other medical conditions. Exclusion criteria are also listed, such as prior treatment with certain medications, abnormal liver or renal function, and pregnancy or breastfeeding.",
    "The sample is a phase 1 clinical trial for asthma patients. The trial involves the use of three drugs - rns60, normal saline, and budesonide. The eligibility criteria for the trial include being a non-smoker between the ages of 18 and 65 with a clinical diagnosis of mild to moderate asthma. Participants must also have been prescribed an inhaled corticosteroid medication for at least one month and have normal ECG and chest x-ray results. Women of childbearing potential must have a negative pregnancy test and commit to using adequate contraception during the study. Exclusion criteria include chronic or acute diseases that may interfere with the evaluation of the drugs, pregnancy or intent to become pregnant, and current or prior malignancies.",
    "The sample is a clinical trial for a drug called ino-8875 and a placebo, for the treatment of ocular hypertension and primary open-angle glaucoma. The trial is in phase 1/phase 2 and involves patients between the ages of 18 and 75 with a mean intraocular pressure of \u226524 and \u226434 mm Hg. The trial has inclusion criteria such as the diagnosis of ocular hypertension or primary open-angle glaucoma, and exclusion criteria such as no significant visual field loss, cup-to-disc ratio \u22650.8, central corneal thickness <500 \u00b5m or >600 \u00b5m, history of adult asthma or chronic obstructive pulmonary disease, and any recent or chronic medical condition that might obfuscate the subject's study data. The diseases are listed as glaucoma and ocular hypertension, and the icd-10 codes for these diseases are also provided.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on breast cancer and includes a list of ICD-10 codes associated with the disease. The trial involves the use of two drugs, ixabepilone and capecitabine. The eligibility criteria for the trial includes women who are at least 20 years old and have a confirmed diagnosis of adenocarcinoma originating in the breast. The exclusion criteria includes patients who have undergone three or more prior chemotherapy treatments in the metastatic setting.",
    "The sample is a phase 1 clinical trial for patients with advanced solid tumors, excluding Hodgkin and non-Hodgkin lymphoma. Patients with hepatocellular carcinomas may be enrolled without histological documentation if they meet the consensus non-invasive diagnostic criteria. The trial is testing the effectiveness of the drug combination axitinib plus everolimus. Inclusion criteria include age over 18, ECOG performance status of 0-1, life expectancy of over 3 months, and acceptable biological values. Exclusion criteria include brain metastasis, severe underlying cardiovascular disease, hepatitis B or C carrier or at a chronic state, uncontrolled hypertension or diabetes mellitus, inability to swallow pills, unresolved pneumopathy, and participation in another clinical trial or use of an unapproved medication within 4 weeks prior to study treatment initiation. Pregnant or lactating women are also excluded.",
    "The sample is a phase 1 clinical trial for patients with advanced non-small cell lung cancer who have failed standard therapy or for whom there is no standard therapy. The trial involves the use of three drugs: pazopanib, gemcitabine, and cisplatin. The eligibility criteria include having measurable or evaluable disease, being over 18 years old, having a performance status of ECOG 0-1, and having adequate organ function. Patients must also have recovered from any toxicity attributed to prior therapies and must not have any unstable or serious concurrent conditions. Exclusion criteria include a history or clinical evidence of central nervous system metastases, clinically significant gastrointestinal abnormalities, uncontrolled infection, and prolongation of corrected QT interval. Patients must provide written informed consent and be willing to comply with treatment and follow-up.",
    "The sample is a phase 1 clinical trial for the treatment of brain tumors and central nervous system tumors using cyclosporine, etoposide, and vincristine sulfate. The trial has specific eligibility criteria for patients, including being newly diagnosed with diffuse intrinsic brain stem glioma by MRI, having a clinical history of less than 6 months duration, and meeting certain age and health requirements. Patients cannot have had prior biologic or chemotherapy, and cannot be receiving any other concurrent investigational agents. The trial must be registered within 28 days of diagnosis. The diseases are listed along with their corresponding ICD-10 codes.",
    "The sample is a clinical trial for a drug called hyaluronan, which is being tested on patients who have undergone unilateral ACL reconstruction surgery within six months of injury. The trial is in phase 1/phase 2 and is focused on treating anterior cruciate ligament injury and osteoarthritis. The eligibility criteria include being between 18 and 40 years old, having an autograft ACL graft, and being willing to participate in follow-up for 24 months. The exclusion criteria include being pregnant or breastfeeding, having a previous allergic reaction to hyaluronan, having a history of autoimmune disease or drug abuse, and having chondral lesions greater than Grade 1a on any surfaces.",
    "The sample is a phase 1 trial for Parkinson's disease, with the drug being tested being rotigotine. The eligibility criteria for participants include being between 19 and 45 years old, having a normal body weight, being of Korean descent, and being healthy with no clinically relevant findings. Exclusion criteria include a history of drug or alcohol abuse, recent stroke or transient ischemic attack, epilepsy or seizures, skin hypersensitivity, active skin disease, pregnancy or lactation, and any medical or psychiatric condition that could compromise participation in the trial. Other exclusion criteria include abnormal ECG findings, abnormal physical examination or laboratory results, hepatic dysfunction, positive tests for HIV, Hepatitis B or C, alcohol or drugs, and clinically relevant allergies. Participants must not be taking any medication (excluding oral hormonal contraceptives) currently or within 2 weeks prior to the first day of dosing, and must not have taken herbal medicine therapy within the last 2 weeks. They must also not consume more than 150g of alcohol per week, more than 5 cigarettes per day, or more than 3 cups of caffeinated beverages per day within the last 2 weeks. Finally, they must not have a history of clinically relevant motor disturbance, impairment of memory, sleep disturbance, or neurodegenerative disease.",
    "The sample is a phase 1 clinical trial for a malaria vaccine. The study is being conducted in Burkina Faso and is looking for male and non-pregnant, non-lactating females between the ages of 18 and 45 years. Participants must agree to practice adequate contraception until at least 28 days following their last immunization dose and avoid high-risk sexual behavior for exposure to HIV. The study has inclusion and exclusion criteria, including being in good health, willingness to comply with protocol requirements, and not having a history of certain medical conditions or treatments. The study is also excluding those who have received a recombinant adenovirus vector vaccine in a prior study.",
    "The sample is a record of a clinical trial in phase 1, which is focused on peripheral vascular diseases. The trial includes a list of ICD-10 codes for the diseases being studied. The trial involves two drugs, one called mk-0736 and the other is a placebo (unspecified). The eligibility criteria for the trial include participants with peripheral arterial disease who are between the ages of 18 and 85, and female participants who are postmenopausal or sterile. The exclusion criteria include participants with hepatic, HIV, endocrine, connective tissue, psychiatric disorders, or uncontrolled hypertension.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on treating three types of diseases: Hodgkin's disease, anaplastic large-cell lymphoma, and non-Hodgkin's lymphoma. The trial is testing the effectiveness of a drug called brentuximab vedotin. The eligibility criteria for participants include having a relapsed or refractory CD30-positive malignancy, adequate organ function, and an ECOG performance status of less than 2. However, participants with cardiac abnormalities, a current diagnosis of primary cutaneous ALCL, acute or chronic graft-versus-host disease, or a prior hematopoietic stem cell transplant within a specified timeframe are excluded from the trial. The icd-10 codes for the diseases are also included in the record.",
    "The sample is a clinical trial table that contains information about the phases of the trial, diseases being studied, ICD-10 codes of the diseases, drugs being tested, and eligibility criteria for the trial. The phase of the trial is either phase I, phase II, or phase III. The diseases being studied include leukemia, leukemia myeloid, leukemia myelogenous chronic, bcr-abl positive, Philadelphia chromosome, and hematologic diseases. The ICD-10 codes associated with these diseases are also listed. The drug being tested is radotinib. The eligibility criteria for the trial are listed separately for phase I and phase II and include factors such as age, performance status, laboratory values, and medical history. The exclusion criteria are also listed and include factors such as CNS infiltration, impaired cardiac function, severe GI disease, and use of certain medications.",
    "The sample is a clinical trial for patients with relapsed or refractory multiple myeloma. The trial is in phase 1/phase 2 and the patients must meet certain eligibility criteria to be enrolled. The criteria include having measurable levels of myeloma paraprotein in serum or urine, having a certain Eastern Cooperative Oncology Group (ECOG) performance status score, and having a life expectancy of more than 3 months. The trial also has exclusion criteria, such as having a serious medical condition or laboratory abnormality, being pregnant or lactating, or having a history of certain malignancies. The trial involves the use of the drug Revlimid and patients must not have received more than 3 previous anti-myeloma regimens.",
    "The sample is a clinical trial for a drug called ibi-20089/lucentis, which is being tested for the treatment of age-related macular degeneration and choroidal neovascularization. The trial is in phase 1/phase 2 and the table includes information on the diseases being treated, the icd-10 codes associated with those diseases, and the eligibility criteria for participants. The inclusion criteria include being 55 years or older, having a diagnosis of active, subfoveal choroidal neovascular membranes due to age-related macular degeneration, and having visual acuity from 20/25 to 20/400 in the study eye. The exclusion criteria include having received corticosteroids in the past 30 days, having a history of uncontrolled glaucoma, having had ocular surgery in the past 90 days, and having a history of allergy to corticosteroids. The sample also includes other exclusion criteria related to medical and psychological conditions that could jeopardize the safety of the patient or affect the validity of the study results.",
    "The sample is a phase 1 clinical trial for cancer patients with specific ICD-10 codes. The trial involves the use of drugs such as ic83/ly2603618 and pemetrexed. The eligibility criteria include having at least one lesion that can be evaluated by Response Evaluation Criteria In Solid Tumors (RECIST), having fully recovered from any previous radiation therapy or surgery, having a life expectancy of at least 3 months, and having a negative serum pregnancy test. The exclusion criteria include being pregnant or breastfeeding, not using an approved means of contraception, having a history of brain metastases, and having a known active infection.",
    "The sample is a phase 1 trial with the disease being 'healthy'. The icd-10 codes associated with the disease are 'Z76.3' and 'Z76.2'. The drugs being tested are 'map0004', 'iv placebo (saline)', 'placebo inhaler', and 'iv dihydroergotamine mesylate (dhe)'. The eligibility criteria for the trial include being a healthy non-smoking adult volunteer, male or female, between the ages of 18 and 45, with normal cardiac status, hemoglobin values, echocardiogram, and 12-lead electrocardiogram. The subject must also be able to properly use the Tempo\u00ae Inhaler and not have donated blood in the last 56 days. Exclusion criteria include contraindication to dihydroergotamine mesylate (DHE), use of any excluded concomitant medications within the 10 days prior to Visit 1, history of hemiplegic or basilar migraine, and participation in another investigational trial during the 30 days prior to Visit 1.",
    "The sample is a clinical trial for HIV infection, with a phase 1/phase 2 designation. The trial is testing the drug panobinostat and has eligibility criteria for participants, including being over 18 years old, having documented HIV-1 infection, and having a CD4+ T-cell count above 500/mm3. There are also exclusion criteria, such as having a history of malignancy or transplantation, or having laboratory values outside of normal limits. Women who are pregnant or breastfeeding, or who are of childbearing potential and unwilling or unable to use contraception, are also excluded. The trial requires informed consent and the use of barrier contraception during sexual intercourse for the entire study period.",
    "The sample is a phase 1 clinical trial for patients with neoplastic meningitis. The trial involves the use of two drugs, depocyt and temozolomide. The eligibility criteria include being at least 18 years old, having a histologic diagnosis of systemic malignancy, and having a Karnofsky performance status of at least 60%. Patients must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy before entering the study. They must also have adequate liver and renal function, normal metabolic parameters, and a platelet count of at least 75,000/mm(3) and ANC of at least 1500/mm(3). Patients or their legal guardians must sign a document of informed consent. Exclusion criteria include receiving other therapy specifically designed to treat leptomeningeal disease, having clinical evidence of obstructive hydrocephalus or compartmentalization of the CSF flow, and having any uncontrolled infection. Women of childbearing potential must have a negative serum pregnancy test and must not be lactating. Patients must not have had prior treatment with Temozolomide.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating multiple diseases including hermansky-pudlak syndrome (HPS), pulmonary fibrosis, oculocutaneous albinism, platelet storage pool deficiency, and metabolic disease. The trial involves the use of drugs such as losartan, zileuton, n-acetylcysteine, pravastatin, and erythromycin. The eligibility criteria for participants include having a molecular diagnosis of HPS-1 or HPS-4, being between 18-70 years of age, having severe pulmonary fibrosis, and being available to come to the NIH Clinical Center for admission every 3 months. The exclusion criteria include having interstitial lung disease other than HPS, being pregnant or lactating, having a history of ethanol abuse or recreational drug use in the past two years, having chronic use of high-dose steroids, and having any severe medical complications. Women of child-bearing age must have an effective method of birth control. The trial requires participants to meet certain laboratory criteria and have the ability to give informed consent.",
    "The sample is a phase 1 clinical trial for patients with advanced solid tumors. The trial is testing the effectiveness of the drug ixabepilone (oral formulation). The eligibility criteria for the trial include being 18 years or older, having a confirmed diagnosis of solid tumor malignancy, having measurable or non-measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria, having a Karnofsky Performance Status (KPS) of 70-100, and having recovered from toxicities resulting from previous therapies. Exclusion criteria include having had more than 3 prior cytotoxic regimens in the metastatic setting, having current or recent gastrointestinal (GI) disease that would impact the absorption of the study drug, inability to swallow whole capsules, inadequate hepatic and renal function, and previous exposure to any epothilone.",
    "The sample is a clinical trial in the early phase 1, focused on treating nausea and vomiting. The trial involves the use of haloperidol and placebo drugs. The eligibility criteria for the trial include being between 18 and 70 years old, having no previous adverse reaction to haloperidol, being in good health, and having no significant cardiovascular, gastrointestinal, hematologic, neurologic, renal, hepatic or pulmonary disease. Exclusionary criteria include having any other significant clinical disorder or laboratory finding that makes it undesirable to participate in the study, recent cerebral trauma, being pregnant or nursing, having a history of seizures, taking medications that can interact with haloperidol, and having significant cardiovascular, gastrointestinal, hematologic, neurologic, renal, hepatic or pulmonary disease.",
    "The sample is a phase 1 clinical trial for candidates with documented atrial fibrillation who are undergoing cardioversion. The trial involves two groups, one receiving mangosteen juice and the other receiving a placebo juice. The eligibility criteria include being over 18 years old, having a clinically indicated cardioversion, and being on anticoagulation therapy as per Mayo Clinic guidelines. Exclusion criteria include having a reversible cause of atrial fibrillation, recent cardiac surgery or myocardial infarction, and various other medical conditions. The trial requires written informed consent and cooperation with study procedures.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying the effectiveness of various drugs in treating unresectable locally advanced or metastatic gastric or esophagogastric junction adenocarcinoma. The eligibility criteria for participants include having a confirmed diagnosis of the disease, a performance status of 0 or 1, and being at least 18 years old. There are also exclusion criteria, such as having received previous systemic therapy for the disease or having tumors of squamous cell histology.",
    "The sample is a phase 1 clinical trial for cervical cancer and precancerous conditions. The trial is testing the effectiveness of the drug zoledronate. The eligibility criteria for patients include having biopsy-confirmed cervical intraepithelial neoplasia (CIN) 2/3 or 3, visible lesions by colposcopy, and no suspicion of invasive cervical cancer. Patients must also have normal creatinine levels and screening laboratory values, not be pregnant or nursing, and have no known hypersensitivity to bisphosphonates. They must also not be immunocompromised, have HIV positivity, aspirin-sensitive asthma, or unexplained abnormal vaginal bleeding. Prior concurrent therapy with certain drugs is not allowed during the trial.",
    "The sample is a clinical trial for patients with prostate cancer in phase 1/phase 2. The trial involves the use of drugs such as docetaxel, prednisone, and vatalanib. The eligibility criteria include having histologically documented adenocarcinoma of the prostate, progressive, systemic (metastatic) disease despite castrate levels of testosterone due to orchiectomy or luteinizing-hormone releasing hormone (LHRH) agonist, and meeting certain criteria for measurable or nonmeasurable disease with PSA levels. Patients must also meet certain patient characteristics such as having a Karnofsky performance status \u2265 60%, life expectancy > 12 weeks, and no pre-existing grade 3 or 4 clinical peripheral neuropathy. Prior concurrent therapy is also taken into consideration.",
    "The sample is a record of a clinical trial that is in phase 1/phase 2. The trial is focused on kidney transplantation and the associated diseases, which are listed as \"kidney transplantation\" in the record. The icd-10 codes for these diseases are also provided. The trial involves the use of two drugs, aeb071 and mycophenolic acid. The eligibility criteria for the trial are listed under \"Inclusion criteria\" and \"Exclusion criteria\". Inclusion criteria include patients of any race who are 18 years or older and have received a kidney transplant from a deceased or living donor. The graft must be functional within 36 hours of transplantation. Exclusion criteria include patients who require medication prohibited by the protocol, patients infected with hepatitis B or C or HIV, patients with a history of cancer, patients with severe systemic infections, and patients with heart diseases associated with an increased risk for arrhythmias. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "This sample is a phase 1 clinical trial for HIV infections. The trial is testing the effectiveness of the drug GM-CSF. The eligibility criteria for participants include being HIV negative, having certain major histocompatibility alleles, good general health, and access to the participating site for follow-up during the 15-month study. Exclusion criteria include having received certain vaccines or immunosuppressive medications within a certain time frame, having certain medical conditions or illnesses, and being pregnant or breastfeeding.",
    "The sample is a phase 1 clinical trial for patients with metastatic solid malignancies who are eligible to receive a cisplatin-based regimen. The trial also includes patients with HER2-RH- breast cancer during the optimal tolerated regimen validation procedure. The trial requires patients to have measurable or evaluable disease, a WHO performance status of \u2264 1, and a negative dipstick proteinuria test or proteinuria <1g/24h. The corrected QT interval (QTc) must be \u2264 480 msecs using Bazett's formula. Patients who have received prior treatment with cisplatin reaching a cumulative dose > 300 mg/m2, have HER2 positive breast cancer, are at high risk of bleeding, have clinically significant gastrointestinal abnormalities, have calcium and magnesium levels inferior to standard levels, have potassium levels inferior to standard levels, have other concurrent severe and/or uncontrolled medical disease, or have hearing impairment/tinnitus > or = grade 2 are excluded from the trial.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying metastatic colorectal cancer, colon cancer, colorectal cancer, and rectal cancer. The ICD-10 codes associated with these diseases are also listed. The drugs being tested are placebo, amg 655, modified folfox6, and bevacizumab. The eligibility criteria for participants include having confirmed metastatic adenocarcinoma of the colon or rectum, being at least 18 years old, having adequate hematologic, renal, hepatic, and coagulation function, and not having certain medical conditions or recent surgeries.",
    "The sample is a phase 1 clinical trial for patients with hematologic malignancies such as multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's disease, and Waldenstrom's macroglobulinemia. The trial involves the use of the drugs carfilzomib and dexamethasone. The eligibility criteria include being at least 18 years old, having a confirmed diagnosis of one of the specified diseases, being refractory or relapsed following at least two prior therapies, and having adequate cardiovascular and hepatic function. Exclusion criteria include being pregnant or lactating, having received certain types of therapy within a certain timeframe, having certain medical conditions, and having participated in an investigational therapeutic study within one month prior to the trial. The trial requires written informed consent and the use of dual methods of contraception for female subjects of child-bearing potential.",
    "The sample is a clinical trial for patients with acute myeloid leukemia (AML) or high risk myelodysplastic disorders (MDS). The trial is in phase 1/phase 2 and the patients must be aged 15 to 60 years, or older than 60 if deemed fit to receive intensive chemotherapy by the treating physician. The patients must not have received any prior chemotherapy (except hydrea) for AML or MDS. The trial involves the drugs idarubicin, sorafenib, and ara-c. The eligibility criteria include a diagnosis of AML or high risk MDS, certain serum biochemical values, ability to take oral medication, and understanding and providing signed informed consent. The exclusion criteria include certain medical conditions, nursing women, women of childbearing potential who are not willing to maintain adequate contraception, and patients with certain cardiac diseases or infections.",
    "The sample is a phase 1 clinical trial for advanced breast cancer patients. The trial includes the drugs cyclophosphamide, docetaxel, and doxorubicin hydrochloride. The eligibility criteria include having histologically or cytologically confirmed advanced breast cancer, being female and between the ages of 18 and 69, having a WHO performance status of 0-2 or a Karnofsky score of 60-100%, and meeting various hematopoietic, hepatic, renal, and cardiovascular requirements. Patients must not have any other serious illnesses or medical conditions, and must not be pregnant or nursing. Prior anthracycline or taxoid therapy must have been completed at least 6 months prior to the trial. Patients must not have received a cumulative anthracycline dose greater than 240 mg/m^2. Other concurrent experimental drugs or systemic anticancer therapy are not allowed.",
    "The sample is a phase 1 clinical trial for patients with advanced solid tumors. The trial is testing the drug Osi-906 and the eligibility criteria includes having a documented malignancy that is now advanced and/or metastatic and refractory to established forms of therapy or for which no effective therapy exists. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of </= 2 and a predicted life expectancy of at least 12 weeks. Patients may have had prior therapy, but must have recovered from any treatment-related toxicities. Other eligibility criteria include normal fasting glucose, electrolyte levels, and adequate hematopoietic, hepatic, and renal function. Patients must also practice effective contraceptive measures and provide written informed consent to participate in the study. Exclusion criteria include a history of diabetes mellitus, significant cardiac disease, active seizure disorder, concurrent anticancer therapy, and active or uncontrolled infections or serious illnesses.",
    "The sample is a phase 1 clinical trial for HIV infection. The eligibility criteria include having a documented HIV-1 infection, being on a stable antiretroviral regimen for at least 12 weeks, having a plasma HIV-1 RNA level of less than 50 copies/mL, and having a CD4 cell count of over 300 cells/mm3. Other criteria include having certain laboratory values within normal ranges, having a negative pregnancy test for women of reproductive potential, and having a Karnofsky performance score of over 90. Exclusion criteria include having a viral load measurement of over 50 copies/mL within the last 12 weeks, having a history of active skin disease or diabetes, and being pregnant or breastfeeding.",
    "The sample is a clinical trial for pancreatic cancer and pancreatic ductal adenocarcinoma patients who have not received prior therapy. The trial is in phase 1/phase 2 and involves the use of bevacizumab, 5-fluorouracil, oxaliplatin, and gemcitabine. The eligibility criteria include having a life expectancy of at least 4 months, being over 18 years old, and having certain blood counts and liver function tests within normal limits. Exclusion criteria include having certain medical conditions or recent surgeries, being pregnant or lactating, and having certain heart or bleeding disorders. The trial aims to evaluate the safety and efficacy of the drugs in treating the disease.",
    "The sample is a phase 1 clinical trial for the treatment of aplastic anemia. The trial involves the use of drugs such as cyclophosphamide, cyclosporine, and mycophenolate mofetil. The eligibility criteria for the trial include having life-threatening marrow failure of nonmalignant etiology, failure to respond to the best available immunosuppressive treatment protocol, and lack of an HLA-identical family member or closely matched unrelated marrow donor. The trial also requires the use of unrelated UCB units matched for at least 4 of 6 loci or related UCB units matched for at least 3 of 6 loci. The exclusion criteria include severe disease other than aplastic anemia, HIV seropositive patients, patients with clonal cytogenetic abnormalities or myelodysplastic syndrome, patients with paroxysmal nocturnal hemoglobinuria or Fanconi anemia, patients over 40 years of age, and related or unrelated cord blood units with less than 1.5 x 10^7 Total Nucleated Cells per kg recipient weight or without full testing and negative results for hepatitis A, B, C, HIV, HTLV-1, CMV viruses.",
    "The sample is a phase 1 clinical trial for patients with advanced cancer who have failed standard therapy and are deemed suitable for participation. The trial involves the use of a drug called sgx523 capsules. The eligibility criteria include having a solid tumor, meeting certain laboratory values, having evidence of phospho-MET expression on tumor material, and having no residual toxic effects of previous therapy. Exclusion criteria include pregnancy, cardiac disease requiring medical therapy, active infections, psychiatric or seizure disorders, and other severe concurrent nonmalignant diseases. Patients receiving prohibited medications or anti-coagulant therapy or with known allergy to SGX523 formulation or its excipients are also excluded.",
    "The sample is a phase 1 clinical trial for patients with hematologic malignancies. The trial includes patients with various diseases, such as acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplasia, chronic myelogenous leukemia, and aggressive non-Hodgkin's lymphoma. The trial drug being tested is clofarabine. The eligibility criteria include having a documented disease, being between the ages of 18-60, having a consenting HLA-matched donor, having a performance status ECOG 0-1, and meeting certain baseline laboratory values. Patients who relapse less than 6 months following autologous stem cell transplantation are not eligible. The exclusion criteria include having an active infection, having HIV disease, being pregnant or nursing, and not providing signed written informed consent.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on treating various types of cancers, including lymphoma, sarcoma, wilmstumor, and neuroblastoma. The trial involves the use of two drugs, vorinostat (saha) and velcade (ps-341, bortezomib). The eligibility criteria for the trial include patients who are older than 12 months and less than or equal to 21 years of age, with a diagnosis and histologic verification of relapsed or refractory solid tumors, including CNS tumors and lymphomas. The patients must have fully recovered from acute toxic effects from all prior therapy and have adequate organ function as determined by laboratory evaluation. The trial is intended for patients whose current disease state has no known curative therapy or therapy proven to prolong survival. The performance score for patients must be Karnofsky greater than or equal to 60% for patients greater than 16 years of age or Lansky greater than or equal to 60 for patients less than or equal to 16 years of age.",
    "The sample is a clinical trial for patients with advanced, histologically-confirmed solid tumors that are refractory to standard therapy or for which no standard therapy exists. The trial is in phase 1/phase 2 and the treatment being tested is camptothecin (cpt) conjugated to a linear, cyclodextrin-based polymer. The eligibility criteria include having measurable or evaluable disease, not having received prior chemotherapy or radiation for at least 4 weeks prior to the first dose of the study drug, and having acceptable organ and marrow function. Exclusion criteria include being pregnant or nursing, having had chemotherapy or radiotherapy within 4 weeks prior to the first dose of the study drug, and having a history of congestive heart failure requiring medical therapy. The trial also has specific criteria for brain metastases, ECOG performance status, life expectancy, and other medical conditions.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on the disease cystic fibrosis, which is identified through either sweat chloride or DNA analysis. The trial involves the use of two drugs, recombinant human igf-1 and placebo. The eligibility criteria for the trial include a diagnosis of cystic fibrosis, age of 18 years or older, and a specific Tanner stage for both male and female participants. The exclusion criteria include various medical conditions, recent receipt of human growth hormone, pregnancy or breastfeeding, and non-compliance with medical regimens. The trial requires subcutaneous injections and prohibits participation by individuals with known allergies to components in the IGF-I preparation.",
    "The sample is a list of clinical trial phases, diseases, ICD-10 codes, drugs, and eligibility criteria. The phase of the trial can be either phase I, phase II, or phase III. The diseases listed include various types of lymphoma, and the ICD-10 codes are provided for each disease. The drugs being tested in the trial are vorinostat, ifosfamide, carboplatin, and etoposide. The eligibility criteria include having relapsed or primary refractory lymphoid malignancy, having measurable disease, having a SWOG performance status of 0, 1, or 2, and meeting various laboratory values and medical history requirements. There are also exclusion criteria, such as having a history of impaired cardiac status or being HIV positive.",
    "The sample is a phase 1 clinical trial for the treatment of urothelial carcinoma using the drug ipilimumab. The trial is for individuals who have not received prior treatment for their cancer and are ineligible for chemotherapy. The eligibility criteria include adequate hematologic, kidney, and liver function, and exclusion criteria include pregnancy, prior treatment with ipilimumab or other anti-CTLA4 antibody, and concurrent malignancy. Additionally, individuals with autoimmune diseases or motor neuropathy of autoimmune origin are excluded from the trial. The sample also includes a list of icd-10 codes for the disease and a list of inclusion and exclusion criteria.",
    "The sample is a clinical trial for non-small cell lung cancer patients in phase 1/phase 2. The trial involves the use of three drugs, tlk286, carboplatin, and paclitaxel. The trial has specific eligibility criteria, including being 18 years or older, having histologically confirmed NSCLC, having stage IV or IIIB disease, having measurable disease by RECIST, having an ECOG status of 0-1, and having adequate liver, renal, and bone marrow function. The trial also has exclusion criteria, such as having prior chemotherapy, immunotherapy, or biologic therapy for metastatic NSCLC, having a history of bone marrow transplantation or stem cell support, and being pregnant or lactating.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for patients. In this particular sample, the trial is in phase 1/phase 2 and is studying liver carcinoma. The icd-10 codes associated with the disease are listed as \"C22.0\", \"D01.5\", and \"C22.7\". The drugs being used in the trial are \"ave1642\", \"sorafenib\", and \"erlotinib\". The eligibility criteria for patients are listed under inclusion and exclusion criteria, which include factors such as organ function, performance status, and prior exposure to certain compounds. The sample also includes a disclaimer that the information provided is not exhaustive and may not include all relevant considerations for a patient's participation in the trial.",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a phase 1 trial that involves patients with type 2 diabetes and inadequate glycemic control. The trial is testing the efficacy of the drug canagliflozin versus a placebo. The eligibility criteria for the trial include having a diagnosis of type 2 diabetes, being on metformin monotherapy, and receiving therapy with an antihypertensive agent for at least 4 weeks prior to screening. The exclusion criteria include a history of diabetic ketoacidosis, type 1 diabetes mellitus, pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy, as well as a severe hypoglycemic episode within 6 months before screening. The sample also includes a list of diseases, their corresponding ICD-10 codes, and the criteria for eligibility and exclusion.",
    "The sample is a phase 1 clinical trial for non-small cell lung cancer. The trial is testing the effectiveness of the drug cetuximab. The eligibility criteria for the trial include having histologically confirmed non-small cell lung cancer, being inoperable stage III, having a WHO performance status of 0 or 1, having adequate bone marrow, renal, and hepatic function, and having a life expectancy of more than 6 months. The trial also requires participants to have measurable cancer and to be willing and able to comply with study prescriptions. Exclusion criteria include having a different type of cancer, a history of prior chest radiotherapy, recent myocardial infarction, and inadequate pulmonary function.",
    "The sample is a clinical trial for non small cell lung cancer patients in phase 1/phase 2. The trial involves the use of a combination of drugs, including pemetrexed, cisplatin, and LY2603618. The eligibility criteria for the trial include having a cytologic or histologic diagnosis of nonsquamous NSCLC that is classified as Stage IV, being eligible for a first line of palliative treatment with a platinum doublet, having archived or fresh tumor tissue, having a performance status \u22641 on the ECOG scale, and having adequate hematologic, hepatic, and renal organ function. The exclusion criteria include having serious preexisting medical conditions or serious concomitant systemic disorders that would compromise the safety of the participant, having central nervous system metastases, having current active infection, having known allergy to the drugs used in the trial, having clinically significant third-space fluid collections, and having received more than 2 previous lines of chemotherapy for the advanced/metastatic disease.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on treating lymphoma, non-Hodgkin lymphoma, and other advanced solid tumors with a drug called azd4877. The trial is also looking at treating B-cell non-Hodgkin lymphoma that is not eligible for curative therapy or has relapsed. The eligibility criteria for the trial include having relatively good overall health other than the cancer, while the exclusion criteria include poor bone marrow function, serious heart conditions, and poor liver or kidney function. The sample also includes a list of icd-10 codes for the diseases being studied.",
    "The sample is a phase 1 clinical trial for cancer patients with specific ICD-10 codes. The drug being tested is called snx-5422. The eligibility criteria for the trial includes being over 18 years old, having a confirmed solid tumor malignancy, being refractory to available therapy or having no therapy available, and having adequate organ function. The exclusion criteria includes having a CNS malignancy, significant GI disease, or being at risk for prolonged QT interval.",
    "The sample is a phase 1 clinical trial for patients with metastatic and/or advanced solid tumors, including lymphomas, for which standard treatment does not offer or no longer offers curative or life-prolonging potential. The trial involves the drug MLN8054 and has eligibility criteria such as being 18 years or older, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and having suitable venous access for blood sampling. Patients must also have recovered from the reversible effects of prior antineoplastic therapy and meet other criteria related to their health and medical history. The trial has exclusion criteria such as pregnancy or lactation, major surgery within the 28 days preceding the first dose of study treatment, and serious infection within the 28 days before the first dose of study treatment.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, metastatic colorectal cancer), the ICD-10 codes associated with the disease, the drugs being tested (pimasertib, placebo, and folfiri), and the eligibility criteria for participants. The eligibility criteria include requirements such as confirmation of K-Ras mutated colon/rectum cancer, evidence of measurable metastatic disease, and exclusion criteria such as bone marrow impairment, renal impairment, and history of CNS metastases. The sample also includes information about exclusion criteria such as pregnancy or nursing, retinal degenerative disease, and legal incapacity.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying psoriasis and psoriasis vulgaris. The icd-10 codes associated with these diseases are listed. The drugs being tested are hat1 topical solution and calcipotriol. The eligibility criteria for participants are also listed, including requirements such as having a psoriasis area and severity index (PASI) score between 3 and 12, being between 18-65 years old, and not having any other topical or systemic medications that could affect the course of psoriasis during the study period. There are also exclusion criteria listed, such as having a history of cancer or being currently pregnant or lactating.",
    "The sample is a phase 1 clinical trial for patients with advanced, refractory solid tumors. The trial is testing the drug cudc-101. The eligibility criteria include having no further standard of care options or having refused standard therapy, measurable or evaluable disease, being at least 18 years old, having an ECOG performance score of less than 2, and a life expectancy of at least 3 months. Other criteria include having certain blood counts and liver function tests within normal limits, not having certain medical conditions, and being able to provide informed consent. The trial excludes patients who have received anticancer therapy within 4 weeks of study entry, have used investigational agents within 30 days of study entry, have certain cardiac diseases, or have known infections with HIV, hepatitis B, or hepatitis C. The trial also cautions against the use of certain medications and requires the use of adequate birth control for women of childbearing potential.",
    "The sample is a phase 1 clinical trial for tumors. The trial is testing a drug called bms-275183. The eligibility criteria for the trial includes having a non-hematologic malignancy that has progressed or no standard therapy is known, being four weeks from last chemotherapy or two weeks from last non-cytotoxic therapy, having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1, having no more than 3 prior chemotherapy regimens in advanced/metastatic setting, having an absolute neutrophil count of >=1,500/mm3 and platelets of >=100,000/mm3, having a bilirubin of <=1.5 x Upper Limit of Normal (ULN), Aspartate aminotransferase of <=2.5 x ULN, having a serum creatinine of <=1.5 x ULN, being a man or woman of at least 18 years of age, and women of childbearing potential must use adequate method of contraception throughout and up to 4 weeks after the study. The exclusion criteria includes women of childbearing potential and men not using adequate method of birth control, pregnant or breastfeeding women, prior radiation >=25% of bone marrow containing skeleton, uncontrolled, significant, or active cardiovascular or pulmonary disease or infection or psychiatric disorder, neuropathy, active brain metastases, inability to swallow capsules, history of gastrointestinal disease, surgery or malabsorption, or requiring use of a feeding tube, and concurrent chemotherapy, hormonal therapy, immunotherapy, or radiotherapy.",
    "The sample is a clinical trial for patients with non-small cell lung cancer in phases I and II. The trial includes patients with locally advanced stage IIIA or IIIB disease that is considered unresectable and requires radiotherapy. The trial involves the use of three drugs: bortezomib, paclitaxel, and carboplatin. The eligibility criteria include various medical conditions such as performance status, blood count, liver function, and heart disease. Patients who are pregnant or nursing, have uncontrolled infections, or have had prior radiation therapy or systemic chemotherapy for NSCLC are not eligible for the trial. The trial also has contraindications for pregnant or nursing women, men or women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception, and patients with severe underlying diseases.",
    "The sample is a phase 1 clinical trial for patients with rectal cancer. The trial involves the use of three drugs: bevacizumab, capecitabine, and erlotinib. The eligibility criteria for the trial include having a confirmed diagnosis of adenocarcinoma of the rectum, being between the ages of 18 and 75, having a performance status of 0 or 1, and having no distant metastatic disease. Patients must also meet certain laboratory criteria, such as having a hemoglobin level of at least 9 g/dL and a platelet count of at least 100,000/mm^3. The trial has several exclusion criteria, including prior radiotherapy to the pelvis, any prior chemotherapy, and prior VEGF or EGFR-directed therapy. Patients must also not be pregnant or lactating, have uncontrolled infections, or have inadequately controlled hypertension. The trial has a total of 25 exclusion criteria.",
    "The sample is a phase 1 clinical trial for the treatment of locally advanced or metastatic squamous non-small-cell lung cancer using the drug AXL1717 in combination with cytotoxic chemotherapy (Gemcitabine HCL/Carboplatin). The eligibility criteria include being at least 18 years old, having a confirmed diagnosis of the specified type of lung cancer, and having preserved major organ functions. Exclusion criteria include ongoing infections or major recent or ongoing diseases, constipation, known malignancy in the central nervous system, and other active malignancies during the previous 3 years. Women who are pregnant or lactating, or who are of childbearing potential, are also excluded. The trial requires signed written informed consent.",
    "The sample is a phase 1 clinical trial for patients with advanced solid tumors, tumors, or cancer. The trial involves the use of three drugs: mk-2206, paclitaxel, and trastuzumab. The eligibility criteria include having confirmed metastatic or locally advanced, unresectable HER2+ cancer, being at least 18 years old, having a performance status of 0-2 on the ECOG Performance Scale, and having adequate organ function. Patients must also be able to swallow capsules and have no surgical or anatomical condition that would prevent them from swallowing and absorbing oral medications. Exclusion criteria include having had chemotherapy, radiotherapy, or hormonal therapy within 3 weeks, having less than 4 weeks post major surgical procedure, and having known active CNS metastases and/or carcinomatous meningitis. Patients must also not have a primary central nervous system tumor, known hypersensitivity to the components of the study drug or its analogs, or clinically significant heart disease.",
    "The sample is a phase 1 clinical trial for patients with mild to moderate persistent allergic asthma. The trial is testing the effectiveness of the drug fluticasone compared to a placebo. The eligibility criteria include having a history of asthma, being in good health, having a positive response to an inhaled allergen challenge, and being a nonsmoker. Exclusion criteria include having a history of certain illnesses or diseases, taking certain medications, and consuming excessive amounts of alcohol or caffeine. The trial requires patients to avoid strenuous physical activity before each visit and to refrain from using any medication not permitted in the study.",
    "The sample is a phase 1 clinical trial with the disease being studied being \"healthy\". The icd-10 codes associated with the disease are \"Z76.3\" and \"Z76.2\". The drugs being tested are \"bibr 796 bs\" and \"placebo\". The eligibility criteria for the trial include being a healthy male or female between the ages of 18 and 60 with a BMI between 18.5 and 29.9 kg/m2. Participants must also be able to communicate well with the investigator and comply with study requirements. Exclusion criteria include any medical findings deviating from normal, gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic or hormonal disorders, and a history of allergy/hypersensitivity. Participants must also not have taken certain medications or engaged in certain activities within a certain timeframe prior to the trial.",
    "The sample is a phase 1 clinical trial for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. The trial involves the drug dinaciclib and has eligibility criteria that include having received at least one prior therapy, having an Eastern Cooperative Oncology Group (ECOG) Performance status \u2264 2, and a life expectancy of \u226512 weeks. Exclusion criteria include having symptomatic brain metastases or primary central nervous system malignancy, being pregnant or breastfeeding, and having previously been treated with a cyclin dependent kinase (CDK) inhibitor such as dinaciclib or flavopiridol. The sample also includes a list of diseases and their corresponding ICD-10 codes, as well as the eligibility criteria for the trial.",
    "The sample is a phase 1 clinical trial for patients with advanced and/or metastatic solid tumors or refractory non-Hodgkin's lymphoma. The trial is testing the effectiveness of a drug called cdki at7519. The eligibility criteria include having a confirmed diagnosis of the specified diseases, no more than 3 prior regimens for metastatic disease, and no untreated brain or meningeal metastases. Patients must also meet certain patient characteristics such as having an ECOG performance status of 0-2 and normal levels of various blood tests. Prior concurrent therapy is allowed, but there are restrictions on the timing of certain treatments. Patients must not have pre-existing cardiovascular conditions or symptomatic cardiac dysfunction and must not be pregnant or nursing.",
    "The sample is a phase 1 clinical trial for pancreatic cancer. The eligibility criteria include having pathologically confirmed adenocarcinoma or poorly differentiated carcinoma of the pancreas, ampulla of Vater, or distal bile duct, being medically inoperable, unresectable, or borderline resectable, and having no previously resected disease. Patients must also have a Karnofsky performance status of 60-100%, WBC > 3,000/\u03bcL, platelet count > 100,000/\u03bcL, bilirubin \u2264 2 mg/dL, SGOT < 5 times upper limit of normal (ULN), creatinine < 1.5 times ULN, and adequate oral nutrition. They must not have any active malignancy within the past 3 years, except cervical carcinoma in situ or nonmelanoma skin cancer that has been removed, and no severe, active comorbidity. Prior concurrent therapy is not allowed, including no prior chemotherapy, no prior radiotherapy to any upper abdominal site, and no concurrent prophylactic colony-stimulating factors during radiotherapy.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on treating esophageal neoplasms, squamous cell carcinoma, adenocarcinoma, and esophageal cancer. The trial involves the use of drugs such as capecitabine, [18-f] fluorodeoxyglucose, 5-fluorouracil, and carboplatin. The eligibility criteria for the trial include a confirmed diagnosis of adenocarcinoma or squamous cell carcinoma of the esophagus, evidence of tumor penetration through the esophageal wall or involvement of regional lymph nodes, and no prior chest radiation therapy or chemotherapy for esophageal cancer. Patients must also have acceptable liver, kidney, and bone marrow function, and must not have any infections requiring antibiotic treatment. The trial excludes patients receiving any other investigational agents, those with evidence of distant metastases, uncontrolled medical illness, any malignancy other than non-melanoma skin cancer or carcinoma in situ of the cervix, pregnant and breastfeeding women, and HIV-positive patients.",
    "The sample is a clinical trial for patients with Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia or recurrent adult acute lymphoblastic leukemia. The trial is in phase 1/phase 2 and involves the drugs entinostat and imatinib mesylate. The eligibility criteria include confirmation of BCR-ABL1 in leukemia cells, prior treatment with tyrosine kinase inhibitors, ECOG performance status of 0, 1 or 2, and various laboratory values within normal limits. Patients who have undergone stem cell transplantation are eligible if they meet certain criteria. Female patients of childbearing age must have a negative pregnancy test and agree to use contraception. Patients may not be receiving any other investigational agents and must not have received previous treatment with entinostat or other HDAC inhibitors. Patients with active CNS leukemia or uncontrolled intercurrent illness are excluded from the study. Pregnant women and HIV-positive patients on combination antiretroviral therapy are also ineligible.",
    "The sample is a clinical trial for phase 1, which involves testing the effectiveness of cetuximab and lapatinib on patients with colorectal cancer, lung cancer, and head and neck cancer. The trial has specific eligibility criteria, including having at least one measurable lesion, being over 18 years old, and having progressed after standard therapy. There are also exclusion criteria, such as having untreated brain metastasis or a severe medical condition that could affect participation in the study. The trial requires patients to provide informed consent and comply with the protocol.",
    "The sample is a record of a clinical trial that is in phase 1/phase 2. The trial is focused on the disease systemic sclerosis, which is associated with a list of icd-10 codes. The trial is testing the effectiveness of two drugs, rapamycin and methotrexate, on patients who meet certain eligibility criteria. These criteria include satisfying the American College of Rheumatology classification criteria for systemic sclerosis, having skin thickening proximal to the elbows and/or knees, and having cutaneous involvement for less than 5 years from the onset of the first non-Raynaud's manifestation. The sample also lists exclusion criteria, such as severe intractable malabsorption and chronic debilitation from any underlying disease. Patients who have been off putative disease modifying therapies for one month prior to entry are also excluded from the trial.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying malignant pleural mesothelioma and solid tumors. The icd-10 codes for the diseases are listed as C45.9, C45.0, C45.1, C45.2, and C45.7. The drugs being used are pemetrexed, cisplatin, and cbp501, as well as pemetrexed and cisplatin. The eligibility criteria include having a confirmed diagnosis of the disease, measurable disease according to the modified Response Evaluation Criteria in Solid Tumors, being at least 18 years old, having an ECOG Performance Status of 0-2, and having adequate organ function. There are also exclusion criteria, such as having an ongoing or active infection, previous history of another malignancy within 5 years, and presence of CNS metastases.",
    "The sample is a phase 1 clinical trial for pancreatic cancer. The trial is open to patients with locally advanced, metastatic, or recurrent disease that has been histologically confirmed. Patients must have measurable or evaluable disease by physical exam, plain radiographs, CT scan, or MRI, and must not have brain metastases. Patients must also meet certain criteria related to their health status, including ECOG performance status, life expectancy, blood counts, liver and kidney function, and absence of other medical conditions. Patients must not have received prior therapy for metastatic disease, except for certain cases involving prior fluorouracil as a radiosensitizer. Patients must not have had major surgery within the past 2 weeks, and must not consume grapefruit or grapefruit juice during the trial.",
    "The sample is a phase 1 clinical trial for patients with soft tissue sarcoma or mesothelioma. The trial is testing the effectiveness of the drug combination of azacitidine and temozolomide. The eligibility criteria include having confirmed soft tissue sarcoma or mesothelioma, being ineligible for other high priority studies, having measurable disease, and having received prior chemotherapy with the exception of temozolomide or azacitidine. Patients must also meet certain laboratory and clinical parameters, be willing to use effective contraception, and provide written informed consent. Exclusion criteria include hypersensitivity to azacitidine or mannitol, pregnancy or breastfeeding, other types of cancer, uncontrolled infection or serious systemic disease, prior treatment with temozolomide or azacitidine, and uncontrolled central nervous system metastases.",
    "The sample is a phase 1 clinical trial for patients with various types of solid tumors or lymphomas that are refractory to standard treatment or have no potentially curative treatment options available. The trial requires patients to have a performance status of ECOG 0-2 and meet various medical criteria, including having no CNS metastases, normal cardiac function, and no significant pulmonary disease. Patients must also be willing to return to Mayo Clinic for follow-up and cannot have received certain types of prior therapy or be on certain concurrent medications. The trial involves the drugs tanespimycin and bortezomib and requires patients to undergo biopsy.",
    "The sample is a phase 1 clinical trial for patients with severe peripheral arterial disease. The trial involves testing the effectiveness of two drugs, biwh 3 and placebo. The eligibility criteria for the trial include being at least 18 years old, having a life expectancy of at least six months, and having severe PAOD with Chronic Critical Limb Ischaemia, Fontaine class III or IV due to atherosclerotic disease. Patients with certain medical conditions or abnormalities in laboratory values are excluded from the trial. Additionally, patients who have used certain medications or have certain medical conditions are also excluded. Women of childbearing potential must use a form of birth control during the trial.",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a phase 1 trial for the treatment of colorectal cancer. The record includes the names of the diseases being studied, the corresponding ICD-10 codes, the drugs being used in the trial, and the eligibility criteria for participants. The inclusion criteria include age restrictions, confirmation of CRC diagnosis, prior therapy with specific drugs, and measurable lesions. The exclusion criteria include certain medical conditions and prior treatment with specific drugs. The record also notes that there may be additional inclusion/exclusion criteria.",
    "The sample is a phase 1 clinical trial for patients with advanced cancer that has progressed after treatment and has no standard therapy that is curative or provides clinical benefit. The trial is testing the drug ENMD-2076. The eligibility criteria include having histologic proof of advanced cancer, meeting certain criteria for disease progression, being over 18 years old, having certain laboratory values within normal limits, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and agreeing to use effective contraceptive methods. Exclusion criteria include pregnancy or nursing, recent radiotherapy or chemotherapy, participation in any clinical trial involving conventional or investigational drugs within 28 days prior to initiation of ENMD-2076 dosing, active, acute, or chronic clinically significant infections, uncontrolled severe hypertension or congestive heart failure, and additional uncontrolled serious medical or psychiatric illness.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is for acute lymphoblastic leukemia and is in phase 1/phase 2. The drugs being used are bortezomib, dexamethasone, peg-asparaginase, doxorubicin, cytarabine, methotrexate, vincristine, and triple it therapy. The eligibility criteria include age restrictions, diagnosis requirements, performance level, prior therapy, reproductive function, and exclusion criteria such as drug allergies, renal and liver/pancreatic function, cardiac function, and infection.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating mucositis and head and neck cancer using drugs such as placebo, palifermin, and cisplatin. The trial has eligibility criteria for the participants, including having a newly diagnosed histologically confirmed squamous cell carcinoma and being scheduled to receive adjuvant concurrent chemoradiation treatment within 12 weeks of surgery. The trial also has exclusion criteria, such as having tumors of the lips, paranasal sinuses, salivary glands, or unknown primary tumors, and having a history of pancreatitis or prior radiotherapy or chemotherapy.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial involves testing the drug \"bi 660848\" and a placebo on male participants between the ages of 21 and 50 with a BMI between 18.5 and 30 kg/m2. The trial is focused on the treatment of pain and includes both healthy participants and those with certain diseases. The diseases are listed along with their corresponding ICD-10 codes. The eligibility criteria for the trial are also listed, including requirements for a complete medical history, normal vital signs, and a signed informed consent form. The exclusion criteria are also listed, which include any relevant medical conditions, drug use, and lifestyle factors that could affect the trial results.",
    "The sample is a clinical trial for patients with bladder cancer in phase 1/phase 2. The trial is looking at the effectiveness of paclitaxel, nanoparticle albumin-bound as a treatment for recurrent bladder cancer that is refractory to standard intravesical therapy. The eligibility criteria include having a diagnosis of transitional cell carcinoma of the urinary bladder, being over 18 years old, having a performance status of ECOG 0,1, and having no more than grade 1 peripheral neuropathy. Patients must also have adequate hematologic and hepatic function, and women of childbearing potential must have a negative pregnancy test and use effective contraception. Exclusion criteria include prior systemic docetaxel or paclitaxel therapy, concurrent treatment with any chemotherapeutic agent, and history of neuropathy of any cause.",
    "The sample is a clinical trial for pancreatic cancer patients who are deemed unresectable due to local involvement of vessels or organs. The trial is a combination of phase 1 and phase 2. The trial involves the use of three drugs: oxaliplatin, 5fu, and folfox 6. The eligibility criteria include having a clear clinical diagnosis of localized pancreatic cancer, no prior chemotherapy or abdominal radiation therapy, Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1, clinically measurable or evaluable disease, life expectancy of at least 12 weeks, adequate bone marrow reserve, adequate renal function, adequate biliary function, age over 18 years, signed informed consent, no known allergy to one of the study drugs, and no prior malignancy within the last 5 years. The exclusion criteria include active or uncontrolled infection, presence of metastatic disease, inadequate organ function, pregnancy, serious concomitant systemic disorder, and use of any investigational agent within a month of treatment.",
    "The sample is a phase 1 clinical trial for the treatment of acute coronary syndrome. The trial involves the use of drugs such as losmapimod and moxifloxacin, as well as their respective placebos. The eligibility criteria for the trial include being healthy, between the ages of 18 and 65, and meeting certain weight and BMI requirements. Additionally, female participants must either be non-childbearing or agree to use contraception during the trial. Exclusion criteria include cardiac abnormalities, allergies to the drugs being used, and a history of certain medical conditions. Participants must also refrain from using certain medications and supplements prior to the trial. The trial is not open to pregnant or lactating females, and participants must be willing and able to follow the procedures outlined in the protocol.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on squamous cell cancer and includes a list of ICD-10 codes associated with the disease. The trial involves several drugs, including cilengitide, cetuximab, 5-fluorouracil, and cisplatin. The eligibility criteria for the trial include a confirmed diagnosis of SCCHN, at least one measurable lesion, and a Karnofsky performance status of greater than or equal to 70 or an ECOG PS of 0-1 at trial entry. Exclusion criteria include prior systemic chemotherapy, surgery or irradiation within 4 weeks before trial entry, nasopharyngeal carcinoma, documented or symptomatic brain or leptomeningeal metastasis, and previous treatment with epidermal growth factor receptor (EGFR) targeting therapy or signal transduction inhibitors.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on treating leukemia and myelodysplastic syndromes using the drugs vorinostat and decitabine. The eligibility criteria for the trial include being at least 18 years old with refractory/relapsed AML, being at least 4 weeks from prior treatment and having recovered from all prior treatment side effects, having no known liver or kidney problems, being able to swallow capsules, and being willing to practice birth control during the study. The exclusion criteria include having received prior treatment with valproic acid, decitabine or azacitidine, being less than 18 years of age or if patient has untreated AML is below 60 years of age, having an active infection that requires antibiotics, having uncontrolled illness, having known human immunodeficiency virus (HIV) infection or HIV-related malignancy, having a known history of hepatitis B or C infection, currently having another active cancer other than certain types of skin cancer, and being heterosexual and able to have a child and unwilling to practice birth control during the study.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on neoplasms, which are malignant tumors. The trial is looking at the effectiveness of the drugs bay86-9766 on patients with advanced or refractory solid tumors that are not responding to standard therapy. The trial is only open to Japanese patients who are at least 18 years old and have a life expectancy of at least 12 weeks. The trial has specific inclusion and exclusion criteria, including having a measurable lesion or evaluable disease, having an Eastern cooperative oncology group performance status (ECOG-PS) of 0 or 1, and not having uncontrolled hypertension or chronic active hepatitis B or C. The trial also excludes patients who have inadequate bone marrow, liver, or renal function, or who are unable to swallow oral medications.",
    "The sample is a phase 1 clinical trial for patients with locally advanced or metastatic colorectal cancer. The trial involves the use of three drugs, zd6474, cetuximab, and irinotecan. The eligibility criteria include having 1-2 prior therapies for metastatic colorectal cancer, being K-ras wildtype, having measurable disease according to the RECIST criteria, being 18 years of age or older, having an ECOG Performance Status of 0-2, and having adequate bone marrow, renal, and hepatic function. Patients must also agree to use an effective form of contraception during the study and 90 days following the last dose of medication. Exclusion criteria include having a history of prior malignancy within the past 3 years, prior therapy with gefitinib, erlotinib, cetuximab, ABX-EGF or other specific EGFR inhibitor, known hypersensitivity to any components of each drug, being pregnant or lactating, having any other medical condition deemed by the clinician to be likely to interfere, and having evidence of severe or uncontrolled systemic disease or any concurrent illness that, in the opinion of the investigator, makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating metastatic or inoperable breast cancer, colon cancer, or melanoma using a drug called pd-0325901. The trial requires patients to meet certain eligibility criteria, such as being over 18 years old, having adequate renal, liver, and bone marrow function, and having a measurable lesion that has not been irradiated. Patients must also not have any ongoing radiation therapy or radio-cytotoxic therapy within the prior 4 weeks, no concurrent serious infection or life-threatening illness unrelated to the tumor, and no untreated brain metastases. The trial also has exclusion criteria, such as no parathyroid disorder or history of malignancy associated hypercalcemia and no history of any cancer other than the present condition, unless in complete remission and off all therapy for that disease for a minimum of 3 years.",
    "The sample is a phase 1 clinical trial for patients with previously untreated or systemically treated poor prognosis non-small cell lung cancer. The trial is testing the effectiveness of the drug sorafenib in combination with palliative thoracic irradiation therapy. The eligibility criteria include having an evaluable primary tumor and/or regional lymphatic metastases, being 18 years or older, having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 or greater, and having adequate bone marrow, liver, and renal function. Women of childbearing potential must have a negative pregnancy test and both men and women must agree to use adequate contraception. Exclusion criteria include having congestive heart failure, uncontrolled hypertension, or a bleeding diathesis or coagulopathy. Patients with squamous cell carcinoma are also excluded.",
    "The sample is a phase 1 clinical trial for the treatment of rheumatoid arthritis. The trial includes patients who meet the American College of Rheumatology classification criteria for the diagnosis of rheumatoid arthritis and have active disease. The patients must have had an inadequate response to at least one disease-modifying antirheumatic drug (DMARD), non-biologic or biologic, due to ineffectiveness or intolerance. The trial excludes pregnant or lactating women, patients with serious medical conditions that would make treatment with CP-690,550 potentially unsafe, and patients with a history of asthma, multiple allergies, or severe allergy to any substance. The trial involves the use of CP-690,550 or placebo as the drug treatment. The eligibility criteria for the trial are listed under inclusion and exclusion criteria.",
    "The sample is a clinical trial for non-small cell lung cancer patients in phase 1/phase 2. The trial involves the use of drugs such as carboplatin, paclitaxel, and medi-575. The eligibility criteria include having inoperable Stage IIIB or Stage IV non-small cell lung cancer, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and a life expectancy of at least 3 months. Participants must also have adequate hematologic and organ function, be suitable candidates for therapy with carboplatin/paclitaxel, and have at least one measurable lesion. Exclusion criteria include concurrent enrollment in another clinical study, previous monoclonal antibody treatment specifically directed against platelet-derived growth factor (PDGF) or PDGF receptors, and history of serious allergy or reaction to any component of the MEDI-575 formulation.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on treating various diseases including preleukemia, myeloproliferative disorders, lymphoma, myeloma, and graft versus host disease. The diseases are identified by their corresponding ICD-10 codes. The trial involves the use of three drugs: fludarabine, melphalan, and campath. The eligibility criteria for the trial are listed, including various inclusion and exclusion criteria. The inclusion criteria include patients with relapsed or refractory acute myelogenous or lymphoid leukemia, chronic myelogenous leukemia in accelerated phase or blast-crisis, and multiple myeloma at high risk for disease recurrence, among others. The exclusion criteria include clinical progression and contra-indications for vaccination.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on treating metastatic breast cancer using a combination of drugs including ct-p6, herceptin, and paclitaxel. The trial has eligibility criteria for inclusion and exclusion. Inclusion criteria include being a female with Her 2 over-expression and ECOG 0 or 1. Exclusion criteria include having current clinical or radiographic evidence of CNS metastases, current known infection, or being a pregnant or nursing mother. The icd-10 codes associated with the disease are also listed.",
    "The sample is a clinical trial for patients with head and neck cancer who have not responded to previous treatment. The trial is in phase 1/phase 2 and involves the use of three drugs: carboplatin, cetuximab, and rad001. The eligibility criteria include having measurable disease, being diagnosed with squamous cell carcinoma of the head and neck, and having a performance status of 0-2. Patients must also have adequate bone marrow, liver, and renal function, and a life expectancy of at least 4 months. Exclusion criteria include having uncontrolled brain or leptomeningeal metastases, receiving anticancer therapies within 4 weeks of the start of the study, and having a known hypersensitivity to the drugs being used. Patients must also not have any severe or uncontrolled medical conditions that could affect their participation in the study.",
    "The sample is a phase 1 trial with only one disease, which is \"healthy\". The icd-10 codes associated with this disease are \"Z76.3\" and \"Z76.2\". The trial involves testing the drugs \"glpg1205 single ascending doses, oral suspension\", \"placebo single ascending doses, oral suspension\", \"glpg1205, multiple ascending doses, oral suspension\", and \"placebo, multiple ascending doses, oral suspension\". The eligibility criteria for the trial include being a healthy male between the ages of 18-50 with a BMI between 18-30 kg/m2. The exclusion criteria include any condition that might interfere with the procedures or tests in the study, drug or alcohol abuse, and smoking.",
    "The sample is a clinical trial for patients with locally advanced, inoperable or metastatic pancreatic adenocarcinoma. The trial is in phase 1/phase 2 and the drug being tested is a combination of bay86-9766 and gemcitabine. The eligibility criteria include having at least one measurable lesion, a certain performance status, and normal cardiac function. Exclusion criteria include a history of cardiac disease, active infections, and previous systemic therapy for pancreatic cancer or other malignancies. The sample also includes a list of diseases (pancreatic neoplasms) and their corresponding ICD-10 codes.",
    "The sample is a phase 1 clinical trial for patients with advanced lung, pancreatic, and esophageal cancer. The trial involves the use of the drugs amg 706, gemcitabine, and cisplatin. The eligibility criteria include having a competent understanding of the informed consent form, a performance status of 0 or 1, adequate hematological, renal, and hepatic function, and a life expectancy of at least 3 months. Exclusion criteria include having had more than one prior chemotherapy regimen, a history of venous thrombosis, and recent myocardial infarction or cerebrovascular accident. The full list of inclusion and exclusion criteria can be found in the investigator's documentation.",
    "The sample is a phase 1 clinical trial for the treatment of inflammation and psoriasis. The trial involves administering either an anti-IL-20 drug or a placebo to subjects who have moderate to severe chronic plaque psoriasis for at least 6 months, with or without psoriatic arthritis. The trial has specific inclusion and exclusion criteria, including a minimum affected body surface area and physician's global assessment score, as well as restrictions on concomitant treatments and certain medical conditions. The trial also requires subjects to use effective birth control and excludes those with a history of HIV, hepatitis B and/or C, lymphoproliferative disease, or malignancy within the last 5 years.",
    "The sample is a phase 1 clinical trial for patients with acute myeloid leukemia. The trial is open to untreated AML patients over the age of 60 or relapsed/refractory AML patients over the age of 18 who have received up to 2 previous lines of intensive chemotherapy. The trial drug is rad001 (everolimus). Patients must meet certain eligibility criteria, including having a life expectancy of greater than 3 months in relation to diseases other than AML/MDS, having an ECOG performance status of 0-3, and having normal electrolyte levels and adequate hepatic and renal function. Patients with certain medical conditions or who are non-compliant with medication are excluded from the trial. Male patients with a female partner of childbearing potential must agree to use at least 2 effective contraceptive methods throughout the study and for 6 months following the last dose.",
    "The sample is a clinical trial for Friedreich's Ataxia, a genetic disease affecting the nervous system. The trial is in Phase 1/Phase 2 and involves testing the effectiveness of the drug deferiprone compared to a placebo. The trial has specific inclusion and exclusion criteria, including a confirmed diagnosis of FRDA, a FARS score between 20 and 85, and no exposure to certain antioxidants for at least one month prior to the study. The trial also excludes individuals with iron deficiency, abnormal ALT levels, or a history of malignancy or drug abuse. Participants must provide written informed consent and adhere to study restrictions and appointments.",
    "The sample is a phase 1 clinical trial for the treatment of dry eye. The trial involves testing the effectiveness of two drugs, ebi-005-1 and ebi-005-1 placebo, on healthy adult males and females between the ages of 18 and 65 years who have best correction vision of greater than or equal to 20/40 in each eye and who have not used tobacco or nicotine-containing products for at least 6 months prior to dosing. The trial has a list of inclusion and exclusion criteria, including no history of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease, and no history of laser refractive surgery, corneal transplantation, dry eyes, or radiotherapy to the eyes. The trial also requires subjects to tolerate topical administration to the eye and to provide a signed and dated Institutional Review Board (IRB) approved informed consent form (ICF) prior to any protocol-specific screening procedures.",
    "The sample is a phase 1 clinical trial for indolent B cell Non-Hodgkin's lymphoma patients who have had prior therapy. The trial is testing the effectiveness of bendamustine hydrochloride as a treatment. The eligibility criteria include having confirmed indolent B cell Non-Hodgkin's lymphoma, not having received treatment for more than 4 weeks following prior therapy, being aged between 20 and 75 years, and agreeing to in-patient treatment during the first course of therapy. Exclusion criteria include having infections, serious complications such as hepatic or renal failure, serious heart failure, serious digestive symptoms, being positive for HBV, HCV or HIC, receiving other investigational drugs within 3 months before registration in the study, having had an allogenic transplant, being pregnant or lactating, and not agreeing to contraception. Patients who are judged by the investigator as being unsuitable for inclusion in the study are also excluded.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on lung cancer and the icd-10 codes associated with it. The drug being tested is called ipi-504. The eligibility criteria for the trial include a confirmed diagnosis of Stage IIIb or Stage IV NSCLC, as well as measurable disease by RECIST criteria. There are also exclusion criteria, such as previous treatment with certain Hsp90 inhibitors and inadequate hematologic, renal, or hepatic function.",
    "The sample is a record from a clinical trial table. It pertains to a phase 1 trial for the treatment of acute myeloid leukemia using a drug called tki258. The record includes the eligibility criteria for the trial, including inclusion criteria such as a confirmed diagnosis of acute myeloid leukemia and being 18 years or older, and exclusion criteria such as intracranial disease or epidural disease, clinically significant cardiac disease, and uncontrolled diabetes mellitus. The record also includes the disease name, icd-10 codes, and drug name associated with the trial.",
    "The sample is a clinical trial for patients with HER-2-overexpressing breast cancer and radiographic evidence of metastatic disease. The trial is in phase 1/phase 2 and involves the drugs trastuzumab and rad001. The eligibility criteria include having a history of trastuzumab resistance, a performance status of 0-2, and meeting certain medical requirements such as having a certain level of blood counts and not having uncontrolled illnesses. Patients must also have measurable disease and cannot be receiving any other investigational agents. The trial has exclusion criteria such as having uncontrolled intercurrent illness, prior treatment with investigational drugs, and a history of noncompliance to medical regimens. Patients must sign an informed consent document and must be willing and able to comply with the protocol.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, ICD-10 codes associated with the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on advanced metastatic gastric cancer and recurrent gastric cancer. The ICD-10 codes associated with these diseases are listed. The drug being tested is paclitaxel. The eligibility criteria for participants include having a proper bone marrow, kidney, and liver function, and not having any remarkable dysfunction of the heart and lungs. Patients with certain medical histories or conditions are excluded from the trial.",
    "The sample is a phase 1 clinical trial for patients with metastatic or unresectable renal cell carcinoma containing predominant clear cell histology. The trial involves the use of the drugs rad001 and sorafenib. The eligibility criteria include having measurable disease, being at least 21 years old, having an ECOG performance status of 0-1, and having adequate bone marrow, hepatic, and renal function. Patients must also be able to swallow oral medications and have resolved any pre-existing toxicity from prior therapy. Exclusion criteria include having certain types of renal cell carcinoma, prior treatment with certain drugs, and certain medical conditions. Patients must also be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.",
    "The sample is a phase 1 clinical trial for patients with breast cancer and nausea/vomiting. The trial involves the use of two drugs, aprepitant and cyclophosphamide, and has specific eligibility criteria for patients, including a minimum life expectancy of 2 months, certain blood counts, and no contraindications to aprepitant. The trial also has prior concurrent therapy requirements and excludes patients taking certain medications that may interact with the drugs being tested. The diseases and their corresponding ICD-10 codes are listed in the table.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on cardiovascular diseases, dilated cardiomyopathy, heart diseases, and congestive heart failure. The trial is testing the effectiveness of allopurinol and dobutamine as treatments. The eligibility criteria for participants include having a diagnosis of idiopathic cardiomyopathy, being in NYHA Class I-II heart failure, having stable heart failure medication for at least 1 month prior to study entry, and being able to lie flat for 45 minutes. There are also exclusion criteria, such as a history of poorly controlled hypertension, acute gout, or a contraindication to MRI.",
    "The sample is a phase 1 clinical trial for patients with advanced solid tumors that have not responded to standard therapy or for which no standard therapy exists. The trial is testing the drug tki258. Patients must have a WHO performance status of 2 or less and meet certain laboratory values. Patients with brain cancer or severe medical conditions that could affect participation in the study are excluded. Female patients who are pregnant, breastfeeding, or not willing to use effective birth control are also excluded. Other inclusion and exclusion criteria may apply as defined by the protocol. The diseases being studied include neoplasm, cancer, and tumors, and their corresponding ICD-10 codes are listed.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on pancreatic cancer and the icd-10 code associated with it is C25.3. The drugs being tested are cp-675,206 and gemcitabine. The eligibility criteria for the trial include having metastatic pancreatic cancer, adequate bone marrow, liver and kidney function, an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1, being chemotherapy naive, and having inoperable pancreatic cancer. The exclusion criteria include not having received prior systemic therapy for pancreatic cancer, not having previously received anti-CTLA4 therapy, and having a history of chronic inflammatory or autoimmune disease.",
    "This sample is a phase 1 clinical trial for the treatment of hypercholesterolemia. The trial includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being tested, including alirocumab, ezetimibe, ezetimibe placebo, and fenofibrate. The eligibility criteria for the trial include healthy male or female subjects between the ages of 18 and 65 with LDL-C levels greater than 130 mg/dL who are not currently receiving lipid lowering therapy. Exclusion criteria include subjects with a history or presence of clinically relevant illness, those currently taking statins, ezetimibe, or fenofibrate, and those who do not meet the eligibility criteria. The sample also includes a disclaimer that the information provided is not intended to contain all considerations relevant to a patient's potential participation in the trial.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying prostate cancer. The icd-10 codes associated with the disease are listed, as well as the drugs being used in the trial (docetaxel and gemcitabine). The eligibility criteria for participants are also listed, including requirements such as a certain stage of the disease, PSA levels, and satisfactory liver and kidney function. The sample also includes exclusion criteria, such as previous treatment with certain medications or radiation therapy.",
    "The sample is a phase 1 clinical trial for the treatment of inflammation and rheumatoid arthritis using anti-IL-20 and placebo drugs. The trial has specific inclusion and exclusion criteria, including a diagnosis of rheumatoid arthritis, active symptoms, and stable methotrexate treatment. Exclusion criteria include other autoimmune diseases, infectious diseases, and past or current malignancy. The trial is not open to women who are breastfeeding. The diseases and their corresponding ICD-10 codes are listed in the table.",
    "The sample is a phase 1 clinical trial for the treatment of migraines using the drug sumatriptan. The eligibility criteria include being between the ages of 18 and 55, having a BMI between 18 and 32, and being in good health with no significant medical conditions. Female participants must either be sexually inactive or using an acceptable form of birth control. Exclusion criteria include a history of migraines, allergies to sumatriptan or sulphonamides, recent surgery or hospitalization, and abnormal values for hematology, clinical chemistry, or urinalysis. Participants must also be willing to adhere to the study visit schedule and other protocol requirements.",
    "The sample is a phase 1 clinical trial for patients with advanced solid tumors that have recurred or progressed following standard therapy. The trial is testing two drugs, arry-520 and filgrastim, administered intravenously and subcutaneously respectively. The eligibility criteria include having histological or cytological evidence of malignancy, an ECOG performance status of 0, 1 or 2, and adequate hematology counts and serum chemistry values. The exclusion criteria include recent treatment with investigational products or anti-neoplastic therapy, major surgery, and radiotherapy. The trial also excludes patients with positive serology for HIV, hepatitis C, and/or active hepatitis B.",
    "The sample is a phase 1 clinical trial for patients with metastatic or unresectable breast cancer that is estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) negative. The trial is testing the effectiveness of the drugs dinaciclib and epirubicin hydrochloride. Patients must meet certain eligibility criteria, such as having no more than two prior chemotherapy regimens for metastatic breast cancer and a life expectancy of greater than 3 months. Patients must also have no history of prior therapy with dinaciclib and must have completed and recovered from the effects of prior chemotherapy. The trial has exclusion criteria, such as patients who have had chemotherapy or radiotherapy within 3 weeks prior to entering the study or those who have not recovered from adverse events. Patients with untreated brain metastases and pregnant women are also excluded from the study.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on the treatment of type 2 diabetes mellitus using the drug dapagliflozin. The trial includes a list of inclusion and exclusion criteria for participants, such as being diagnosed with type 2 diabetes and having a steady dosage of voglibose treatment for at least 8 weeks. The trial also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a clinical trial for a drug called rituximab (anti-cd20) for the treatment of Sjogren's syndrome. The trial is in phase 1/phase 2 and the eligibility criteria include having stimulated whole saliva secretion of at least 0.15 ml/min, being over 18 years old, having primary Sjogren's syndrome according to the revised European-U.S. criteria, and having positive autoantibodies (IgM-Rf > 10 and SS-A and/or SS-B). Exclusion criteria include having any other connective tissue disease, having received certain treatments within a certain time frame, having certain abnormal lab values, and having certain medical conditions that would make participation in the study too risky. Participants must also use a reliable method of contraception during the study and provide written informed consent.",
    "The sample is a phase 1 clinical trial for patients with locally advanced or metastatic cancer for which no preferable therapy exists. The trial is testing the effectiveness of enzastaurin hydrochloride as a treatment option. The eligibility criteria include having a histologic or cytologic diagnosis of cancer, measurable or nonmeasurable disease, and an ECOG performance status of 0-2. Patients must also meet certain laboratory values and have no concurrent serious systemic disorder or known hypersensitivity to the drug being tested. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 1 clinical trial for patients with ovarian carcinoma. The trial includes patients who are 18 to 75 years old, have biopsy-proven ovarian, tubal or primary peritoneal epithelial adenocarcinomas, and have a performance status of 0 or 1. Patients at high risk of clinical relapse, as well as those who have recurred and are in second chemotherapy-induced remission, are also included. The trial excludes patients with performance status ECOG =2,3,4, those who are on warfarin or prior therapeutic anticoagulation, and those who have another primary malignancy that has required active intervention within 5 years, with the exception of basal cell skin cancer or a cervical carcinoma in situ. Patients with severe and/or uncontrolled medical disease, those who had a major surgery within 2 weeks prior to study entry, and those with known bleeding disorder are also excluded. The trial has eligibility criteria related to end organ function, including total bilirubin, SGOT and SGPT, creatinine, ANC, and platelets. The drug used in the trial is fondaparinux.",
    "The sample is a phase 1 clinical trial for patients with metastatic or unresectable solid tumors that are refractory to or have progressed following standard therapies, or for diseases for which no standard therapy exists. The trial is limited to patients with differentiated thyroid cancer and renal cell carcinoma. The trial involves the use of two drugs, rosiglitazone and xl184, and has specific inclusion and exclusion criteria. Inclusion criteria include having a measurable lesion, a BMI between 18 and 33 kg/m2, a Karnofsky Performance Status of \u2265 70, and adequate organ and marrow function. Exclusion criteria include having certain prior treatments, experiencing clinically-significant hematemesis or hemoptysis, not recovering from toxicity due to prior therapies, having a primary brain tumor or brain metastases or spinal cord compression, having a PT/INR or PTT at screening \u2265 1.5 times the laboratory upper limit of normal, having uncontrolled, significant intercurrent illness, having an inherited bleeding diathesis or coagulopathy with the risk of bleeding, being pregnant or breastfeeding, having HIV, Hepatitis B, or Hepatitis C, having an allergy or hypersensitivity to components of either of the study treatment formulations, having a history of any medical or surgical conditions that would potentially interfere with or alter the gastrointestinal absorption, distribution, metabolism, or excretion of the study drug, having a history of, or clinical evidence of, pancreatic injury or pancreatitis, having hepatic impairment, being treated with drug(s) that are known to be either extensively metabolized by CYP2C8 or inhibitors of either CYP2C8 or CYP3A4, or inducers of CYP3A isozymes, using any prohibited prescription medications or products prior to the first Check-in, being unable or unwilling to forgo the use of such products from the first Check-in through the Day 23 Discharge, unless deemed acceptable by the investigator, having poor peripheral venous access, receiving warfarin (or other coumarin derivatives) at study entry and unable to switch to low molecular weight heparin, or receiving dialysis.",
    "The sample is a phase 1 clinical trial for patients with non-Hodgkin lymphoma. The trial is testing the effectiveness of the drugs SB-485232 and rituximab. The eligibility criteria include having a confirmed diagnosis of CD20+ B cell NHL that has progressed after standard therapy or for which there is no effective standard therapy. Patients must also have measurable or evaluable disease, a predicted life expectancy of at least 12 weeks, and an ECOG Performance Status of 0 or 1. Exclusion criteria include significant cardiac, pulmonary, metabolic, renal, hepatic, gastrointestinal or autoimmune conditions, as well as pregnancy or breastfeeding. Patients must also not be receiving concurrent chemotherapy, immunotherapy, radiotherapy, or investigational therapy. The trial requires a signed and dated written informed consent form from the patient.",
    "The sample is a phase 1 clinical trial for the treatment of advanced solid tumors, specifically carcinoma, renal cell. The trial involves the use of two drugs, pazopanib and lapatinib. The eligibility criteria include having a confirmed diagnosis of advanced solid tumor, a performance status of 0 or 1, adequate bone marrow reserve and hepato-renal function, and the ability to swallow and retain oral medication. Exclusion criteria include prior treatment with pazopanib or lapatinib, clinically significant gastrointestinal abnormalities, poorly controlled hypertension, and use of other anti-angiogenesis agents or ErbB inhibitors. Women and men with potential to have children must be willing to practice acceptable methods of birth control during the study. Pregnant or lactating females are excluded from the trial.",
    "The sample is a phase 1 clinical trial for the treatment of chronic lymphocytic leukemia. The trial includes patients with confirmed diagnosis of CD20-positive B-CLL and Rai Stage III/IV or Binet Stage C disease, or Rai Stage I/II or Binet Stage B disease that requires treatment. The trial involves the use of drugs such as fludarabine, obinutuzumab, bendamustine, and cyclophosphamide. The eligibility criteria include adequate baseline bone marrow function, no previous treatment for CLL by chemotherapy, radiotherapy, or immunotherapy, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. The exclusion criteria include treatment with any other investigational agent or participation in another clinical trial within 28 days prior to the start of Cycle 1, transformation of CLL to aggressive B-cell malignancy, and various other medical conditions. Women who are pregnant or lactating and fertile men or women of childbearing potential are also excluded unless using adequate contraception.",
    "The sample is a phase 1 clinical trial for patients with metastatic melanoma. The trial involves the use of two drugs, disulfiram and arsenic trioxide. The eligibility criteria include having measurable disease, undergoing certain imaging tests, having progressed after at least one prior systemic therapy, and having a performance status of 0-2. Exclusion criteria include pregnancy or nursing, severe myocardial disease or coronary occlusion, psychoses, hypersensitivity to disulfiram or other thiuram derivatives, and inability to abstain from alcohol intake during the trial.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating prostate cancer, including recurrent, stage I, III, and IV prostate cancer. The trial involves the use of three drugs: sunitinib malate, docetaxel, and prednisone. The eligibility criteria for the trial include having a histological diagnosis of adenocarcinoma of the prostate, being at least 18 years old, having metastatic prostate cancer that is unresponsive or refractory to hormone therapy, and having adequate hepatic and renal function. The trial also has exclusion criteria, such as not having received chemotherapy or biologic therapy within 28 days prior to the start of therapy, not having ongoing problems with bowel obstruction or short bowel syndrome, and not having a known severe and/or uncontrolled concurrent medical disease. The trial requires informed consent from all participants.",
    "The sample is a phase 1 clinical trial for patients with solid tumors or lymphoma who are resistant or refractory to approved therapies or for whom no appropriate therapies are available. The trial involves the drug lenvatinib and has a set of inclusion and exclusion criteria that patients must meet in order to participate. The inclusion criteria include having completed all previous treatments at least four weeks prior to study entry, being at least 18 years old, having a Karnofsky performance status of at least 70%, and providing written informed consent. The exclusion criteria include having brain tumors or brain or leptomeningeal metastases, certain laboratory parameters outside of normal ranges, uncontrolled infections, clinically significant cardiac impairment or unstable ischemic heart disease, recent treatment with investigational drugs, pregnancy or lactation, and various other medical conditions.",
    "The sample is a phase 1 clinical trial for patients diagnosed with B-CLL/SLL (B-chronic lymphocytic leukemia/small lymphocytic lymphoma) who have relapsed after at least one prior fludarabine-containing regimen and require treatment based on NCI-WG criteria. The trial involves the use of rituximab and alemtuzumab drugs. The eligibility criteria include confirmation of the diagnosis at Brigham & Women's Hospital or Dana-Farber Cancer Institute, measurable disease, age >= 18, WHO Performance status <= 2, and expected survival > 3 months. Exclusion criteria include history of HIV, active infection uncontrolled by appropriate antibacterial, antiviral or antifungal therapy, known CNS involvement with CLL, pregnant or currently lactating women, prior anti-neoplastic therapy within the last three weeks, and patients who have received prior rituximab or alemtuzumab will not be excluded.",
    "The sample is a clinical trial for Crohn's disease, with a phase 1/phase 2 designation. The trial includes patients with colonic or ileocolonic CD who have been diagnosed for at least 3 months and have active CD, defined as a Crohn's Disease Activity Index (CDAI) of greater than 200 but less than 320 at the time of entry into the study. Patients must be over 18 years old and receiving stable doses of certain medications for a specified period of time prior to enrollment. The trial has both inclusion and exclusion criteria, with patients with only small bowel CD, fistulizing CD, or gastroduodenal CD without colonic involvement being excluded, as well as patients with known ulcerative colitis or who are expected to require surgery within 30 days for complications of CD. Patients with severe cardiac, pulmonary, or renal disease, a history of malignancy other than resected basal cell carcinoma of the skin, or who have participated in another clinical research study in the past 8 weeks are also excluded. Pregnant patients are not eligible for the trial.",
    "The sample is a phase 1 clinical trial for patients with solid tumors, specifically advanced colorectal cancer or other adenocarcinomas. The trial is testing the effectiveness of the drugs belinostat and 5-fluorouracil (5-fu) on patients who have experienced tumor progression after standard chemotherapy or where no approved treatment exists. Patients must have at least one measurable lesion, a Karnofsky performance score of at least 70%, a life expectancy of at least 3 months, and meet various other eligibility criteria related to liver, kidney, hematologic, and coagulation function. Patients must also be willing to comply with protocol procedures and use effective contraception if of child-producing potential. Exclusion criteria include significant cardiovascular disease, infections requiring IV systemic therapy, and serious concurrent medical illness.",
    "The sample is a clinical trial for patients with non-small cell lung cancer in phase 1/phase 2. The trial includes patients who are 70 years or older with either stage IIIB disease with malignant pleural effusion or stage IV disease. Patients must have measurable disease and an Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1. Patients must also meet certain criteria for renal, hepatic, and bone marrow function, and must be able to take dexamethasone, folic acid, and vitamin B-12 supplementation. Patients must not have certain exclusion criteria, such as lung carcinoma of squamous cell histology or any histology in close proximity to a major vessel, with or without cavitation, or a history of hemoptysis, hematemesis, coagulopathy, or thrombosis. The trial requires patients to sign informed consent and comply with study and/or follow-up procedures.",
    "The sample is a clinical trial for patients with chronic lymphocytic leukemia or lymphoplasmocytic lymphoma. The trial is in phase 1/phase 2 and involves the use of drugs such as busulfan, cyclophosphamide, and fludarabine phosphate. The eligibility criteria include having poor prognostic features and low probability of successful autografting, as well as meeting certain disease characteristics such as having a clonal CDR III rearrangement detected by polymerase chain reaction. Patients must also meet certain patient characteristics such as having normal organ function and not having concurrent alcohol or drug abuse. Prior concurrent therapy is not specified.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on prostate cancer, specifically castration-resistant prostate cancer (CRPC). The trial is testing the drug MDV3100. The eligibility criteria for the trial include having confirmed adenocarcinoma of the prostate, ongoing androgen deprivation therapy, and progressive disease after prior androgen deprivation therapy. The exclusion criteria include having metastases in the brain, a history of another malignancy within the previous 5 years, and evidence of serious drug hypersensitivity.",
    "The sample is a clinical trial for the treatment of acute myeloid leukemia. The trial is in phase 1/phase 2 and involves the use of voreloxin injection and cytarabine. The eligibility criteria for the trial include having relapsed or refractory AML, being treated with one to three induction/reinduction AML regimens, having at least 10% blasts by BM biopsy or aspirate, and having an ECOG Performance Status score of 0 or 1. There are also several exclusion criteria, such as having a history of myocardial infarction or cerebrovascular accident/transient ischemic attack within the 3 months before treatment with vosaroxin, and having any other medical, psychological, or social condition that contraindicates participation in the clinical study. Women who are pregnant or breastfeeding, or of childbearing potential, are also excluded from the trial.",
    "The sample is a clinical trial for the treatment of b-cell chronic lymphocytic leukemia and small lymphocytic lymphoma. The trial is in phase 1/phase 2 and involves the drug pci-32765. The eligibility criteria for the trial include confirmed diagnosis of CLL/SLL, age requirements, ECOG performance status of \u2264 2, and willingness to participate in all required evaluations and procedures. Exclusion criteria include prior malignancy, recent immunotherapy or chemotherapy, CNS involvement by lymphoma, and significant screening ECG abnormalities.",
    "The sample is a clinical trial with a phase 1/phase 2 design, focused on patients with metastatic infiltrating carcinoma of the breast. The trial aims to test the efficacy of a combination of drugs, including cyclophosphamide, doxorubicin hydrochloride, fludarabine phosphate, paclitaxel, and mesna. The trial also includes eligibility criteria, such as a Karnofsky performance status of greater than or equal to 70%, normal urinalysis, and a corrected carbon monoxide diffusing capacity (DLCO) greater than 50%. The trial excludes patients with autoimmune diseases, active inflammatory bowel disease, clinically significant cardiomyopathy, and brain metastases, among other conditions. The trial also includes exclusion criteria specific to vaccinia administration, such as a history of seizures, encephalitis, or multiple sclerosis, and allergy or complications with past vaccinia vaccination.",
    "The sample is a clinical trial for breast cancer patients who have Her-2 positive and ER-negative or ER-low breast cancer that has not spread to other parts of the body. The trial is in phase 1/phase 2 and the drug being tested is trastuzumab (herceptin\u00ae). The eligibility criteria include having had a core biopsy or incisional biopsy of the breast cancer but not yet having definitive breast surgery, not having a BRCA mutation found on genetic testing, and not having received any treatment for their breast cancer, including chemotherapy, hormonal therapy, or trastuzumab.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes associated with those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on infertility in females. The icd-10 codes associated with the disease include N97.9, N97.0, N97.1, N97.2, N97.8, and Z31.81. The drugs being used in the trial are g-csf and saline. The eligibility criteria for participants include having endometrial growth of less than 7 mm and being unresponsive to standard treatment for invitro fertilization and embryo transfer. Exclusion criteria include having sickle cell disease, renal insufficiency, upper respiratory infection or pneumonia, chronic neutropenia, or a known past or present malignancy.",
    "The sample is a phase 1 clinical trial for patients with metastatic breast cancer. The trial is testing the effectiveness of lapatinib ditosylate and doxil as treatments for the disease. The eligibility criteria for patients include having confirmed adenocarcinoma of the breast with evidence of metastatic disease, measurable disease, and a life expectancy of at least 12 weeks. Patients must also meet certain health requirements, such as having a normal bilirubin level and a LVEF of at least 50%. Prior concurrent therapy is allowed, but certain medications and treatments are not permitted during the trial.",
    "The sample is a phase 1 clinical trial for patients with a confirmed solid tumor malignancy. The trial involves treatment with a combination of investigational agents and either docetaxel or gemcitabine hydrochloride. Patients must have measurable or evaluable disease and an ECOG performance status of 0-1. They must also meet certain criteria related to blood counts, liver and kidney function, and other medical disorders. Patients cannot have had prior high-dose chemotherapy or more than three prior chemotherapy regimens. They also cannot receive any other licensed or investigational anticancer treatment during the trial. Concurrent systemic steroids and androgen-deprivation therapy are allowed.",
    "The sample is a clinical trial with a combination of two drugs, ji-101 and everolimus, for patients with advanced solid tumors that are refractory to standard therapy or for whom no standard therapy is available. The trial is in phase 1/phase 2 and includes patients with various types of cancer, including neuroendocrine, ovarian, and colon cancer. The eligibility criteria include being at least 18 years old, having at least one measurable tumor, and having normal organ and marrow function. Exclusion criteria include having a history of drug or alcohol abuse within the past two years, being pregnant or breastfeeding, and having a history of significant retinopathy or any progressive eye disease that could lead to severe loss of visual acuity or visual field loss during the study period.",
    "The sample is a record from a clinical trial database. It includes information about the phase of the trial, which is a combination of phase 1 and phase 2. The trial is focused on the treatment of chronic hepatitis C, and the icd-10 codes associated with the disease are listed. The trial involves two drugs, bms-791325 and placebo. The eligibility criteria for the trial are also listed, including requirements for HCV genotype, viral load, and BMI, as well as exclusion criteria such as co-infection with HIV or HBV.",
    "The sample is a phase 1 clinical trial for high-risk or relapsed solid tumors or brain tumors, including metastatic or relapsed Ewing's sarcoma, rhabdomyosarcoma, Wilms' tumor, neuroblastoma, retinoblastoma, germ cell tumors, soft tissue sarcomas, ovarian sarcoma, primitive neuroectodermal tumors of the bone, chordomas, and hepatoblastoma. Patients must be between the ages of 1 and 45 and have certain performance and blood count criteria. The trial involves receiving peripheral blood stem cell transplantation only if in complete remission or in very good partial remission with no disease progression. There are also exclusion criteria, such as having osteogenic sarcoma or being pregnant or nursing. The trial involves the use of drugs such as amifostine trihydrate, busulfan, filgrastim, melphalan, and thiotepa.",
    "The sample is a clinical trial for patients with Hepato Cellular Carcinoma (HCC) who are awaiting liver transplant or undergoing evaluation for it. The trial is in the early phase 1 and the drug being tested is Nexavar. The eligibility criteria include being over 18 years old, having confirmed diagnosis of HCC within Milan criteria, having Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1, and having adequate bone marrow, liver, and renal function. Exclusion criteria include prior use of sorafenib, known brain metastasis, uncontrolled hypertension, and major surgery or significant traumatic injury within 4 weeks of first study drug.",
    "The sample is a record of a clinical trial with the phase \"early phase 1\". The trial is focused on the disease \"asthma\" and includes a list of ICD-10 codes associated with the disease. The drug being tested is \"iloprost\". The eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include age between 18-60, history of asthma controlled by inhaled rescue medication or inhaled corticosteroids, ability to give informed consent, ability to perform pulmonary function tests, ability to tolerate the initial Ventavis inhalation, and ability to comply with the study protocol. Exclusion criteria include cigarette smoking, serious concomitant diseases, pregnancy or lack of contraception, allergies or intolerance to inhaled iloprost, participation in other ongoing research studies, psychological problems that may interfere with the investigation, history of bleeding disorder or use of anticoagulants, viral upper respiratory tract infection within the last 6 weeks, and asthmatics requiring higher doses of inhaled corticosteroids or using certain medications. Any screening laboratory blood test value outside the normal range will also exclude the individual from the study.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, prostate cancer), the ICD-10 codes associated with the disease, the drug being tested (he3235), and the eligibility criteria for participants. The eligibility criteria include requirements such as age, disease progression, and performance status, as well as exclusion criteria such as active infections or significant cardiovascular, hepatic, respiratory, or renal abnormalities. The sample also notes that additional criteria may apply to expansion cohorts.",
    "The sample is a table that contains information about a clinical trial for the treatment of renal cell carcinoma. The table includes the phase of the trial (phase 1/phase 2), a list of diseases (in this case, only renal cell carcinoma), a list of ICD-10 codes for the disease, a list of drugs being tested (a combination of temsirolimus and sunitinib), and eligibility criteria for the trial. The eligibility criteria include inclusion and exclusion criteria for both the dose escalation phase and the expanded cohort phase of the trial. The criteria specify requirements for the subject's medical history, prior treatments, and measurable lesions.",
    "The sample is a phase 1 clinical trial for patients with advanced solid tumors or lymphoma that are considered incurable using standard treatment. The trial involves the use of two drugs, gemcitabine hydrochloride and triapine, and has eligibility criteria including a certain performance status, blood counts, liver and kidney function, and no history of allergic reactions to similar compounds. Patients must also not have certain illnesses or be receiving certain treatments concurrently. The trial allows for prior use of gemcitabine hydrochloride but not 3-AP or fixed-dose gemcitabine hydrochloride. The sample includes a list of diseases and corresponding ICD-10 codes.",
    "The sample is a phase 1 clinical trial for asthma. The study includes both men and women between the ages of 18 and 65, with a body weight of at least 50 kg and a BMI within the range of 19-29.9 kg/m2. Participants must be non-smokers or ex-smokers who have given up smoking for more than 12 months with a history of less than 10 pack years. They must also be able to read, comprehend, and write English at a sufficient level to complete study-related materials and give written informed consent. The trial involves the use of two drugs, gsk679586 and placebo. The eligibility criteria include a history of asthma for at least 6 months prior to the screening visit, currently requiring no treatment or intermittent treatment with inhaled short-acting beta2-agonist only. The pre-bronchodilator FEV1 must be greater than 70% but less than 90% of predicted at screening with at least 12% reversibility after short-acting beta2-agonist. The skin prick test must be positive for an allergen that is appropriate for nasal challenge. The exclusion criteria include a history of sensitivity to any of the study medications, previous exposure to humanised antibody therapy for any reason, and a strong family history of Th1 cytokine-related inflammatory disorders. Participants must not have received any type of vaccination in the last two months or have participated in a clinical trial and received a drug or a new chemical entity within 30 days or 5 half-lives prior to the first dose of current study medication. They must also not have a history of chronic urogenital infections or other chronic infections, or have received more than four new chemical entities within 12 months prior to the first dosing day. Additionally, they must not have used prescription or non-prescription drugs, including vitamins, herbal and dietary supplements, within 7 days prior to the first dose of study medication, unless in the opinion of the Investigator and sponsor the medication will not interfere with the study procedures or compromise subject safety. The trial also excludes those with a history of alcohol/drug abuse or dependence within 12 months of the study, a positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening, a positive test for human immunodeficiency virus (HIV) antibodies, or a positive pre-study urine drug/urine alcohol screen.",
    "The sample is a phase 1 clinical trial for HIV infections using the drug maraviroc. The eligibility criteria include being at least 16 years old, having an HIV RNA level of at least 1000 copies/mL, and being able to receive at least 3 active drugs other than maraviroc in the new OBT based on screening genotypic resistance testing results. The exclusion criteria include having a potentially life-threatening laboratory abnormality or medical condition, severe hepatic impairment, or end-stage renal disease or other disease states requiring dialysis therapy. The diseases being studied are HIV infections and the corresponding ICD-10 code is Z21.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on treating patients with intracranial glioblastoma multiforme or gliosarcoma using the drugs enzastaurin and temozolomide. The eligibility criteria for the trial include having a confirmed diagnosis of the specified diseases, having undergone biopsy or resection no more than 5 weeks prior to treatment, and having adequate organ function demonstrated by lab tests. The exclusion criteria include being unable to swallow tablets, being unable to discontinue use of certain antiepileptic drugs, having an active infection, having a significant medical illness that cannot be controlled with therapy, or concurrent therapy with an anticoagulant.",
    "The sample is a phase 1 trial for a drug called rv568 and a placebo to treat respiratory syncytial virus infections. The trial is looking for healthy male subjects aged 18-45 years who are willing to use adequate contraception throughout the study and have negative hepatitis B, hepatitis C, and HIV screens. The trial also requires low titres of RSV neutralising antibody measured during screening. The eligibility criteria include exclusion of subjects with acute or chronic illness, clinically relevant abnormality, febrile illness, or symptoms of upper or lower respiratory tract infection in the 28 days prior to viral inoculation, history of asthma, COPD, pulmonary hypertension, reactive airway disease, or any chronic lung condition, diabetes, history or evidence of autoimmune disease or known impaired immune responsiveness, recent or recurrent history of autonomic dysfunction, anatomic or neurological abnormality impairing the gag reflex or associated with an increased risk of aspiration, any abnormality significantly altering the anatomy of the nose or nasopharynx, known IgA deficiency, immotile cilia syndrome, or Kartagener's syndrome, any nasal or sinus surgery within 4 months prior to virus administration, history of smoking in the past 6 months, positive test for drugs or alcohol at screening, inadequate venous access, abnormal pulmonary function at screening, abnormal laboratory or ECG at screening, acute or chronic use of medication to treat nasal congestion, use of any prescription drugs, herbal supplements, within 4 weeks prior to virus challenge, and/or over-the-counter medication, dietary supplements within 2 weeks prior to virus challenge, treatment with systemic glucocorticoids, antiviral drugs, immunoglobulins or blood transfusions within 1 month, or any other cytotoxic or immunosuppressive drug within 6 months prior to dosing, receipt of any systemic chemotherapy agent at any time, treatment with any investigational drug within 3 months, or prior participation in a clinical trial of any RSV IMP, medication or experimental RSV viral challenge delivered directly to the respiratory tract within 1 year prior to dosing, or receipt of more than 4 investigational drug within 12 months, history of multiple and recurring allergies and/or adverse reaction to any components of the challenge virus preparation, allergy to gentamicin, significant history of seasonal hay fever or seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR), or chronic nasal or sinus condition, intention to travel between first and last visit (to countries for which vaccinations are recommended or where high risk of infection exists), healthcare workers (including doctors, nurses, medical students and allied healthcare professionals) anticipated to have patient contact within two weeks of viral challenge, household member or close contact (for an additional 2 weeks after discharge from the isolation facility) who is less than 3 years of age, any person with any known immunodeficiency, any person receiving immunosuppressant medications, any person undergoing or soon to undergo cancer chemotherapy within 28 days of viral challenge, any person who has diagnosed emphysema or COPD, is elderly residing in a nursing home, or with severe lung disease or medical condition, including but not exclusive to the conditions listed, any person who has received a transplant (bone marrow or solid organ), employees or relatives of Retroscreen Virology or RespiVert Ltd, and other findings in the medical interview, physical exam, or screening investigations that, in the opinion of the Investigator, deem the subject unsuitable for the study.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on neoplasms, which are cancerous tumors. The icd-10 codes associated with the diseases are listed as C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being tested is regorafenib, also known as stivarga or bay73-4506. The eligibility criteria for the trial are listed, including requirements for age, confirmed solid tumors, and Eastern Cooperative Oncology Group performance status. There are also exclusion criteria listed, such as a history of arterial or venous thrombotic or embolic events and clinically significant bleeding.",
    "The sample is a clinical trial with a combination of vincristine sulfate liposome injection and rituximab for patients with non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma and mantle cell lymphoma. The trial is in phase 1/phase 2 and includes patients who have had one or more prior chemotherapy regimens and measurable disease in at least one site. The eligibility criteria include confirmation of CD20 expression on lymphoma cells, Eastern Cooperative Oncology Group (ECOG) \u22642, and total bilirubin and serum creatinine \u22642 times the ULN. Exclusion criteria include previous malignancies with less than a 5-year complete remission interval, history of or active CNS-lymphoma, and allergy to vincristine or other vinca alkaloids.",
    "The sample is a clinical trial for patients with relapsed CD20-positive B-cell non-Hodgkin's lymphoma. The trial is in phase 1/phase 2 and involves a list of drugs including y zevalin, in zevalin, rituxan, bcnu, vp -16, ara-c, melphalan, and g-csf. The eligibility criteria include being chemosensitive, having no prior anti-cancer therapy within three weeks, and having acceptable hematologic status. Patients must also have a prestudy performance status of 0, 1, or 2 according to the World Health Organization and be between the ages of 18 and 65. Exclusion criteria include impaired bone marrow reserve, prior radioimmunotherapy, and presence of central nervous system lymphoma.",
    "The sample is a record from a clinical trial table. It includes information about the phase of the trial, which is phase 1, and a list of diseases including advanced cancer, solid tumors, cancer, and neoplasms. The icd-10 codes associated with these diseases are also provided. The drug being tested in the trial is rigosertib sodium. The eligibility criteria for patients to participate in the trial are listed, including having a confirmed metastatic or unresectable malignancy, meeting certain blood count and organ function requirements, and agreeing to use contraception. The exclusion criteria are also listed, including recent major surgery or treatment with other investigational agents, and having certain medical conditions or illnesses.",
    "The sample is a phase 1 clinical trial for patients with both hepatitis C virus and HIV infections. The trial is testing the effectiveness of a drug called bavituximab. The eligibility criteria for the trial include being 18 years or older, having detectable HIV RNA PCR and chronic hepatitis C infection, having normal blood counts and renal function, and agreeing to use an approved form of contraception. Exclusion criteria include having liver disease other than chronic hepatitis C, bleeding disorders, a history of thromboembolic events, and concurrent therapy with certain medications. The trial is looking to determine the safety and efficacy of bavituximab in treating patients with both hepatitis C and HIV infections.",
    "The sample is a phase 1 clinical trial for patients with metastatic or unresectable solid tumors, including lung, breast, ovary, cervix, prostate, uterus, renal, bladder, and neuroendocrine tumors. The trial involves the use of two drugs, temsirolimus and vinorelbine ditartrate. Patients must have a SWOG performance status of 0-2 and a projected life expectancy of at least 3 months. They must also meet various eligibility criteria, including adequate liver and hematologic function, negative pregnancy test for women of childbearing potential, and no unresolved toxicity greater than CTC grade 1 from previous anticancer therapy. Patients must have recovered from acute toxicities from previous surgery, chemotherapy, or radiation therapy. The trial excludes patients who have received prior therapy with vinorelbine or an mTor inhibitor, have received investigational agents within 30 days prior to commencing study treatment, or have ongoing long-term use of steroids for chronic conditions.",
    "The sample is a phase 1 clinical trial for patients with metastatic breast cancer. The trial is testing the effectiveness of the drugs erlotinib and rad001. The eligibility criteria include having confirmed adenocarcinoma of the breast, having failed previous taxane therapy, and not having symptomatic brain metastases. Patients must also meet certain patient characteristics, such as having an ECOG performance status of 0-1 and normal levels of certain blood counts and liver function tests. The trial has both inclusion and exclusion criteria for prior concurrent therapy, such as prior trastuzumab use and not using concurrent endocrine therapy. The sample also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a record from a clinical trial table. It includes information about the phase of the trial, which is phase 1, and a list of diseases being studied, which are carcinoma and lymphoma. The icd-10 codes associated with these diseases are also provided. The drug being tested is intravenous ezn-2968, which is an anti-hif-1\u03b1 lna as-odn. The eligibility criteria for patients to participate in the trial are also listed, including requirements for diagnosis, prior treatment, and age. Additionally, there are exclusion criteria for patients who are not eligible to participate in the trial.",
    "The sample is a clinical trial for patients with melanoma that involves treatment with Normothermic Isolated Limb Infusion (ILI) of melphalan. The trial is in phase 1/phase 2 and the disease being studied is neoplasms. The icd-10 codes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are ADH-1 and melphalan. The eligibility criteria for the trial include signed written informed consent, measurable disease, and adequate performance status and organ function. Exclusion criteria include a history of tumors that have shown clinically significant evidence of active bleeding within 12 weeks before study entry and uncontrolled congestive heart failure, coronary artery disease, or life-threatening arrhythmias.",
    "The sample is a phase 1 clinical trial for patients with type 2 diabetes mellitus. The trial includes Chinese male and female patients who have been treated with diet and exercise or a maximum of two oral antidiabetic agents, except thiazolidinediones, for at least 12 weeks before randomization. The trial aims to test the efficacy of the drug bi10773 compared to a placebo. The eligibility criteria include having a glycosylated haemoglobin A1(HbA1c) level between 7.0% and 8.5%, being between the ages of 21 and 70, and having a BMI between 19 and 40 kg/m2. The trial also requires patients to have signed and dated written informed consent in accordance with GCP and local legislation. The exclusion criteria include patients who did not discontinue the antidiabetic treatment with insulin or glitazones, uncontrolled hyperglycaemia, and clinically relevant concomitant diseases other than type 2 diabetes, hyperlipidaemia, and medically treated hypertension. The trial also excludes patients with any late stage complication of diabetes, renal insufficiency, cardiac insufficiency, neurological disorders, acute or relevant chronic infections, and a history of relevant allergy/hypersensitivity.",
    "The sample is a phase 1 clinical trial for patients with non-small cell lung cancer. The trial is testing the effectiveness of cisplatin and vinorelbine drugs on patients who have undergone surgery to remove the cancer. The trial has four different cohorts, each with specific eligibility criteria. Patients must be 18 years or older, have no distant metastasis, and meet other laboratory criteria. Patients with previous or concomitant malignancies, severe medical problems, or psychiatric or addictive disorders are excluded from the trial. Female patients must have a negative pregnancy test and use adequate contraceptive precautions during the study period.",
    "The sample is a phase 1 clinical trial for HIV-1 infected males who have not been previously exposed to the drug rilpivirine. The trial requires subjects to have a plasma HIV RNA level of less than 50 copies/mL and be currently receiving a stable antiretroviral regimen. Inclusion criteria also include being in good health, having a BMI between 18 and 32, and using two forms of barrier contraception during heterosexual intercourse. Exclusion criteria include current alcohol or drug abuse, active opportunistic infection or significant co-morbidities, and recent head injury or chronic ongoing neurological diseases. The trial will involve a lumbar puncture examination and MRI of the brain.",
    "The sample is a clinical trial for a drug called dapagliflozin, aimed at treating type 2 diabetes mellitus. The trial is in phase 1 and the table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being used, and the eligibility criteria for participants. The inclusion criteria for participants with type 2 diabetes mellitus include a stable dose of metformin or sulfonylurea for at least 2 months, a fasting plasma glucose concentration of \u2264 200 mg/dl, and HbA1C \u2264 10%. The inclusion criteria for healthy subjects include no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations. The exclusion criteria for all subjects include uncontrolled type 2 diabetes mellitus, fasting plasma glucose > 200 mg/dL, and HbA1C > 10.0%.",
    "The sample is a record of a clinical trial in phase 1, focused on the disease lymphoma. The trial includes patients with AML, a certain type of ALL, NHL, and MM, as well as certain types of cancer of the lymph nodes and leukemias. The drug being tested is azd4877. The eligibility criteria for the trial include having a disease that has failed with other treatments and being in relatively good overall health other than the cancer. Exclusion criteria include poor bone marrow function, serious heart conditions, and poor liver or kidney function.",
    "The sample is a record of a clinical trial with a phase 1 designation. The trial is focused on diabetes and diabetes mellitus type 2, with a list of corresponding ICD-10 codes. The trial is testing the effectiveness of insulin degludec as a treatment option. The eligibility criteria for the trial include having a clinical diagnosis of type 2 diabetes for at least 12 months and having a body mass index (BMI) of 35.0 kg/m2 or less. The exclusion criteria include having donated blood or plasma in the past month or more than 500 mL within 3 months prior to screening, being a smoker who smokes more than 5 cigarettes or the equivalent per day, and not being able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria. In this particular sample, the trial is in phase 1/phase 2 and is focused on chronic myelogenous leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. The drug being tested is dasatinib. The eligibility criteria include subjects who completed a previous study and are deemed suitable for continuation, as well as exclusion criteria such as pregnancy or breastfeeding, unwillingness to undergo transplantation, and previous intolerance to dasatinib.",
    "The sample is a clinical trial for patients with previously untreated aggressive non-Hodgkin's Lymphoma. The trial is in phase 1/phase 2 and the diseases being studied are lymphoma and non-Hodgkin's lymphoma. The icd-10 codes associated with these diseases are listed as [\"S33.110S\", \"S33.111S\", \"S33.120S\", \"S33.121S\", \"S33.130S\", \"S33.131S\", \"S33.140S\"]. The drugs being used in the trial are cyclophosphamide, doxorubicin, vincristine, and prednisone. The eligibility criteria for the trial include having measurable or evaluable disease, being 18 years or older, and having no evidence of grade 3 or more neurosensory or neuromotor dysfunction. Patients with inadequate bone marrow and organ function, HIV positive patients, and those with Hepatitis B or C are excluded from the trial. The trial also excludes patients with CNS involvement by Lymphoma, uncontrolled intercurrent disease, active infection or fever, and those who are not using adequate contraceptive precautions. Pregnancy or breastfeeding is also an exclusion criterion.",
    "The sample is a phase 1 clinical trial for patients with relapsed epithelial ovarian cancer, including fallopian tube and primary peritoneal cancer. The trial involves the use of liposomal doxorubicin as salvage therapy for recurrent disease, along with decitabine. The eligibility criteria include having received up to four previous lines of chemotherapy, a Karnofsky performance status of > 70%, and a life expectancy of at least 6 months. Exclusion criteria include metastatic disease to the central nervous system, serious illnesses requiring antibiotics, and a history of autoimmune disease. Patients must also be willing and able to give valid written informed consent.",
    "The sample is a phase 1 clinical trial for Alzheimer's disease. The trial is testing a drug called GSK933776 and a placebo. The eligibility criteria for the trial include having a clinical diagnosis of probable Alzheimer's disease, being between the ages of 55 and 80, having a Mini Mental State Examination (MMSE) score of 18-26, and having a permanent caregiver who is willing to oversee compliance with the protocol. Exclusion criteria include having any other central nervous system disorder that could be interpreted as a cause of dementia, living in a nursing home, being unable to provide informed consent due to cognitive status, and having a history of significant psychiatric illness or neurological disease other than Alzheimer's disease. The trial also excludes individuals with certain medical conditions or who are taking certain medications.",
    "The sample is a phase 1 clinical trial with healthy male volunteers aged between 20 to 54 years. The trial involves the investigation of a drug called hm10560a and a placebo. The eligibility criteria include having a body mass index between 19 and 26, being medically healthy with no clinically significant screening results, and being able to participate in all procedures. The exclusion criteria include having a history of significant gastrointestinal, cardiac, pulmonary, hepato- and nephro-disease, psychiatric disorder, malignancy tumor, hormonal disorder, diabetes mellitus, and hypertension or history of immunosuppressant treatment. The trial also requires the participants to abstain from alcohol and smoking during the study period and to consent to contraception until 2 months after the end of the study.",
    "The sample is a clinical trial for breast cancer patients in phase 1/phase 2. The trial is testing the effectiveness of two drugs, ptk787 and trastuzumab, on patients with measurable, unresectable, locally recurrent, or metastatic breast cancer. Patients must have HER2 gene amplification by FISH and cannot have received prior cytotoxic chemotherapy or trastuzumab for locally recurrent or metastatic disease. The trial has specific inclusion and exclusion criteria, including limitations on the number of metastatic sites and no history of CNS disease or other forms of cancer therapy within 21 days prior to being registered for protocol therapy. Patients must also meet certain health requirements, such as having controlled blood pressure and no impairment of gastrointestinal function that may significantly alter the absorption of PTK787.",
    "The sample is a phase 1 clinical trial with healthy adult participants. The trial is testing the effectiveness of two drugs, sam-531 and donepezil. The eligibility criteria include being between the ages of 18 and 50, having a body mass index between 18 and 30, and being deemed healthy by the investigator based on medical history, physical examination, laboratory tests, vital signs, and electrocardiogram. Exclusion criteria include having any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, hematologic, or psychiatric disease, having a clinically significant abnormal standard EEG, and consuming caffeine or alcohol within 48 hours before the study. The diseases listed in the sample are \"healthy\" and \"adult\", and the icd-10 codes associated with these diseases are \"Z76.3\" and \"Z76.2\".",
    "The sample is a clinical trial for patients with metastatic or locally recurrent adenocarcinoma of the colon or rectum that is not amenable to potentially curative surgical resection. The trial is in phase 1/phase 2 and involves the drugs zd1839 and oxaliplatin. The eligibility criteria include having failed prior therapy with fluorouracil, leucovorin calcium, and irinotecan, having at least one measurable lesion, and meeting certain patient characteristics such as being at least 18 years old and having a life expectancy of at least 3 months. The trial also has various exclusion criteria, such as having peripheral neuropathy greater than grade 1 or other concurrent uncontrolled illness that would preclude study. The sample includes detailed information on the disease characteristics, patient characteristics, and prior concurrent therapy.",
    "The sample is a phase 1 clinical trial for breast cancer patients. The trial includes patients with histologic confirmation of invasive, but non-inflammatory carcinoma of the breast. Patients with stage I (T1N0) are not eligible for the neo-adjuvant portion of the protocol. High-risk patients with stage I disease are eligible for adjuvant therapy. Patients with pure mucinous carcinomas, tubular carcinomas or pure medullary carcinomas are eligible if the patient's tumor is larger than 3 cm in size or if the patient has tumor involvement of the lymph nodes (>2mm). Patients with bilateral breast cancers are eligible. Patients with pN2a (metastasis in four to nine axillary lymph nodes) are eligible as are patients with pN3a (ten or more axillary lymph nodes). Patients with infraclavicular lymph node involvement are NOT eligible. Patients must have clinically measurable disease to be treated in the neoadjuvant setting. The trial includes patients with a prior history of breast cancer if the current primary breast cancer is of a higher stage than the original breast cancer and the patient has not received any of the current study medications including past doxorubicin. Patients should have adequate bone marrow, liver, and renal function. Patients who had surgical therapy prior to referral will be eligible for randomization to systemic chemotherapy administered in the adjuvant setting. Patients who have overexpression of the her-2/neu oncogene are eligible for the study. The exclusion criteria include patients with N2 or N3 nodal disease, inflammatory breast cancer, or metastatic disease. Patients with hypersensitivity reactions to any of the study medications must be excluded. Patients with history of other malignancies will be excluded, except non-melanoma skin cancer and non-invasive cervical cancer. Patients with uncompensated congestive heart failure are not eligible. Patients who are pregnant or lactating are not eligible. Patients who have had an organ allograft are ineligible. Patients with serious concurrent infections are ineligible. Sexually active male patients unwilling to practice contraception during the study are ineligible. Patients with pre-existing peripheral neuropathy > grade 1 are also ineligible.",
    "The sample is a record from a clinical trial table. It pertains to a phase 1 trial for the treatment of melanoma, a type of skin cancer. The trial involves the use of three drugs: genasense\u00ae (oblimersen), abraxane\u00ae (paclitaxel protein-bound particles for injectable suspension), and temodar\u00ae (temozolomide). The eligibility criteria for the trial include having measurable disease, an Eastern Cooperative Oncology Group Performance Status less than or equal to 2, and serum LDH less than or equal to 1.1 times the upper limit of normal. Prior immunotherapy, radiotherapy, or cytokine, biologic, or vaccine therapy is permitted in the adjuvant and/or metastatic setting. The exclusion criteria include prior treatment with cytotoxic chemotherapy, nonmeasurable disease only, history or presence of brain metastasis or leptomeningeal disease, significant medical disease other than cancer, known human immunodeficiency virus infection, pregnant or lactating, known hypersensitivity to temozolomide, phosphorothioate-containing oligonucleotides, or products containing human albumin, and use of any experimental therapy within 3 weeks prior to baseline evaluations, other anticancer treatment (such as chemotherapy, radiation, or biologic or investigational therapies) while receiving therapy in this study.",
    "The sample is a phase 1 clinical trial for the treatment of HCV infection. The trial includes both male and female participants between the ages of 18 and 60 who do not have cirrhosis or liver fibrosis corresponding to Metavir Stages 0 to 3. Participants must have stable liver disease with ALT values less than 5 times the upper limit of normal and serologic evidence of detectable plasma HCV-RNA of at least 100,000 IU/ml at screening. They must also have documented HCV Genotype 1 chronic hepatitis C and be judged to be in good health based on medical history and physical examination. Participants must be treatment-na\u00efve or experienced and must meet a number of other eligibility criteria, including normal hematology and clinical chemistry, acceptable methods of contraception, and negative pregnancy tests. Exclusion criteria include participation in other clinical trials, active use of hard illicit drugs or alcohol, liver cirrhosis, other causes of liver disease, and various other medical conditions.",
    "The sample is a phase 1 clinical trial for patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. The trial involves two drugs, intravenous docetaxel with intraperitoneal oxaliplatin and intravenous oxaliplatin with intraperitoneal docetaxel. The eligibility criteria include having a confirmed platinum-sensitive or platinum-resistant cancer, not having had more than three prior regimens, and not having had a platinum or taxane agent within the past 6 months. Patients must also have an ECOG Performance Score of \u22642 and adequate bone marrow, renal, and hepatic function. Exclusion criteria include having an active infection or extra-abdominal metastases, known hypersensitivity to the drugs, and pregnancy or lactation. Patients must be able to provide informed consent and use effective contraception during the study and for 90 days following the last dose of study medication.",
    "The sample is a clinical trial for neonatal seizures, with a phase 1/phase 2 designation. The trial is looking at the effectiveness of the drug bumetanide in treating seizures in newborns. The inclusion criteria for the trial include a gestational age of 37-43 weeks, an APGAR score of less than 5 at 5 minutes, and other clinical indicators of seizures. The trial also requires written informed consent from the parent or guardian and EEG monitoring within the first 48 hours of birth. Exclusion criteria include suspected or confirmed brain malformations, inborn errors of metabolism, genetic syndromes, or major congenital malformations, as well as other medical conditions such as anuria/renal failure or severe electrolyte depletion.",
    "The sample is a phase 1 clinical trial for cancer patients who have not responded to standard therapies or for whom there is no approved or curative therapy. The trial involves two drugs, gsk1120212 and gsk2110183, and requires archived tissue or a fresh biopsy at screening. Eligibility criteria include being at least 18 years old, having adequate organ system function, and having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. Women of childbearing potential and men with reproductive potential must practice acceptable methods of birth control. The trial also includes specific inclusion criteria for Part 2A and Part 2B, and exclusion criteria such as a history of Type 1 diabetes, active gastrointestinal disease, and known active infection requiring treatment.",
    "The sample is a record from a clinical trial table that includes information about a phase 1 trial for patients with Type 1 Diabetes Mellitus. The record includes the list of diseases and their corresponding ICD-10 codes, as well as the list of drugs used in the trial. The eligibility criteria for the trial are also provided, including inclusion and exclusion criteria. The record specifies that the trial is intended for Japanese patients who are currently on treatment with basal-bolus insulin. The record also notes that the information provided is not exhaustive and that other considerations may be relevant for potential participants in the trial.",
    "This sample is for a clinical trial in the early phase 1 for breast cancer. The trial is testing the effectiveness of two drugs, lapatinib ditosylate and paclitaxel albumin-stabilized nanoparticle formulation. The eligibility criteria for participants include having histologically confirmed breast cancer, measurable disease, and HER2/neu 3+ by immunohistochemistry or positive by fluorescent in situ hybridization. Participants must also meet certain patient characteristics such as having a life expectancy of more than 12 weeks, being able to swallow and retain oral medication, and having no ongoing or active infection. Prior concurrent therapy is not allowed, and participants must not have any uncontrolled illness or gastrointestinal tract disease that would preclude the ability to take oral medication. The trial is also testing the effects of certain medications and substances on the study drug, and participants must not be taking certain medications or substances during the trial.",
    "The sample is a phase 1 clinical trial for the treatment of dementia. The trial involves testing various drugs and placebos on male participants between the ages of 18 and 40 who are non-smokers and in good health. The eligibility criteria include not having a history of certain illnesses or head injuries, and not taking any medication except for acetaminophen. The diseases being treated are listed as \"dementia\" and the icd-10 codes associated with the disease are also provided. The drugs being tested include a placebo, as well as various combinations of donepezil, mk-3134, and scopolamine. The eligibility criteria are also provided in detail."
]